10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2016

Commission file number 001-15925

COMMUNITY HEALTH SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

Delaware	13-3893191
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification Number)
4000 Meridian Boulevard Franklin, Tennessee	37067 (Zip Code)
(Address of principal executive offices)

615-465-7000

(Registrant’s telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes þ    No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes þ    No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer þ	Accelerated filer ¨	Non-accelerated filer ¨	Smaller reporting company ¨
	(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes ¨    No þ

As of April 28, 2016, there were outstanding 113,754,186 shares of the Registrant’s Common Stock, $0.01 par value.

Community Health Systems, Inc.

Form 10-Q

For the Three Months Ended March 31, 2016

Part I.	Financial Information		Page
	Item 1.	Financial Statements:
		Condensed Consolidated Statements of Income - Three Months Ended March 31, 2016 and March 31, 2015 (Unaudited)	2
		Condensed Consolidated Statements of Comprehensive (Loss) Income - Three Months Ended March 31, 2016 and March 31, 2015 (Unaudited)	3
		Condensed Consolidated Balance Sheets - March 31, 2016 and December 31, 2015 (Unaudited)	4
		Condensed Consolidated Statements of Cash Flows - Three Months Ended March 31, 2016 and March 31, 2015 (Unaudited)	5
		Notes to Condensed Consolidated Financial Statements (Unaudited)	6
	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	47
	Item 3.	Quantitative and Qualitative Disclosures about Market Risk	69
	Item 4.	Controls and Procedures	69
Part II.	Other Information
	Item 1.	Legal Proceedings	70
	Item 1A.	Risk Factors	76
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	76
	Item 3.	Defaults Upon Senior Securities	76
	Item 4.	Mine Safety Disclosures	76
	Item 5.	Other Information	76
	Item 6.	Exhibits	77
Signatures			78
Index to Exhibits			79

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(In millions, except share and per share data)

(Unaudited)

	Three Months Ended
	March 31,
	2016		2015
Operating revenues (net of contractual allowances and discounts)	$	5,754	$	5,646
Provision for bad debts		755		735
Net operating revenues		4,999		4,911
Operating costs and expenses:
Salaries and benefits		2,317		2,257
Supplies		799		762
Other operating expenses		1,173		1,099
Government settlement and related costs		-		8
Electronic health records incentive reimbursement		(18)		(26)
Rent		119		116
Depreciation and amortization		298		296
Impairment of long-lived assets		17		-
Total operating costs and expenses		4,705		4,512
Income from operations		294		399
Interest expense, net		251		241
Loss from early extinguishment of debt		-		8
Equity in earnings of unconsolidated affiliates		(20)		(18)
Income from continuing operations before income taxes		63		168
Provision for income taxes		26		56
Income from continuing operations		37		112
Discontinued operations, net of taxes:
Loss from operations of entities sold or held for sale		-		(11)
Impairment of hospitals sold or held for sale		(1)		(1)
Loss on sale, net		-		(1)
Loss from discontinued operations, net of taxes		(1)		(13)
Net income		36		99
Less: Net income attributable to noncontrolling interests		25		20
Net income attributable to Community Health Systems, Inc. stockholders	$	11	$	79
Basic earnings (loss) per share attributable to Community
Health Systems, Inc. common stockholders:
Continuing operations	$	0.11	$	0.80
Discontinued operations		(0.01)		(0.11)
Net income	$	0.10	$	0.69
Diluted earnings (loss) per share attributable to Community
Health Systems, Inc. common stockholders:
Continuing operations	$	0.11	$	0.79
Discontinued operations		(0.01)		(0.11)
Net income	$	0.10	$	0.68
Weighted-average number of shares outstanding:
Basic		110,247,867		114,419,590
Diluted		110,309,372		115,057,668

See accompanying notes to the condensed consolidated financial statements.

2

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME

(In millions)

(Unaudited)

	Three Months Ended
	March 31,
	2016		2015
Net income	$	36	$	99
Other comprehensive (loss) income, net of income taxes:
Net change in fair value of interest rate swaps, net of tax		(19)		(9)
Net change in fair value of available-for-sale securities, net of tax		2		1
Amortization and recognition of unrecognized pension cost components, net of tax		1		1
Other comprehensive loss		(16)		(7)
Comprehensive income		20		92
Less: Comprehensive income attributable to noncontrolling interests		25		20
Comprehensive (loss) income attributable to Community Health Systems, Inc. stockholders	$	(5)	$	72

See accompanying notes to the condensed consolidated financial statements.

3

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In millions, except share data)

(Unaudited)

	March 31, 2016		December 31, 2015
ASSETS
Current assets:
Cash and cash equivalents	$	181	$	184
Patient accounts receivable, net of allowance for doubtful accounts of $4,051 and $4,110 at March 31, 2016 and December 31, 2015, respectively		3,723		3,611
Supplies		587		580
Prepaid income taxes		2		27
Prepaid expenses and taxes		218		197
Other current assets (including assets of hospitals held for sale of $5 and $17 at March 31, 2016 and December 31, 2015, respectively)		545		567
Total current assets		5,256		5,166
Property and equipment		15,084		14,906
Less accumulated depreciation and amortization		(4,980)		(4,794)
Property and equipment, net		10,104		10,112
Goodwill		9,022		8,965
Other assets, net (including assets of hospitals held for sale of $25 and $41 at March 31, 2016 and December 31, 2015, respectively)		2,342		2,352
Total assets	$	26,724	$	26,595
LIABILITIES AND EQUITY
Current liabilities:
Current maturities of long-term debt	$	249	$	229
Accounts payable		1,179		1,258
Accrued interest		158		227
Accrued liabilities (including liabilities of hospitals held for sale of $2 and $6 at March 31, 2016 and December 31, 2015, respectively)		1,468		1,358
Total current liabilities		3,054		3,072
Long-term debt		16,665		16,556
Deferred income taxes		599		593
Other long-term liabilities		1,723		1,698
Total liabilities		22,041		21,919
Redeemable noncontrolling interests in equity of consolidated subsidiaries		565		571
EQUITY
Community Health Systems, Inc. stockholders’ equity:
Preferred stock, $.01 par value per share, 100,000,000 shares authorized; none issued		-		-
Common stock, $.01 par value per share, 300,000,000 shares authorized; 114,731,736 shares issued and 113,756,187 shares outstanding at March 31, 2016, and 113,732,933 shares issued and 112,757,384 shares outstanding at December 31, 2015		1		1
Additional paid-in capital		1,952		1,963
Treasury stock, at cost, 975,549 shares at March 31, 2016 and December 31, 2015		(7)		(7)
Accumulated other comprehensive loss		(89)		(73)
Retained earnings		2,146		2,135
Total Community Health Systems, Inc. stockholders’ equity		4,003		4,019
Noncontrolling interests in equity of consolidated subsidiaries		115		86
Total equity		4,118		4,105
Total liabilities and equity	$	26,724	$	26,595

See accompanying notes to the condensed consolidated financial statements.

4

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In millions)

(Unaudited)

	Three Months Ended
	March 31,
	2016		2015
Cash flows from operating activities:
Net income	$	36	$	99
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization		298		296
Government settlement and related costs		-		8
Stock-based compensation expense		14		14
Loss on sale, net		-		1
Impairment of hospitals sold or held for sale		1		2
Impairment of long-lived assets		17		-
Loss from early extinguishment of debt		-		8
Other non-cash expenses, net		14		(7)
Changes in operating assets and liabilities, net of effects of acquisitions and divestitures:
Patient accounts receivable		(109)		(202)
Supplies, prepaid expenses and other current assets		(14)		14
Accounts payable, accrued liabilities and income taxes		64		(284)
Other		(27)		(10)
Net cash provided by (used in) operating activities		294		(61)
Cash flows from investing activities:
Acquisitions of facilities and other related equipment		(99)		(13)
Purchases of property and equipment		(224)		(241)
Proceeds from disposition of hospitals and other ancillary operations		12		62
Proceeds from sale of property and equipment		4		3
Purchases of available-for-sale securities		(37)		(59)
Proceeds from sales of available-for-sale securities		40		56
Increase in other investments		(67)		(39)
Net cash used in investing activities		(371)		(231)
Cash flows from financing activities:
Proceeds from exercise of stock options		-		17
Repurchase of restricted stock shares for payroll tax withholding requirements		(7)		(20)
Deferred financing costs and other debt-related costs		-		(20)
Redemption of noncontrolling investments in joint ventures		(16)		(7)
Distributions to noncontrolling investors in joint ventures		(18)		(23)
Borrowings under credit agreements		1,564		1,251
Proceeds from receivables facility		31		75
Repayments of long-term indebtedness		(1,480)		(1,268)
Net cash provided by financing activities		74		5
Net change in cash and cash equivalents		(3)		(287)
Cash and cash equivalents at beginning of period		184		509
Cash and cash equivalents at end of period	$	181	$	222
Supplemental disclosure of cash flow information:
Interest payments	$	(307)	$	(300)
Income tax (payments) refunds, net	$	-	$	(1)

See accompanying notes to the condensed consolidated financial statements.

5

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

The unaudited condensed consolidated financial statements of Community Health Systems, Inc. (the “Parent” or “Parent Company”) and its subsidiaries (the “Company”) as of March 31, 2016 and December 31, 2015 and for the three-month ended March 31, 2016 and 2015, have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). In the opinion of management, such information contains all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for such periods. All intercompany transactions and balances have been eliminated. The results of operations for the three months ended March 31, 2016, are not necessarily indicative of the results to be expected for the full fiscal year ending December 31, 2016. Certain information and disclosures normally included in the notes to condensed consolidated financial statements have been condensed or omitted as permitted by the rules and regulations of the Securities and Exchange Commission (the “SEC”). The Company believes the disclosures are adequate to make the information presented not misleading. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2015, contained in the Company’s Annual Report on Form 10-K filed with the SEC on February 17, 2016 (“2015 Form 10-K”).

Noncontrolling interests in less-than-wholly-owned consolidated subsidiaries of the Parent are presented as a component of total equity on the condensed consolidated balance sheets to distinguish between the interests of the Parent Company and the interests of the noncontrolling owners. Noncontrolling interests that are redeemable or may become redeemable at a fixed or determinable price at the option of the holder or upon the occurrence of an event outside of the control of the Company are presented in mezzanine equity on the condensed consolidated balance sheets.

Throughout these notes to the condensed consolidated financial statements, Community Health Systems, Inc., and its consolidated subsidiaries are referred to on a collective basis as the “Company.” This drafting style is not meant to indicate that the publicly traded Parent or any particular subsidiary of the Parent owns or operates any asset, business, or property. The hospitals, operations and businesses described in this filing are owned and operated, and management services provided, by distinct and indirect subsidiaries of Community Health Systems, Inc.

Allowance for Doubtful Accounts. Accounts receivable are reduced by an allowance for amounts that could become uncollectible in the future. Substantially all of the Company’s receivables are related to providing healthcare services to patients at its hospitals and affiliated businesses.

The Company estimates the allowance for doubtful accounts by reserving a percentage of all self-pay accounts receivable without regard to aging category, based on collection history, adjusted for expected recoveries and any anticipated changes in trends. The Company’s ability to estimate the allowance for doubtful accounts is not impacted by not utilizing an aging of net accounts receivable as the Company believes that substantially all of the risk exists at the point in time such accounts are identified as self-pay. For all other non-self-pay payor categories, the Company reserves an estimated amount on historical collection rates for the uncontractualized portion of all accounts aging over 365 days from the date of discharge. These amounts represent an immaterial percentage of the outstanding accounts receivable. The percentage used to reserve for all self-pay accounts is based on the Company’s collection history. The Company collects substantially all of its third-party insured receivables, which include receivables from governmental agencies.

Collections are impacted by the economic ability of patients to pay and the effectiveness of the Company’s collection efforts. Significant changes in payor mix, business office operations, economic conditions or trends in federal and state governmental healthcare coverage could affect the Company’s collection of accounts receivable and the estimates of the collectability of future accounts receivable and are considered in the Company’s estimates of accounts receivable collectability. The Company also continually reviews its overall reserve adequacy by monitoring historical cash collections as a percentage of trailing net revenue less provision for bad debts, as well as by analyzing current period net revenue and admissions by payor classification, aged accounts receivable by payor, days revenue outstanding, the composition of self-pay receivables between pure self-pay patients and the patient responsibility portion of third-party insured receivables and the impact of recent acquisitions and dispositions.

6

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Operating revenues, net of contractual allowances and discounts (but before the provision for bad debts), recognized during the three months ended March 31, 2016 and 2015, were as follows (in millions):

	Three Months Ended
	March 31,
	2016		2015
Medicare	$	1,431	$	1,398
Medicaid		593		586
Managed Care and other third-party payors		3,022		2,946
Self-pay		708		716
Total	$	5,754	$	5,646

Electronic Health Records Incentive Reimbursement. The federal government has implemented a number of regulations and programs designed to promote the use of electronic health records (“EHR”) technology and, pursuant to the Health Information Technology for Economic and Clinical Health Act (“HITECH”), established requirements for a Medicare and Medicaid incentive payments program for eligible hospitals and professionals that adopt and meaningfully use certified EHR technology. The Company utilizes a gain contingency model to recognize EHR incentive payments. Recognition occurs when the eligible hospitals adopt or demonstrate meaningful use of certified EHR technology for the applicable payment period and have available the Medicare cost report information for the relevant full cost report year used to determine the final incentive payment.

Medicaid EHR incentive payments are calculated based on prior period Medicare cost report information available at the time when eligible hospitals adopt, implement, upgrade or demonstrate meaningful use of certified EHR technology. Since the information for the relevant full Medicare cost report year is available at the time of attestation, the incentive income from resolving the gain contingency is recognized when eligible hospitals adopt, implement, upgrade or demonstrate meaningful use of certified EHR technology.

Medicare EHR incentive payments are calculated based on the Medicare cost report information for the full cost report year that began during the federal fiscal year in which meaningful use is demonstrated. Since the necessary information is only available at the end of the relevant full Medicare cost report year and after the cost report is settled, the incentive income from resolving the gain contingency is recognized when eligible hospitals demonstrate meaningful use of certified EHR technology and the information for the applicable full Medicare cost report year to determine the final incentive payment is available.

In some instances, the Company may receive estimated Medicare EHR incentive payments prior to when the Medicare cost report information used to determine the final incentive payment is available. In these instances, recognition of the gain for EHR incentive payments is deferred until all recognition criteria described above are met.

Eligibility for annual Medicare incentive payments is dependent on providers successfully attesting to the meaningful use of EHR technology. Medicaid incentive payments are available to providers in the first payment year that they adopt, implement or upgrade certified EHR technology; however, providers must demonstrate meaningful use of such technology in any subsequent payment years to qualify for additional incentive payments. Medicaid EHR incentive payments are fully funded by the federal government and administered by the states; however, the states are not required to offer EHR incentive payments to providers.

The Company recognized approximately $18 million and $26 million for the three months ended March 31, 2016 and 2015, respectively, of incentive reimbursement for HITECH incentives from Medicare and Medicaid related to certain of the Company’s hospitals and for certain of the Company’s employed physicians that have demonstrated meaningful use of certified EHR technology or have completed attestations to their adoption or implementation of certified EHR technology. These incentive reimbursements are presented as a reduction of operating costs and expenses on the condensed consolidated statements of income. The Company received cash related to the incentive reimbursement for HITECH incentives of approximately $85 million and $54 million for the three months ended March 31, 2016 and 2015, respectively. The Company recorded $34 million and $75 million as deferred revenue in connection with the receipt of these payments at March 31, 2016 and 2015, respectively, as all criteria for gain recognition had not been met.

7

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

New Accounting Pronouncements. In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. This ASU provides companies the option of applying a full or modified retrospective approach upon adoption. This ASU is effective for fiscal years beginning after December 15, 2016. However, the FASB recently issued a final ASU that defers the effective date by one year, with early adoption permitted for annual periods beginning after December 15, 2016. The Company expects to adopt this ASU on January 1, 2018 and is currently evaluating its plan for adoption and the impact on its revenue recognition policies, procedures and control framework and the resulting impact on its consolidated financial position, results of operations and cash flows.

In April 2015, the FASB issued ASU 2015-03, which requires debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct reduction from the carrying amount of that debt liability, consistent with the accounting for debt discounts. The ASU did not change the measurement or recognition guidance for debt issuance costs. This ASU is effective for fiscal years beginning after December 31, 2015. The Company adopted this ASU on January 1, 2016, which resulted in the reclassification of approximately $266 million of debt issuance costs from other long-term assets to a reduction of the related long-term debt. The adoption of this ASU was applied retroactively to all periods presented, and had no impact on the Company’s results of operations or cash flows.

In November 2015, the FASB issued ASU 2015-17, which amended the balance sheet classification requirements for deferred income taxes to simplify their presentation in the statement of financial position. The ASU requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. This ASU is effective for fiscal years beginning after December 31, 2016, with early adoption permitted. The Company early adopted the provisions of this ASU for the presentation and classification of its deferred tax assets at December 31, 2015. The effect of this change primarily resulted in the current portion of deferred income taxes at December 31, 2015 being included in the noncurrent deferred income tax liability.

In January 2016, the FASB issued ASU 2016-01, which amends the measurement, presentation and disclosure requirements for equity investments, other than those accounted for under the equity method or that require consolidation of the investee. The ASU eliminates the classification of equity investments as available-for-sale with any changes in fair value of such investments recognized in other comprehensive income, and requires entities to measure equity investments at fair value, with any changes in fair value recognized in net income. This ASU is effective for fiscal years beginning after December 15, 2017, with early adoption permitted. The Company expects to adopt this ASU on January 1, 2018, and is currently evaluating the impact that adoption of this ASU will have on its consolidated financial position and results of operations.

In February 2016, the FASB issued ASU 2016-02, which amends the accounting for leases, requiring lessees to recognize most leases on their balance sheet with a right-of-use asset and a lease liability. Leases will be classified as either finance or operating leases, which will impact the expense recognition of such leases over the lease term. The ASU also modifies the lease classification criteria for lessors and eliminates some of the real estate leasing guidance previously applied for certain leasing transactions. This ASU is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company expects to adopt this ASU on January 1, 2019. Because of the number of leases the Company utilizes to support its operations, the adoption of this ASU is expected to have a significant impact on the Company’s consolidated financial position and results of operations. Management is currently evaluating the extent of this anticipated impact on the Company’s consolidated financial position and results of operations, and the quantitative and qualitative factors that will impact the Company as part of the adoption of this ASU, as well as any changes to its leasing strategy that may occur because of the changes to the accounting and recognition of leases.

In March 2016, the FASB issued ASU 2016-09, which was issued to simplify some of the accounting guidance for share-based compensation. Among the areas impacted by the amendments in this ASU is the accounting for income taxes related to share-based payments, accounting for forfeitures, classification of awards as equity or liabilities, and classification on the statement of cash flows. This ASU is effective for fiscal years beginning after December 15, 2016, with early adoption permitted. The Company expects to adopt this ASU on January 1, 2017. Management is evaluating the impact that the adoption of this ASU will have on its consolidated financial position, results of operations and cash flows.

8

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

2. ACCOUNTING FOR STOCK-BASED COMPENSATION 

Stock-based compensation awards have been granted under the Community Health Systems, Inc. Amended and Restated 2000 Stock Option and Award Plan, amended and restated as of March 20, 2013 (the “2000 Plan”), and the Community Health Systems, Inc. 2009 Stock Option and Award Plan, amended and restated as of March 19, 2014 (the “2009 Plan”). In addition, at the annual meeting of stockholders to be held on May 17, 2016 (the “2016 Annual Meeting”), the Company’s stockholders will be voting on whether or not to approve the amendment and restatement of the 2009 Plan (the “Amended 2009 Plan”) which was approved by the Board on March 16, 2016, subject to stockholder approval at the 2016 Annual Meeting.

The 2000 Plan allowed for the grant of incentive stock options intended to qualify under Section 422 of the Internal Revenue Code (the “IRC”), as well as stock options which do not so qualify, stock appreciation rights, restricted stock, restricted stock units, performance-based shares or units and other share awards. Prior to being amended in 2009, the 2000 Plan also allowed for the grant of phantom stock. Persons eligible to receive grants under the 2000 Plan include the Company’s directors, officers, employees and consultants. All options granted under the 2000 Plan have been “nonqualified” stock options for tax purposes. Generally, vesting of these granted options occurs in one-third increments on each of the first three anniversaries of the award date. Options granted prior to 2005 have a 10-year contractual term, options granted in 2005 through 2007 have an eight-year contractual term and options granted in 2008 through 2011 have a 10-year contractual term. The Company has not granted stock option awards under the 2000 Plan since 2011. Pursuant to the amendment and restatement of the 2000 Plan dated March 20, 2013, no further grants will be awarded under the 2000 Plan.

The 2009 Plan provides (and, if approved by the Company’s stockholders at the 2016 Annual Meeting, the Amended 2009 Plan will provide) for the grant of incentive stock options intended to qualify under Section 422 of the IRC and for the grant of stock options which do not so qualify, stock appreciation rights, restricted stock, restricted stock units, performance-based shares or units and other share awards. Persons eligible to receive grants under the 2009 Plan include (and, if approved by the Company’s stockholders at the 2016 Annual Meeting, the Amended 2009 Plan will include) the Company’s directors, officers, employees and consultants. To date, all options granted under the 2009 Plan have been “nonqualified” stock options for tax purposes. Generally, vesting of these granted options occurs in one-third increments on each of the first three anniversaries of the award date. Options granted in 2011 or later have a 10-year contractual term. As of March 31, 2016, 1,122,376 shares of unissued common stock were reserved for future grants under the 2009 Plan. In addition, if the Amended 2009 Plan is approved by the Company’s stockholders at the 2016 Annual Meeting, then 5,000,000 additional shares of unissued common stock would be reserved for future grants under the Amended 2009 Plan.

The exercise price of all options granted under the 2000 Plan and the 2009 Plan has been equal to the fair value of the Company’s common stock on the option grant date.

The following table reflects the impact of total compensation expense related to stock-based equity plans on the reported operating results for the respective periods (in millions):

	Three Months Ended
	March 31,
	2016		2015
Effect on income from continuing operations before income taxes	$	(14)	$	(14)
Effect on net income	$	(8)	$	(8)

At March 31, 2016, $66 million of unrecognized stock-based compensation expense related to outstanding unvested restricted stock and restricted stock units (the terms of which are summarized below) was expected to be recognized over a weighted-average period of 24 months. There is no expense to be recognized related to stock options. There were no modifications to awards during the three months ended March 31, 2016 and 2015.

9

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Options outstanding and exercisable under the 2000 Plan and the 2009 Plan as of March 31, 2016, and changes during the three-month period following December 31, 2015, were as follows (in millions, except share and per share data):

					Weighted-	Aggregate
					Average	Intrinsic
			Weighted-		Remaining	Value as of
			Average		Contractual	March 31,
	Shares		Exercise Price		Term	2016
Outstanding at December 31, 2015		1,232,158	$	31.65
Granted		-		-
Exercised		-		-
Forfeited and cancelled		(9,334)		29.85
Outstanding at March 31, 2016		1,222,824	$	31.66	3.8 years	$	-
Exercisable at March 31, 2016		1,222,824	$	31.66	3.8 years	$	-

No stock options were granted during the three months ended March 31, 2016 and 2015. The aggregate intrinsic value (the number of in-the-money stock options multiplied by the difference between the Company’s closing stock price on the last trading day of the reporting period ($18.51) and the exercise price of the respective stock options) in the table above represents the amount that would have been received by the option holders had all option holders exercised their options on March 31, 2016. This amount changes based on the market value of the Company’s common stock. The aggregate intrinsic value of options exercised during the three months ended March 31, 2015 was $5 million. There were no options exercised during the three months ended March 31, 2016. The aggregate intrinsic value of options vested and expected to vest approximates that of the outstanding options.

The Company has also awarded restricted stock under the 2000 Plan and the 2009 Plan to its directors and employees of certain subsidiaries. The restrictions on these shares generally lapse in one-third increments on each of the first three anniversaries of the award date. Certain of the restricted stock awards granted to the Company’s senior executives contain a performance objective that must be met in addition to any time-based vesting requirements. If the performance objective is not attained, the awards will be forfeited in their entirety. Once the performance objective has been attained, restrictions will lapse in one-third increments on each of the first three anniversaries of the award date. In addition, 835,000 restricted stock awards granted March 1, 2014 had a performance objective that was measured based on the realization of synergies related to the acquisition of Health Management Associates, Inc. (“HMA”) over a two-year period that began on February 1, 2014. The performance objective could be met in part in the first year or in whole or in part over such two-year period. Depending on the degree of attainment of the performance objective, restrictions would lapse on a portion of the award grant over the first three anniversaries of the award date at a level dependent upon the amount of synergies realized. If the synergies related to the HMA merger had not reached a certain level, then the awards would have been forfeited in their entirety. Based on the synergy levels attained in the first annual measurement period ended on January 31, 2015, the performance objective for the first measurement period was met, and one-third of the awards vested on March 1, 2015. Based on the synergy levels attained in the second annual measurement period ended on January 31, 2016, the performance objective for the second measurement period was also met, so the full amount of each award has been earned and one-third of the awards vested on March 1, 2016. The remaining one-third of each award will vest on March 1, 2017. Notwithstanding the above-mentioned performance objectives and vesting requirements, the restrictions with respect to restricted stock granted under the 2000 Plan and the 2009 Plan will lapse earlier in the event of death, disability or termination of employment by the Company for any reason other than for cause of the holder of the restricted stock, or change in control of the Company. Restricted stock awards subject to performance standards that have not yet been satisfied are not considered outstanding for purposes of determining earnings per share until the performance objectives have been satisfied.

10

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Restricted stock outstanding under the 2000 Plan and the 2009 Plan as of March 31, 2016, and changes during the three-month period following December 31, 2015, were as follows (in millions, except share and per share data):

			Weighted-
			Average Grant
	Shares		Date Fair Value
Unvested at December 31, 2015		2,845,579	$	44.18
Granted		1,340,000		15.48
Vested		(1,301,337)		43.36
Forfeited		(4,667)		43.05
Unvested at March 31, 2016		2,879,575		31.20

Restricted stock units (“RSUs”) have been granted to the Company’s outside directors under the 2000 Plan and the 2009 Plan. On March 1, 2015, each of the Company’s outside directors received a grant under the 2009 Plan of 3,504 RSUs. On March 1, 2016, each of the Company’s outside directors received a grant under the 2009 Plan of 11,017 RSUs. Both the 2015 and 2016 grants had a grant date fair value of approximately $170,000. Vesting of these RSUs occurs in one-third increments on each of the first three anniversaries of the award date.

RSUs outstanding under the 2000 Plan and the 2009 Plan as of March 31, 2016, and changes during the three-month period following December 31, 2015, were as follows (in millions, except share and per share data):

				Weighted-
				Average Grant
	Shares			Date Fair Value
Unvested at December 31, 2015		42,678		$	44.59
Granted		77,119			15.43
Vested		(21,432	)		43.60
Forfeited		-			-
Unvested at March 31, 2016		98,365			21.95

3. COST OF REVENUE

Substantially all of the Company’s operating costs and expenses are “cost of revenue” items. Operating costs that could be classified as general and administrative by the Company would include the Company’s corporate office costs at its Franklin, Tennessee office, which were $60 million and $77 million for the three months ended March 31, 2016 and 2015, respectively. Included in these corporate office costs is stock-based compensation of $14 million for both the three months ended March 31, 2016 and 2015.

4. USE OF ESTIMATES

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements. Actual results could differ from these estimates under different assumptions or conditions.

11

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

5. ACQUISITIONS AND DIVESTITURES

Acquisitions

The Company accounts for all transactions that represent business combinations using the acquisition method of accounting, where the identifiable assets acquired, the liabilities assumed and any noncontrolling interest in the acquired entity are recognized and measured at their fair values on the date the Company obtains control in the acquiree. Such fair values that are not finalized for reporting periods following the acquisition date are estimated and recorded as provisional amounts. Adjustments to these provisional amounts during the measurement period (defined as the date through which all information required to identify and measure the consideration transferred, the assets acquired, the liabilities assumed and any noncontrolling interests has been obtained, limited to one year from the acquisition date) are recorded as of the date of acquisition. Any material impact to comparative information for periods after acquisition, but before the period in which adjustments are identified, is reflected in those prior periods as if the adjustments were considered as of the acquisition date. Goodwill is determined as the excess of the fair value of the consideration conveyed in the acquisition over the fair value of the net assets acquired.

Excluding acquisition and integration expenses related to the acquisition of HMA, approximately $2 million of acquisition costs related to prospective and closed acquisitions were expensed during both the three months ended March 31, 2016 and March 31, 2015 and are included in other operating expenses on the condensed consolidated statements of income. Approximately $1 million of acquisition and related integration expense related to the HMA acquisition were recognized during the three months ended March 31, 2015.

On March 1, 2016, one or more subsidiaries of the Company completed the acquisition of an 80% ownership interest in a joint venture entity with Indiana University Health that includes substantially all of the assets of IU Health La Porte Hospital in La Porte, Indiana (227 licensed beds) and IU Health Starke Hospital in Knox, Indiana (50 licensed beds), and affiliated outpatient centers and physician practices. The total cash consideration paid for long-lived assets and working capital in this joint venture was approximately $69 million and $10 million, respectively, with additional consideration of $32 million assumed in liabilities, for a total consideration of $96 million. Based upon the Company’s preliminary purchase price allocation relating to this acquisition as of March 31, 2016, approximately $49 million of goodwill has been recorded. The preliminary allocation of the purchase price has been determined by the Company based on available information and is subject to settling amounts related to purchased working capital and final appraisals of tangible and intangible assets. Adjustments to the purchase price allocation are not expected to be material.

Other Acquisitions

During the three months ended March 31, 2016, one or more subsidiaries of the Company paid approximately $4 million to acquire the operating assets and related businesses of certain physician practices, clinics and other ancillary businesses that operate within the communities served by the Company’s affiliated hospitals. In connection with these acquisitions, during the three months ended March 31, 2016, the Company allocated approximately $2 million of the consideration paid to property and equipment and net working capital and the remainder, approximately $7 million consisting of intangible assets that do not qualify for separate recognition, to goodwill. The value of the noncontrolling interest recorded in these acquisitions was $5 million.

Divestitures

In April 2014, FASB issued ASU 2014-08, which changes the requirements for reporting discontinued operations. A discontinued operation continues to include a component of an entity or a group of components of an entity, or a business activity. However, in a shift reflecting stakeholder concerns that too many disposals of small groups of assets that were recurring in nature qualified for reporting as discontinued operations, a disposal of a component of an entity or a group of components of an entity will be required to be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results. A business or nonprofit activity that, on acquisition, meets the criteria to be classified as held for sale will still be a discontinued operation. Additional disclosures will be required for significant components of the entity that are disposed of or are held for sale but do not qualify as discontinued operations. This ASU is effective for fiscal years beginning after December 15, 2014 and is to be applied on a prospective basis for disposals or components initially classified as held for sale after that date. The Company adopted this ASU on January 1, 2015 and the adoption resulted in the following divestitures occurring subsequent to the date of adoption being included in continuing operations for the three months ended March 31, 2016 and 2015 (the impact of the adoption of ASU 2014-08 in relation to the hospitals and other assets spun off to Quorum Health Corporation (“QHC”) are discussed in footnote 6 below).

12

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Effective February 1, 2016, one or more subsidiaries of the Company sold Lehigh Regional Medical Center (88 licensed beds) in Lehigh Acres, Florida, (“Lehigh”) and related outpatient services to Prime Healthcare Services, Inc. (“Prime”) for approximately $11 million in cash. In connection with the divestiture of Lehigh, the Company recorded an impairment charge of approximately $4 million related to the allocated goodwill during the three months ended March 31, 2016.

Effective January 1, 2016, one or more subsidiaries of the Company sold Bartow Regional Medical Center (72 licensed beds) in Bartow, Florida, (“Bartow”) and related outpatient services to BayCare Health Systems, Inc. for approximately $60 million in cash, which was received at a preliminary closing on December 31, 2015. In connection with the divestiture of Bartow, the Company recorded an impairment charge of approximately $5 million related to the allocated goodwill during the three months ended March 31, 2016.

Effective July 31, 2015, one or more subsidiaries of the Company sold certain assets used in the operation of Payson Regional Medical Center (44 licensed beds) in Payson, Arizona (“Payson”) to Banner Health for approximately $20 million in cash. The Company previously operated Payson under the terms of an operating lease with Mogollon Health Alliance, Inc., an Arizona nonprofit corporation, that expired on July 31, 2015. The lease termination and sale closed effective July 31, 2015.

Pursuant to the Company’s adoption of ASU 2014-08, the divestiture of Lehigh, Bartow and Payson do not meet the requirement for presentation in discontinued operations. The financial results included in discontinued operations for divestitures or hospitals held for sale at December 31, 2014, prior to the Company’s adoption of ASU 2014-08, are summarized below.

During the three months ended June 30, 2015, one or more subsidiaries of the Company finalized an agreement to terminate the lease and cease operations of Fallbrook Hospital (47 licensed beds) in Fallbrook, California. In agreeing to terminate the lease, the Company received approximately $3 million in cash from the Fallbrook Healthcare District, as the landlord, as consideration for certain operating assets of the hospital.

Effective April 1, 2015, one or more subsidiaries of the Company sold Chesterfield General Hospital (59 licensed beds) in Cheraw, South Carolina and Marlboro Park Hospital (102 licensed beds) in Bennettsville, South Carolina and related outpatient services to M/C Healthcare, LLC for approximately $4 million in cash.

Effective March 1, 2015 one or more subsidiaries of the Company sold Dallas Regional Medical Center (202 licensed beds) in Mesquite, Texas to Prime for approximately $25 million in cash.

Effective March 1, 2015 one or more subsidiaries of the Company sold Riverview Regional Medical Center (281 licensed beds) in Gadsden, Alabama to Prime for approximately $25 million in cash. This hospital was required to be divested by the Federal Trade Commission as a condition of its approval of the HMA merger.

Effective February 1, 2015, one or more subsidiaries of the Company sold Harris Hospital (133 licensed beds) in Newport, Arkansas and related healthcare services to White County Medical Center in Searcy, Arkansas for approximately $5 million in cash.

Effective January 1, 2015, one or more subsidiaries of the Company sold Carolina Pines Regional Medical Center (116 licensed beds) in Hartsville, South Carolina and related outpatient services to Capella Healthcare for approximately $74 million in cash, which was received at the closing on December 31, 2014. This hospital was required to be divested by the Federal Trade Commission as a condition of its approval of the HMA merger.

During the year ended December 31, 2014, the Company made the decision to sell and began actively marketing several smaller hospitals, which are classified as held for sale at March 31, 2016. In addition, HMA entered into a definitive agreement to sell Williamson Memorial Hospital (76 licensed beds) located in Williamson, West Virginia prior to the HMA merger, and the Company has continued the effort to divest this facility. In connection with management’s decision to sell these facilities and the sale of the seven hospitals (excluding Payson) noted above during 2015, the Company has classified the results of operations of the above mentioned hospitals as discontinued operations in the accompanying condensed consolidated statements of income, and classified these hospitals as held for sale in the accompanying condensed consolidated balance sheet.

13

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Net operating revenues and loss from discontinued operations for the respective periods are as follows (in millions):

	Three Months Ended
	March 31,
	2016		2015
Net operating revenues	$	27	$	56
Loss from operations of entities sold or held for sale before income taxes		-		(17)
Impairment of hospitals sold or held for sale		(2)		(1)
Loss on sale, net		-		(1)
Loss from discontinued operations, before taxes		(2)		(19)
Income tax benefit		(1)		(6)
Loss from discontinued operations, net of taxes	$	(1)	$	(13)

Interest expense was allocated to discontinued operations based on sale proceeds available for debt repayment.

Other Hospital Closures

During the three months ended March 31, 2016, the Company announced the planned closure of McNairy Regional Hospital in Selmer, Tennessee, scheduled for the second quarter of 2016. The Company recorded an impairment charge of approximately $7 million during the three months ended March 31, 2016, to adjust the value of the supplies inventory and long-lived assets of this hospital, including property and equipment and capitalized software costs, based on their estimated fair value and future utilization.

6. SPIN-OFF OF QUORUM HEALTH CORPORATION

On August 3, 2015, the Company announced a plan to spin off 38 hospitals and Quorum Health Resources, LLC into Quorum Health Corporation, an independent, publicly traded corporation. The transaction was structured to be generally tax free to the Company and its stockholders.

On April 29, 2016, the Company completed the spin-off of QHC and distributed, on a pro rata basis, all of the shares of QHC common stock to the Company’s stockholders of record as of April 22, 2016. These stockholders of record as of April 22, 2016 received a distribution of one share of QHC common stock for every four shares of Company common stock held as of the record date plus cash in lieu of any fractional shares. Immediately following the completion of the spin-off, the Company’s stockholders owned 100% of the outstanding shares of QHC common stock. Following the spin-off, QHC became an independent public company with its common stock listed for trading under the symbol “QHC” on the New York Stock Exchange.

In connection with the spin-off, the Company and QHC entered into a separation and distribution agreement as well as certain ancillary agreements on April 29, 2016. These agreements allocate between the Company and QHC the various assets, employees, liabilities and obligations (including investments, property and employee benefits and tax-related assets and liabilities) that comprise the separate companies and govern certain relationships between, and activities of, the Company and QHC for a period of time after the spin-off.

The results of operations for QHC have continued to be presented in continuing operations in the condensed consolidated statement of income as the Company has determined that the spin-off of QHC does not meet the criteria as discontinued operations under ASU 2014-08.

14

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

7. INCOME TAXES

The total amount of unrecognized benefit that would affect the effective tax rate, if recognized, was approximately $5 million as of March 31, 2016. A total of approximately $3 million of interest and penalties is included in the amount of the liability for uncertain tax positions at March 31, 2016. It is the Company’s policy to recognize interest and penalties related to unrecognized benefits in its condensed consolidated statements of income as income tax expense.

It is possible the amount of unrecognized tax benefit could change in the next 12 months as a result of a lapse of the statute of limitations and settlements with taxing authorities; however, the Company does not anticipate the change will have a material impact on the Company’s condensed consolidated results of operations or condensed consolidated financial position.

The Company, or one of its subsidiaries, files income tax returns in the United States federal jurisdiction and various state jurisdictions. The Company has extended the federal statute of limitations through March 31, 2017 for Triad Hospitals, Inc. for the tax periods ended December 31, 1999, December 31, 2000, April 30, 2001, June 30, 2001, December 31, 2001, December 31, 2002, December 31, 2003, December 31, 2004, December 31, 2005, December 31, 2006 and July 25, 2007. With few exceptions, the Company is no longer subject to state income tax examinations for years prior to 2011. The Company’s federal income tax returns for the 2009 and 2010 tax years are currently under examination by the Internal Revenue Service. The Company believes the results of these examinations will not be material to its consolidated results of operations or consolidated financial position. The Company has extended the federal statute of limitations through December 31, 2016 for Community Health Systems, Inc. for the tax periods ended December 31, 2007, 2008, 2009 and 2010, and through March 31, 2017 for the tax periods ended December 31, 2011 and 2012.

The Company’s effective tax rates were 41.3% and 33.2% for the three months ended March 31, 2016 and 2015, respectively. The increase in the Company’s effective tax rate for the three months ended March 31, 2016, when compared to the three months ended March 31, 2015, was primarily related to a disproportionate substantial decrease in income from continuing operations before income taxes, when compared to an increase in net income attributable to noncontrolling interests for those same periods, which is not tax affected in the condensed consolidated statement of income. Including the expense related to income attributable to noncontrolling interests, the effective tax rate for the three months ended March 31, 2016 and 2015 would have been 68.4% and 37.8%, respectively. The increase in the Company’s effective tax rate for the three months ended March 31, 2016 is primarily due to the impact of permanent tax differences recognized as part of the hospitals divested by the Company during this three-month period.

Cash paid for income taxes, net of refunds received, resulted in net cash paid of less than $1 million and $1 million during the three months ended March 31, 2016 and 2015, respectively.

8. GOODWILL AND OTHER INTANGIBLE ASSETS

Goodwill

The changes in the carrying amount of goodwill for the three months ended March 31, 2016 are as follows (in millions):

Balance as of December 31, 2015	$	8,965
Goodwill acquired as part of acquisitions during current year		57
Balance as of March 31, 2016	$	9,022

Goodwill is allocated to each identified reporting unit, which is defined as an operating segment or one level below the operating segment (referred to as a component of the entity). Management has determined that the Company’s operating segments and hospital management services operations meet the criteria to be classified as reporting units. At March 31, 2016, the hospital operations reporting unit, the home care agency operations reporting unit and the hospital management services reporting unit had approximately $8.9 billion, $47 million and $33 million, respectively, of goodwill.

15

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Goodwill is evaluated for impairment at the same time every year and when an event occurs or circumstances change that, more likely than not, reduce the fair value of the reporting unit below its carrying value. There is a two-step method for determining goodwill impairment. Step one is to compare the fair value of the reporting unit with the unit’s carrying amount, including goodwill. If this test indicates the fair value is less than the carrying value, then step two is required to compare the implied fair value of the reporting unit’s goodwill with the carrying value of the reporting unit’s goodwill. The Company performed its last annual goodwill evaluation during the fourth quarter of 2015. No impairment was indicated by this evaluation. The next annual goodwill evaluation will be performed during the fourth quarter of 2016.

The Company estimates the fair value of the related reporting units using both a discounted cash flow model as well as an EBITDA multiple model. The cash flow forecasts are adjusted by an appropriate discount rate based on the Company’s estimate of a market participant’s weighted-average cost of capital. These models are both based on the Company’s best estimate of future revenues and operating costs and are reconciled to the Company’s consolidated market capitalization, with consideration of the amount a potential acquirer would be required to pay, in the form of a control premium, in order to gain sufficient ownership to set policies, direct operations and control management decisions.

Intangible Assets

No intangible assets other than goodwill were acquired during the three months ended March 31, 2016. The gross carrying amount of the Company’s other intangible assets subject to amortization was $79 million at March 31, 2016 and $82 million at December 31, 2015 and the net carrying amount was $27 million at March 31, 2016 and $31 million at December 31, 2015. The carrying amount of the Company’s other intangible assets not subject to amortization was $120 million March 31, 2016 and $121 million at December 31, 2015, respectively. Other intangible assets are included in other assets, net on the Company’s condensed consolidated balance sheets. Substantially all of the Company’s intangible assets are contract-based intangible assets related to operating licenses, management contracts, or non-compete agreements entered into in connection with prior acquisitions.

The weighted-average remaining amortization period for the intangible assets subject to amortization is approximately four years. There are no expected residual values related to these intangible assets. Amortization expense on these intangible assets was $4 million and $3 million during the three months ended March 31, 2016 and 2015, respectively. Amortization expense on intangible assets is estimated to be $11 million for the remainder of 2016, $5 million in 2017, $4 million in 2018, $2 million in 2019, $2 million in 2020, $2 million in 2021 and $1 million thereafter.

The gross carrying amount of capitalized software for internal use was approximately $1.5 billion at both March 31, 2016 and December 31, 2015, and the net carrying amount considering accumulated amortization was approximately $737 million at March 31, 2016 and $771 million at December 31, 2015. The estimated amortization period for capitalized internal-use software is generally three years, except for capitalized costs related to significant system conversions, which is generally eight to ten years. There is no expected residual value for capitalized internal-use software. At March 31, 2016, there was approximately $56 million of capitalized costs for internal-use software that is currently in the development stage and will begin amortization once the software project is complete and ready for its intended use. Amortization expense on capitalized internal-use software was $55 million and $53 million during the three months ended March 31, 2016 and 2015, respectively. Amortization expense on capitalized internal-use software is estimated to be $165 million for the remainder of 2016, $185 million in 2017, $102 million in 2018, $74 million in 2019, $65 million in 2020, $60 million in 2021 and $86 million thereafter.

16

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

9. EARNINGS PER SHARE 

The following table sets forth the components of the numerator and denominator for the computation of basic and diluted earnings per share for income from continuing operations, discontinued operations and net income attributable to Community Health Systems, Inc. common stockholders (in millions, except share data):

	Three Months Ended
	March 31,
	2016		2015
Numerator:
Income from continuing operations, net of taxes	$	37	$	112
Less: Income from continuing operations attributable to noncontrolling interests, net of taxes		25		20
Income from continuing operations attributable to Community Health Systems, Inc. common stockholders — basic and diluted	$	12	$	92
Loss from discontinued operations, net of taxes	$	(1)	$	(13)
Less: Loss from discontinued operations attributable to noncontrolling interests, net of taxes		-		-
Loss from discontinued operations attributable to Community Health Systems, Inc. common stockholders — basic and diluted	$	(1)	$	(13)
Denominator:
Weighted-average number of shares outstanding — basic		110,247,867		114,419,590
Effect of dilutive securities:
Restricted stock awards		45,257		181,120
Employee stock options		13,038		452,659
Other equity-based awards		3,210		4,299
Weighted-average number of shares outstanding — diluted		110,309,372		115,057,668
	Three Months Ended
	March 31,
	2016		2015
Dilutive securities outstanding not included in the computation of earnings per share because their effect is antidilutive:
Employee stock options and restricted stock awards		2,672,726		-

10. STOCKHOLDERS’ EQUITY

Authorized capital shares of the Company include 400,000,000 shares of capital stock consisting of 300,000,000 shares of common stock and 100,000,000 shares of preferred stock. Each of the aforementioned classes of capital stock has a par value of $0.01 per share. Shares of preferred stock, none of which were outstanding as of March 31, 2016, may be issued in one or more series having such rights, preferences and other provisions as determined by the Board of Directors without approval by the holders of common stock.

17

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

On November 6, 2015, the Company adopted a new open market repurchase program for up to 10,000,000 shares of the Company’s common stock, not to exceed $300 million in repurchases. The repurchase program will expire on the earlier of November 5, 2018, when the maximum number of shares has been repurchased, or when the maximum dollar amount has been expended. During the year ended December 31, 2015, the Company repurchased and retired 532,188 shares at a weighted-average price of $27.31 per share, which is the cumulative number of shares repurchased and retired under this program. No shares were repurchased under this program during the three months ended March 31, 2016.

On December 10, 2014, the Company adopted an open market repurchase program for up to 5,000,000 shares of the Company’s common stock, not to exceed $150 million in repurchases. This repurchase program expired on December 1, 2015. No shares were repurchased under this program during the three months ended March 31, 2015.

The Company is a holding company which operates through its subsidiaries. The Company’s Credit Facility and the indentures governing the senior and senior secured notes contain various covenants under which the assets of the subsidiaries of the Company are subject to certain restrictions relating to, among other matters, dividends and distributions, as referenced in the paragraph below.

With the exception of a special cash dividend of $0.25 per share paid by the Company in December 2012, historically, the Company has not paid any cash dividends. Subject to certain exceptions, the Company’s Credit Facility limits the ability of the Company’s subsidiaries to pay dividends and make distributions to the Company, and limits the Company’s ability to pay dividends and/or repurchase stock, to an amount not to exceed $200 million in the aggregate plus an additional $25 million in any particular year plus the aggregate amount of proceeds from the exercise of stock options. The indentures governing the senior and senior secured notes also restrict the Company’s subsidiaries from, among other matters, paying dividends and making distributions to the Company, which thereby limits the Company’s ability to pay dividends and/or repurchase stock. As of March 31, 2016, under the most restrictive test under these agreements (and subject to certain exceptions), the Company has approximately $318 million remaining available with which to pay permitted dividends and/or repurchase shares of stock or its senior and senior secured notes.

The following schedule presents the reconciliation of the carrying amount of total equity, equity attributable to the Company, and equity attributable to the noncontrolling interests for the three-month period ended March 31, 2016 (in millions):

			Community Health Systems, Inc. Stockholders
	Redeemable Noncontrolling Interest		Common Stock		Additional Paid-In Capital		Treasury Stock		Accumulated Other Comprehensive Income (Loss)		Retained Earnings		Noncontrolling Interest		Total Stockholders’ Equity
Balance, December 31, 2015	$	571	$	1	$	1,963	$	(7)	$	(73)	$	2,135	$	86	$	4,105
Comprehensive income		19		-		-		-		(16)		11		6		1
Distributions to noncontrolling interests, net of contributions		(14)		-		-		-		-		-		(4)		(4)
Purchase of subsidiary shares from noncontrolling interests		(10)		-		(3)		-		-		-		(3)		(6)
Other reclassifications of noncontrolling interests		(1)		-		-		-		-		-		1		1
Noncontrolling interests in acquired entity		-		-		-		-		-		-		29		29
Income tax payable increase from vesting of restricted shares		-		-		(15)		-		-		-		-		(15)
Cancellation of restricted stock for tax withholdings on vested shares		-		-		(7)		-		-		-		-		(7)
Share-based compensation		-		-		14		-		-		-		-		14
Balance, March 31, 2016	$	565	$	1	$	1,952	$	(7)	$	(89)	$	2,146	$	115	$	4,118

18

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

The following schedule discloses the effects of changes in the Company’s ownership interest in its less-than-wholly-owned subsidiaries on Community Health Systems, Inc. stockholders’ equity (in millions):

	Three Months Ended
	March 31, 2016
Net income attributable to Community Health Systems, Inc. stockholders	$	11
Transfers to the noncontrolling interests:
Net decrease in Community Health Systems, Inc. paid-in capital for purchase of subsidiary partnership interests		(3)
Net transfers to the noncontrolling interests		(3)
Change to Community Health Systems, Inc. stockholders’ equity from net income attributable to Community Health Systems, Inc. stockholders and transfers to noncontrolling interests	$	8

11. EQUITY INVESTMENTS

As of March 31, 2016, the Company owned equity interests of 27.5% in four hospitals in Las Vegas, Nevada, and 26.1% in one hospital in Las Vegas, Nevada, in which Universal Health Services, Inc. (“UHS”) owns the majority interest, and an equity interest of 38.0% in three hospitals in Macon, Georgia, in which HCA Holdings, Inc. (“HCA”) owns the majority interest.

Summarized combined financial information for these unconsolidated entities in which the Company owns an equity interest is as follows (in millions):

	Three Months Ended
	March 31,
	2016		2015
Revenues	$	415	$	375
Operating costs and expenses		324		315
Income from continuing operations before taxes		91		60

The summarized financial information was derived from the financial information provided to the Company by those unconsolidated entities.

In March 2005, the Company began purchasing items, primarily medical supplies, medical equipment and pharmaceuticals, under an agreement with HealthTrust Purchasing Group, L.P. (“HealthTrust”), a group purchasing organization in which the Company is a noncontrolling partner. As part of the HMA merger, the Company acquired HMA’s ownership in HealthTrust. As of March 31, 2016, the Company had a 24.7% ownership interest in HealthTrust.

The Company’s investment in all of its unconsolidated affiliates was $504 million at March 31, 2016 and $479 million December 31, 2015, and is included in other assets, net in the accompanying condensed consolidated balance sheets. Included in the Company’s results of operations is the Company’s equity in pre-tax earnings from all of its investments in unconsolidated affiliates, which was $20 million and $18 million for the three months ended March 31, 2016 and 2015, respectively.

19

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

12. LONG-TERM DEBT

Long-term debt consists of the following (in millions):

	March 31,		December 31,
	2016		2015
Credit Facility:
Term A Loan	$	820	$	844
Term F Loan		1,668		1,671
Term G Loan		1,565		1,568
Term H Loan		2,879		2,884
Revolving credit loans		323		147
8% Senior Notes due 2019		1,993		1,992
7 1⁄8% Senior Notes due 2020		1,187		1,186
5 1⁄8% Senior Secured Notes due 2018		1,588		1,587
5 1⁄8% Senior Secured Notes due 2021		968		967
6 7⁄8% Senior Notes due 2022		2,924		2,921
Receivables Facility		699		699
Capital lease obligations		219		227
Other		81		92
Total debt		16,914		16,785
Less current maturities		(249)		(229)
Total long-term debt	$	16,665	$	16,556

Credit Facility

The Company’s wholly-owned subsidiary, CHS, has senior secured financing under a credit facility with a syndicate of financial institutions led by Credit Suisse, as administrative agent and collateral agent. In connection with the HMA merger, the Company and CHS entered into a third amendment and restatement of its credit facility (the “Credit Facility”), providing for additional financing and recapitalization of certain of the Company’s term loans, including (i) the replacement of the revolving credit facility with a new $1.0 billion revolving facility maturing in 2019 (the “Revolving Facility”), (ii) the addition of a new $1.0 billion Term A facility due 2019 (the “Term A Facility”), (iii) a Term D facility in an aggregate principal amount equal to approximately $4.6 billion due 2021 (which included certain term C loans that were converted into such Term D facility (collectively, the “Term D Facility”)), (iv) the conversion of certain term C loans into Term E Loans and the borrowing of new Term E Loans in an aggregate principal amount of approximately $1.7 billion due 2017 and (v) the addition of flexibility commensurate with the Company’s post-acquisition structure. In addition to funding a portion of the consideration in connection with the HMA merger, some of the proceeds of the Term A Facility and Term D Facility were used to refinance the outstanding $637 million existing term A facility due 2016 and the $60 million of term B loans due 2014, respectively. The Revolving Facility includes a subfacility for letters of credit. On March 9, 2015, CHS entered into Amendment No. 1 and Incremental Term Loan Assumption Agreement to refinance the existing Term E Loans due 2017 into Term F Loans due 2018, in an original aggregated principal amount of $1.7 billion. On May 18, 2015, CHS entered into an Incremental Term Loan Assumption Agreement to provide for a new $1.6 billion incremental Term G facility and a new approximately $2.9 billion incremental Term H facility. The proceeds of the Term G facility and Term H facility were used to repay the Company’s existing Term D facility in full.

20

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

The loans under the Credit Facility bear interest on the outstanding unpaid principal amount at a rate equal to an applicable percentage plus, at CHS’ option, either (a) an Alternate Base Rate (as defined) determined by reference to the greater of (1) the Prime Rate (as defined) announced by Credit Suisse or (2) the Federal Funds Effective Rate (as defined) plus 0.50% or (3) the adjusted London Interbank Offered Rate (“LIBOR”) on such day for a three-month interest period commencing on the second business day after such day plus 1% or (b) LIBOR. Loans in respect of the Revolving Facility and the Term A Facility will accrue interest at a rate per annum initially equal to LIBOR plus 2.75%, in the case of LIBOR borrowings, and Alternate Base Rate plus 1.75%, in the case of Alternate Base Rate borrowings. In addition, the margin in respect of the Revolving Facility and the Term A Facility will be subject to adjustment determined by reference to a leverage-based pricing grid. Loans in respect of the Term F Facility will accrue interest at a rate per annum equal to LIBOR plus 3.25%, in the case of LIBOR borrowings, and Alternate Base Rate plus 2.25%, in the case of Alternate Base Rate Borrowings. The Term G Loan and Term H Loan will accrue interest at a rate per annum equal to LIBOR plus 2.75% and 3.00%, respectively, in the case of LIBOR borrowings, and Alternate Base Rate plus 1.75% and 2.00%, respectively, in the case of Alternate Base Rate Borrowings. The Term G Loan and the Term H Loan are subject to a 1.00% LIBOR floor and a 2.00% Alternate Base Rate floor.

The term loan facility must be prepaid in an amount equal to (1) 100% of the net cash proceeds of certain asset sales and dispositions by the Company and its subsidiaries, subject to certain exceptions and reinvestment rights, (2) 100% of the net cash proceeds of issuances of certain debt obligations or receivables-based financing by the Company and its subsidiaries, subject to certain exceptions, and (3) 50%, subject to reduction to a lower percentage based on the Company’s leverage ratio (as defined in the Credit Facility generally as the ratio of total debt on the date of determination to the Company’s EBITDA, as defined, for the four quarters most recently ended prior to such date), of excess cash flow (as defined) for any year, subject to certain exceptions. Voluntary prepayments and commitment reductions are permitted in whole or in part, without any premium or penalty, subject to minimum prepayment or reduction requirements.

The borrower under the Credit Facility is CHS. All of the obligations under the Credit Facility are unconditionally guaranteed by the Company and certain of its existing and subsequently acquired or organized domestic subsidiaries. All obligations under the Credit Facility and the related guarantees are secured by a perfected first priority lien or security interest in substantially all of the assets of the Company, CHS and each subsidiary guarantor, including equity interests held by the Company, CHS or any subsidiary guarantor, but excluding, among others, the equity interests of non-significant subsidiaries, syndication subsidiaries, securitization subsidiaries and joint venture subsidiaries.

CHS has agreed to pay letter of credit fees equal to the applicable percentage then in effect with respect to Eurodollar rate loans under the Revolving Facility times the maximum aggregate amount available to be drawn under all letters of credit outstanding under the subfacility for letters of credit. The issuer of any letter of credit issued under the subfacility for letters of credit will also receive a customary fronting fee and other customary processing charges. CHS is obligated to pay commitment fees of 0.50% per annum (subject to adjustment based upon the Company’s leverage ratio) on the unused portion of the Revolving Facility.

The Credit Facility contains customary representations and warranties, subject to limitations and exceptions, and customary covenants restricting the Company’s and its subsidiaries’ ability, subject to certain exceptions, to, among other things (1) declare dividends, make distributions or redeem or repurchase capital stock, (2) prepay, redeem or repurchase other debt, (3) incur liens or grant negative pledges, (4) make loans and investments and enter into acquisitions and joint ventures, (5) incur additional indebtedness or provide certain guarantees, (6) make capital expenditures, (7) engage in mergers, acquisitions and asset sales, (8) conduct transactions with affiliates, (9) alter the nature of the Company’s businesses, (10) grant certain guarantees with respect to physician practices, (11) engage in sale and leaseback transactions or (12) change the Company’s fiscal year. The Company is also required to comply with specified financial covenants (consisting of a maximum secured net leverage ratio and an interest coverage ratio) and various affirmative covenants. The Company was in compliance with all such covenants at March 31, 2016.

Events of default under the Credit Facility include, but are not limited to, (1) CHS’ failure to pay principal, interest, fees or other amounts under the credit agreement when due (taking into account any applicable grace period), (2) any representation or warranty proving to have been materially incorrect when made, (3) covenant defaults subject, with respect to certain covenants, to a grace period, (4) bankruptcy events, (5) a cross default to certain other debt, (6) certain undischarged judgments (not paid within an applicable grace period), (7) a change of control, (8) certain ERISA-related defaults and (9) the invalidity or impairment of specified security interests, guarantees or subordination provisions in favor of the administrative agent or lenders under the Credit Facility.

21

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

As of March 31, 2016, the availability for additional borrowings under the Credit Facility, after taking into account the $334 million outstanding at that date, was approximately $666 million pursuant to the Revolving Facility, of which $68 million was set aside for outstanding letters of credit. CHS has the ability to amend the Credit Facility to provide for one or more tranches of term loans or increases in the Revolving Facility in an aggregate principal amount of $1.5 billion, which CHS has not yet accessed. As of March 31, 2016, the weighted-average interest rate under the Credit Facility, excluding swaps, was 4.3%.

8% Senior Notes due 2019

On November 22, 2011, CHS completed its offering of $1.0 billion aggregate principal amount of 8% Senior Notes due 2019 (the “8% Senior Notes”), which were issued in a private placement. The net proceeds from this issuance, together with available cash on hand, were used to finance the purchase of up to $1.0 billion aggregate principal amount of CHS’ then outstanding 8 ⁷⁄₈% Senior Notes and related fees and expenses. On March 21, 2012, CHS completed the secondary offering of an additional $1.0 billion aggregate principal amount of 8% Senior Notes, which were issued in a private placement (at a premium of 102.5%). The net proceeds from this issuance were used to finance the purchase of approximately $850 million aggregate principal amount of CHS’ then outstanding 8 ⁷⁄₈% Senior Notes, to pay related fees and expenses and for general corporate purposes. The 8% Senior Notes bear interest at 8% per annum, payable semiannually in arrears on May 15 and November 15, commencing May 15, 2012. Interest on the 8% Senior Notes accrues from the date of original issuance. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months.

On and after November 15, 2015, CHS is entitled, at its option, to redeem all or a portion of the 8% Senior Notes upon not less than 30 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below:

Period	Redemption Price
November 15, 2015 to November 14, 2016		104.000 %
November 15, 2016 to November 14, 2017		102.000 %
November 15, 2017 to November 15, 2019		100.000 %

Pursuant to a registration rights agreement entered into at the time of the issuance of the 8% Senior Notes, as a result of an exchange offer made by CHS, substantially all of the 8% Senior Notes issued in November 2011 and March 2012 were exchanged in May 2012 for new notes (the “8% Exchange Notes”) having terms substantially identical in all material respects to the 8% Senior Notes (except that the 8% Exchange Notes were issued under a registration statement pursuant to the Securities Act of 1933, as amended (the “1933 Act”)). References to the 8% Senior Notes shall also be deemed to include the 8% Exchange Notes unless the context provides otherwise.

7 ¹⁄₈% Senior Notes due 2020

On July 18, 2012, CHS completed an underwritten public offering under its automatic shelf registration filed with the SEC of $1.2 billion aggregate principal amount of 7 ¹⁄₈% Senior Notes due 2020 (the “7 ¹⁄₈% Senior Notes”). The net proceeds from this issuance were used to finance the purchase or redemption of $934 million aggregate principal amount plus accrued interest of CHS’ outstanding 8 ⁷⁄₈% Senior Notes, to pay for consents delivered in connection therewith, to pay related fees and expenses, and for general corporate purposes. The 7 ¹⁄₈% Senior Notes bear interest at 7.125% per annum, payable semiannually in arrears on July 15 and January 15, commencing January 15, 2013. Interest on the 7 ¹⁄₈% Senior Notes accrues from the date of original issuance. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months.

Except as set forth below, CHS is not entitled to redeem the 7 ¹⁄₈% Senior Notes prior to July 15, 2016.

Prior to July 15, 2016, CHS may redeem some or all of the 7 ¹⁄₈% Senior Notes at a redemption price equal to 100% of the principal amount of the notes redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the 7 ¹⁄₈% Senior Notes indenture. On and after July 15, 2016, CHS is entitled, at its option, to redeem all or a portion of the 7 ¹⁄₈% Senior Notes upon not less than 30 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below:

22

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Period	Redemption Price
July 15, 2016 to July 14, 2017		103.563 %
July 15, 2017 to July 14, 2018		101.781 %
July 15, 2018 to July 15, 2020		100.000 %

5 ¹⁄₈% Senior Secured Notes due 2018

On August 17, 2012, CHS completed an underwritten public offering under its automatic shelf registration filed with the SEC of $1.6 billion aggregate principal amount of 5 ¹⁄₈% Senior Secured Notes due 2018 (the “2018 Senior Secured Notes”). The net proceeds from this issuance, together with available cash on hand, were used to finance the prepayment of $1.6 billion of the outstanding term loans due 2014 under the Credit Facility and related fees and expenses. The 2018 Senior Secured Notes bear interest at 5.125% per annum, payable semiannually in arrears on August 15 and February 15, commencing February 15, 2013. Interest on the 2018 Senior Secured Notes accrues from the date of original issuance. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months. The 2018 Senior Secured Notes are secured by a first-priority lien subject to a shared lien of equal priority with certain other obligations, including obligations under the Credit Facility, and subject to prior ranking liens permitted by the indenture governing the 2018 Senior Secured Notes on substantially the same assets, subject to certain exceptions, that secure CHS’ obligations under the Credit Facility.

On and after August 15, 2015, CHS is entitled, at its option, to redeem all or a portion of the 2018 Senior Secured Notes upon not less than 30 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below:

Period	Redemption Price
August 15, 2015 to August 14, 2016		102.563 %
August 15, 2016 to August 14, 2017		101.281 %
August 15, 2017 to August 15, 2018		100.000 %

5 ¹⁄₈% Senior Secured Notes due 2021

On January 27, 2014, CHS issued $1.0 billion aggregate principal amount of 5 ¹⁄₈% Senior Secured Notes due 2021 (the “2021 Senior Secured Notes”) in connection with the HMA merger, which were issued in a private placement. The net proceeds from this issuance were used to finance the HMA merger. The 2021 Senior Secured Notes bear interest at 5.125% per annum, payable semiannually in arrears on February 1 and August 1, commencing August 1, 2014. Interest on the 2021 Senior Secured Notes accrues from the date of original issuance. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months. The 2021 Senior Secured Notes are secured by a first-priority lien, subject to a shared lien of equal priority with certain other obligations, including obligations under the Credit Facility, and subject to prior ranking liens permitted by the indenture governing the 2021 Senior Secured Notes, on substantially the same assets, subject to certain exceptions, that secure CHS’ obligations under the Credit Facility.

Except as set forth below, CHS is not entitled to redeem the 2021 Senior Secured Notes prior to February 1, 2017.

Prior to February 1, 2017, CHS is entitled, at its option, to redeem a portion of the 2021 Senior Secured Notes (not to exceed 40% of the outstanding principal amount) at a redemption price equal to 105.125% of the principal amount of the notes redeemed plus accrued and unpaid interest, with the proceeds from certain equity offerings. Prior to February 1, 2017, CHS may redeem some or all of the 2021 Senior Secured Notes at a redemption price equal to 100% of the principal amount of the notes redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the 2021 Senior Secured Notes indenture. On and after February 1, 2017, CHS is entitled, at its option, to redeem all or a portion of the 2021 Senior Secured Notes upon not less than 30 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below:

23

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Period	Redemption Price
February 1, 2017 to January 31, 2018		103.844 %
February 1, 2018 to January 31, 2019		102.563 %
February 1, 2019 to January 31, 2020		101.281 %
February 1, 2020 to January 31, 2021		100.000 %

Pursuant to a registration rights agreement entered into at the time of the issuance of the 2021 Senior Secured Notes, as a result of an exchange offer made by CHS, all of the 2021 Senior Secured Notes issued in January 2014 were exchanged in October 2014 for new notes (the “2021 Exchange Notes”) having terms substantially identical in all material respects to the 2021 Senior Secured Notes (except that the exchange notes were issued under a registration statement pursuant to the 1933 Act). References to the 2021 Senior Secured Notes shall be deemed to be the 2021 Exchange Notes unless the context provides otherwise.

6 ⁷⁄₈% Senior Notes due 2022

On January 27, 2014, CHS issued $3.0 billion aggregate principal amount of 6 ⁷⁄₈% Senior Notes due 2022 (the “6 ⁷⁄₈% Senior Notes”) in connection with the HMA merger, which were issued in a private placement. The net proceeds from this issuance were used to finance the HMA merger. The 6 ⁷⁄₈% Senior Notes bear interest at 6.875% per annum, payable semiannually in arrears on February 1 and August 1, commencing August 1, 2014. Interest on the 6 ⁷⁄₈% Senior Notes accrues from the date of original issuance. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months.

Except as set forth below, CHS is not entitled to redeem the 6 ⁷⁄₈% Senior Notes prior to February 1, 2018.

Prior to February 1, 2017, CHS is entitled, at its option, to redeem a portion of the 6 ⁷⁄₈% Senior Notes (not to exceed 40% of the outstanding principal amount) at a redemption price equal to 106.875% of the principal amount of the notes redeemed plus accrued and unpaid interest, with the proceeds from certain public equity offerings. Prior to February 1, 2018, CHS may redeem some or all of the 6 ⁷⁄₈% Senior Notes at a redemption price equal to 100% of the principal amount of the notes redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the 6 ⁷⁄₈% Senior Notes indenture. On and after February 1, 2018, CHS is entitled, at its option, to redeem all or a portion of the 6 ⁷⁄₈% Senior Notes upon not less than 30 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below:

Period	Redemption Price
February 1, 2018 to January 31, 2019		103.438 %
February 1, 2019 to January 31, 2020		101.719 %
February 1, 2020 to January 31, 2022		100.000 %

Pursuant to a registration rights agreement entered into at the time of the issuance of the 6 ⁷⁄₈% Senior Notes, as a result of an exchange offer made by CHS, all of the 6 ⁷⁄₈% Senior Notes issued in January 2014 were exchanged in October 2014 for new notes (the “6 ⁷⁄₈% Exchange Notes”) having terms substantially identical in all material respects to the 6 ⁷⁄₈% Senior Notes (except that the exchange notes were issued under a registration statement pursuant to the 1933 Act). References to the 6 ⁷⁄₈% Senior Notes shall be deemed to be the 6 ⁷⁄₈% Exchange Notes unless the context provides otherwise.

24

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Receivables Facility

On March 21, 2012, through certain of its subsidiaries, CHS entered into an accounts receivable loan agreement (the “Receivables Facility”) with a group of lenders and banks, Credit Agricolé Corporate and Investment Bank, as a managing agent and as the administrative agent, and The Bank of Nova Scotia, as a managing agent. On March 7, 2013, CHS and certain of its subsidiaries amended the Receivables Facility to add an additional managing agent, The Bank of Tokyo-Mitsubishi UFJ, Ltd., to increase the size of the facility from $300 million to $500 million and to extend the scheduled termination date. Additional subsidiaries also agreed to participate in the Receivables Facility as of that date. On March 31, 2014, CHS and certain of its subsidiaries amended the Receivables Facility to increase the size of the facility from $500 million to $700 million and to extend the scheduled termination date. Additional subsidiaries also agreed to participate in the Receivables Facility as of that date. On November 13, 2015, CHS and certain of its subsidiaries amended the Receivables Facility to extend the scheduled termination date and amend certain other provisions thereof. The existing and future non-self pay patient-related accounts receivable (the “Receivables”) for certain affiliated hospitals serve as collateral for the outstanding borrowings under the Receivables Facility. The interest rate on the borrowings is based on the commercial paper rate plus an applicable interest rate spread. Unless earlier terminated or subsequently extended pursuant to its terms, the Receivables Facility will expire on November 13, 2017, subject to customary termination events that could cause an early termination date. CHS maintains effective control over the Receivables because, pursuant to the terms of the Receivables Facility, the Receivables are sold from certain of CHS’ subsidiaries to CHS, and CHS then sells or contributes the Receivables to a special-purpose entity that is wholly-owned by CHS. The wholly-owned special-purpose entity in turn grants security interests in the Receivables in exchange for borrowings obtained from the group of third-party lenders and banks of up to $700 million outstanding from time to time based on the availability of eligible Receivables and other customary factors. The group of third-party lenders and banks do not have recourse to CHS or its subsidiaries beyond the assets of the wholly-owned special-purpose entity that collateralizes the loan. The Receivables and other assets of the wholly-owned special-purpose entity will be available first and foremost to satisfy the claims of the creditors of such entity. The outstanding borrowings pursuant to the Receivables Facility at March 31, 2016 totaled $699 million and are classified as long-term debt on the condensed consolidated balance sheet. At March 31, 2016, the carrying amount of Receivables included in the Receivables Facility totaled approximately $1.7 billion and is included in patient accounts receivable on the condensed consolidated balance sheet.

The Company has transitioned all of its hospitals to the ICD-10 coding system, which was required of all healthcare providers covered by the Health Insurance Portability and Accountability Act (“HIPAA”). This transition involved a significant capital investment in technology and coding of the Company’s information systems, as well as significant costs related to training of staff involved with coding and billing. As noted in the Company’s 2015 Annual Report on Form 10-K, the potential for delay in billing and collection on patient receivables resulting from these changes or from new payment systems and processes implemented by third-party payors could have an adverse effect on the quality of receivables that serve as collateral under the Receivables Facility, resulting in a potential default or repayment of outstanding borrowings. Should such a repayment of borrowings under the Receivables Facility be required, the Company has availability, and expects that it will continue to have availability, under its Revolving Facility to provide sufficient financial resources and liquidity to fund the repayment.

Loss from Early Extinguishment of Debt

The financing transactions discussed above resulted in a loss from the early extinguishment of debt of $8 million for the three months ended March 31, 2015, and an after-tax loss of $5 million for the three months ended March 31, 2015.

Other Debt

As of March 31, 2016, other debt consisted primarily of the mortgage obligation on the Company’s corporate headquarters and other obligations maturing in various installments through 2020.

25

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

To limit the effect of changes in interest rates on a portion of the Company’s long-term borrowings, the Company is a party to 15 separate interest swap agreements in effect at March 31, 2016, with an aggregate notional amount for currently effective swaps of $3.5 billion. On each of these swaps, the Company receives a variable rate of interest based on the three-month LIBOR in exchange for the payment of a fixed rate of interest. The Company currently pays, on a quarterly basis, interest on the Revolving Facility and the Term A Facility at a rate per annum equal to LIBOR plus 2.75%. Loans in respect of the Term F Facility accrue interest at a rate per annum equal to LIBOR plus 3.25%. The Term G Loan and Term H Loan accrue interest at a rate per annum equal to LIBOR plus 2.75% and 3.00%, in the case of LIBOR borrowings, respectively, and Alternate Base Rate plus 1.75% and 2.00%, respectively, in the case of Alternate Base Rate Borrowings. The Term G Loan and the Term H Loan are subject to a 1.00% LIBOR floor and a 2.00% Alternate Base Rate floor. See Note 13 for additional information regarding these swaps.

The Company paid interest of $307 million and $300 million on borrowings during the three months ended March 31, 2016 and 2015, respectively.

13. FAIR VALUE OF FINANCIAL INSTRUMENTS

The fair value of financial instruments has been estimated by the Company using available market information as of March 31, 2016 and December 31, 2015, and valuation methodologies considered appropriate. The estimates presented in the table below are not necessarily indicative of amounts the Company could realize in a current market exchange (in millions):

	March 31, 2016				December 31, 2015
	Carrying     Amount		Estimated Fair     Value		Carrying     Amount		Estimated Fair     Value
Assets:
Cash and cash equivalents	$	181	$	181	$	184	$	184
Available-for-sale securities		268		268		271		271
Trading securities		63		63		61		61
Liabilities:
Contingent Value Right		2		2		2		2
Credit Facility		7,255		7,255		7,114		7,115
8% Senior Notes		1,993		1,954		1,992		2,018
7 1⁄8% Senior Notes		1,187		1,141		1,186		1,193
2018 Senior Secured Notes		1,588		1,615		1,587		1,610
2021 Senior Secured Notes		968		1,010		967		997
6 7⁄8% Senior Notes		2,924		2,715		2,921		2,858
Receivables Facility and other debt		780		780		791		791

The estimated fair value is determined using the methodologies discussed below in accordance with accounting standards related to the determination of fair value based on the U.S. GAAP fair value hierarchy as discussed in Note 14. The estimated fair value for financial instruments with a fair value that does not equal its carrying value is considered a Level 1 valuation. The Company utilizes the market approach and obtains indicative pricing from the administrative agent to the Credit Facility to determine fair values or through publicly available subscription services such as Bloomberg where relevant.

Cash and cash equivalents. The carrying amount approximates fair value due to the short-term maturity of these instruments (less than three months).

Available-for-sale securities. Estimated fair value is based on closing price as quoted in public markets or other various valuation techniques.

Trading securities. Estimated fair value is based on closing price as quoted in public markets.

Contingent Value Right. Estimated fair value is based on the closing price as quoted on the public market where the CVR is traded.

26

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Credit Facility. Estimated fair value is based on publicly available trading activity and supported with information from the Company’s bankers regarding relevant pricing for trading activity among the Company’s lending institutions.

8% Senior Notes. Estimated fair value is based on the closing market price for these notes.

7 ¹⁄₈% Senior Notes. Estimated fair value is based on the closing market price for these notes.

2018 Senior Secured Notes. Estimated fair value is based on the closing market price for these notes.

2021 Senior Secured Notes. Estimated fair value is based on the closing market price for these notes.

6 ⁷⁄₈% Senior Notes. Estimated fair value is based on the closing market price for these notes.

Receivables Facility and other debt. The carrying amount of the Receivables Facility and all other debt approximates fair value due to the nature of these obligations.

Interest rate swaps. The fair value of interest rate swap agreements is the amount at which they could be settled, based on estimates calculated by the Company using a discounted cash flow analysis based on observable market inputs and validated by comparison to estimates obtained from the counterparty. The Company incorporates credit valuation adjustments (“CVAs”) to appropriately reflect both its own nonperformance or credit risk and the respective counterparty’s nonperformance or credit risk in the fair value measurements. In adjusting the fair value of its interest rate swap agreements for the effect of nonperformance or credit risk, the Company has considered the impact of any netting features included in the agreements.

The Company assesses the effectiveness of its hedge instruments on a quarterly basis. For the three months ended March 31, 2016 and 2015, the Company completed an assessment of the cash flow hedge instruments and determined the hedges to be highly effective. The Company has also determined that the ineffective portion of the hedges do not have a material effect on the Company’s consolidated financial position, operations or cash flows. The counterparties to the interest rate swap agreements expose the Company to credit risk in the event of nonperformance. However, at March 31, 2016, all of the swap agreements entered into by the Company were in a net liability position such that the Company would be required to make the net settlement payments to the counterparties; the Company does not anticipate nonperformance by those counterparties. The Company does not hold or issue derivative financial instruments for trading purposes.

27

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Interest rate swaps consisted of the following at March 31, 2016:

Swap #	Notional Amount     (in millions)		Fixed Interest Rate		Termination Date		Fair Value             (in  millions)
1	$	300		3.447 %		August 6, 2016	$	3
2		100		3.401 %		August 19, 2016		1
3		200		3.429 %		August 19, 2016		2
4		200		3.500 %		August 30, 2016		2
5		100		3.005 %		November 30, 2016		2
6		200		2.055 %		July 25, 2019		7
7		200		2.059 %		July 25, 2019		7
8		400		1.882 %		August 30, 2019		7
9		200		2.515 %		August 30, 2019		8
10		200		2.613 %		August 30, 2019		8
11		300		2.041 %		August 30, 2020		7
12		300		2.738 %		August 30, 2020		16
13		300		2.892 %		August 30, 2020		17
14		300		2.363 %		January 27, 2021		11
15		200		2.368 %		January 27, 2021		7

The Company is exposed to certain risks relating to its ongoing business operations. The risk managed by using derivative instruments is interest rate risk. Interest rate swaps are entered into to manage interest rate fluctuation risk associated with the term loans in the Credit Facility. Companies are required to recognize all derivative instruments as either assets or liabilities at fair value in the condensed consolidated statement of financial position. The Company designates its interest rate swaps as cash flow hedges. For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of the gain or loss on the derivative is reported as a component of other comprehensive income (“OCI”) and reclassified into earnings in the same period or periods during which the hedged transactions affect earnings. Gains and losses on the derivative representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current earnings.

Assuming no change in March 31, 2016 interest rates, approximately $46 million of interest expense resulting from the spread between the fixed and floating rates defined in each interest rate swap agreement will be recognized during the next 12 months. If interest rate swaps do not remain highly effective as a cash flow hedge, the derivatives’ gains or losses resulting from the change in fair value reported through OCI will be reclassified into earnings.

The following tabular disclosure provides the amount of pre-tax loss recognized as a component of OCI during the three months ended March 31, 2016 and 2015 (in millions):

	Amount of Pre-Tax Loss Recognized in
	OCI (Effective Portion)
Derivatives in Cash Flow Hedging Relationships	Three Months Ended March 31,
	2016		2015
Interest rate swaps	$	(43)	$	(22)

28

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

The following tabular disclosure provides the location of the effective portion of the pre-tax loss reclassified from accumulated other comprehensive loss (“AOCL”) into interest expense on the condensed consolidated statements of income during the three months ended March 31, 2016 and 2015 (in millions):

	Amount of Pre-Tax Loss Reclassified from
Location of Loss Reclassified from	AOCL into Income (Effective Portion)
AOCL into Income (Effective Portion)	Three Months Ended March 31,
	2016		2015
Interest expense, net	$	14	$	9

The fair values of derivative instruments in the condensed consolidated balance sheets as of March 31, 2016 and December 31, 2015 were as follows (in millions):

Asset Derivatives

Liability Derivatives

March 31, 2016

December 31, 2015

March 31, 2016

December 31, 2015

Balance Sheet Location

Fair   Value

Balance Sheet Location

Fair   Value

Balance Sheet Location

Fair   Value

Balance Sheet Location

Fair   Value

Derivatives designated as hedging instruments

Other assets, net

$

-

Other assets, net

$

-

Other long-term liabilities

$

105

Other long-term liabilities

$

76

14. FAIR VALUE

Fair Value Hierarchy

Fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, the Company utilizes the U.S. GAAP fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumption about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy).

The inputs used to measure fair value are classified into the following fair value hierarchy:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 includes values determined using pricing models, discounted cash flow methodologies, or similar techniques reflecting the Company’s own assumptions.

In instances where the determination of the fair value hierarchy measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment of factors specific to the asset or liability. Transfers between levels within the fair value hierarchy are recognized by the Company on the date of the change in circumstances that requires such transfer. There were no transfers between levels during the three month periods ending March 31, 2016 or March 31, 2015.

29

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

The following table sets forth, by level within the fair value hierarchy, the financial assets and liabilities recorded at fair value on a recurring basis as of March 31, 2016 and December 31, 2015 (in millions):

	March 31, 2016		Level 1		Level 2		Level 3
Available-for-sale securities	$	268	$	154	$	114	$	-
Trading securities		63		63		-		-
Total assets	$	331	$	217	$	114	$	-
Contingent Value Right (CVR)	$	2	$	2	$	-	$	-
CVR-related liability		261		-		-		261
Fair value of interest rate swap agreements		105		-		105		-
Total liabilities	$	368	$	2	$	105	$	261
	December 31, 2015		Level 1		Level 2		Level 3
Available-for-sale securities	$	271	$	155	$	116	$	-
Trading securities		61		61		-		-
Total assets	$	332	$	216	$	116	$	-
Contingent Value Right (CVR)	$	2	$	2	$	-	$	-
CVR-related liability		261		-		-		261
Fair value of interest rate swap agreements		76		-		76		-
Total liabilities	$	339	$	2	$	76	$	261

Available-for-sale Securities

Available-for-sale securities and trading securities classified as Level 1 are measured using quoted market prices. Level 2 available-for-sale securities primarily consisted of: (i) bonds and notes issued by the United States government and its agencies, domestic and foreign corporations and foreign governments; and (ii) preferred securities issued by domestic and foreign corporations. The estimated fair values of these securities are determined using various valuation techniques, including a multi-dimensional relational model that incorporates standard observable inputs and assumptions such as benchmark yields, reported trades, broker/dealer quotes, issuer spreads, benchmark securities, bids/offers and other pertinent reference data.

Contingent Value Right (CVR)

The CVR represents the estimate of the fair value for the contingent consideration paid to HMA shareholders as part of the HMA merger. The CVR is listed on the NASDAQ and the valuation at March 31, 2016 is based on the quoted trading price for the CVR on the last day of the period. Changes in the estimated fair value of the CVR are recorded through the condensed consolidated statement of income.

30

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

CVR-related Liability

The CVR-related legal liability represents the Company’s estimate of fair value at March 31, 2016 of the liability associated with the legal matters assumed in the HMA merger, which are included in accrued liabilities in the accompanying condensed consolidated balance sheet. This liability did not include those matters previously accrued by HMA as a probable contingency, which were settled and paid during the year ended December 31, 2015. To develop the estimate of fair value, the Company engaged an independent third-party valuation firm to measure the liability. The valuation was made utilizing the Company’s estimates of future outcomes for each legal case and simulating future outcomes based on the timing, probability and distribution of several scenarios using a Monte Carlo simulation model. Other inputs were then utilized for discounting the liability to the measurement date. The HMA legal matters underlying this fair value estimate were evaluated by management to determine the likelihood and impact of each of the potential outcomes. Using that information, as well as the potential correlation and variability associated with each case, a fair value was determined for the estimated future cash outflows to conclude or settle the HMA legal matters included in the analysis, excluding legal fees (which are expensed as incurred). Because of the unobservable nature of the majority of the inputs used to value the liability, the Company has classified the fair value measurement as a Level 3 measurement in the fair value hierarchy.

The fair value of the CVR-related legal liability will be measured each reporting period using similar measurement techniques, updated for the assumptions and facts existing at that date for each of the underlying legal matters. Changes in the fair value of the CVR related legal liability are recorded in future periods through the condensed consolidated statement of income.

Fair Value of Interest Rate Swap Agreements

The valuation of the Company’s interest rate swap agreements is determined using market valuation techniques, including discounted cash flow analysis on the expected cash flows of each agreement. This analysis reflects the contractual terms of the agreement, including the period to maturity, and uses observable market-based inputs, including forward interest rate curves. The fair value of interest rate swap agreements are determined by netting the discounted future fixed cash payments and the discounted expected variable cash receipts. The variable cash receipts are based on the expectation of future interest rates based on observable market forward interest rate curves and the notional amount being hedged.

The Company incorporates CVAs to appropriately reflect both its own nonperformance or credit risk and the respective counterparty’s nonperformance or credit risk in the fair value measurements. In adjusting the fair value of its interest rate swap agreements for the effect of nonperformance or credit risk, the Company has considered the impact of any netting features included in the agreements. The CVA on the Company’s interest rate swap agreements resulted in a decrease in the fair value of the related liability of $6 million and an after-tax adjustment of $4 million to OCI at March 31, 2016. The CVA on the Company’s interest rate swap agreements resulted in a decrease in the fair value of the related liability of $4 million and an after-tax adjustment of $2 million to OCI at December 31, 2015.

The majority of the inputs used to value the Company’s interest rate swap agreements, including the forward interest rate curves and market perceptions of the Company’s credit risk used in the CVAs, are observable inputs available to a market participant. As a result, the Company has determined that the interest rate swap valuations are classified in Level 2 of the fair value hierarchy.

15. SEGMENT INFORMATION

The Company operates in two distinct operating segments, represented by hospital operations (which includes its general acute care hospitals and related healthcare entities that provide inpatient and outpatient healthcare services) and home care agency operations (which provide in-home outpatient care).

Only the hospital operations segment meets the criteria as a separate reportable segment. The financial information for the home care agency segment does not meet the quantitative thresholds for a separate identifiable reportable segment and is combined into the corporate and all other reportable segment.

31

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

The distribution between reportable segments of the Company’s net operating revenues and income from continuing operations before income taxes is summarized in the following tables (in millions):

	Three Months Ended March 31,
	2016		2015
Net operating revenues:
Hospital operations	$	4,944	$	4,857
Corporate and all other		55		54
Total	$	4,999	$	4,911
Income from continuing operations before income taxes:
Hospital operations	$	143	$	273
Corporate and all other		(80)		(105)
Total	$	63	$	168

16. OTHER COMPREHENSIVE INCOME

The following tables present information about items reclassified out of accumulated other comprehensive income (loss) by component for the three months ended March 31, 2016 and 2015 (in millions, net of tax):

	Change in Fair Value of Interest Rate Swaps		Change in Fair Value of Available for Sale Securities		Change in Unrecognized Pension Cost Components		Accumulated Other Comprehensive Income (Loss)
Balance as of December 31, 2015	$	(48)	$	1	$	(26)	$	(73)
Other comprehensive (loss) income before reclassifications		(28)		2		-		(26)
Amounts reclassified from accumulated other comprehensive income		9		-		1		10
Net current-period other comprehensive (loss) income		(19)		2		1		(16)
Balance as of March 31, 2016	$	(67)	$	3	$	(25)	$	(89)
	Change in Fair Value of Interest Rate Swaps		Change in Fair Value of Available for Sale Securities		Change in Unrecognized Pension Cost Components		Accumulated Other Comprehensive Income (Loss)
Balance as of December 31, 2014	$	(43)	$	7	$	(27)	$	(63)
Other comprehensive (loss) income before reclassifications		(15)		1		-		(14)
Amounts reclassified from accumulated other comprehensive income		6		-		1		7
Net current-period other comprehensive (loss) income		(9)		1		1		(7)
Balance as of March 31, 2015	$	(52)	$	8	$	(26)	$	(70)

32

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

The following tables present a subtotal for each significant reclassification to net income out of AOCL and the line item affected in the accompanying condensed consolidated statement of income for the three months ended March 31, 2016 and 2015 (in millions):

	Amount reclassified       from AOCL		Affected line item in the
Details about accumulated other comprehensive income (loss) components	Three Months Ended March 31, 2016		statement where net income is presented
Gains and losses on cash flow hedges
Interest rate swaps	$	(14)	Interest expense, net
		5	Tax benefit
	$	(9)	Net of tax
Amortization of defined benefit pension items
Prior service costs	$	(1)	Salaries and benefits
Actuarial losses		-	Salaries and benefits
		(1)	Total before tax
		-	Tax benefit
	$	(1)	Net of tax
	Amount reclassified from AOCL		Affected line item in the
Details about accumulated other comprehensive income (loss) components	Three Months Ended March 31, 2015		statement where net income is presented
Gains and losses on cash flow hedges
Interest rate swaps	$	(9)	Interest expense, net
		3	Tax benefit
	$	(6)	Net of tax
Amortization of defined benefit pension items
Prior service costs	$	-	Salaries and benefits
Actuarial losses		(1)	Salaries and benefits
		(1)	Total before tax
		-	Tax benefit
	$	(1)	Net of tax

17. CONTINGENCIES

The Company is a party to various legal, regulatory and governmental proceedings incidental to its business. Based on current knowledge, management does not believe that loss contingencies arising from pending legal, regulatory and governmental matters, including the matters described herein, will have a material adverse effect on the consolidated financial position or liquidity of the Company. However, in light of the inherent uncertainties involved in pending legal, regulatory and governmental matters, some of which are beyond the Company’s control, and the very large or indeterminate damages sought in some of these matters, an adverse outcome in one or more of these matters could be material to the Company’s results of operations or cash flows for any particular reporting period.

33

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

With respect to all legal, regulatory and governmental proceedings, the Company considers the likelihood of a negative outcome. If the Company determines the likelihood of a negative outcome with respect to any such matter is probable and the amount of the loss can be reasonably estimated, the Company records an accrual for the estimated loss for the expected outcome of the matter. If the likelihood of a negative outcome with respect to material matters is reasonably possible and the Company is able to determine an estimate of the possible loss or a range of loss, whether in excess of a related accrued liability or where there is no accrued liability, the Company discloses the estimate of the possible loss or range of loss. However, the Company is unable to estimate a possible loss or range of loss in some instances based on the significant uncertainties involved in, and/or the preliminary nature of, certain legal, regulatory and governmental matters.

In connection with the spin-off, the Company agreed to indemnify QHC for certain liabilities relating to outcomes or events occurring prior to the closing of the spin-off, including (i) certain claims and proceedings that were known to be outstanding at or prior to the consummation of the spin-off and involved multiple facilities and (ii) certain claims, proceedings and investigations by governmental authorities or private plaintiffs related to activities occurring at or related to QHC’s healthcare facilities prior to the closing date of the spin-off, but only to the extent, in the case of clause (ii), that such claims are covered by insurance policies maintained by the Company, including professional liability and employer practices. In this regard, the Company will continue to be responsible for HMA Legal Matters (as defined below) covered by the CVR agreement that relate to QHC’s business following the consummation of the spin-off, and any amounts payable by the Company in connection therewith will continue to reduce the amount payable by the Company in respect of the CVRs. Notwithstanding the foregoing, the Company will not indemnify QHC in respect of any claims or proceedings arising out of or related to the business operations of Quorum Health Resources, LLC at any time or QHC’s compliance with its corporate integrity agreement.

HMA Legal Matters and Related CVR

The CVR agreement entitles the holder to receive a one-time cash payment of up to $1.00 per CVR, subject to downward adjustment based on the final resolution of certain litigation, investigations (whether formal or informal, including subpoenas), or other actions or proceedings related to HMA or its affiliates existing on or prior to July 29, 2013 (the date of the Company’s merger agreement with HMA) as more specifically provided in the CVR agreement (all such matters are referred to as the “HMA Legal Matters”), which include, but are not limited to, investigation and litigation matters as previously disclosed by HMA in public filings with the SEC and/or as described in more detail below. The adjustment reducing the ultimate amount paid to holders of the CVR is determined based on the amount of losses incurred by the Company in connection with the HMA Legal Matters as more specifically provided in the CVR agreement, which generally includes the amount paid for damages, costs, fees and expenses (including, without limitation, attorneys’ fees and expenses), and all fines, penalties, settlement amounts, indemnification obligations and other liabilities (all such losses are referred to as “HMA Losses”). If the aggregate amount of HMA Losses exceeds a deductible of $18 million, then the amount payable in respect of each CVR shall be reduced (but not below zero) by an amount equal to the quotient obtained by dividing: (a) the product of (i) all losses in excess of the deductible and (ii) 90%; by (b) the number of CVRs outstanding on the date on which final resolution of the existing litigation occurs. There are 264,544,053 CVRs outstanding as of the date hereof. If total HMA Losses (including HMA Losses that have occurred to date as noted in the table below) exceed approximately $312 million, then the holders of the CVRs will not be entitled to any payment in respect of the CVRs.

The CVRs do not have a finite payment date. Any payments the Company makes under the CVR agreement will be payable within 60 days after the final resolution of the HMA Legal Matters. The CVRs are unsecured obligations of CHS and all payments under the CVRs will be subordinated in right of payment to the prior payment in full of all of the Company’s senior obligations (as defined in the CVR agreement), which include outstanding indebtedness of the Company (subject to certain exceptions set forth in the CVR agreement) and the HMA Losses. The CVR agreement permits the Company to acquire all or some of the CVRs, whether in open market transactions, private transactions or otherwise. As of March 31, 2016, the Company had acquired no CVRs.

34

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

The following table represents the impact of legal expenses paid or incurred to date and settlements paid or deemed final as of March 31, 2016 on the amounts owed to CVR holders (in millions):

			Allocation of Expenses and Settlements Paid
	Total Expenses     and Settlement Cost		Deductible		CHS      Responsibility      at 10%		Reduction to      Amount Owed      to CVR Holders at 90%
As of December 31, 2015	$	58	$	18	$	4	$	36
Settlements paid		-		-		-		-
Legal expenses incurred and/or paid during the three months ended March 31, 2016		1		-		-		1
As of March 31, 2016	$	59	$	18	$	4	$	37

Amounts owed to CVR holders are dependent on the ultimate resolution of the HMA Legal Matters and determination of HMA Losses incurred. The settlement of any or all of the claims and expenses incurred on behalf of the Company in defending itself will (subject to the deductible) reduce the amounts owed to the CVR holders.

Underlying the CVR agreement are a number of claims included in the HMA Legal Matters asserted against HMA. The Company has recorded a liability in connection with those claims as part of the acquired assets and liabilities at the date of acquisition pursuant to the provisions of Financial Accounting Standards Board Accounting Standards Codification Topic 805 “Business Combinations.” For the estimate of the Company’s liabilities associated with the HMA Legal Matters that will be covered by the CVR and were not previously accrued by HMA, the Company recorded a liability of $284 million as part of the acquisition accounting for the HMA merger based on the Company’s estimate of fair value of such liabilities as of the date of acquisition. There was no change in the liability during the three months ended March 31, 2016 and the fair value of such liabilities of $261 million as of March 31, 2016 is recorded in other long-term liabilities on the accompanying condensed consolidated balance sheet. As of March 31, 2016, there is currently no accrual recorded for the probable contingency claims underlying the CVR agreement. The estimated liability for probable contingency claims underlying the CVR agreement that was previously recorded by HMA, and reflected in the purchase accounting for HMA as an acquired liability has been settled and was paid during the year ended December 31, 2015. In addition, although legal fees are not included in the amounts currently accrued, such legal fees are taken into account in determining HMA Losses under the CVR agreement. Certain significant HMA Legal Matters underlying these liabilities are discussed in greater detail below.

35

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

HMA Matters Recorded at Fair Value

Medicare/Medicaid Billing Lawsuits

Beginning during the week of December 16, 2013, eleven qui tam lawsuits filed by private individuals against HMA were unsealed in various United States district courts. The United States has elected to intervene in all or part of eight of these matters; namely U.S. ex rel. Craig Brummer v. Health Management Associates, Inc. et al. (Middle District Georgia) (“Brummer”); U.S. ex rel. Ralph D. Williams v. Health Management Associates, Inc. et al. (Middle District Georgia) (“Williams”); U.S. ex rel. Scott H. Plantz, M.D. et al. v. Health Management Associates, Inc., et al. (Northern District Illinois) (“Plantz”); U.S. ex rel. Thomas L. Mason, M.D. et al. v. Health Management Associates, Inc. et al. (Western District North Carolina) (“Mason”); U.S. ex rel. Jacqueline Meyer, et al. v. Health Management Associates, Inc., Gary Newsome et al. (“Jacqueline Meyer”) (District of South Carolina); U.S. ex rel. George Miller, et al. v. Health Management Associates, Inc. (Eastern District of Pennsylvania) (“Miller”); U.S. ex rel. Bradley Nurkin v. Health Management Associates, Inc. et al. (Middle District of Florida) (“Nurkin”); and U.S. ex rel. Paul Meyer v. Health Management Associates, Inc. et al. (Southern District Florida) (“Paul Meyer”). The United States has elected to intervene with respect to allegations in these cases that certain HMA hospitals inappropriately admitted patients and then submitted reimbursement claims for treating those individuals to federal healthcare programs in violation of the False Claims Act or that certain HMA hospitals had inappropriate financial relationships with physicians which violated the Stark law, the Anti-Kickback Statute, and the False Claims Act. Certain of these complaints also allege the same actions violated various state laws which prohibit false claims. The United States has declined to intervene in three of the eleven matters, namely U.S. ex rel. Anita France, et al. v. Health Management Associates, Inc. (Middle District Florida) (“France”) which involved allegations of wrongful billing and was settled; U.S. ex rel. Sandra Simmons v. Health Management Associates, Inc. et al. (Eastern District Oklahoma) (“Simmons”) which alleges unnecessary surgery by an employed physician and which was settled as to all allegations except alleged wrongful termination; and U.S. ex rel. David Napoliello, M.D. v. Health Management Associates, Inc. (Middle District Florida) (“Napoliello”) which alleges inappropriate admissions. On April 3, 2014, the Multi District Litigation Panel ordered the transfer and consolidation for pretrial proceedings of the eight intervened cases, plus the Napoliello matter, to the District of the District of Columbia under the name In Re: Health Management Associates, Inc. Qui Tam Litigation. On June 2, 2014, the court entered a stay of this matter until October 6, 2014, which was subsequently extended until February 27, 2015, May 27, 2015, September 25, 2015, January 25, 2016, and now until May 25, 2016. The Company intends to defend against the allegations in these matters, but also continues to cooperate with the government in the ongoing investigation of these allegations. The Company has been in discussions with the Civil Division of the United States Department of Justice (“DOJ”) regarding the resolutions of these matters. During the first quarter of 2015, the Company was informed that the Criminal Division continues to investigate former executive-level employees of HMA, and continues to consider whether any HMA entities should be held criminally liable for the acts of the former HMA employees. The Company is voluntarily cooperating with these inquiries and has not been served with any subpoenas or other legal process.

Summary of Recorded Amounts

The table below presents a reconciliation of the beginning and ending liability balances (in millions) during the three months ended March 31, 2016 with respect to the Company’s fair value determination in connection with HMA Legal Matters that were not previously accrued by HMA, the estimated liability in connection with HMA Legal Matters that were previously recorded by HMA as a probable contingency, and the remaining contingencies of the Company in respect of which an accrual has been recorded. In addition, future legal fees (which are expensed as incurred) and costs related to possible indemnification and criminal investigation matters associated with the HMA Legal Matters have not been accrued or included in the table below. Furthermore, although not accrued, such costs, if incurred, will be taken into account in determining the total amount of reductions applied to the amounts owed to CVR holders.

	CVR Related         Liability at  Fair Value		CVR Related Liability for Probable Contingencies		Other Probable       Contingencies
Balance as of December 31, 2015	$	261	$	-	$	10
Expense (income)		-		-		-
Cash payments		-		-		(3)
Balance as of March 31, 2016	$	261	$	-	$	7

36

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

With respect to the “Other Probable Contingencies” referenced in the chart above, in accordance with applicable accounting guidance, the Company establishes a liability for litigation, regulatory and governmental matters for which, based on information currently available, the Company believes that a negative outcome is known or is probable and the amount of the loss is reasonably estimable. For all such matters (whether or not discussed in this contingencies footnote), such amounts have been recorded in other accrued liabilities on the condensed consolidated balance sheet and are included in the table above in the “Other Probable Contingencies” column. Due to the uncertainties and difficulty in predicting the ultimate resolution of these contingencies, the actual amount could differ from the estimated amount reflected as a liability on the condensed consolidated balance sheet.

In the aggregate, attorneys’ fees and other costs incurred but not included in the table above related to probable contingencies, and CVR-related contingencies accounted for at fair value, totaled $1 million and $4 million for the three months ended March 31, 2016 and 2015, respectively, and are included in other operating expenses in the accompanying condensed consolidated statements of income.

Matters for which an Outcome Cannot be Assessed

For all of the legal matters below, the Company cannot at this time assess what the outcome may be and is further unable to determine any estimate of loss or range of loss. Because the matters below are at a preliminary stage and other factors, there are not sufficient facts available to make these assessments.

Class Action Shareholder Federal Securities Cases. Three purported class action cases have been filed in the United States District Court for the Middle District of Tennessee; namely, Norfolk County Retirement System v. Community Health Systems, Inc., et al., filed May 9, 2011; De Zheng v. Community Health Systems, Inc., et al., filed May 12, 2011; and Minneapolis Firefighters Relief Association v. Community Health Systems, Inc., et al., filed June 21, 2011. All three seek class certification on behalf of purchasers of the Company’s common stock between July 27, 2006 and April 11, 2011 and allege that misleading statements resulted in artificially inflated prices for the Company’s common stock. In December 2011, the cases were consolidated for pretrial purposes and NYC Funds and its counsel were selected as lead plaintiffs/lead plaintiffs’ counsel. In lieu of ruling on the Company’s motion to dismiss, the court permitted the plaintiffs to file a first amended consolidated class action complaint, which was filed on October 5, 2015. The Company’s motion to dismiss was filed on November 4, 2015 and oral argument was held on April 11, 2016. Discovery is also continuing. The Company believes this consolidated matter is without merit and will vigorously defend this case.

Shareholder Derivative Actions. Three purported shareholder derivative actions have also been filed in the United States District Court for the Middle District of Tennessee; Plumbers and Pipefitters Local Union No. 630 Pension Annuity Trust Fund v. Wayne T. Smith, et al., filed May 24, 2011; Roofers Local No. 149 Pension Fund v. Wayne T. Smith, et al., filed June 21, 2011; and Lambert Sweat v. Wayne T. Smith, et al., filed October 5, 2011. These three cases allege breach of fiduciary duty arising out of allegedly improper inpatient admission practices, mismanagement, waste and unjust enrichment. These cases have been consolidated into a single, consolidated action. The plaintiffs filed an operative amended derivative complaint in these three consolidated actions on March 15, 2012. The Company’s motion to dismiss was argued on June 13, 2013. On September 27, 2013, the court issued an order granting in part and denying in part the Company’s motion to dismiss. An initial case management order was entered on November 11, 2014, but no trial date has been set. Discovery is continuing. The Company believes all of the plaintiffs’ claims are without merit and will vigorously defend them.

18. SUBSEQUENT EVENTS

The Company evaluated all material events occurring subsequent to the balance sheet date for events requiring disclosure or recognition in the condensed consolidated financial statements.

On April 29, 2016, the Company completed the spin-off of QHC and distributed, on a pro rata basis, all of the shares of QHC common stock to the Company’s stockholders of record as of April 22, 2016. These stockholders of record as of April 22, 2016 received a distribution of one share of QHC common stock for every four shares of Company common stock held as of the record date plus cash in lieu of any fractional shares. Immediately following the completion of the spin-off, the Company’s stockholders owned 100% of the outstanding shares of QHC common stock. Following the spin-off, QHC became an independent public company with its common stock listed for trading under the symbol “QHC” on the New York Stock Exchange.

37

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

In connection with the spin-off, the Company and QHC entered into a separation and distribution agreement as well as certain ancillary agreements on April 29, 2016. These agreements allocate between the Company and QHC the various assets, employees, liabilities and obligations (including investments, property and employee benefits and tax-related assets and liabilities) that comprise the separate companies and govern certain relationships between, and activities of, the Company and QHC for a period of time after the spin-off.

Pursuant to a special distribution paid by QHC to the Company as part of the series of transactions engaged in to complete the spin-off, the Company received approximately $1.2 billion in cash generated from the net proceeds of certain financing arrangements entered into by QHC as part of the separation. The Company has used approximately $194 million of such proceeds to repay a portion of its Term F Loans due 2018. In addition, on May 2, 2016, the Company commenced a cash tender offer for up to $900 million of its approximately $1.6 billion aggregate principal amount outstanding of 5 ¹⁄₈% Senior Secured Notes due 2018 as noted in a press release issued by the Company on such date. The Company intends to use remaining proceeds from such special distribution to repay other outstanding debt and to pay certain expenses incurred in connection with the spin-off and such debt repayment transactions.

As part of the separation and distribution of QHC to the Company’s stockholders, the Company will record the distribution of the assets and liabilities of the QHC entities from its consolidated balance sheet on a historical cost basis as a dividend from stockholders’ equity, and no gain or loss will be recorded.

On April 1, 2016, one or more subsidiaries of the Company completed the acquisition of an 80% interest in Physicians’ Specialty Hospital (20 licensed beds), a Medicare-certified specialty surgical hospital in Fayetteville, Arkansas. The total cash consideration paid at closing was approximately $13 million.

On April 29, 2016, the Company entered into a definitive agreement with UHS to sell its unconsolidated minority equity interests in Valley Health System LLC, a joint venture with UHS representing four hospitals in Las Vegas, Nevada, in which the Company owns a 27.5% interest, and in Summerlin Hospital Medical Center LLC, a joint venture with UHS representing one hospital in Las Vegas, Nevada, in which the Company owns a 26.1% interest. The Company will receive $445 million in cash from UHS in return for the sale of its equity interests in the second quarter of 2016.

19. SUPPLEMENTAL CONDENSED CONSOLIDATING FINANCIAL INFORMATION

The Senior Notes due 2019, 2020 and 2022, which are senior unsecured obligations of CHS, and the 5 ¹⁄₈% Senior Secured Notes due 2018 and 2021 (collectively, “the Notes”) are guaranteed on a senior basis by the Company and by certain of its existing and subsequently acquired or organized 100% owned domestic subsidiaries. The Notes are fully and unconditionally guaranteed on a joint and several basis, with exceptions considered customary for such guarantees, limited to the release of the guarantee when a subsidiary guarantor’s capital stock is sold, or a sale of all of the subsidiary guarantor’s assets used in operations. The following condensed consolidating financial statements present Community Health Systems, Inc. (as parent guarantor), CHS (as the issuer), the subsidiary guarantors, the subsidiary non-guarantors and eliminations. These condensed consolidating financial statements have been prepared and presented in accordance with SEC Regulation S-X Rule 3-10 “Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered.”

The accounting policies used in the preparation of this financial information are consistent with those elsewhere in the condensed consolidated financial statements of the Company, except as noted below:

• Intercompany receivables and payables are presented gross in the supplemental condensed consolidating balance sheets.

• Cash flows from intercompany transactions are presented in cash flows from financing activities, as changes in intercompany balances with affiliates, net.

• Income tax expense is allocated from the parent guarantor to the income producing operations (other guarantors and non-guarantors) and the issuer through stockholders’ equity. As this approach represents an allocation, the income tax expense allocation is considered non-cash for statement of cash flow purposes.

• Interest expense, net has been presented to reflect net interest expense and interest income from outstanding long-term debt and intercompany balances.

38

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

The Company’s intercompany activity consists primarily of daily cash transfers for purposes of cash management, the allocation of certain expenses and expenditures paid for by the Parent on behalf of its subsidiaries, and the push down of investment in its subsidiaries. This activity also includes the intercompany transactions between consolidated entities as part of the Receivables Facility that is further discussed in Note 12. The Company’s subsidiaries generally do not purchase services from one another; thus, the intercompany transactions do not represent revenue generating transactions. All intercompany transactions eliminate in consolidation.

From time to time, subsidiaries of the Company sell and/or repurchase noncontrolling interests in consolidated subsidiaries, which may change subsidiaries between guarantors and non-guarantors.

39

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Condensed Consolidating Statement of Income

Three Months Ended March 31, 2016

	Parent   Guarantor		Issuer		Other Guarantors		Non -   Guarantors		Eliminations		Consolidated
	(In millions)
Operating revenues (net of contractual allowances and discounts)	$	-	$	(6)	$	3,766	$	1,994	$	-	$	5,754
Provision for bad debts		-		-		532		223		-		755
Net operating revenues		-		(6)		3,234		1,771		-		4,999
Operating costs and expenses:
Salaries and benefits		-		-		1,282		1,035		-		2,317
Supplies		-		-		543		256		-		799
Other operating expenses		-		-		817		356		-		1,173
Electronic health records incentive reimbursement		-		-		(11)		(7)		-		(18)
Rent		-		-		65		54		-		119
Depreciation and amortization		-		-		211		87		-		298
Impairment of long-lived assets		-		-		12		5		-		17
Total operating costs and expenses		-		-		2,919		1,786		-		4,705
Income from operations		-		(6)		315		(15)		-		294
Interest expense, net		-		35		200		16		-		251
Equity in earnings of unconsolidated affiliates		(11)		(62)		17		-		36		(20)
Income from continuing operations before income taxes		11		21		98		(31)		(36)		63
Provision for (benefit from) income taxes		-		10		37		(21)		-		26
Income from continuing operations		11		11		61		(10)		(36)		37
Discontinued operations, net of taxes:
Loss from operations of entities sold or held for sale		-		-		(1)		1		-		-
Impairment of hospitals sold or held for sale		-		-		-		(1)		-		(1)
Loss from discontinued operations, net of taxes		-		-		(1)		-		-		(1)
Net income		11		11		60		(10)		(36)		36
Less: Net income attributable to noncontrolling interests		-		-		-		25		-		25
Net income attributable to Community Health Systems, Inc. stockholders	$	11	$	11	$	60	$	(35)	$	(36)	$	11

40

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Condensed Consolidating Statement of Income
Three Months Ended March 31, 2015
	Parent   Guarantor		Issuer		Other   Guarantors		Non -   Guarantors		Eliminations		Consolidated
	(In millions)
Operating revenues (net of contractual allowances and discounts)	$	-	$	(5)	$	3,488	$	2,163	$	-	$	5,646
Provision for bad debts		-		-		447		288		-		735
Net operating revenues		-		(5)		3,041		1,875		-		4,911
Operating costs and expenses:
Salaries and benefits		-		-		1,222		1,035		-		2,257
Supplies		-		-		492		270		-		762
Other operating expenses		-		-		708		391		-		1,099
Government settlement and related costs		-		-		8		-		-		8
Electronic health records incentive reimbursement		-		-		(17)		(9)		-		(26)
Rent		-		-		61		55		-		116
Depreciation and amortization		-		-		200		96		-		296
Total operating costs and expenses		-		-		2,674		1,838		-		4,512
Income from operations		-		(5)		367		37		-		399
Interest expense, net		-		21		211		9		-		241
Loss from early extinguishment of debt		-		8		-		-		-		8
Equity in earnings of unconsolidated affiliates		(79)		(104)		(5)		-		170		(18)
Income from continuing operations before income taxes		79		70		161		28		(170)		168
Provision for (benefit from) income taxes		-		(9)		61		4		-		56
Income from continuing operations		79		79		100		24		(170)		112
Discontinued operations, net of taxes:
Loss from operations of entities sold or held for sale		-		-		-		(11)		-		(11)
Impairment of hospitals sold or held for sale		-		-		(1)		-		-		(1)
Loss on sale, net		-		-		2		(3)		-		(1)
Loss from discontinued operations, net of taxes		-		-		1		(14)		-		(13)
Net income		79		79		101		10		(170)		99
Less: Net income attributable to noncontrolling interests		-		-		-		20		-		20
Net income attributable to Community Health
Systems, Inc. stockholders	$	79	$	79	$	101	$	(10)	$	(170)	$	79

41

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Condensed Consolidating Statement of Comprehensive Income (Loss)
Three Months Ended March 31, 2016
	Parent   Guarantor		Issuer		Other   Guarantors		Non -   Guarantors		Eliminations		Consolidated
	(In millions)
Net income	$	11	$	11	$	60	$	(10)	$	(36)	$	36
Other comprehensive income (loss), net of income taxes:
Net change in fair value of interest rate swaps, net of tax		(19)		(19)		-		-		19		(19)
Net change in fair value of available-for-sale securities, net of tax		2		2		2		-		(4)		2
Amortization and recognition of unrecognized pension cost components, net of tax		1		1		1		-		(2)		1
Other comprehensive income (loss)		(16)		(16)		3		-		13		(16)
Comprehensive income		(5)		(5)		63		(10)		(23)		20
Less: Comprehensive income attributable to noncontrolling interests		-		-		-		25		-		25
Comprehensive (loss) income attributable to Community Health Systems, Inc. stockholders	$	(5)	$	(5)	$	63	$	(35)	$	(23)	$	(5)

Condensed Consolidating Statement of Comprehensive Income (Loss)
Three Months Ended March 31, 2015
	Parent   Guarantor		Issuer		Other   Guarantors		Non -   Guarantors		Eliminations		Consolidated
	(In millions)
Net income	$	79	$	79	$	101	$	10	$	(170)	$	99
Other comprehensive income (loss), net of income taxes:
Net change in fair value of interest rate swaps, net of tax		(9)		(9)		-		-		9		(9)
Net change in fair value of available-for-sale securities, net of tax		1		1		1		-		(2)		1
Amortization and recognition of unrecognized pension cost components, net of tax		1		1		1		-		(2)		1
Other comprehensive income (loss)		(7)		(7)		2		-		5		(7)
Comprehensive income		72		72		103		10		(165)		92
Less: Comprehensive income attributable to noncontrolling interests		-		-		-		20		-		20
Comprehensive income (loss) attributable to Community Health Systems, Inc. stockholders	$	72	$	72	$	103	$	(10)	$	(165)	$	72

42

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Condensed Consolidating Balance Sheet
March 31, 2016
	Parent     Guarantor		Issuer		Other     Guarantors		Non -     Guarantors		Eliminations		Consolidated
	(In millions)
ASSETS
Current assets:
Cash and cash equivalents	$	-	$	-	$	12	$	169	$	-	$	181
Patient accounts receivable, net of allowance for doubtful accounts		-		-		1,232		2,491		-		3,723
Supplies		-		-		408		179		-		587
Prepaid income taxes		2		-		-		-		-		2
Prepaid expenses and taxes		-		-		146		72		-		218
Other current assets		-		-		347		198		-		545
Total current assets		2		-		2,145		3,109		-		5,256
Intercompany receivable		1,178		16,776		1,638		6,299		(25,891)		-
Property and equipment, net		-		-		6,924		3,180		-		10,104
Goodwill		-		-		5,462		3,560		-		9,022
Other assets, net		-		-		2,349		1,258		(1,265)		2,342
Net investment in subsidiaries		3,433		21,416		7,859		-		(32,708)		-
Total assets	$	4,613	$	38,192	$	26,377	$	17,406	$	(59,864)	$	26,724
LIABILITIES AND EQUITY
Current liabilities:
Current maturities of long-term debt	$	-	$	175	$	65	$	9	$	-	$	249
Accounts payable		-		-		874		305		-		1,179
Accrued interest		-		156		1		1		-		158
Accrued liabilities		4		-		956		508		-		1,468
Total current liabilities		4		331		1,896		823		-		3,054
Long-term debt		-		15,739		128		798		-		16,665
Intercompany payable		-		17,347		18,975		13,775		(50,097)		-
Deferred income taxes		599		-		-		-		-		599
Other long-term liabilities		8		1,342		1,343		295		(1,265)		1,723
Total liabilities		611		34,759		22,342		15,691		(51,362)		22,041
Redeemable noncontrolling interests in equity of consolidated subsidiaries		-		-		-		565		-		565
Equity:
Community Health Systems, Inc. stockholders’ equity:
Preferred stock		-		-		-		-		-		-
Common stock		1		-		-		-		-		1
Additional paid-in capital		1,951		1,328		1,530		1,042		(3,899)		1,952
Treasury stock, at cost		(7)		-		-		-		-		(7)
Accumulated other comprehensive loss		(89)		(89)		(21)		(1)		111		(89)
Retained earnings		2,146		2,194		2,526		(6)		(4,714)		2,146
Total Community Health Systems, Inc. stockholders’ equity		4,002		3,433		4,035		1,035		(8,502)		4,003
Noncontrolling interests in equity of consolidated subsidiaries		-		-		-		115		-		115
Total equity		4,002		3,433		4,035		1,150		(8,502)		4,118
Total liabilities and equity	$	4,613	$	38,192	$	26,377	$	17,406	$	(59,864)	$	26,724

43

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Condensed Consolidating Balance Sheet
December 31, 2015
	Parent     Guarantor		Issuer		Other     Guarantors		Non -     Guarantors		Eliminations		Consolidated
	(In millions)
ASSETS
Current assets:
Cash and cash equivalents	$	-	$	-	$	25	$	159	$	-	$	184
Patient accounts receivable, net of allowance for doubtful accounts		-		-		1,197		2,414		-		3,611
Supplies		-		-		400		180		-		580
Prepaid income taxes		27		-		-		-		-		27
Prepaid expenses and taxes		-		-		138		59		-		197
Other current assets		-		-		356		211		-		567
Total current assets		27		-		2,116		3,023		-		5,166
Intercompany receivable		1,159		16,544		1,491		6,404		(25,598)		-
Property and equipment, net		-		-		6,863		3,249		-		10,112
Goodwill		-		-		5,460		3,505		-		8,965
Other assets, net		-		-		2,153		1,245		(1,046)		2,352
Net investment in subsidiaries		3,438		20,964		8,035		-		(32,437)		-
Total assets	$	4,624	$	37,508	$	26,118	$	17,426	$	(59,081)	$	26,595
LIABILITIES AND EQUITY
Current liabilities:
Current maturities of long-term debt	$	-	$	162	$	57	$	10	$	-	$	229
Accounts payable		-		-		866		392		-		1,258
Accrued interest		-		226		-		1		-		227
Accrued liabilities		4		-		901		453		-		1,358
Total current liabilities		4		388		1,824		856		-		3,072
Long-term debt		-		15,604		151		801		-		16,556
Intercompany payable		-		16,861		19,021		13,764		(49,646)		-
Deferred income taxes		593		-		-		-		-		593
Other long-term liabilities		8		1,217		1,149		370		(1,046)		1,698
Total liabilities		605		34,070		22,145		15,791		(50,692)		21,919
Redeemable noncontrolling interests in equity of consolidated subsidiaries		-		-		-		571		-		571
Equity:
Community Health Systems, Inc. stockholders’ equity:
Preferred stock		-		-		-		-		-		-
Common stock		1		-		-		-		-		1
Additional paid-in capital		1,963		1,324		1,506		967		(3,797)		1,963
Treasury stock, at cost		(7)		-		-		-		-		(7)
Accumulated other comprehensive loss		(73)		(73)		(22)		(3)		98		(73)
Retained earnings		2,135		2,187		2,489		14		(4,690)		2,135
Total Community Health Systems, Inc. stockholders’ equity		4,019		3,438		3,973		978		(8,389)		4,019
Noncontrolling interests in equity of consolidated subsidiaries		-		-		-		86		-		86
Total equity		4,019		3,438		3,973		1,064		(8,389)		4,105
Total liabilities and equity	$	4,624	$	37,508	$	26,118	$	17,426	$	(59,081)	$	26,595

44

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Condensed Consolidating Statement of Cash Flows

Three Months Ended March 31, 2016

	Parent				Other		Non -
	Guarantor		Issuer		Guarantors		Guarantors		Eliminations		Consolidated
	(In millions)
Net cash (used in) provided by operating activities	$	-	$	(223)	$	420	$	97	$	-	$	294
Cash flows from investing activities:
Acquisitions of facilities and other related equipment		-		-		(2)		(97)		-		(99)
Purchases of property and equipment		-		-		(159)		(65)		-		(224)
Proceeds from disposition of hospitals and other ancillary operations		-		-		12		-		-		12
Proceeds from sale of property and equipment		-		-		3		1		-		4
Purchases of available-for-sale securities		-		-		(12)		(25)		-		(37)
Proceeds from sales of available-for-sale securities		-		-		10		30		-		40
Increase in other investments		-		-		(53)		(14)		-		(67)
Net cash used in investing activities		-		-		(201)		(170)		-		(371)
Cash flows from financing activities:
Repurchase of restricted stock shares for payroll
tax withholding requirements		(7)		-		-		-		-		(7)
Redemption of noncontrolling investments in joint ventures		-		-		-		(16)		-		(16)
Distributions to noncontrolling investors in joint ventures		-		-		-		(18)		-		(18)
Changes in intercompany balances with affiliates, net		7		89		(215)		119		-		-
Borrowings under credit agreements		-		1,563		1		-		-		1,564
Proceeds from receivables facility		-		-		-		31		-		31
Repayments of long-term indebtedness		-		(1,429)		(18)		(33)		-		(1,480)
Net cash provided by (used in) financing activities		-		223		(232)		83		-		74
Net change in cash and cash equivalents		-		-		(13)		10		-		(3)
Cash and cash equivalents at beginning of period		-		-		25		159		-		184
Cash and cash equivalents at end of period	$	-	$	-	$	12	$	169	$	-	$	181

45

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Condensed Consolidating Statement of Cash Flows

Three Months Ended March 31, 2015

	Parent   Guarantor		Issuer		Other   Guarantors		Non -   Guarantors		Eliminations		Consolidated
	(In millions)
Net cash (used in) provided by operating activities	$	(10)	$	(123)	$	23	$	49	$	-	$	(61)
Cash flows from investing activities:
Acquisitions of facilities and other related equipment		-		-		(11)		(2)		-		(13)
Purchases of property and equipment		-		-		(199)		(42)		-		(241)
Proceeds from disposition of hospitals and other ancillary operations		-		-		4		58		-		62
Proceeds from sale of property and equipment		-		-		-		3		-		3
Purchases of available-for-sale securities		-		-		(22)		(37)		-		(59)
Proceeds from sales of available-for-sale securities		-		-		19		37		-		56
Increase in other investments		-		-		(30)		(9)		-		(39)
Net cash used in investing activities		-		-		(239)		8		-		(231)
Cash flows from financing activities:
Proceeds from exercise of stock options		17		-		-		-		-		17
Repurchase of restricted stock shares for payroll tax withholding requirements		(20)		-		-		-		-		(20)
Deferred financing costs and other debt-related costs		-		(20)		-		-		-		(20)
Redemption of noncontrolling investments in joint ventures		-		-		-		(7)		-		(7)
Distributions to noncontrolling investors in joint ventures		-		-		-		(23)		-		(23)
Changes in intercompany balances with affiliates, net		13		77		(101)		11		-		-
Borrowings under credit agreements		-		1,250		1		-		-		1,251
Proceeds from receivables facility		-		-		-		75		-		75
Repayments of long-term indebtedness		-		(1,184)		(15)		(69)		-		(1,268)
Net cash provided by (used in) financing activities		10		123		(115)		(13)		-		5
Net change in cash and cash equivalents		-		-		(331)		44		-		(287)
Cash and cash equivalents at beginning of period		-		-		368		141		-		509
Cash and cash equivalents at end of period	$	-	$	-	$	37	$	185	$	-	$	222

46

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read this discussion together with our unaudited condensed consolidated financial statements and the accompanying notes included herein.

Throughout this Quarterly Report on Form 10-Q, we refer to Community Health Systems, Inc., or the Parent Company, and its consolidated subsidiaries in a simplified manner and on a collective basis, using words like “we,” “our,” “us” and the “Company”. This drafting style is suggested by the Securities and Exchange Commission, or SEC, and is not meant to indicate that the publicly traded Parent Company or any particular subsidiary of the Parent Company owns or operates any asset, business or property. The hospitals, operations and businesses described in this filing are owned and operated, and management services provided, by distinct and indirect subsidiaries of Community Health Systems, Inc.

Executive Overview

We are one of the largest publicly traded hospital companies in the United States and a leading operator of general acute care hospitals in communities across the country. We provide healthcare services through the hospitals that we own and operate and affiliated businesses in non-urban and selected urban markets throughout the United States. We generate revenues by providing a broad range of general and specialized hospital healthcare services and other outpatient services to patients in the communities in which we are located. As of March 31, 2016, we owned or leased 194 hospitals included in continuing operations, comprised of 190 general acute care hospitals and four stand-alone rehabilitation or psychiatric hospitals. As of April 29, 2016, immediately following the completion of the spin-off of Quorum Health Corporation, or QHC, as discussed below, we owned or leased 157 hospitals included in continuing operations, comprised of 154 general acute care hospitals and three stand-alone rehabilitation or psychiatric hospitals. In addition to our hospitals and related businesses, we own and operate home care agencies, located primarily in markets where we also operate a hospital. Until the completion of the spin-off to QHC on April 29, 2016, as discussed below, we also provided management advisory and consulting services to non-affiliated general acute care hospitals located throughout the United States through our former subsidiary Quorum Health Resources, LLC, or QHR. For the hospitals and home care agencies that we own and operate, we are paid for our services by governmental agencies, private insurers and directly by the patients we serve. For our management advisory and consulting services, we are paid by the non-affiliated hospitals utilizing our services.

On August 3, 2015, we announced a plan to spin off 38 hospitals and QHR into QHC, an independent, publicly traded corporation. The transaction was structured to be generally tax free to us and our stockholders. On April 29, 2016, we completed the spin-off of these 38 hospitals and QHR into QHC and distributed, on a pro rata basis, all of the shares of QHC common stock to our stockholders of record as of April 22, 2016. These stockholders of record as of April 22, 2016 received a distribution of one share of QHC common stock for every four shares of our common stock held as of the record date plus cash in lieu of any fractional shares. Immediately following the completion of the spin-off, our stockholders owned 100% of the outstanding shares of QHC common stock. Following the spin-off, QHC became an independent public company with its common stock listed for trading under the symbol “QHC” on the New York Stock Exchange.

In connection with the spin-off, we entered into a separation and distribution agreement as well as certain ancillary agreements with QHC on April 29, 2016. These agreements allocate between QHC and us the various assets, employees, liabilities and obligations (including investments, property and employee benefits and tax-related assets and liabilities) that comprise the separate companies and govern certain relationships between, and activities of, QHC and us for a period of time after the spin-off.

On March 1, 2016, we completed the acquisition of an 80% ownership interest in a joint venture with Indiana University Health that includes IU Health La Porte Hospital in La Porte, Indiana and IU Health Starke Hospital in Knox, Indiana, and affiliated outpatient centers and physician practices.

On April 1, 2016, we completed the acquisition of 80% interest in Physicians’ Specialty Hospital (20 licensed beds), a Medicare-certified specialty surgical hospital in Fayetteville, Arkansas.

On April 29, 2016, we entered into a definitive agreement with Universal Health Services, Inc., or UHS, to sell our unconsolidated minority equity interests in Valley Health System LLC, a joint venture with UHS representing four hospitals in Las Vegas, Nevada, in which we own a 27.5% interest, and in Summerlin Hospital Medical Center LLC, a joint venture with UHS representing one hospital in Las Vegas, Nevada, in which we own a 26.1% interest. We will receive $445 million in cash from UHS in return for the sale of our equity interests in the second quarter of 2016.

47

Operating results and statistical data for the three months ended March 31, 2016, exclude our hospitals that have previously been classified as discontinued operations for accounting purposes. In addition, during the year ended December 31, 2015, we divested seven hospitals previously recorded in discontinued operations and one additional hospital. Two of these hospitals were required to be divested by the Federal Trade Commission as a condition of its approval of our acquisition of Health Management Associates, Inc., or HMA, merger.

We are also in the process of negotiating with potential buyers to enter into definitive agreements to sell ten additional hospitals as well as our investment in certain non-hospital operations, and we currently expect those transactions to close during the third quarter of 2016; however, there can be no assurance that these dispositions will be completed or, if they are completed, the ultimate timing of the completion of these dispositions. These ten additional hospitals and non-hospital operations that have been targeted for sale represented approximately $1.0 billion of annual net operating revenues during 2015. These potential transactions, and transactions that have already been completed in 2016, are intended to further implement our strategy to divest of underperforming assets, reduce our debt and refine our portfolio to a more sustainable group of hospitals with higher operating margins. When consistent with this strategy, we may also consider additional hospitals for disposition.

Our net operating revenues for the three months ended March 31, 2016, increased $88 million to approximately $5.0 billion compared to approximately $4.9 billion for the three months ended March 31, 2015. Our provision for bad debts increased to $755 million, or 13.1% of operating revenues (before the provision for bad debts) for the three months ended March 31, 2016, from $735 million, or 13.0% of operating revenues (before the provision for bad debts) for the three months ended March 31, 2015.

We had income from continuing operations before noncontrolling interests of $37 million during the three months ended March 31, 2016, compared to $112 million for the three months ended March 31, 2015. Income from continuing operations before noncontrolling interests for the three months ended March 31, 2016 included an after-tax charge of $14 million for the impairment of long-lived assets and an after-tax charge of $2 million related to costs incurred for the spin-off of QHC. Income from continuing operations before noncontrolling interests for the three months ended March 31, 2015, included an after-tax charge of $5 million for loss from early extinguishment of debt, $1 million after-tax expense for acquisition and integration expenses from the HMA merger and an after-tax charge of $5 million for the government legal settlements for several qui tam matters settled in principle and related legal expenses. These after-tax charges were partially offset by an after-tax income of $4 million from fair value adjustments, net of legal expenses, related to the HMA legal proceedings underlying the CVR agreement. Consolidated inpatient admissions for the three months ended March 31, 2016, decreased 2.6%, compared to the three months ended March 31, 2015, and consolidated adjusted admissions for the three months ended March 31, 2016, increased 0.7%, compared to the three months ended March 31, 2015. Same-store inpatient admissions for the three months ended March 31, 2016, decreased 2.0%, compared to the three months ended March 31, 2015, and same-store adjusted admissions for the three months ended March 31, 2016, increased 1.3%, compared to the three months ended March 31, 2015.

Self-pay revenues represented approximately 12.3% and 12.6% for the three months ended March 31, 2016 and 2015, respectively. During 2015 and through the three months ended March 31, 2016, we experienced a decline in self-pay admissions and adjusted admissions resulting in a corresponding decline in self-pay revenues as a percentage of total net operating revenues. This decrease is reflective of an increase in Medicaid admissions and revenues, primarily in Medicaid expansion states, as a result of the implementation of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, collectively, the Reform Legislation. The reduction in self-pay admissions and revenue was also experienced in non-expansion states, although to a lesser degree. The amount of foregone revenue related to providing charity care services as a percentage of net operating revenues was approximately 2.3% and 2.2% for the three months ended March 31, 2016 and 2015, respectively. Direct and indirect costs incurred in providing charity care services were approximately 0.3% for both the three months ended March 31, 2016 and March 31, 2015.

The U.S. Congress and certain state legislatures have introduced and passed a large number of proposals and legislation designed to make major changes in the healthcare system, including changes that increased access to health insurance. The Reform Legislation mandates that substantially all U.S. citizens maintain medical insurance coverage and expands health insurance coverage through a combination of public program expansion and private sector health insurance reforms. Based on projections issued by the CBO in March 2016, the incremental insurance coverage due to the Reform Legislation could result in 24 million formerly uninsured Americans gaining coverage by the end of 2026.

48

As the number of persons with access to health insurance in the United States increases, there may be a resulting increase in the number of patients using our facilities who have health insurance coverage. Prior to giving effect to the spin-off of QHC, we operated hospitals in eight of the 10 states that experienced the largest reductions in uninsured rates among adult residents between 2013 and 2015, and after giving effect to the spin-off of QHC, we continue to operate hospitals in five of such 10 states. Most of these states with the greatest reductions in the number of uninsured adult residents have established a health insurance exchange operated either by the state or in partnership with the federal government and also expanded Medicaid. However, states may opt out of the Medicaid coverage expansion provisions of the Reform Legislation without losing existing federal Medicaid funding. A number of states have opted out of the Medicaid coverage expansion provisions, but could ultimately decide to expand their programs at a later date. Of the 28 states in which we operated hospitals that were included in continuing operations as of March 31, 2016, 15 states have taken action to expand their Medicaid programs, including Louisiana, which is expected to implement Medicaid coverage expansion at some point in 2016. At this time, the other 13 states have not, including Florida, Tennessee and Texas, where we operated a significant number of hospitals as of March 31, 2016. Some states that have opted out are evaluating options such as waiver plans to operate an alternative Medicaid expansion plan. Failure to expand Medicaid or implement an effective alternative in these states will likely have a negative impact on the goal of reducing the number of uninsured individuals.

We believe our hospitals are well positioned to participate in the provider networks of various qualified health plans, or QHPs, offering plan options on the health insurance exchanges created pursuant to the Reform Legislation. For the 2016 plan year, all of our hospitals in continuing operations as of March 31, 2016 have arrangements to participate in at least one health insurance exchange agreement, approximately 90% of such hospitals participate in two or more contracts, approximately 87% of such hospitals participate in the first or second lowest cost bronze plan networks (QHPs with a 60% actuarial value) and approximately 90% of such hospitals participate in the first or second lowest cost silver plan networks (QHPs with a 70% actuarial value).

The Reform Legislation makes a number of changes to Medicare and Medicaid, such as reductions to the Medicare annual market basket update for federal fiscal years 2010 through 2019, a productivity offset to the Medicare market basket update, and a reduction to the Medicare and Medicaid disproportionate share hospital payments, each of which could adversely impact the reimbursement received under these programs.

The Reform Legislation includes provisions aimed at reducing fraud, waste and abuse in the healthcare industry. These provisions allocate significant additional resources to federal enforcement agencies and expand the use of private contractors to recover potentially inappropriate Medicare and Medicaid payments. The Reform Legislation amends several existing federal laws, including the Anti-Kickback Statute and the False Claims Act, to make it easier for government agencies and private plaintiffs to prevail in lawsuits brought against healthcare providers. These amendments also make it easier for potentially severe fines and penalties to be imposed on healthcare providers that violate applicable laws and regulations.

We believe the expansion of private sector health insurance and Medicaid coverage will, over time, increase our reimbursement related to providing services to individuals who were previously uninsured, which should reduce our expense from uncollectible accounts receivable. The various provisions in the Reform Legislation that directly or indirectly affect reimbursement take effect over a number of years. In addition, we believe that the Reform Legislation has had a positive impact on net operating revenues and income from continuing operations during 2015 and the three months ended March 31, 2016 as the result of the expansion of private sector and Medicaid coverage that has already occurred from the Reform Legislation, and we believe that the net impact of the Reform Legislation on our net operating revenues will continue to be positive. Other provisions of the Reform Legislation, such as requirements related to employee health insurance coverage, have increased and will continue to increase our operating costs.

Because of the many variables involved, including clarifications and modifications resulting from the rule-making process, legislative efforts to repeal or modify the law, future judicial interpretations resulting from court challenges to its constitutionality and interpretation, the development of agency guidance, whether and how many states ultimately decide to expand Medicaid coverage, the number of uninsured who elect to purchase health insurance coverage, budgetary issues at federal and state levels, and the potential for delays in the implementation of the Reform Legislation, it is difficult to predict the ultimate effect of the Reform Legislation. We may not be able to fully realize the positive impact the Reform Legislation may otherwise have on our business, results of operations, cash flow, capital resources and liquidity. Furthermore, we cannot predict whether we will be able to modify certain aspects of our operations to offset any potential adverse consequences from the Reform Legislation.

49

Payment under the Medicare program for physician services, which is based upon the Medicare Physician Fee Schedule, or MPFS, changed in April 2015 with the enactment of the Medicare Access and CHIP Reauthorization Act of 2015, or MACRA. The law effectively eliminated a payment reduction that was scheduled for physicians and other practitioners who treat Medicare patients. MACRA provides for a 0.5% update to the MPFS for each calendar year through 2019. In addition, MACRA requires the establishment of the Merit-Based Incentive Payment System, or MIPS, beginning in 2019, under which physicians will receive performance-based payment incentives or payment reductions based on their performance with respect to clinical quality, resource use, clinical improvement activities, and meaningful use of electronic health records. MIPS will consolidate certain existing physician incentive programs, and also requires the Centers for Medicare and Medicaid Services, or CMS, to provide, beginning in 2019, incentive payments for physicians and other eligible professionals that participate in alternative payment models, such as accountable care organizations. In addition, MACRA extended the Medicare Inpatient Low Volume payment and Medicare Dependent Hospital programs to qualifying hospitals through September 30, 2017. If additional legislation is not passed to extend these Medicare hospital payment programs, we could experience a reduction in future reimbursement.

The federal government has implemented a number of regulations and programs designed to promote the use of electronic health records, or EHR, technology and pursuant to the Health Information Technology for Economic and Clinical Health Act, or HITECH, established requirements for a Medicare and Medicaid incentive payments program for eligible hospitals and professionals that adopt and meaningfully use certified EHR technology. These payments are intended to incentivize the meaningful use of EHR. Our hospital facilities have been implementing EHR technology on a facility-by-facility basis since 2011. We recognize incentive reimbursement related to the Medicare or Medicaid incentives as we are able to implement the certified EHR technology and meet the defined “meaningful use criteria,” and information from completed cost report periods is available from which to calculate the incentive reimbursement. The timing of recognizing incentive reimbursement does not correlate with the timing of recognizing operating expenses and incurring capital costs in connection with the implementation of EHR technology which may result in material period-to-period changes in our future results of operations.

As of October 1, 2014, eligible hospitals and, as of January 1, 2015, professionals that have not demonstrated meaningful use of certified EHR technology and have not applied and qualified for a hardship exception are subject to penalties. Eligible hospitals are subject to a reduced market basket update to the inpatient prospective payment system standardized amount as of 2015 and for each subsequent fiscal year. Eligible professionals are subject to a 1% per year cumulative reduction applied to the Medicare physician fee schedule amount for covered professional services, subject to a cap of 5%.

Although we believe that our hospital facilities are currently in compliance with the meaningful use standards, there can be no assurance that all of our facilities will remain in compliance and therefore not be subject to the HITECH penalty provisions. We recognized approximately $18 million and $26 million during the three months ended March 31, 2016 and 2015, respectively, for HITECH incentive reimbursements from Medicare and Medicaid related to certain of our hospitals and for certain of our employed physicians, which are presented as a reduction of operating expenses.

As a result of our current levels of cash, available borrowing capacity, long-term outlook on our debt repayments, the refinancing of our term loans and our continued projection of our ability to generate cash flows, we anticipate that we will be able to invest the necessary capital in our business over the next twelve months. We believe there continues to be ample opportunity for growth in substantially all of our markets by decreasing the need for patients to travel outside their communities for healthcare services. Furthermore, we continue to benefit from synergies from our acquisitions and will continue to strive to improve operating efficiencies and procedures in order to improve our profitability at all of our hospitals.

50

Sources of Revenue

The following table presents the approximate percentages of operating revenues, net of contractual allowances and discounts (but before provision for bad debts), by payor source for the periods indicated. The data for the periods presented are not strictly comparable due to the effect that hospital acquisitions have had on these statistics.

	Three Months Ended              March 31,
	2016		2015
Medicare		24.9 %		24.8 %
Medicaid		10.3		10.4
Managed Care and other third-party payors		52.5		52.2
Self-pay		12.3		12.6
Total		100.0 %		100.0 %

As shown above, we receive a substantial portion of our revenues from the Medicare and Medicaid programs. Included in Managed Care and other third-party payors is operating revenues from insurance companies with which we have insurance provider contracts, Medicare managed care, insurance companies for which we do not have insurance provider contracts, workers’ compensation carriers and non-patient service revenue, such as rental income and cafeteria sales. In the future, we generally expect revenues received from the Medicare and Medicaid programs to increase due to the general aging of the population. In addition, the Reform Legislation has increased and is expected to continue to increase the number of insured patients in states that have expanded Medicaid, which in turn, has reduced and is expected to continue to reduce the percentage of revenues from self-pay patients. The Reform Legislation, however, imposes significant reductions in amounts the government pays Medicare managed care plans. The trend toward increased enrollment in Medicare managed care may adversely affect our operating revenue growth. Other provisions in the Reform Legislation impose minimum medical-loss ratios and require insurers to meet specific benefit requirements. Furthermore, in the normal course of business, managed care programs, insurance companies and employers actively negotiate the amounts paid to hospitals. The trend toward increased enrollment in managed care may adversely affect our operating revenue growth. There can be no assurance that we will retain our existing reimbursement arrangements or that these third-party payors will not attempt to further reduce the rates they pay for our services.

Net operating revenues include amounts estimated by management to be reimbursable by Medicare and Medicaid under prospective payment systems and provisions of cost-based reimbursement and other payment methods. In addition, we are reimbursed by non-governmental payors using a variety of payment methodologies. Amounts we receive for the treatment of patients covered by Medicare, Medicaid and non-governmental payors are generally less than the standard billing rates. We account for the differences between the estimated program reimbursement rates and the standard billing rates as contractual allowance adjustments, which we deduct from gross revenues to arrive at net operating revenues. Final settlements under some of these programs are subject to adjustment based on administrative review and audit by third parties. We account for adjustments to previous program reimbursement estimates as contractual allowance adjustments and report them in the periods that such adjustments become known. Contractual allowance adjustments related to final settlements and previous program reimbursement estimates impacted net operating revenues and net income by an insignificant amount in each of the three months ended March 31, 2016 and 2015.

The payment rates under the Medicare program for hospital inpatient and outpatient acute care services are based on a prospective payment system, depending upon the diagnosis of a patient’s condition. These rates are indexed for inflation annually, although increases have historically been less than actual inflation. On August 17, 2015, CMS published the final rule to increase this index by 2.4% for hospital inpatient acute care services that are reimbursed under the prospective payment system, beginning October 1, 2015. The final rule also makes other payment adjustments that, coupled with the 0.8% reduction for documentation and coding, a 0.5% multifactor productivity reduction, and a 0.2% reduction to hospital inpatient rates implemented pursuant to the Reform Legislation, yielded an estimated net 0.9% increase in reimbursement for hospitals. For fiscal year 2016, an additional reduction applies to hospitals that do not submit required patient quality data. We are complying with this data submission requirement.

51

Payments may also be affected by admission and medical review criteria for inpatient services commonly known as the “two midnight rule.” Under the rule, for admissions on or after October 1, 2013, services to Medicare beneficiaries are only payable as inpatient hospital services when there is a reasonable expectation that the hospital care is medically necessary and will be required across two midnights, absent unusual circumstances. Stays expected to need less than two midnights of hospital care are subject to medical review on a case-by-case basis. Enforcement through Recovery Audit Contractor audits is expected to begin in 2016. Reductions in the rate of increase or overall reductions in Medicare reimbursement may cause a decline in the growth of our net operating revenues.

Currently, several states utilize supplemental reimbursement programs for the purpose of providing reimbursement to providers to offset a portion of the cost of providing care to Medicaid and indigent patients. These programs are designed with input from CMS and are funded with a combination of state and federal resources, including, in certain instances, fees or taxes levied on the providers. Similar programs are also being considered by other states. The programs are generally authorized for a specified period of time and require CMS’s approval to be extended. CMS has indicated that it will take into account a state’s status with respect to expanding its Medicaid program in considering whether to extend these supplemental programs. We are unable to predict whether or on what terms CMS will extend the supplemental programs in the states in which we operate, including Texas. Some of these programs are scheduled to expire in 2016. As a result of existing supplemental programs, we recognize revenue and related expenses in the period in which amounts are estimable and collection is reasonably assured. Reimbursement under these programs is reflected in net operating revenues and included as Medicaid revenue in the table above, and fees, taxes or other program related costs are reflected in other operating expenses.

Results of Operations

Our hospitals offer a variety of services involving a broad range of inpatient and outpatient medical and surgical services. These include general acute care, emergency room, general and specialty surgery, critical care, internal medicine, obstetrics, diagnostic services, psychiatric and rehabilitation services. The strongest demand for hospital services generally occurs during January through April and the weakest demand for these services occurs during the summer months. Accordingly, eliminating the effect of new acquisitions, our net operating revenues and earnings are historically highest during the first quarter and lowest during the third quarter.

The following tables summarize, for the periods indicated, selected operating data.

	Three Months Ended         March  31,
	2016		2015
Consolidated:
Net operating revenues		100.0 %		100.0 %
Operating expenses (a)		(87.8)		(85.9)
Depreciation and amortization		(6.0)		(6.0)
Impairment of long-lived assets		(0.3)		-
Income from operations		5.9		8.1
Interest expense, net		(5.0)		(4.9)
Loss from early extinguishment of debt		-		(0.2)
Equity in earnings of unconsolidated affiliates		0.4		0.4
Income from continuing operations before income taxes		1.3		3.4
Provision for income taxes		(0.6)		(1.1)
Income from continuing operations		0.7		2.3
Loss from discontinued operations, net of taxes		-		(0.3)
Net income		0.7		2.0
Less: Net income attributable to noncontrolling interests		(0.5)		(0.4)
Net income attributable to Community Health Systems, Inc. stockholders		0.2 %		1.6 %

52

	Three Months Ended         March 31, 2016
Percentage increase (decrease) from same period prior year:
Net operating revenues		1.8 %
Admissions		(2.6)
Adjusted admissions (b)		0.7
Average length of stay		(2.2)
Net income attributable to Community Health Systems, Inc. (c)		(86.1)
Same-store percentage increase (decrease) from same period prior year (d):
Net operating revenues		2.2 %
Admissions		(2.0)
Adjusted admissions (b)		1.3

(a) Operating expenses include salaries and benefits, supplies, other operating expenses, government settlement and related costs, electronic health records incentive reimbursement and rent.

(b) Adjusted admissions is a general measure of combined inpatient and outpatient volume. We computed adjusted admissions by multiplying admissions by gross patient revenues and then dividing that number by gross inpatient revenues.

(c) Includes loss from discontinued operations.

(d) Includes acquired hospitals to the extent we operated them in both periods and excludes our hospitals that have previously been classified as discontinued operations for accounting purposes.

Three Months Ended March 31, 2016 Compared to Three Months Ended March 31, 2015

Net operating revenues increased by 1.8% to approximately $5.0 billion for the three months ended March 31, 2016, from approximately $4.9 billion for the three months ended March 31, 2015. Our provision for bad debts increased to $755 million, or 13.1% of operating revenues (before the provision for bad debts) for the three months ended March 31, 2016, from $735 million, or 13.0% of operating revenues (before the provision for bad debts) for the three months ended March 31, 2015. Net operating revenues from hospitals owned throughout both periods increased $106 million or, 2.2% during the three months ended March 31, 2016, as compared to the three months ended March 31, 2015. Non-same-store net operating revenues decreased $17 million during the three months ended March 31, 2016, in comparison to the prior year period. The increase in same-store net operating revenues was attributable to favorable changes in payor mix with corresponding reductions in charity care and self-pay discounts as a percentage of revenue. On a consolidated basis, inpatient admissions decreased by 2.6% and adjusted admissions increased by 0.7% during the three months ended March 31, 2016 as compared to the three months ended March 31, 2015. On a same-store basis, net operating revenues per adjusted admissions increased 0.8%, while inpatient admissions decreased by 2.0% and adjusted admissions increased by 1.3% during the three months ended March 31, 2016 as compared to the three months ended March 31, 2015.

Operating expenses as a percentage of net operating revenues increased from 91.9% during the three months ended March 31, 2015 to 94.1% during the three months ended March 31, 2016. Operating expenses, excluding depreciation and amortization and impairment of long-lived assets, as a percentage of net operating revenues, increased from 85.9% for the three months ended March 31, 2015 to 87.8% for the three months ended March 31, 2016. Salaries and benefits, as a percentage of net operating revenues, increased from 46.0% for the three months ended March 31, 2015 to 46.3% for the three months ended March 31, 2016. This increase in salaries and benefits, as a percentage of net operating revenues, was primarily due to annual merit increases and increases in physician employment. Supplies, as a percentage of net operating revenues, increased from 15.5% for the three months ended March 31, 2015 to 16.0% for the three months ended March 31, 2016, primarily as a result of an increase in drug and implant costs over the same period in the prior year. Other operating expenses, as a percentage of net operating revenues, increased from 22.4% for the three months ended March 31, 2015 to 23.5% for the three months ended March 31, 2016. This increase in other operating expenses, as a percentage of net operating revenues, was primarily impacted by higher costs for outsourced services for housekeeping and dietary services, information systems maintenance, property tax increases, and higher contract labor at our hospitals and ancillary facilities. Government settlement and related costs, as a percentage of net revenues decreased from 0.1% for the three months ended March 31, 2015 to less than 0.1% for the three months ended March 31, 2016. Rent, as a percentage of net operating revenues, was 2.4% for each of the three months ended March 31, 2016 and the three months ended March 31, 2015.

53

EHR incentive reimbursements represent those incentives under HITECH for which the recognition criterion has been met. We recognized approximately $18 million and $26 million of incentive reimbursements, or 0.4% and 0.5% of net operating revenues, for the three months ended March 31, 2016 and 2015, respectively. We received cash payments of $85 million and $54 million for these incentives during the three months ended March 31, 2016 and 2015, respectively. As of March 31, 2016 and 2015, $34 million and $75 million, respectively, was recorded as deferred revenue as all criteria for gain recognition had not been met at that date.

Depreciation and amortization as a percentage of net operating revenues, was 6.0% for each of the three months ended March 31, 2016 and the three months ended March 31, 2015.

Impairment for long-lived assets was $17 million for the three months ended March 31, 2016 due to impairment of approximately $10 million recorded related to the reporting unit goodwill and fixed assets allocated to two hospitals sold during the three months ended March 31, 2016 and impairment of approximately $7 million related to the impairment of certain long-lived assets at one of our smaller hospitals where the decision was made during the three months ended March 31, 2016, to permanently close the hospital. No impairment for long-lived assets was recorded in the three months ended March 31, 2015.

Interest expense, net, increased by $10 million to $251 million for the three months ended March 31, 2016 compared to $241 million for the three months ended March 31, 2015, primarily due to an increase in our average outstanding debt during the three months ended March 31, 2016, which resulted in an increase in interest expense of $2 million. Additionally, interest expense increased by $3 million, which resulted from an increase in interest rates during the three months ended March 31, 2016, compared to the same period in 2015, an increase in interest expense of $2 million as a result of more interest being capitalized during the three months ended March 31, 2016, as compared to the same period in 2015, due to the growth in major construction projects during the current three month period and an increase in interest expense of $3 million due to one additional day of interest expense since 2016 was a leap year.

A loss from early extinguishment of debt of $8 million was recognized during the three months ended March 31, 2015 resulting from the repayment of certain outstanding term loans as part of the amendment of the Credit Facility.

Equity in earnings of unconsolidated affiliates, as a percentage of net operating revenues, was at 0.4% for each of the three months ended March 31, 2016 and the three months ended March 31, 2015.

The net results of the above mentioned changes resulted in income from continuing operations before income taxes decreasing $105 million from $168 million for the three months ended March 31, 2015 to $63 million for the three months ended March 31, 2016.

Provision for income taxes from continuing operations decreased from $56 million for the three months ended March 31, 2015 to $26 million for the three months ended March 31, 2016 due to the decrease in income from continuing operations before income taxes. Our effective tax rates were 41.3% and 33.2% for the three months ended March 31, 2016 and 2015, respectively. The increase in our effective tax rate for the three months ended March 31, 2016, when compared to the three months ended March 31, 2015, was primarily related to a disproportionate substantial decrease in income from continuing operations before income taxes, when compared to an increase in net income attributable to noncontrolling interests for those same periods, which is not tax affected in our condensed consolidated statement of income. Including the expense related to income attributable to noncontrolling interests, the effective tax rate for the three months ended March 31, 2016 and 2015 would have been 68.4% and 37.8%, respectively. The increase in our effective tax rate for the three months ended March 31, 2016 is primarily due to the impact of permanent tax differences recognized as part of the hospitals we divested during the quarter.

Income from continuing operations, as a percentage of net operating revenues, decreased from 2.3% for the three months ended March 31, 2015 to 0.7% for the three months ended March 31, 2016.

Discontinued operations for these periods include the results of operations of certain hospitals owned or leased by us as of March 31, 2016 and 2015, which were classified as being held for sale or sold. The operation of these hospitals resulted in a loss, net of taxes, of $11 million included in discontinued operations during the three months ended March 31, 2015. An after-tax impairment charge of $1 million was recorded during the three months ended March 31, 2016, based on the difference between the estimated fair value and the carrying value of the assets held for sale, including an allocation of reporting unit goodwill, compared to an impairment charge of $1 million during the three months ended March 31, 2015. In addition, a loss on the sale of hospitals, net of tax, of $1 million was recorded during the three months ended March 31, 2015. Overall, discontinued operations during the three months ended March 31, 2016, consisted of a loss, net of taxes, of $1 million, compared to a loss, net of taxes, of $13 million during the three months ended March 31, 2015.

54

Net income, as a percentage of net operating revenues, decreased from 2.0% for the three months ended March 31, 2015 to 0.7% for the three months ended March 31, 2016.

Net income attributable to noncontrolling interests, as a percentage of net operating revenues, increased from 0.4% for the three months ended March 31, 2015 to 0.5% for the three months ended March 31, 2016.

Net income attributable to Community Health Systems, Inc. was $11 million for the three months ended March 31, 2016 compared to $79 million for the three months ended March 31, 2015. The decrease in net income attributable to Community Health Systems, Inc. is primarily due to the increases in salaries and benefits, supplies and other operating expenses, as discussed above.

Liquidity and Capital Resources

Net cash provided by (used in) operating activities increased $355 million, from approximately $61 billion in cash used in operating activities for the three months ended March 31, 2015 to approximately $294 million in cash provided by operating activities for the three months ended March 31, 2016. The increase in cash provided by operating activities was primarily the result of an increase in cash receipts related to the collections of accounts receivable, a decrease in cash outflow related to the timing of payments on accounts payable and a decrease in cash outflow related to the timing of payments on employee compensation accruals. These increases in cash flow were partially offset by an increase in cash paid for supplies, prepaids, and other current assets. Total cash paid for interest during the three months ended March 31, 2016 increased to approximately $307 million compared to $300 million for the three months ended March 31, 2015, which is related to the timing of interest payments. Less than $1 million was paid for income taxes for the three months ended March 31, 2016, compared to approximately $1 million paid for income taxes for the three months ended March 31, 2015. Included in net cash provided by operating activities for the three months ended March 31, 2016 was $85 million of cash received for HITECH incentive reimbursements, compared to $54 million received for the three months ended March 31, 2015.

The cash used in investing activities increased $140 million, from approximately $231 million for the three months ended March 31, 2015 to approximately $371 million for the three months ended March 31, 2016. The increase in cash used in investing activities was primarily due to a increase in cash paid for acquisitions of facilities and other related equipment of $86 million as a result of no hospital acquisitions during the three months ended March 31, 2015 compared to the acquisition of two hospitals during the three months ended March 31, 2016, as well as a decrease in 2016 in proceeds from the disposition of hospitals and other ancillary operations of $50 million and an increase in cash used for other investments (primarily from internal-use software expenditures) of $28 million for the three months ended March 31, 2016. These increases were offset by a decrease in the cash used for the purchase of property and equipment of $17 million, an increase in proceeds from the sale of property and equipment of $1 million and an increase in the net impact of the purchases and sales of available-for-sale securities of $6 million. Included in cash outflows for other investments for the three months ended March 31, 2016 is approximately $9 million of capital expenditures related to the purchase and implementation of certified EHR technology, including implementation of Cerner software at several hospital locations. The remaining cash outflows for other investments for the three months ended March 31, 2016 consists primarily of purchases and development of other internal-use software and payments made under non-employee physician recruiting agreements of $58 million. We anticipate being able to fund future routine capital expenditures with cash flows generated from operations.

Our net cash provided by financing activities was $74 million for the three months ended March 31, 2016, compared to $5 million for the three months ended March 31, 2015. The increase in cash provided by financing activities, in comparison to the prior year period, is primarily due to a reduction in the cash paid to repurchase vested restricted stock for payroll tax withholding requirements of $13 million, a reduction in cash paid for deferred financing costs and other debt-related costs of $20 million, an increase in our long-term borrowings of $313 million, which was mostly offset by an increase in the repayments of our long-term debt of $212 million. These increases were offset by a decrease in the proceeds from the exercise of stock options of $17 million, an increase in cash paid for the redemption of noncontrolling investments in joint ventures of $9 million and a reduction in the proceeds from the receivables facility of $44 million.

Capital Expenditures

Cash expenditures for purchases of facilities were $99 million for the three months ended March 31, 2016, compared to $13 million for the three months ended March 31, 2015. The increase was primarily related to the acquisition of two hospitals during the three months ended March 31, 2016 compared to no hospital acquisitions during the three months ended March 31, 2015. Our expenditures during for the three months ended March 31, 2016 and 2015 were primarily related to the purchase of physician practices and other ancillary services.

55

Excluding the cost to construct replacement hospitals, our cash expenditures for routine capital for the three months ended March 31, 2016 totaled $216 million compared to $207 million for the three months ended March 31, 2015. These capital expenditures related primarily to the purchase of additional equipment, minor renovations and information systems infrastructure. Costs to construct replacement hospitals totaled $8 million for the three months ended March 31, 2016, compared to $34 million for the three months ended March 31, 2015. The costs to construct replacement hospitals for the three months ended March 31, 2016 represent both planning and construction costs for the replacement hospital in York, Pennsylvania. The costs to construct replacement hospitals for the three months ended March 31, 2015, included planning and construction costs for the replacement hospitals in both York, Pennsylvania and Birmingham, Alabama. Completion of the replacement hospital, Grandview Medical Center in Birmingham, Alabama, and transfer of all operations was completed on October 10, 2015.

Pursuant to a hospital purchase agreement in effect as of March 31, 2016, we have committed to build a replacement facility in York, Pennsylvania by July 2017. Construction costs, including equipment costs, for the York replacement facility are currently estimated to be approximately $125 million.

Pursuant to a hospital purchase agreement from our March 1, 2016 acquisition of IU Health La Porte Hospital and IU Health Starke Hospital, we have committed to build replacement facilities in both La Porte, Indiana and Knox, Indiana within five years, or by March 2021. Construction costs, including equipment costs, for the La Porte and Starke replacement facilities are currently estimated to be approximately $125 million and $15 million, respectively.

Capital Resources

Net working capital was approximately $2.2 billion at March 31, 2016, compared to $2.1 billion at December 31, 2015, an increase of $110 million, primarily the result of increases in patient accounts receivable and prepaid expenses along with decreases in accounts payable and accrued interest. This increase in working capital was partially offset by an increase in employee compensation.

We have senior secured financing under a credit facility with a syndicate of financial institutions led by Credit Suisse, as administrative agent and collateral agent. In connection with the HMA merger, we and CHS/Community Health Systems, Inc., or CHS, entered into a third amendment and restatement of its Credit Facility, providing for additional financing and recapitalization of certain of our term loans, including (i) the replacement of the revolving credit facility with a new $1.0 billion revolving facility maturing in 2019, or Revolving Facility, (ii) the addition of a new $1.0 billion Term A facility due 2019, or the Term A Facility, (iii) a Term D facility in an aggregate principal amount equal to approximately $4.6 billion due 2021 (which included certain term C loans that were converted into such Term D facility (collectively, the Term D Facility)), (iv) the conversion of certain term C loans into Term E Loans and the borrowing of new Term E Loans in an aggregate principal amount of approximately $1.7 billion due 2017 and (v) the addition of flexibility commensurate with the our post-acquisition structure. In addition to funding a portion of the consideration in connection with the HMA merger, some of the proceeds of the Term A Facility and Term D Facility were used to refinance the outstanding $637 million existing term A facility due 2016 and the $60 million of term B loans due 2014, respectively. The Revolving Facility includes a subfacility for letters of credit. On March 9, 2015, CHS entered into Amendment No. 1 and Incremental Term Loan Assumption Agreement to refinance the existing Term E Loans due 2017 into Term F Loans due 2018, in an original aggregated principal amount of $1.7 billion. On May 18, 2015, CHS entered into an Incremental Term Loan Assumption Agreement to provide for a new $1.6 billion incremental Term G facility and a new approximately $2.9 billion incremental Term H facility. The proceeds of the Term G facility and Term H facility were used to repay the Company’s existing Term D facility in full. On April 29, 2016, we used approximately $194 million of the special distribution paid by QHC to us as part of the series of transactions engaged in to complete the spin-off to repay a portion of its Term F Loans due 2018.

The loans under the Credit Facility bear interest on the outstanding unpaid principal amount at a rate equal to an applicable percentage plus, at our option, either (a) an Alternate Base Rate (as defined) determined by reference to the greater of (1) the Prime Rate (as defined) announced by Credit Suisse or (2) the Federal Funds Effective Rate (as defined) plus 0.5% or (3) the adjusted LIBOR rate on such day for a three-month interest period commencing on the second business day after such day plus 1% or (b) LIBOR. Loans in respect of the Revolving Facility and the Term A Facility will accrue interest at a rate per annum initially equal to LIBOR plus 2.75%, in the case of LIBOR borrowings, and Alternate Base Rate plus 1.75%, in the case of Alternate Base Rate borrowings. In addition, the margin in respect of the Revolving Facility and the Term A Facility will be subject to adjustment determined by reference to a leverage-based pricing grid. Loans in respect of the Term F Facility will accrue interest at a rate per annum equal to LIBOR plus 3.25%, in the case of LIBOR borrowings, and Alternate Base Rate plus 2.25%, in the case of Alternate Base Rate Borrowings. The Term G Loan and Term H Loan will accrue interest at a rate per annum equal to LIBOR plus 2.75% and 3.00%, respectively, in the case of LIBOR borrowings, and Alternate Base Rate plus 1.75% and 2.00%, respectively, in the case of Alternate Base Rate Borrowings. The Term G Loan and the Term H Loan are subject to a 1.00% LIBOR floor and a 2.00% Alternate Base Rate floor.

56

The term loan facility must be prepaid in an amount equal to (1) 100% of the net cash proceeds of certain asset sales and dispositions by us and our subsidiaries, subject to certain exceptions and reinvestment rights, (2) 100% of the net cash proceeds of issuances of certain debt obligations or receivables-based financing by us and our subsidiaries, subject to certain exceptions, and (3) 50%, subject to reduction to a lower percentage based on our leverage ratio (as defined in the Credit Facility generally as the ratio of total debt on the date of determination to our EBITDA, as defined, for the four quarters most recently ended prior to such date), of excess cash flow (as defined) for any year, subject to certain exceptions. Voluntary prepayments and commitment reductions are permitted in whole or in part, without any premium or penalty, subject to minimum prepayment or reduction requirements.

The borrower under the Credit Facility is CHS. All of our obligations under the Credit Facility are unconditionally guaranteed by Community Health Systems, Inc. and certain of its existing and subsequently acquired or organized domestic subsidiaries. All obligations under the Credit Facility and the related guarantees are secured by a perfected first priority lien or security interest in substantially all of the assets of Community Health Systems, Inc., CHS and each subsidiary guarantor, including equity interests held by us or any subsidiary guarantor, but excluding, among others, the equity interests of non-significant subsidiaries, syndication subsidiaries, securitization subsidiaries and joint venture subsidiaries.

We have agreed to pay letter of credit fees equal to the applicable percentage then in effect with respect to Eurodollar rate loans under the Revolving Facility times the maximum aggregate amount available to be drawn under all letters of credit outstanding under the subfacility for letters of credit. The issuer of any letter of credit issued under the subfacility for letters of credit will also receive a customary fronting fee and other customary processing charges. We are obligated to pay commitment fees of 0.50% per annum (subject to adjustment based upon our leverage ratio), on the unused portion of the Revolving Facility.

The Credit Facility contains customary representations and warranties, subject to limitations and exceptions, and customary covenants restricting our and our subsidiaries’ ability, subject to certain exception, to, among other things, (1) declare dividends, make distributions or redeem or repurchase capital stock, (2) prepay, redeem or repurchase other debt, (3) incur liens or grant negative pledges, (4) make loans and investments and enter into acquisitions and joint ventures, (5) incur additional indebtedness or provide certain guarantees, (6) make capital expenditures, (7) engage in mergers, acquisitions and asset sales, (8) conduct transactions with affiliates, (9) alter the nature of our businesses, (10) grant certain guarantees with respect to physician practices, (11) engage in sale and leaseback transactions or (12) change our fiscal year. We and our subsidiaries are also required to comply with specified financial covenants (consisting of a maximum secured net leverage ratio and an interest coverage ratio) and various affirmative covenants. We were in compliance with all such covenants at March 31, 2016.

Events of default under the Credit Facility include, but are not limited to, (1) our failure to pay principal, interest, fees or other amounts under the credit agreement when due (taking into account any applicable grace period), (2) any representation or warranty proving to have been materially incorrect when made, (3) covenant defaults subject, with respect to certain covenants, to a grace period, (4) bankruptcy events, (5) a cross default to certain other debt, (6) certain undischarged judgments (not paid within an applicable grace period), (7) a change of control, (8) certain ERISA-related defaults and (9) the invalidity or impairment of specified security interests, guarantees or subordination provisions in favor of the administrative agent or lenders under the Credit Facility.

As of March 31, 2016, the availability for additional borrowings under our Credit Facility, after taking into account the $334 million outstanding at that date, was $666 million pursuant to the Revolving Facility, of which $68 million was set aside for outstanding letters of credit. We believe that these funds, along with internally generated cash and continued access to the capital markets, will be sufficient to finance future acquisitions, capital expenditures and working capital requirements during the next 12 months.

In connection with the consummation of the HMA merger, CHS issued: (i) $1.0 billion aggregate principal amount of 5.125% Senior Secured Notes due 2021, or the 2021 Senior Secured Notes, pursuant to an indenture, as supplemented, dated as of January 27, 2014, collectively, the Secured Indenture, by and among CHS, the Parent Company, the other guarantors from time to time party thereto, Regions Bank, as trustee, and Credit Suisse AG, as collateral agent, or the Collateral Agent and (ii) $3.0 billion aggregate principal amount of 6.875% Senior Notes due 2022, or the 6 ⁷⁄₈% Senior Notes, pursuant to an indenture, as supplemented, dated as of January 27, 2014, collectively, the Unsecured Indenture, by and among CHS, the Parent Company, the other guarantors from time to time party thereto, and Regions Bank, as trustee, or the Unsecured Indenture.

On November 22, 2011, CHS completed its offering of $1.0 billion aggregate principal amount of 8% Senior Notes due 2019, which were issued in a private placement. On March 21, 2012, CHS completed the secondary offering of $1.0 billion aggregate principal amount of 8% Senior Notes, which were issued in a private placement (at a premium of 102.5%). The net proceeds from these issuances were used to finance the purchase of approximately $1.85 billion aggregate principal amount of CHS’ then outstanding 8 ⁷⁄₈% Senior Notes, to pay related fees and expenses and for general corporate purposes.

57

On July 18, 2012, CHS completed an underwritten public offering under our automatic shelf registration filed with the SEC of $1.2 billion aggregate principal amount of 7 ¹⁄₈% Senior Notes due 2020. The net proceeds of the offering were used to finance the purchase or redemption of the then outstanding $934 million principal amount plus accrued interest of the 8 ⁷⁄₈% Senior Notes, to pay for consents delivered in connection therewith, to pay related fees and expenses, and for general corporate purposes.

On August 17, 2012, CHS completed an underwritten public offering under our automatic shelf registration filed with the SEC of $1.6 billion aggregate principal amount of 5 ¹⁄₈% Senior Secured Notes due 2018. The 5 ¹⁄₈% Senior Secured Notes are secured by a first-priority lien subject to a shared lien of equal priority with certain other obligations, including obligations under the Credit Facility, and subject to prior ranking liens permitted by the indenture governing the 5 ¹⁄₈% Senior Secured Notes on substantially the same assets, subject to certain exceptions, that secure CHS’ obligations under the Credit Facility. The net proceeds of the offering, together with available cash on hand, were used to finance the prepayment of $1.6 billion of the outstanding term loans due 2014 under the Credit Facility and related fees and expenses. On May 2, 2016, we commenced a cash tender offer for up to $900 million of the 5 ¹⁄₈% Senior Secured Notes as noted in a press release issued by us on such date.

On January 27, 2014, CHS completed its offering of $1.0 billion aggregate principal amount of 5.125% Senior Secured Notes due 2021 and $3.0 billion aggregate principal amount of 6.875% Senior Notes due 2022, which were issued in a private placement. The net proceeds from these issuances were used to finance the HMA merger.

On March 21, 2012, through certain of its subsidiaries, CHS entered into an accounts receivable loan agreement, or the Receivables Facility, with a group of lenders and banks, Credit Agricolé Corporate and Investment Bank, as a managing agent and as the administrative agent, and The Bank of Nova Scotia, as a managing agent. On March 7, 2013, CHS and certain of its subsidiaries amended the Receivables Facility to add an additional managing agent, The Bank of Tokyo-Mitsubishi UFJ, Ltd., to increase the size of the facility from $300 million to $500 million and to extend the scheduled termination date. Additional subsidiaries also agreed to participate in the Receivables Facility as of that date. On March 31, 2014, CHS and certain of its subsidiaries amended the Receivables Facility to increase the size of the facility from $500 million to $700 million and to extend the scheduled termination date. Additional subsidiaries also agreed to participate in the Receivables Facility as of that date. On November 13, 2015, CHS and certain of its subsidiaries amended the Receivables Facility to extend the scheduled termination date and amend certain other provisions thereof. The existing and future non-self pay patient-related accounts receivable, or the Receivables, for certain hospitals of CHS and its subsidiaries serve as collateral for the outstanding borrowings under the Receivables Facility. The interest rate on the borrowings is based on the commercial paper rate plus an applicable interest rate spread. Unless earlier terminated or subsequently extended pursuant to its terms, the Receivables Facility will expire on November 13, 2017, subject to customary termination events that could cause an early termination date. CHS maintains effective control over the Receivables because, pursuant to the terms of the Receivables Facility, the Receivables are sold from certain of CHS’ subsidiaries to CHS, and CHS then sells or contributes the Receivables to a special-purpose entity that is wholly-owned by CHS. The wholly-owned special-purpose entity in turn grants security interests in the Receivables in exchange for borrowings obtained from the group of third-party lenders and banks of up to $700 million outstanding from time to time based on the availability of eligible Receivables and other customary factors. The group of third-party lenders and banks do not have recourse to CHS or its subsidiaries beyond the assets of the wholly-owned special-purpose entity that collateralizes the loan. The Receivables and other assets of the wholly-owned special-purpose entity will be available first and foremost to satisfy the claims of the creditors of such entity. The outstanding borrowings pursuant to the Receivables Facility at March 31, 2016 totaled $699 million and are classified as long-term debt on the condensed consolidated balance sheet. At March 31, 2016, the carrying amount of Receivables included in the Receivables Facility totaled approximately $1.7 billion and is included in patient accounts receivable on the condensed consolidated balance sheet.

We have transitioned all of our hospitals to the ICD-10 coding system, which was required effective October 1, 2015 of all healthcare providers covered by the Health Insurance Portability and Accountability Act, or HIPAA. This transition continues to involve a significant focus on our technology and information systems, as well as costs related to training of hospital employees and providers and corporate support staff involved with coding and billing. As noted in the risk factors as previously set forth in our Annual Report on Form 10-K filed with the SEC on February 17, 2016, or 2015 Form 10-K, the potential for delay in billing and collection on patient receivables resulting from these changes or from new payment systems and processes implemented by third-party payors could have an adverse effect on the quality of receivables that serve as collateral under the Receivables Facility, resulting in a potential default or repayment of outstanding borrowings. Should such a repayment of borrowings under the Receivables Facility be required, we have availability, and expect to continue to have availability, under the Revolving Facility to provide sufficient financial resources and liquidity to fund the repayment.

58

As of March 31, 2016, we are currently a party to the following interest rate swap agreements to limit the effect of changes in interest rates on approximately 43.5% of our variable rate debt. On each of these swaps, we receive a variable rate of interest based on the three-month LIBOR, in exchange for the payment by us of a fixed rate of interest. We currently pay, on a quarterly basis, interest on the Revolving Facility and the Term A Facility at a rate per annum equal to LIBOR plus 2.75%. Loans in respect of the Term F Facility accrue interest at a rate per annum equal to LIBOR plus 3.25%. The Term G Loan and Term H Loan accrue interest at a rate per annum equal to LIBOR plus 2.75% and 3.00%, respectively, in the case of LIBOR borrowings, and Alternate Base Rate plus 1.75% and 2.00%, respectively, in the case of Alternate Base Rate Borrowings. The Term G Loan and the Term H Loan are subject to a 1.00% LIBOR floor and a 2.00% Alternate Base Rate floor.

Swap #	Notional Amount (in millions)		Fixed Interest Rate		Termination Date		Fair Value (in       millions)
1	$	300		3.447 %		August 6, 2016	$	3
2		100		3.401 %		August 19, 2016		1
3		200		3.429 %		August 19, 2016		2
4		200		3.500 %		August 30, 2016		2
5		100		3.005 %		November 30, 2016		2
6		200		2.055 %		July 25, 2019		7
7		200		2.059 %		July 25, 2019		7
8		400		1.882 %		August 30, 2019		7
9		200		2.515 %		August 30, 2019		8
10		200		2.613 %		August 30, 2019		8
11		300		2.041 %		August 30, 2020		7
12		300		2.738 %		August 30, 2020		16
13		300		2.892 %		August 30, 2020		17
14		300		2.363 %		January 27, 2021		11
15		200		2.368 %		January 27, 2021		7

The swaps that were in effect prior to the HMA merger remain in effect after the refinancing for the HMA merger and will continue to be used to limit the effects of changes in interest rates on portions of our amended credit facility.

The Credit Facility and/or our outstanding notes contain various covenants that limit our ability to take certain actions including; among other things, our ability to:

• incur, assume or guarantee additional indebtedness;

• issue redeemable stock and preferred stock;

• repurchase capital stock;

• make restricted payments, including paying dividends and making certain loans and investments;

• redeem debt that is subordinated in right of payment to our outstanding notes;

• create liens;

• sell or otherwise dispose of assets, including capital stock of subsidiaries;

• enter into agreements that restrict dividends from subsidiaries;

• merge, consolidate, sell or otherwise dispose of substantially all of our assets;

• enter into transactions with affiliates; and

• guarantee certain obligations.

59

In addition, our Credit Facility contains restrictive covenants and requires us to maintain specified financial ratios and satisfy other financial condition tests. Our ability to meet these restricted covenants and financial ratios and tests can be affected by events beyond our control, and we cannot assure you that we will meet those tests. A breach of any of these covenants could result in a default under our Credit Facility and/or our outstanding notes. Upon the occurrence of an event of default under our Credit Facility or our outstanding notes, all amounts outstanding under our Credit Facility and the notes may become immediately due and payable and all commitments under the Credit Facility to extend further credit may be terminated.

Pursuant to a special distribution paid by QHC to us on April 29, 2016, as part of the series of transactions engaged in to complete the spin-off, we received approximately $1.2 billion in cash generated from the net proceeds of certain financing arrangements entered into by QHC as part of the separation. As set forth above, we have used approximately $194 million of such proceeds to repay a portion of our Term F Loans due 2018, and commenced a cash tender offer on May 2, 2016, for up to $900 million of our approximately $1.6 billion aggregate principal amount outstanding of 5 ¹⁄₈% Senior Secured Notes due 2018. We intend to use remaining proceeds from such special distribution to repay other outstanding debt and to pay certain expenses incurred in connection with the spin-off and such debt repayment transactions.

We believe that internally generated cash flows, availability for additional borrowings under our Credit Facility of $666 million (consisting of a $1.0 billion Revolving Facility, of which $68 million is set aside for outstanding letters of credit and $334 million was outstanding at March 31, 2016) and our ability to amend the Credit Facility to provide for one or more tranches of term loans in an aggregate principal amount of $1.5 billion, and our continued access to the capital markets will be sufficient to finance acquisitions, capital expenditures, working capital requirements, and any equity or debt repurchases or other debt repayments we may elect to make through the next 12 months. In addition, we may elect to utilize proceeds received from any dispositions of hospitals or investments to repay outstanding debt.

We may elect from time to time to purchase our common stock under our open market repurchase program adopted on November 6, 2015, which authorizes us to purchase up to 10,000,000 shares of our common stock, not to exceed $300 million in repurchases (we have currently repurchased 532,188 shares under such program, all of which shares were repurchased during the three months ended December 31, 2015). In addition, we may elect from time to time to purchase our outstanding debt in open market purchases, privately negotiated transactions or otherwise. Any such equity or debt repurchases will depend upon prevailing market conditions, our liquidity requirements, contractual restrictions, applicable securities laws requirements, and other factors.

On May 6, 2015, we filed a universal automatic shelf registration statement on Form S-3ASR that will permit us, from time to time, in one or more public offerings, to offer debt securities, common stock, preferred stock, warrants, depositary shares, or any combination of such securities. The shelf registration statement will also permit our subsidiary, CHS, to offer debt securities that would be guaranteed by us, from time to time in one or more public offerings. The terms of any such future offerings would be established at the time of the offering.

The ratio of earnings to fixed charges is a measure of our ability to meet our fixed obligations related to our indebtedness. The following table shows the ratio of earnings to fixed charges for the three months ended March 31, 2016:

	Three Months Ended   March 31, 2016
Ratio of earnings to fixed charges (1)	1.17 x

(1) Fixed charges include interest expensed and capitalized during the year plus an estimate of the interest component of rent expense. There are no shares of preferred stock outstanding. See exhibit 12 filed as part of this Report for the calculation of this ratio.

60

Off-balance Sheet Arrangements

In the past, we have utilized operating leases as a financing tool for obtaining the operations of specified hospitals without acquiring, through ownership, the related assets of the hospital and without a significant outlay of cash at the front end of the lease. We utilize the same operating strategies to improve operations at those hospitals held under operating leases as we do at those hospitals that we own. We have not entered into any operating leases for hospital operations since December 2000. At March 31, 2016, we operated three hospitals under operating leases that had an immaterial impact on our consolidated operating results. The terms of the three operating leases we currently have in place expire between December 2020 and June 2028, not including lease extension options. If we allow these leases to expire, we would no longer generate revenues nor incur expenses from these hospitals.

Noncontrolling Interests

We have sold noncontrolling interests in certain of our subsidiaries or acquired subsidiaries with existing noncontrolling interest ownership positions. As of March 31, 2016, we have hospitals in 29 of the markets we serve, with noncontrolling physician ownership interests ranging from less than 1% to 40%, including one hospital that also has a non-profit entity as a partner. In addition, we have 11 other hospitals with noncontrolling interests owned by non-profit entities. Redeemable noncontrolling interests in equity of consolidated subsidiaries was $565 million and $571 million as of March 31, 2016 and December 31, 2015, respectively, and noncontrolling interests in equity of consolidated subsidiaries was $115 million and $86 million as of March 31, 2016 and December 31, 2015, respectively. The amount of net income attributable to noncontrolling interests was $25 million and $20 million for the three months ended March 31, 2016 and 2015, respectively. As a result of the change in the Stark Law “whole hospital” exception included in the Reform Legislation, we are not permitted to introduce physician ownership at any of our wholly-owned hospital facilities or increase the aggregate percentage of physician ownership in any of our existing hospital joint ventures in excess of the aggregate physician ownership level held at the time of the adoption of the Reform Legislation.

Reimbursement, Legislative and Regulatory Changes

Ongoing legislative and regulatory efforts could reduce or otherwise adversely affect the payments we receive from Medicare and Medicaid. Within the statutory framework of the Medicare and Medicaid programs, including programs currently unaffected by the Reform Legislation, there are substantial areas subject to administrative rulings, interpretations and discretion which may further affect payments made under those programs, and the federal and state governments might, in the future, reduce the funds available under those programs or require more stringent utilization and quality reviews of hospital facilities. Additionally, there may be a continued rise in managed care programs and additional restructuring of the financing and delivery of healthcare in the United States. These events could cause our future financial results to decline. We cannot estimate the impact of Medicare and Medicaid reimbursement changes that have been enacted or are under consideration. We cannot predict whether additional reimbursement reductions will be made or whether any such changes would have a material adverse effect on our business, financial conditions, results of operations, cash flow, capital resources and liquidity.

Inflation

The healthcare industry is labor intensive. Wages and other expenses increase during periods of inflation and when labor shortages occur in the marketplace. In addition, our suppliers pass along rising costs to us in the form of higher prices. We have implemented cost control measures, including our case and resource management program, to curb increases in operating costs and expenses. We have generally offset increases in operating costs by increasing reimbursement for services, expanding services and reducing costs in other areas. However, we cannot predict our ability to cover or offset future cost increases, particularly any increases in our cost of providing health insurance benefits to our employees as a result of the Reform Legislation.

Critical Accounting Policies

The discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amount of assets and liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities at the date of our condensed consolidated financial statements. Actual results may differ from these estimates under different assumptions or conditions.

Critical accounting policies are defined as those that are reflective of significant judgments and uncertainties, and potentially result in materially different results under different assumptions and conditions. We believe that our critical accounting policies are limited to those described below.

61

  Third-party Reimbursement

Net operating revenues include amounts estimated by management to be reimbursable by Medicare and Medicaid under prospective payment systems and provisions of cost-reimbursement and other payment methods. In addition, we are reimbursed by non-governmental payors using a variety of payment methodologies. Amounts we receive for treatment of patients covered by these programs are generally less than the standard billing rates. Contractual allowances are automatically calculated and recorded through our internally developed “automated contractual allowance system.” Within the automated system, payors’ historical paid claims data are utilized to calculate the contractual allowances. This data is automatically updated on a monthly basis. All hospital contractual allowance calculations are subjected to monthly review by management to ensure reasonableness and accuracy. We account for the differences between the estimated program reimbursement rates and the standard billing rates as contractual allowance adjustments, which we deduct from gross revenues to arrive at operating revenues (net of contractual allowances and discounts). The process of estimating contractual allowances requires us to estimate the amount expected to be received based on payor contract provisions. The key assumption in this process is the estimated contractual reimbursement percentage, which is based on payor classification and historical paid claims data. Our automated contractual allowance system does not maintain the contractual allowance at the patient account level as it estimates an average contractual allowance by payor classification. Due to the complexities involved in these estimates, actual payments we receive could be different from the amounts we estimate and record. If the actual contractual reimbursement percentage under government programs and managed care contracts differed by 1% at March 31, 2016 from our estimated reimbursement percentage, net income for the three months ended March 31, 2016 would have changed by approximately $45 million, and net accounts receivable at March 31, 2016 would have changed by $140 million. Final settlements under some of these programs are subject to adjustment based on administrative review and audit by third parties. We account for adjustments to previous program reimbursement estimates as contractual allowance adjustments and report them in the periods that such adjustments become known. Contractual allowance adjustments related to final settlements and previous program reimbursement estimates impacted net operating revenues and net income by an insignificant amount in each of the three month periods ended March 31, 2016 and 2015.

  Allowance for Doubtful Accounts

Substantially all of our accounts receivable are related to providing healthcare services to patients at our hospitals and affiliated businesses. Collection of these accounts receivable is our primary source of cash and is critical to our operating performance. Our primary collection risks relate to uninsured patients and outstanding patient balances for which the primary insurance payor has paid some but not all of the outstanding balance, with the remaining outstanding balance (generally deductibles and co-payments) owed by the patient. For all procedures scheduled in advance, our policy is to verify insurance coverage prior to the date of the procedure. Insurance coverage is not verified in advance of procedures for walk-in and emergency room patients.

We estimate the allowance for doubtful accounts by reserving a percentage of all self-pay accounts receivable without regard to aging category, based on collection history, adjusted for expected recoveries and any anticipated changes in trends. Our ability to estimate the allowance for doubtful accounts is not impacted by not utilizing an aging of our net accounts receivable as we believe that substantially all of the risk exists at the point in time such accounts are identified as self-pay. For all other non-self-pay payor categories, we reserve an estimated amount based on historical collection rates for the uncontractualized portion of all accounts aging over 365 days from the date of discharge. These amounts represent an immaterial percentage of our outstanding accounts receivable. The percentage used to reserve for all self-pay accounts is based on our collection history. We believe that we collect substantially all of our third-party insured receivables, which include receivables from governmental agencies.

Collections are impacted by the economic ability of patients to pay and the effectiveness of our collection efforts. Significant changes in payor mix, business office operations, economic conditions or trends in federal and state governmental healthcare coverage could affect our collection of accounts receivable and are considered in our estimates of accounts receivable collectability. If the actual collection percentage differed by 1% at March 31, 2016 from our estimated collection percentage as a result of a change in expected recoveries, net income for the three months ended March 31, 2016 would have changed by $26 million, and net accounts receivable at March 31, 2016 would have changed by $82 million. We also continually review our overall reserve adequacy by monitoring historical cash collections as a percentage of trailing net revenue less provision for bad debts, as well as by analyzing current period net revenue and admissions by payor classification, days revenue outstanding, the composition of self-pay receivables between pure self-pay patients and the patient responsibility portion of third-party insured receivables and the impact of recent acquisitions and dispositions.

62

Our policy is to write-off gross accounts receivable if the balance is under $10.00 or when such amounts are placed with outside collection agencies. We believe this policy accurately reflects our ongoing collection efforts and is consistent with industry practices. We had approximately $4.1 billion and $4.0 billion at March 31, 2016 and December 31, 2015, respectively, being pursued by various outside collection agencies. We expect to collect less than 3%, net of estimated collection fees, of the amounts being pursued by outside collection agencies. As these amounts have been written-off, they are not included in our gross accounts receivable or our allowance for doubtful accounts. Collections on amounts previously written-off are recognized as a reduction to bad debt expense when received. However, we take into consideration estimated collections of these future amounts written-off in evaluating the reasonableness of our allowance for doubtful accounts.

All of the following information is derived from our hospitals, excluding clinics, unless otherwise noted.

Patient accounts receivable from our hospitals represent approximately 95% of our total consolidated accounts receivable.

Days revenue outstanding, adjusted for the impact of receivables for state Medicaid supplemental payment programs, was 64 days at March 31, 2016 and 63 days at December 31, 2015. Our target range for days revenue outstanding is from 60 to 65 days.

Total gross accounts receivable (prior to allowance for contractual adjustments and doubtful accounts) was approximately $21.5 billion as of March 31, 2016 and approximately $20.5 billion as of December 31, 2015.

The approximate percentage of total gross accounts receivable (prior to allowances for contractual adjustments and doubtful accounts) summarized by payor is as follows:

	March 31, 2016		December 31, 2015
Insured receivables		62.4 %		60.6 %
Self-pay receivables		37.6		39.4
Total		100.0 %		100.0 %

For the hospital segment, the combined total of the allowance for doubtful accounts for self-pay accounts receivable and related allowances for other self-pay discounts and contractuals, as a percentage of gross self-pay receivables, was approximately 89% and 88% at March 31, 2016 and December 31, 2015, respectively. If the receivables that have been written-off, but where collections are still being pursued by outside collection agencies, were included in both the allowances and gross self-pay receivables specified above, the percentage of combined allowances to total self-pay receivables would have been approximately 93% and 92% at March 31, 2016 and December 31, 2015, respectively.

  Goodwill and Other Intangibles

Goodwill represents the excess of the fair value of the consideration conveyed in the acquisition over the fair value of net assets acquired. Goodwill is evaluated for impairment at the same time every year and when an event occurs or circumstances change that, more likely than not, reduce the fair value of the reporting unit below its carrying value. There is a two-step method for determining goodwill impairment. Step one is to compare the fair value of the reporting unit with the unit’s carrying amount, including goodwill. If this test indicates the fair value is less than the carrying value, then step two is required to compare the implied fair value of the reporting unit’s goodwill with the carrying value of the reporting unit’s goodwill.

At March 31, 2016, we had approximately $9.0 billion of goodwill recorded on our books. Substantially all of our goodwill resides at our hospital operations reporting unit. We performed our last annual goodwill evaluation during the fourth quarter of 2015. No impairment was indicated by this evaluation, however, a decline in our stock price during the fourth quarter of 2015 and lower projections of future discounted cash flows reduced the excess of estimated fair value to approximately 10% over the carrying value of our hospital operations reporting unit. This decline in the excess fair value over carrying value of our hospital operations reporting unit increases the risk that future declines in fair value could result in goodwill impairment. The determination of fair value in step one of our goodwill impairment analysis is based on an estimate of fair value for each reporting unit utilizing known and estimated inputs at the evaluation date. Some of those inputs include, but are not limited to, the most recent price of our common stock, estimates of future revenue and expense growth, expected capital expenditures, income tax rates, and costs of invested capital. Future estimates of fair value could be adversely affected if the actual outcome of one or more of these assumptions changes materially in the future, including a decline in our stock price, lower than expected hospital volumes, or increased operating costs.

63

Impairment or Disposal of Long-Lived Assets

Whenever events or changes in circumstances indicate that the carrying values of certain long-lived assets may be impaired, we project the undiscounted cash flows expected to be generated by these assets. If the projections indicate that the reported amounts are not expected to be recovered, such amounts are reduced to their estimated fair value based on a quoted market price, if available, or an estimate based on valuation techniques available in the circumstances.

  Professional Liability Claims

As part of our business of owning and operating hospitals, we are subject to legal actions alleging liability on our part. We accrue for losses resulting from such liability claims, as well as loss adjustment expenses that are out-of-pocket and directly related to such liability claims. These direct out-of-pocket expenses include fees of outside counsel and experts. We do not accrue for costs that are part of our corporate overhead, such as the costs of our in-house legal and risk management departments. The losses resulting from professional liability claims primarily consist of estimates for known claims, as well as estimates for incurred but not reported claims. The estimates are based on specific claim facts, our historical claim reporting and payment patterns, the nature and level of our hospital operations, and actuarially determined projections. The actuarially determined projections are based on our actual claim data, including historic reporting and payment patterns which have been gathered over approximately a 20-year period. As discussed below, since we purchase excess insurance on a claims-made basis that transfers risk to third-party insurers, the liability we accrue does include an amount for the losses covered by our excess insurance. We also record a receivable for the expected reimbursement of losses covered by our excess insurance. Since we believe that the amount and timing of our future claims payments are reliably determinable, we discount the amount we accrue for losses resulting from professional liability claims using the risk-free interest rate corresponding to the timing of our expected payments.

The net present value of the projected payments was discounted using a weighted-average risk-free rate of 1.6%, 1.7% and 1.6% in 2015, 2014 and 2013, respectively. This liability is adjusted for new claims information in the period such information becomes known to us. Professional malpractice expense includes the losses resulting from professional liability claims and loss adjustment expense, as well as paid excess insurance premiums, and is presented within other operating expenses in the accompanying condensed consolidated statements of income.

Our processes for obtaining and analyzing claims and incident data are standardized across all of our hospitals and have been consistent for many years. We monitor the outcomes of the medical care services that we provide and for each reported claim, we obtain various information concerning the facts and circumstances related to that claim. In addition, we routinely monitor current key statistics and volume indicators in our assessment of utilizing historical trends. The average lag period between claim occurrence and payment of a final settlement is between four and five years, although the facts and circumstances of individual claims could result in the timing of such payments being different from this average. Since claims are paid promptly after settlement with the claimant is reached, settled claims represent less than 1.0% of the total liability at the end of any period.

For purposes of estimating our individual claim accruals, we utilize specific claim information, including the nature of the claim, the expected claim amount, the year in which the claim occurred and the laws of the jurisdiction in which the claim occurred. Once the case accruals for known claims are determined, information is stratified by loss layers and retentions, accident years, reported years, geography, and claims relating to the acquired HMA hospitals versus claims relating to our other hospitals. Several actuarial methods are used against this data to produce estimates of ultimate paid losses and reserves for incurred but not reported claims. Each of these methods uses our company-specific historical claims data and other information. This company-specific data includes information regarding our business, including historical paid losses and loss adjustment expenses, historical and current case loss reserves, actual and projected hospital statistical data, a variety of hospital census information, employed physician information, professional liability retentions for each policy year, geographic information and other data.

Based on these analyses, we determine our estimate of the professional liability claims. The determination of management’s estimate, including the preparation of the reserve analysis that supports such estimate, involves subjective judgment of management. Changes in reserving data or the trends and factors that influence reserving data may signal fundamental shifts in our future claim development patterns or may simply reflect single-period anomalies. Even if a change reflects a fundamental shift, the full extent of the change may not become evident until years later. Moreover, since our methods and models use different types of data and we select our liability from the results of all of these methods, we typically cannot quantify the precise impact of such factors on our estimates of the liability. Due to our standardized and consistent processes for handling claims and the long history and depth of our company-specific data, our methodologies have produced reliably determinable estimates of ultimate paid losses.

64

The impact of risk management patient safety quality programs and initiatives implemented at our hospitals, as well as decreasing obstetric admissions, surgeries, admissions and a slightly lower same-store acuity case mix, resulted in the current accident year expense decreasing, as a percentage of net operating revenues, for each year presented. Income/expense related to prior accident years reflects changes in estimates resulting from the filing of claims for prior year incidents, claim settlements, updates from litigation and our ongoing investigation of open claims. Expense/income from discounting reflects the changes in the weighted-average risk-free interest rate used and timing of estimated payments for discounting in each year.

We are primarily self-insured for these claims; however, we obtain excess insurance that transfers the risk of loss to a third-party insurer for claims in excess of our self-insured retentions. Our excess insurance is underwritten on a claims-made basis. For claims reported prior to June 1, 2002, substantially all of our professional and general liability risks were subject to a less than $1 million per occurrence self-insured retention and for claims reported from June 1, 2002 through June 1, 2003, these self-insured retentions were $2 million per occurrence. Substantially all claims reported after June 1, 2003 and before June 1, 2005 are self-insured up to $4 million per claim. Substantially all claims reported on or after June 1, 2005 and before June 1, 2014 are self-insured up to $5 million per claim. Substantially all claims reported on or after June 1, 2014 are self-insured up to $10 million per claim. Management, on occasion, has selectively increased the insured risk at certain hospitals based upon insurance pricing and other factors and may continue that practice in the future. Excess insurance for all hospitals has been purchased through commercial insurance companies and generally covers us for liabilities in excess of the self-insured retentions. The excess coverage consists of multiple layers of insurance, the sum of which totals up to $95 million per occurrence and in the aggregate for claims reported on or after June 1, 2003, up to $145 million per occurrence and in the aggregate for claims reported on or after January 1, 2008, up to $195 million per occurrence and in the aggregate for claims reported on or after June 1, 2010, and up to $220 million per occurrence and in the aggregate for claims reported on or after June 1, 2015. In addition, for integrated occurrence malpractice claims, there is an additional $50 million of excess coverage for claims reported on or after June 1, 2014 and an additional $75 million of excess coverage for claims reported on or after June 1, 2015. For certain policy years prior to June 1, 2014, if the first aggregate layer of excess coverage becomes fully utilized, then the self-insured retention will increase to $10 million per claim for any subsequent claims in that policy year until our total aggregate coverage is met.

Effective June 1, 2014, the hospitals acquired from HMA were insured on a claims-made basis as described above and through commercial insurance companies as described above for substantially all claims reported on or after June 1, 2014 except for physician-related claims with an occurrence date prior to June 1, 2014. Prior to June 1, 2014, the former HMA hospitals obtained insurance coverage through a wholly-owned captive insurance subsidiary and a risk retention group subsidiary which are domiciled in the Cayman Islands and South Carolina, respectively. Those insurance subsidiaries, which are collectively referred to as the “Insurance Subsidiaries,” provided (i) claims-made coverage to all of the former HMA hospitals and (ii) occurrence-basis coverage to most of the physicians employed by the former HMA hospitals. The employed physicians not covered by the Insurance Subsidiaries generally maintained claims-made policies with unrelated third party insurance companies. To mitigate the exposure of the program covering the former HMA hospitals and other healthcare facilities, the Insurance Subsidiaries bought claims-made reinsurance policies from unrelated third parties for claims above self-retention levels of $10 million or $15 million per claim, depending on the policy year.

Effective January 1, 2008, the former Triad Hospitals, Inc., or Triad, hospitals were insured on a claims-made basis as described above and through commercial insurance companies as described above for substantially all claims occurring on or after January 1, 2002 and reported on or after January 1, 2008. Substantially all losses for the former Triad hospitals in periods prior to May 1, 1999 were insured through a wholly-owned insurance subsidiary of HCA Holdings, Inc., or HCA, Triad’s owner prior to that time, and excess loss policies maintained by HCA. HCA has agreed to indemnify the former Triad hospitals in respect of claims covered by such insurance policies arising prior to May 1, 1999. From May 1, 1999 through December 31, 2006, the former Triad hospitals obtained insurance coverage on a claims incurred basis from HCA’s wholly-owned insurance subsidiary with excess coverage obtained from other carriers that is subject to certain deductibles. Effective for claims incurred after December 31, 2006, Triad began insuring its claims from $1 million to $5 million through its wholly-owned captive insurance company, replacing the coverage provided by HCA. Substantially all claims occurring during 2007 were self-insured up to $10 million per claim.

There have been no significant changes in our estimate of the reserve for professional liability claims during the three months ended March 31, 2016.

  Income Taxes

We must make estimates in recording provision for income taxes, including determination of deferred tax assets and deferred tax liabilities and any valuation allowances that might be required against the deferred tax assets. We believe that future income will enable us to realize certain deferred tax assets, subject to the valuation allowance we have established.

65

The total amount of unrecognized benefit that would impact the effective tax rate, if recognized, was approximately $5 million as of March 31, 2016. A total of approximately $3 million of interest and penalties is included in the amount of liability for uncertain tax positions at March 31, 2016. It is our policy to recognize interest and penalties related to unrecognized benefits in our condensed consolidated statements of income as income tax expense.

It is possible the amount of unrecognized tax benefit could change in the next 12 months as a result of a lapse of the statute of limitations and settlements with taxing authorities; however, we do not anticipate the change will have a material impact on our condensed consolidated results of operations or condensed consolidated financial position.

We, or one of our subsidiaries, files income tax returns in the United States federal jurisdiction and various state jurisdictions. We have extended the federal statute of limitations through March 31, 2017 for Triad Hospitals, Inc. for the tax periods ended December 31, 1999, December 31, 2000, April 30, 2001, June 30, 2001, December 31, 2001, December 31, 2002, December 31, 2003, December 31, 2004, December 31, 2005, December 31, 2006 and July 25, 2007. With few exceptions, we are no longer subject to state income tax examinations for years prior to 2011. Our federal income tax returns for the 2009 and 2010 tax years are currently under examination by the Internal Revenue Service. We believe the results of these examinations will not be material to our consolidated results of operations or consolidated financial position. We have extended the federal statute of limitations through December 31, 2016 for Community Health Systems, Inc. for the tax periods ended December 31, 2007, 2008, 2009 and 2010, and through March 31, 2017 for the tax periods ended December 31, 2011 and 2012.

Recent Accounting Pronouncements

In April 2014, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2014-08, which changes the requirements for reporting discontinued operations. A discontinued operation continues to include a component of an entity or a group of components of an entity, or a business activity. However, in a shift reflecting stakeholder concerns that too many disposals of small groups of assets that are recurring in nature qualified for reporting as discontinued operations, a disposal of a component of an entity or a group of components of an entity will be required to be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results. A business or nonprofit activity that, on acquisition, meets the criteria to be classified as held for sale will still be a discontinued operation. Additional disclosures will be required for significant components of the entity that are disposed of or are held for sale but do not qualify as discontinued operations. This ASU is effective for fiscal years beginning after December 15, 2014 and is to be applied on a prospective basis for disposals or components initially classified as held for sale after that date. We adopted this ASU on January 1, 2015 and the adoption resulted in divestitures occurring subsequent to the date of adoption being included in continuing operations for the three months ended March 31, 2016 and 2015.

In May 2014, the FASB issued ASU 2014-09, which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. This ASU provides companies the option of applying a full or modified retrospective approach upon adoption. This ASU is effective for fiscal years beginning after December 15, 2016. However, the FASB recently issued a final ASU that defers the effective date by one year, with early adoption permitted for annual periods beginning after December 15, 2016. We expect to adopt this ASU on January 1, 2018 and are currently evaluating our plan for adoption and the impact on our revenue recognition policies, procedures and control framework and the resulting impact on our consolidated financial position, results of operations and cash flows.

In April 2015, the FASB issued ASU 2015-03, which requires debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct reduction from the carrying amount of that debt liability, consistent with the accounting for debt discounts. The ASU did not change the measurement or recognition guidance for debt issuance costs. This ASU is effective for fiscal years beginning after December 31, 2015. We adopted this ASU on January 1, 2016, which resulted in the reclassification of approximately $266 million of debt issuance costs from other long-term assets to a reduction of the related long-term debt.

In November 2015, the FASB issued ASU 2015-17, which amended the balance sheet classification requirements for deferred income taxes to simplify their presentation in the statement of financial position. The ASU requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. This ASU is effective for fiscal years beginning after December 31, 2016, with early adoption permitted. We early adopted the provisions of this ASU for the presentation and classification of its deferred tax assets at December 31, 2015. The effect of this change primarily resulted in the current portion of deferred income taxes at December 31, 2015 being included in the noncurrent deferred income tax liability.

66

In January 2016, the FASB issued ASU 2016-01, which amends the measurement, presentation and disclosure requirements for equity investments, other than those accounted for under the equity method or that require consolidation of the investee. The ASU eliminates the classification of equity investments as available-for-sale with any changes in fair value of such investments recognized in other comprehensive income, and requires entities to measure equity investments at fair value, with any changes in fair value recognized in net income. This ASU is effective for fiscal years beginning after December 15, 2017, with early adoption permitted. We expect to adopt this ASU on January 1, 2018, and are currently evaluating the impact that adoption of this ASU will have on our consolidated financial position and results of operations.

In February 2016, the FASB issued ASU 2016-02, which amends the accounting for leases, requiring lessees to recognize most leases on their balance sheet with a right-of-use asset and a lease liability. Leases will be classified as either finance or operating leases, which will impact the expense recognition of such leases over the lease term. The ASU also modifies the lease classification criteria for lessors and eliminates some of the real estate leasing guidance previously applied for certain leasing transactions. This ASU is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. We expect to adopt this ASU on January 1, 2019. Because of the number of leases we utilize to support our operations, the adoption of this ASU is expected to have a significant impact on our consolidated financial position and results of operations. We are currently evaluating the extent of this anticipated impact on our consolidated financial position and results of operations and the quantitative and qualitative factors that will impact us as part of the adoption of this ASU, as well as any changes to our leasing strategy because of the changes to the accounting and recognition of leases.

In March 2016, the FASB issued ASU 2016-09, which was issued to simplify some of the accounting guidance for share-based compensation. Among the areas impacted by the amendments in this ASU is the accounting for income taxes related to share-based payments, accounting for forfeitures, classification of awards as equity or liabilities, and classification on the statement of cash flows. This ASU is effective for fiscal years beginning after December 15, 2016, with early adoption permitted. We expect to adopt this ASU on January 1, 2017. We are evaluating the impact that the adoption of this ASU will have on our consolidated financial position, results of operations and cash flows.

FORWARD-LOOKING STATEMENTS

Some of the matters discussed in this Report include forward-looking statements. Statements that are predictive in nature, that depend upon or refer to future events or conditions or that include words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” “thinks,” and similar expressions are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results and performance to be materially different from any future results or performance expressed or implied by these forward-looking statements. These factors include the following:

• general economic and business conditions, both nationally and in the regions in which we operate,

• implementation, effect of, and changes to, adopted and potential federal and state healthcare reform legislation and other federal, state or local laws or regulations affecting the healthcare industry,

• the extent to which states support increases, decreases or changes in Medicaid programs, implement health insurance exchanges or alter the provision of healthcare to state residents through regulation or otherwise,

• the success and long-term viability of health insurance exchanges, which may be impacted by whether a sufficient number of payors participate,

• risks associated with our substantial indebtedness, leverage and debt service obligations, including our ability to incur additional indebtedness,

• demographic changes,

• changes in, or the failure to comply with, governmental regulations,

• potential adverse impact of known and unknown government investigations, audits, and federal and state false claims act litigation and other legal proceedings,

• our ability, where appropriate, to enter into and maintain provider arrangements with payors and the terms of these arrangements, which may be further impacted by the increasing consolidation of health insurers and managed care companies,

67

• changes in, or the failure to comply with, contract terms with payors and changes in reimbursement rates paid by federal or state healthcare programs or commercial payors,

• any potential impairments in the carrying value of goodwill, other intangible assets, or other long-lived assets, or changes in the useful lives of other intangible assets,

• changes in inpatient or outpatient Medicare and Medicaid payment levels,

• the effects related to the continued implementation of the sequestration spending reductions and the potential for future deficit reduction legislation,

• increases in the amount and risk of collectability of patient accounts receivable, including the impact of the implementation of ICD-10 and decreases in collectability which may result from, among other things, self-pay growth in states that have not expanded Medicaid and difficulties in recovering payments for which patients are responsible, including co-pays and deductibles,

• the efforts of insurers, healthcare providers and others to contain healthcare costs, including the trend toward value-based purchasing,

• our ongoing ability to demonstrate meaningful use of certified EHR technology and recognize income for the related Medicare or Medicaid incentive payments,

• increases in wages as a result of inflation or competition for highly technical positions and rising supply and drug costs due to market pressure from pharmaceutical companies and new product releases,

• liabilities and other claims asserted against us, including self-insured malpractice claims,

• competition,

• our ability to attract and retain, at reasonable employment costs, qualified personnel, key management, physicians, nurses and other healthcare workers,

• trends toward treatment of patients in less acute or specialty healthcare settings, including ambulatory surgery centers or specialty hospitals,

• changes in medical or other technology,

• changes in U.S. GAAP,

• the availability and terms of capital to fund additional acquisitions or replacement facilities or other capital expenditures,

• our ability to successfully make acquisitions or complete divestitures, including the intended disposition of an additional ten hospitals and certain investments as referenced herein, our ability to complete any such acquisitions or divestitures on desired terms or at all, the timing of the completion of any such acquisitions or divestitures, and our ability to realize the intended benefits from any such acquisitions or divestitures,

• our ability to successfully integrate any acquired hospitals, including those of HMA, or to recognize expected synergies from acquisitions,

• the impact of the acquisition of HMA on third-party relationships,

• the impact of seasonal severe weather conditions,

• our ability to obtain adequate levels of general and professional liability insurance,

• timeliness of reimbursement payments received under government programs,

• effects related to outbreaks of infectious diseases,

68

• the impact of the external, criminal cyber-attack suffered by us in the second quarter of 2014, including potential reputational damage, the outcome of our investigation and any potential governmental inquiries, the outcome of litigation filed against us in connection with this cyber-attack, the extent of remediation costs and additional operating or other expenses that we may continue to incur, and the impact of potential future cyber-attacks or security breaches,

• the effects of the spin-off of QHC that was completed on April 29, 2016 on our business, including our ability to achieve the anticipated benefits of the spin-off,

• changes to our intended use of the cash proceeds of the spin-off of QHC, and

• the other risk factors set forth in our 2015 Form 10-K and our other public filings with the SEC.

Although we believe that these forward-looking statements are based upon reasonable assumptions, these assumptions are inherently subject to significant regulatory, economic and competitive uncertainties and contingencies, which are difficult or impossible to predict accurately and may be beyond the control of the Company. Accordingly, the Company cannot give any assurance that its expectations will in fact occur and cautions that actual results may differ materially from those in the forward-looking statements. Given these uncertainties, prospective investors are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements are made as of the date of this filing. The Company undertakes no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

We are exposed to interest rate changes, primarily as a result of our Credit Facility which bears interest based on floating rates. In order to manage the volatility relating to the market risk, we entered into interest rate swap agreements described under the heading “Liquidity and Capital Resources” in Part I, Item 2. We utilize risk management procedures and controls in executing derivative financial instrument transactions. We do not execute transactions or hold derivative financial instruments for trading purposes. Derivative financial instruments related to interest rate sensitivity of debt obligations are used with the goal of mitigating a portion of the exposure when it is cost effective to do so. As of March 31, 2016, our approximately $3.5 billion notional amount of interest rate swap agreements outstanding represented approximately 43.5% of our variable rate debt.

A 1% change in interest rates on variable rate debt in excess of that amount covered by interest rate swaps would have resulted in interest expense fluctuating approximately $14 million and $17 million for the three months ended March 31, 2016 and 2015, respectively.

Item 4. Controls and Procedures

Our Chief Executive Officer and Chief Financial Officer, with the participation of other members of management, have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a- 15(e) and 15d-15(e)) under the Securities and Exchange Act of 1934, as amended, as of the end of the period covered by this report. Based on such evaluations, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective (at the reasonable assurance level) to ensure that the information required to be included in this report has been recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and to ensure that the information required to be included in this report was accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

There have been no changes in our internal control over financial reporting during the three months ended March 31, 2016 that have materially affected or are reasonably likely to materially affect our internal controls over financial reporting.

69

PART II OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we receive inquiries or subpoenas from state regulators, state Medicaid Fraud Control units, fiscal intermediaries, the Centers for Medicare and Medicaid Services, the Department of Justice and other government entities regarding various Medicare and Medicaid issues. In addition to the matters discussed below, we are currently responding to subpoenas and administrative demands concerning (a) certain cardiology procedures, medical records and policies at a New Mexico hospital, (b) a civil investigative demand concerning cardiology devices at a Pennsylvania hospital, (c) an inquiry regarding a sleep lab at a Louisiana hospital, (d) a subpoena regarding wound care services at one of our Florida hospitals (which appears to be related to the recently unsealed case styled U.S. ex rel. Van Raalte, v. Healogics, Inc.), (e) a subpoena concerning provider based billing status for hyperbaric oxygen therapy at one of our Tennessee hospitals, (f) a civil investigative demand concerning neonatal services at one of our Washington hospitals, (g) a subpoena concerning a physician relationship at one of our Texas hospitals and (h) a letter inquiring about a medical director for sub-acute services at our hospitals in Tucson, Arizona. In addition, we are subject to other claims and lawsuits arising in the ordinary course of our business. Based on current knowledge, management does not believe that loss contingencies arising from pending legal, regulatory and governmental matters, including the matters described herein, will have a material adverse effect on the consolidated financial position or liquidity of the Company. However, in light of the inherent uncertainties involved in pending legal, regulatory and governmental matters, some of which are beyond our control, and the very large or indeterminate damages sought in some of these matters, an adverse outcome in one or more of these matters could be material to our results of operations or cash flows for any particular reporting period. Settlements of suits involving Medicare and Medicaid issues routinely require both monetary payments as well as corporate integrity agreements. Additionally, qui tam or “whistleblower” actions initiated under the civil False Claims Act may be pending but placed under seal by the court to comply with the False Claims Act’s requirements for filing such suits. In September 2014, the Criminal Division of the United States Department of Justice, or DOJ, announced that all qui tam cases will be shared with their Division to determine if a parallel criminal investigation should be opened. The Criminal Division has also frequently stated an intention to pursue corporations in criminal prosecutions. From time to time, we detect issues of non-compliance with Federal healthcare laws pertaining to claims submission and reimbursement practices and/or financial relationships with physicians. We avail ourselves of various mechanisms to address potential overpayments arising out of these issues, including repayment of claims, rebilling of claims, and participation in voluntary disclosure protocols offered by the Centers for Medicare and Medicaid Services and the Office of the Inspector General. Participating in voluntary repayments and voluntary disclosure protocols can have the potential for significant settlement obligations or even enforcement action.

The following legal proceedings are described in detail because, although they may not be required to be disclosed in this Part II, Item 1 under SEC rules, due to the nature of the business of the Company, we believe that the following discussion of these matters may provide useful information to security holders. This discussion does not include claims and lawsuits covered by medical malpractice, general liability or employment practices insurance and risk retention programs, none of which claims or lawsuits would in any event be required to be disclosed in this Part II, Item 1 under SEC rules. Certain of the matters referenced below are also discussed in the Notes to Condensed Consolidated Financial Statements at Part I, Item 1 under Note 17 “Contingencies.”

Community Health Systems, Inc. Legal Proceedings

Shareholder Litigation

Class Action Shareholder Federal Securities Cases. Three purported class action cases have been filed in the United States District Court for the Middle District of Tennessee; namely, Norfolk County Retirement System v. Community Health Systems, Inc., et al., filed May 9, 2011; De Zheng v. Community Health Systems, Inc., et al., filed May 12, 2011; and Minneapolis Firefighters Relief Association v. Community Health Systems, Inc., et al., filed June 21, 2011. All three seek class certification on behalf of purchasers of our common stock between July 27, 2006 and April 11, 2011 and allege that misleading statements resulted in artificially inflated prices for our common stock. In December 2011, the cases were consolidated for pretrial purposes and NYC Funds and its counsel were selected as lead plaintiffs/lead plaintiffs’ counsel. In lieu of ruling on our motion to dismiss, the court permitted the plaintiffs to file a first amended consolidated class action complaint which was filed on October 5, 2015. Our motion to dismiss was filed on November 4, 2015 and oral argument took place on April 11, 2016. Discovery is also continuing. We believe this consolidated matter is without merit and will vigorously defend this case.

70

Shareholder Derivative Actions. Three purported shareholder derivative actions have also been filed in the United States District Court for the Middle District of Tennessee; Plumbers and Pipefitters Local Union No. 630 Pension Annuity Trust Fund v. Wayne T. Smith, et al., filed May 24, 2011; Roofers Local No. 149 Pension Fund v. Wayne T. Smith, et al., filed June 21, 2011; and Lambert Sweat v. Wayne T. Smith, et al., filed October 5, 2011. These three cases allege breach of fiduciary duty arising out of allegedly improper inpatient admission practices, mismanagement, waste and unjust enrichment. These cases have been consolidated into a single, consolidated action. The plaintiffs filed an operative amended derivative complaint in these three consolidated actions on March 15, 2012. Our motion to dismiss was argued on June 13, 2013. On September 27, 2013, the court issued an order granting in part and denying in part our motion to dismiss. An initial case management order was entered on November 11, 2014, but no trial date has been set. Discovery is continuing. We believe all of the plaintiffs’ claims are without merit and will vigorously defend them.

Other Government Investigations

Dothan, Alabama – Independent Lab Billing. On February 12, 2015, our hospital in Dothan, Alabama received a Civil Investigative Demand, or CID, from the United States Department of Justice for information concerning its status as a “covered hospital” under certain lab billing regulations. These regulations discuss permissible billing of the technical component of lab tests performed for hospital patients by an independent laboratory. The CID seeks documentation and explanation whether the hospital qualifies as a covered hospital for billing purposes under the applicable regulations. We are cooperating fully with this investigation.

Blue Island, Illinois – Patient Status. On October 9, 2015, our hospital in Blue Island, Illinois received a CID from the Office of the United States Attorney in Chicago, Illinois concerning allegations of upcoding observation and other outpatient services and improperly falsifying inpatient admission orders. The CID requests medical records and documentation concerning status change, from observation to inpatient. We are fully cooperating with this investigation. Because this matter related solely to assets that were transferred to QHC in the spin-off, QHC is responsible for future costs and liabilities related to this matter.

Qui Tam Cases – Government Declined Intervention

On February 4, 2014, a redacted case then styled (Sealed Party) v. Pottstown Hospital Co., LLC d/b/a Pottstown Memorial Medical Center and Community Health Systems, Inc. was filed in the Eastern District of Pennsylvania. On May 6, 2014, the district court ordered the seal lifted. The relator is Alan E. Cooper, M.D. The complaint alleges the hospital traded on call agreements for referrals. There is no indication that the DOJ has intervened in this matter. This matter was previously reported in prior filings in the Legal Proceedings section as subpoenas to two Pennsylvania hospitals and one of our subsidiaries concerning on call agreements and physician directorships. On June 5, 2014, we filed motions to dismiss the complaint and on June 30, 2014 the relator filed his response. Oral argument occurred on October 15, 2014 and the matter was taken under advisement and discovery was stayed. Our motions to dismiss were granted with prejudice on March 13, 2015; the relator filed an appeal and oral argument on the appeal was originally set for November 20, 2015 but by order of the court was submitted on paper only. We are awaiting a decision. We will continue to vigorously defend this matter.

On July 28, 2015, a first amended complaint was filed by a relator in the matter of U.S. ex rel. Howard v. Taos Health Systems, Inc. d/b/a Holy Cross Hospital. Our affiliate Quorum Health Resources, also a defendant in this case, provides senior level management personnel under contract to the non-affiliated hospital. The action is pending in the United States District Court, State of New Mexico. Relator, who previously practiced emergency medicine at the hospital, alleges fraudulent billing for midlevel practitioners by the hospital and retaliation in his termination. The United States declined to intervene in this matter. This matter has been settled and dismissed.

71

Commercial Litigation and Other Lawsuits

Becker v. Community Health Systems, Inc. d/b/a Community Health Systems Professional Services Corporation d/b/a Community Health Systems d/b/a Community Health Systems PSC, Inc. d/b/a Rockwood Clinic P.S. and Rockwood Clinic, P.S. (Superior Court, Spokane, Washington). This suit was filed on February 29, 2012, by a former chief financial officer at Rockwood Clinic in Spokane, Washington. Becker claims he was wrongfully terminated for allegedly refusing to certify a budget for Rockwood Clinic in 2012. On February 29, 2012, he also filed an administrative complaint with the Department of Labor, Occupational Safety and Health Administration alleging that he is a whistleblower under Sarbanes-Oxley, which was dismissed by the agency and was appealed to an administrative law judge for a hearing that occurred on January 19-26, 2016 and will be ready for decision pending submittal of final briefing. At a hearing on July 27, 2012, the trial court dismissed Community Health Systems, Inc. from the state case and subsequently certified the state case for an interlocutory appeal of the denial to dismiss his employer and the management company. The appellate court accepted the interlocutory appeal, and it was argued on April 30, 2014. On August 14, 2014, the court denied our appeal. On October 20, 2014, we filed a petition to review the denial with the Washington Supreme Court. Our appeal was accepted and oral argument was heard on June 9, 2015. On September 15, 2015, the court denied our appeal and remanded to the trial court where it is now set for trial on September 12, 2016. We are vigorously defending these actions.

Eliel Ntakirutimana, M.D. and Anesthesia Healthcare Partners of Laredo, P.A., Jose Berlioz, M.D. and Jose Berlioz, M.D., P.A. d/b/a Safari Pediatrics v. Laredo Texas Hospital Company, L.P. d/b/a Laredo Medical Center, CHS/Community Health Systems, Inc., Webb Hospital Corporation, Community Health Systems Professional Services Corporation, Community Health Systems, Inc., Abraham “Abe” Martinez, Argelia “Argie” Martinez, Michael Portacci, Wayne Smith, Timothy P. Adams, and Timothy Schmidt. On December 28, 2012, two physicians and each of their professional associations, who previously contracted as independent contractors with Laredo Medical Center under contracts that could be terminated without cause upon certain written notice, filed a first amended complaint. The first amended complaint alleged claims for breaches of contracts, unjust enrichment, violation of the Texas Theft Liability Act, negligence, breach of fiduciary duty, knowing participation in breach of fiduciary duty, defamation and business disparagement, R.I.C.O., economic duress/coercion, tortious interference with contracts or prospective business relations, conspiracy, respondent superior, actual and apparent authority, ratification, vice-principal liability, and joint enterprise liability. The first amended complaint, in part, alleges facts concerning payments made by Dr. Eliel Ntakirutimana to former Laredo Medical Center CEO, Abe Martinez, who is also a defendant in the suit. On October 23, 2013, an Order staying the case until further notice was entered. On April 13, 2016 the magistrate judge entered an Order lifting the stay and setting a scheduling conference for June 8, 2016.

Cyber Attack. As previously disclosed on a Current Report on Form 8-K filed by us on August 18, 2014, our computer network was the target of an external, criminal cyber-attack that we believe occurred between April and June, 2014. We and Mandiant (a FireEye Company), the forensic expert engaged by us in connection with this matter, believe the attacker was a foreign “Advanced Persistent Threat” group who used highly sophisticated malware and technology to attack our systems. The attacker was able to bypass our security measures and successfully copy and transfer outside the Company certain non-medical patient identification data (such as patient names, addresses, birthdates, telephone numbers and social security numbers), but not including patient credit card, medical or clinical information. We continue to work closely with federal law enforcement authorities in connection with their investigation and possible prosecution of those determined to be responsible for this attack. Mandiant has conducted a thorough investigation of this incident and continues to advise us regarding security and monitoring efforts. We are providing appropriate notification to affected patients and regulatory agencies as required by federal and state law. We are offering identity theft protection services to individuals affected by this attack.

We have incurred certain expenses to remediate and investigate this matter, and expect to continue to incur expenses of this nature in the foreseeable future. In addition, multiple purported class action lawsuits have been filed against us and certain subsidiaries. These lawsuits allege that sensitive information was unprotected and inadequately encrypted by us. The plaintiffs claim breach of contract and other theories of recovery, and are seeking damages, as well as restitution for any identity theft. On February 4, 2015, the United States Judicial Panel on Multidistrict Litigation ordered the transfer of the purported class actions pending outside of the District Court for the Northern District of Alabama to the District Court for the Northern District of Alabama for coordinated or consolidated pretrial proceedings. A consolidated complaint was filed and we filed a motion to dismiss on September 21, 2015, which was partially argued on February 10, 2016. In an oral ruling from the bench, the court greatly limited the potential class by ruling only plaintiffs with specific injury resulting from the breach had standing to sue. Further, on jurisdictional grounds, the court dismissed Community Health Systems, Inc. from all non-Tennessee based cases. Finally, the court set April 15, 2016 for further argument on whether the remaining plaintiffs have sufficiently stated a cause of action to continue their cases. On April 15, 2016 in an oral ruling from the bench, the court dismissed additional claims and following this oral ruling only eight of the forty plaintiffs remained with significant limitations imposed on their ability to assert claims for damages. At this time, we are unable to predict the outcome of this litigation or determine the potential impact, if any, that could result from this litigation, but we intend to vigorously defend these lawsuits. This matter may subject us to additional litigation, potential governmental inquiries, potential reputational damage, and additional remediation, operating and other expenses.

72

Suit Under California Insurance Code. People of the State of California, ex rel. Liberty Mutual Insurance Corporation et. al. v. CPH Hospital Management, LLC, et. al. This case is a whistleblower suit under California Insurance Fraud Prevention Act and California Unfair Competition Act brought by 57 workers’ compensation insurance companies alleging 17 hospitals, 15 orthopedic doctors and numerous other entities conspired to fraudulently mark up the pricing for non-FDA approved and counterfeit orthopedic pedicle screws and paid kick-backs to doctors to use the screws. Abilene Medical Center, Abilene, Texas is our only affiliated entity named in the suit. On September 30, 2015, we filed a Demurrer to the complaint and a motion to Quash Service. On December 17, 2015, our Demurrer was granted and our hospital was dismissed from the case.

Mounce v. Community Health Systems, Inc. This case is a purported class action lawsuit served on July 29, 2015, claiming our affiliated Arkansas hospitals violated payor contracts by allegedly improperly asserting hospital liens against third-party tortfeasors and seeking class certifications for any similarly situated plaintiffs at any affiliated Arkansas hospital. We believe these claims are without merit and will vigorously defend the case.

Certain Legal Proceedings Related to HMA

Medicare/Medicaid Billing Lawsuits

On January 11, 2010, HMA and one of its subsidiaries were named in a qui tam lawsuit entitled U.S. ex rel. J. Michael Mastej v. Health Management Associates, Inc. et al. in the United States District Court for the Middle District of Florida, Tampa Division. The plaintiff’s complaint alleged that, among other things, the defendants erroneously submitted claims to Medicare and that those claims were falsely certified to be in compliance with Section 1877 of the Social Security Act of 1935 (commonly known as the “Stark law”) and the Anti-Kickback Statute. The plaintiff’s complaint further alleged that the defendants’ conduct violated the False Claims Act. The plaintiff seeks recovery of all Medicare and Medicaid reimbursement that the defendants received as a result of the alleged false certifications and treble damages under the False Claims Act, as well as a civil penalty for each Medicare and Medicaid claim supported by such alleged false certifications. On August 18, 2010, the plaintiff filed a first amended complaint that was similar to the original complaint. On February 23, 2011, the case was transferred to the United States District Court for the Middle District of Florida, Fort Myers Division. On May 5, 2011, the plaintiff filed a second amended complaint, which was similar to the first amended complaint. On May 17, 2011, the defendants moved to dismiss the second amended complaint for failure to state a claim with the particularity required and failure to state a claim upon which relief can be granted. On January 26, 2012, the United States gave notice of its decision not to intervene in this lawsuit. On February 16, 2012, the court granted the defendants’ motion to dismiss, without prejudice. The court’s order permitted the plaintiff to file an amended complaint. On March 8, 2012, the plaintiff filed a third amended complaint, which was similar to the first amended complaint and the second amended complaint. On March 26, 2012, the defendants moved to dismiss the third amended complaint on the same bases set forth in earlier motions to dismiss. On March 19, 2013, the United States District Court for the Middle District of Florida, Tampa Division, dismissed the third amended complaint with prejudice. On March 28, 2013, the United States of America filed a motion to clarify that the dismissal with prejudice did not relate to the United States. On April 4, 2013, the defendants filed an opposition to the United States’ motion for clarification. The Government’s motion remains pending at this time. The case was appealed by Mastej to the Eleventh Circuit Court of Appeals and on October 30, 2014 the appellate court affirmed the dismissal of part of the case and reversed the dismissal of part of the case. The relator sought further relief from the United States Supreme Court, which was denied on June 1, 2015. The case has been remanded to the district court and has been set for trial during the November 1, 2016 trial term. We intend to vigorously defend HMA and its subsidiary against the allegations in this matter.

73

Beginning during the week of December 16, 2013 eleven qui tam lawsuits filed by private individuals against HMA were unsealed in various United States district courts. The United States has elected to intervene in all or part of eight of these matters; namely U.S. ex rel. Craig Brummer v. Health Management Associates, Inc. et al. (Middle District Georgia) (“Brummer”); U.S. ex rel. Ralph D. Williams v. Health Management Associates, Inc. et al. (Middle District Georgia) (“Williams”); U.S. ex rel. Scott H. Plantz, M.D. et al. v. Health Management Associates, Inc., et al. (Northern District Illinois) (“Plantz”); U.S. ex rel. Thomas L. Mason, M.D. et al. v. Health Management Associates, Inc. et al. (Western District North Carolina) (“Mason”); U.S. ex rel. Jacqueline Meyer, et al. v. Health Management Associates, Inc., Gary Newsome et al. (“Jacqueline Meyer”) (District of South Carolina); U.S. ex rel. George Miller, et al. v. Health Management Associates, Inc. (Eastern District of Pennsylvania) (“Miller”); U.S. ex rel. Bradley Nurkin v. Health Management Associates, Inc. et al. (Middle District of Florida) (“Nurkin”); and U.S. ex rel. Paul Meyer v. Health Management Associates, Inc. et al. (Southern District Florida) (“Paul Meyer”). The United States has elected to intervene with respect to allegations in these cases that certain HMA hospitals inappropriately admitted patients and then submitted reimbursement claims for treating those individuals to federal healthcare programs in violation of the False Claims Act or that certain HMA hospitals had inappropriate financial relationships with physicians which violated the Stark law, the Anti-Kickback Statute, and the False Claims Act. Certain of these complaints also allege the same actions violated various state laws which prohibit false claims. The United States has declined to intervene in three of the eleven matters, namely U.S. ex rel. Anita France, et al. v. Health Management Associates, Inc. (Middle District Florida) (“France”) which involved allegations of wrongful billing and was settled; U.S. ex rel. Sandra Simmons v. Health Management Associates, Inc. et al. (Eastern District Oklahoma) (“Simmons”) which alleges unnecessary surgery by an employed physician and which was settled as to all allegations except alleged wrongful termination; and U.S. ex rel. David Napoliello, M.D. v. Health Management Associates, Inc. (Middle District Florida) (“Napoliello”) which alleges inappropriate admissions. On April 3, 2014, the Multi District Litigation Panel ordered the transfer and consolidation for pretrial proceedings of the eight intervened cases, plus the Napoliello matter, to the District of the District of Columbia under the name In Re: Health Management Associates, Inc. Qui Tam Litigation. On June 2, 2014, the court entered a stay of this matter until October 6, 2014, which was subsequently extended until February 27, 2015, May 27, 2015, September 25, 2015, January 25, 2016, and now until May 25, 2016. We intend to defend against the allegations in these matters, but have also been cooperating with the government in the ongoing investigation of these allegations. We have been in discussions with the Civil Division of the DOJ regarding the resolution of these matters. During the first quarter of 2015, we were informed the Criminal Division continues to investigate former executive-level employees of HMA and continues to consider whether any HMA entities should be held criminally liable for the acts of the former HMA employees. We are voluntarily cooperating with these inquiries and have not been served with any subpoenas or other legal process.

Securities and Exchange Commission Investigations

On April 25, 2013, HMA received a subpoena from the SEC, issued pursuant to an investigation, requesting documents related to accounts receivable, billing write-downs, contractual adjustments, reserves for doubtful accounts, and accounts receivable aging, and revenue from Medicare, Medicaid and from privately insured or uninsured patients. On June 5, 2013, HMA received a supplemental subpoena from the SEC which requests additional financial reports. Subsequent subpoenas have been directed to us, our accountants, the former accountants for HMA and certain individuals. On July 17, 2014, we received an additional subpoena from the SEC seeking numerous categories of documents relating to the financial statement adjustments taken in the fourth quarter of 2013 in the areas described above. This investigation is ongoing and we are unable to determine the potential impact, if any, of this investigation.

74

Class Action Lawsuits

On April 30, 2012, two class action lawsuits that were brought against HMA and certain of its then executive officers, one of whom was at that time also a director, were consolidated in the United States District Court for the Middle District of Florida under the caption In Re: Health Management Associates, Inc., et al. and three pension fund plaintiffs were appointed as lead plaintiffs. On July 30, 2012, the lead plaintiffs filed an amended consolidated complaint purportedly on behalf of stockholders who purchased HMA’s common stock during the period from July 27, 2009, through January 9, 2012. The amended consolidated complaint (i) alleges that HMA made false and misleading statements in certain public disclosures regarding its business and financial results and (ii) asserts claims for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended. Among other things, the plaintiffs claim that HMA inflated its earnings by engaging in fraudulent Medicare billing practices that entailed admitting patients to observation status when they should not have been admitted at all and to inpatient status when they should have been admitted to observation status. The plaintiffs seek unspecified monetary damages. On October 22, 2012, the defendants moved to dismiss the plaintiffs’ amended consolidated complaint for failure to state a claim or plead facts required by the Private Securities Litigation Reform Act. The plaintiffs filed an unopposed stipulation and proposed order to suspend briefing on the defendants’ motion to dismiss because they intended to seek leave of court to file a proposed second amended consolidated complaint. On December 15, 2012, the court entered an order approving the stipulation and providing a schedule for briefing with respect to the proposed amended pleadings. On February 25, 2013, the plaintiffs filed a second amended consolidated complaint, which asserted substantially the same claims as the amended consolidated complaint. As of August 15, 2013, the defendants’ motion to dismiss the second amended complaint for failure to state a claim and plead facts required by the Private Securities Litigation Reform Act was fully briefed and awaiting the Court’s decision. On May 22, 2014, the court granted the motion to dismiss and on June 20, 2014 the plaintiffs appealed to the Eleventh Circuit, where oral argument was heard on February 6, 2015. On May 11, 2015, the Eleventh Circuit Court affirmed the granting of the motion to dismiss. On June 11, 2015, plaintiffs filed an application for an en banc review. We intend to vigorously defend against the allegations in this lawsuit. We are unable to predict the outcome or determine the potential impact, if any, that could result from its final resolution.

Management of Significant Legal Proceedings

In accordance with our governance documents, including our Governance Guidelines and the charter of the Audit and Compliance Committee, our management of significant legal proceedings is overseen by the independent members of the Board of Directors and, in particular, the Audit and Compliance Committee. The Audit and Compliance Committee is charged with oversight of compliance, regulatory and litigation matters, and enterprise risk management. Management has been instructed to refer all significant legal proceedings and allegations of financial statement fraud, error, or misstatement to the Audit and Compliance Committee for its oversight and evaluation. Consistent with New York Stock Exchange, NASDAQ and Sarbanes-Oxley independence requirements, the Audit and Compliance Committee is comprised entirely of individuals who are independent of our management, and all three members of the Audit and Compliance Committee are “audit committee financial experts” as defined in the Securities Exchange Act, as amended.

In addition, the Audit and Compliance Committee and the other independent members of the Board of Directors oversee the functions of the voluntary compliance program, including its auditing and monitoring functions and confidential disclosure program. In recent years, the voluntary compliance program has addressed the potential for a variety of billing errors that might be the subject of audits and payment denials by the CMS Recovery Audit Contractors’ permanent project, including MS-DRG coding, outpatient hospital and physician coding and billing, and medical necessity for services (including a focus on hospital stays of very short duration). Efforts by management, through the voluntary compliance program, to identify and limit risk from these government audits have included significant policy and guidance revisions, training and education, and auditing. The Board of Directors now oversees and reviews periodic reports of our compliance with the Corporate Integrity Agreement, or CIA, that we entered into with the United States Department of Health and Human Services Office of the Inspector General during 2014.

For the past several years, our Board of Directors has met monthly to review the status of the lawsuits and investigations relating to allegations of improper billing for inpatient care at our hospitals and to oversee management in connection with our investigation and defense of these matters. Following the consummation of the HMA merger, these meetings have been expanded to include the review and oversight of the legal proceedings related to HMA that are covered by the CVR. The independent members of our Board of Directors remain fully engaged in the oversight of these matters.

75

Item 1A. Risk Factors

There have been no material changes with regard to the risk factors previously disclosed in our most recent annual report in the 2015 Form 10-K.

Item 2. Unregistered Sale of Equity Securities and Use of Proceeds

The following table contains information about our purchases of common stock during the three months ended March 31, 2016.

Period	Total Number of Shares         Purchased (a)		Average Price Paid per         Share		Total Number of Shares     Purchased as Part of Publicly     Announced Plans or     Programs(b)		Maximum Number of Shares     That May Yet Be Purchased     Under the Plans or     Programs(b)
January 1, 2016 -
January 31, 2016		1,091	$	26.53		-		9,467,812
February 1, 2016 -
February 29, 2016		69,407		15.12		-		9,467,812
March 1, 2016 -
March 31, 2016		287,464		15.43		-		9,467,812
Total		357,962	$	15.40		-		9,467,812

(a) Includes 357,962 shares withheld by us to satisfy the payment of tax obligations related to the vesting of restricted stock awards.

(b) On November 9, 2015, we announced the adoption of a new open market repurchase program for up to 10,000,000 shares of our common stock, not to exceed $300 million in repurchases. The new repurchase program will expire on the earlier of November 5, 2018, when the maximum number of shares has been repurchased, or when the maximum dollar amount has been expended. No shares were repurchased under this program during the three months ended March 31, 2016.

With the exception of a special cash dividend of $0.25 per share paid by us in December 2012, historically, we have not paid any cash dividends. Subject to certain exceptions, our Credit Facility limits the ability of our subsidiaries to pay dividends and make distributions to us, and limits our ability to pay dividends and/or repurchase stock, to an amount not to exceed $200 million in the aggregate plus an additional $25 million in any particular year plus the aggregate amount of proceeds from the exercise of stock options. The indentures governing our senior and senior secured notes also restrict our subsidiaries from, among other matters, paying dividends and making distributions to us, which thereby limits our ability to pay dividends and/or repurchase stock. As of March 31, 2016, under the most restrictive test under these agreements (and subject to certain exceptions), we have approximately $318 million remaining available with which to pay permitted dividends and/or repurchase shares of our stock or our senior and senior secured notes.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

76

Item 6. Exhibits

No.			Description
	2.1		Separation and Distribution Agreement, dated April 29, 2016, by and between Community Health Systems, Inc. and Quorum Health Corporation (incorporated by reference to Exhibit 2.1 to Community Health Systems, Inc.’s Current Report on Form 8-K filed April 29, 2016 (No. 001-15925))
	2.2		Tax Matters Agreement, dated April 29, 2016, by and between Community Health Systems, Inc. and Quorum Health Corporation (incorporated by reference to Exhibit 2.2 to Community Health Systems, Inc.’s Current Report on Form 8-K filed April 29, 2016 (No. 001-15925))
	2.3		Employee Matters Agreement, dated April 29, 2016, by and between Community Health Systems, Inc. and Quorum Health Corporation (incorporated by reference to Exhibit 2.3 to Community Health Systems, Inc.’s Current Report on Form 8-K filed April 29, 2016 (No. 001-15925))
	4.1	*	Fourteenth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 8.000% Senior Notes due 2019, dated as of March 31, 2016, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as successor Trustee
	4.2	*	Eleventh Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 7.125% Senior Notes due 2020, dated as of March 31, 2016, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as Trustee
	4.3	*	Eleventh Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 5.125% Senior Secured Notes due 2018, dated as of March 31, 2016, by and among CHS/Community Health Systems, Inc., the guarantors party thereto, Regions Bank, as Trustee and Credit Suisse AG, as Collateral Agent
	4.4	*	Eighth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 5.125% Senior Secured Notes due 2021, dated as of March 31, 2016, by and among CHS/Community Health Systems, Inc., the guarantors party thereto, Regions Bank, as Trustee and Credit Suisse AG, as Collateral Agent
	4.5	*	Eighth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 6.875% Senior Notes due 2022, dated as of March 31, 2016, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as Trustee
	10.1	*†	Form of Performance Based Restricted Stock Award Agreement (Most Highly Compensated Executive Officers) for Community Health Systems, Inc. 2009 Stock Option and Award Plan (for awards granted on or after March 1, 2016)
	12	*	Computation of Ratio of Earnings to Fixed Charges
	31.1	*	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
	31.2	*	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
	32.1	**	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
	32.2	**	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
	101.INS	*	XBRL Instance Document
	101.SCH	*	XBRL Taxonomy Extension Schema
	101.CAL	*	XBRL Taxonomy Extension Calculation Linkbase
	101.DEF	*	XBRL Taxonomy Extension Definition Linkbase
	101.LAB	*	XBRL Taxonomy Extension Label Linkbase
	101.PRE	*	XBRL Taxonomy Extension Presentation Linkbase

* Filed herewith.

** Furnished herewith

† Indicates a management contract or compensatory plan or arrangement

77

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

COMMUNITY HEALTH SYSTEMS, INC. (Registrant)
By:	/s/    Wayne T. Smith
	Wayne T. Smith
	Chairman of the Board and
	Chief Executive Officer
	(principal executive officer)
By:	/s/    W. Larry Cash
	W. Larry Cash
	President of Financial Services, Chief
	Financial Officer and Director
	(principal financial officer)
By:	/s/    Kevin J. Hammons
	Kevin J. Hammons
	Senior Vice President and Chief
	Accounting Officer
	(principal accounting officer)

Date: May 3, 2016

78

Index to Exhibits

No.			Description
	2.1		Separation and Distribution Agreement, dated April 29, 2016, by and between Community Health Systems, Inc. and Quorum Health Corporation (incorporated by reference to Exhibit 2.1 to Community Health Systems, Inc.’s Current Report on Form 8-K filed April 29, 2016 (No. 001-15925))
	2.2		Tax Matters Agreement, dated April 29, 2016, by and between Community Health Systems, Inc. and Quorum Health Corporation (incorporated by reference to Exhibit 2.2 to Community Health Systems, Inc.’s Current Report on Form 8-K filed April 29, 2016 (No. 001-15925))
	2.3		Employee Matters Agreement, dated April 29, 2016, by and between Community Health Systems, Inc. and Quorum Health Corporation (incorporated by reference to Exhibit 2.3 to Community Health Systems, Inc.’s Current Report on Form 8-K filed April 29, 2016 (No. 001-15925))
	4.1	*	Fourteenth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 8.000% Senior Notes due 2019, dated as of March 31, 2016, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as successor Trustee
	4.2	*	Eleventh Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 7.125% Senior Notes due 2020, dated as of March 31, 2016, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as Trustee
	4.3	*	Eleventh Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 5.125% Senior Secured Notes due 2018, dated as of March 31, 2016, by and among CHS/Community Health Systems, Inc., the guarantors party thereto, Regions Bank, as Trustee and Credit Suisse AG, as Collateral Agent
	4.4	*	Eighth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 5.125% Senior Secured Notes due 2021, dated as of March 31, 2016, by and among CHS/Community Health Systems, Inc., the guarantors party thereto, Regions Bank, as Trustee and Credit Suisse AG, as Collateral Agent
	4.5	*	Eighth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 6.875% Senior Notes due 2022, dated as of March 31, 2016, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as Trustee
	10.1	*†	Form of Performance Based Restricted Stock Award Agreement (Most Highly Compensated Executive Officers) for Community Health Systems, Inc. 2009 Stock Option and Award Plan (for awards granted on or after March 1, 2016)
	12	*	Computation of Ratio of Earnings to Fixed Charges
	31.1	*	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
	31.2	*	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
	32.1	**	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
	32.2	**	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
	101.INS	*	XBRL Instance Document
	101.SCH	*	XBRL Taxonomy Extension Schema
	101.CAL	*	XBRL Taxonomy Extension Calculation Linkbase
	101.DEF	*	XBRL Taxonomy Extension Definition Linkbase
	101.LAB	*	XBRL Taxonomy Extension Label Linkbase
	101.PRE	*	XBRL Taxonomy Extension Presentation Linkbase

* Filed herewith.

** Furnished herewith

† Indicates a management contract or compensatory plan or arrangement

79

EX-4.1

Exhibit 4.1

FOURTEENTH SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of March 31, 2016, among CHS/COMMUNITY HEALTH SYSTEMS, INC., a Delaware corporation (the “Issuer”), the party identified as a New Subsidiary Guarantor on the signature pages hereto (the “New Subsidiary Guarantor”) and REGIONS BANK, as successor Trustee under the Indenture (the “Trustee”).

W I T N E S S E T H:

WHEREAS, each of the Issuer, the Guarantors and the Trustee have heretofore executed and delivered an Indenture as amended, supplemented, waived or otherwise modified (the “Indenture”), dated as of November 22, 2011, providing for the issuance of the 8.000% Senior Notes due 2019 (the “Securities”);

WHEREAS, the undersigned New Subsidiary Guarantor has deemed it advisable and in its best interest to execute and deliver this Supplemental Indenture, and to become a New Subsidiary Guarantor under the Indenture; and

WHEREAS, pursuant to Section 9.01(4) of the Indenture, the Trustee, the Issuer and the New Subsidiary Guarantor are authorized to execute and deliver this Supplemental Indenture.

NOW THEREFORE, in consideration of the foregoing and for good and valuable consideration, the receipt of which is hereby acknowledged, the Issuer, the New Subsidiary Guarantor and the Trustee mutually covenant and agree for the equal and ratable benefit of the Holders of the Securities as follows:

SECTION 1. Capitalized Terms. Capitalized terms used herein but not defined shall have the meanings assigned to them in the Indenture.

SECTION 2. Guaranties. The New Subsidiary Guarantor hereby agrees to guarantee the Issuer’s obligations under the Securities on the terms and subject to the conditions set forth in Article 10 of the Indenture and to be bound by all other applicable provisions of the Indenture as a Subsidiary Guarantor.

SECTION 3. Ratification of Indenture; Supplemental Indentures Part of Indenture. Except as expressly amended hereby, the Indenture is in all respects ratified and confirmed and all the terms, conditions and provisions thereof shall remain in full force and effect. This Supplemental Indenture shall form a part of the Indenture for all purposes, shall inure to the benefit of the Trustee and every Holder of Securities heretofore or hereafter authenticated and the Issuer, the Trustee and every Holder of Securities heretofore or hereafter authenticated and delivered shall be bound hereby.

SECTION 4. Governing Law. THIS SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.

SECTION 5. Trustee Makes No Representation. The Trustee makes no representation as to the validity or sufficiency of this Supplemental Indenture.

SECTION 6. Counterparts. The parties may sign any number of copies of this Supplemental Indenture. Each signed copy shall be an original, but all of them together represent the same agreement. The exchange of copies of this Supplemental Indenture and of signature pages by facsimile or other electronic transmission shall constitute effective execution and delivery of this Supplemental Indenture as to the parties hereto and may be used in lieu of the original Supplemental Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or other electronic transmission shall be deemed to be their original signatures for all purposes.

1

SECTION 7. Effect of Headings. The Section headings herein are for convenience only and shall not effect the construction of this Supplemental Indenture.

[Signature page follows]

2

IN WITNESS WHEREOF, the parties have caused this Supplemental Indenture to be duly executed as of this 31^st day of March, 2016.

CHS/Community Health Systems, Inc.,

a Delaware corporation

By: /s/ James W. Doucette                

     James W. Doucette

     Senior Vice President and Treasurer

Laredo Texas Hospital Company, L.P.,

a Texas limited partnership

By: Webb Hospital Corporation, its general partner

    By: /s/ James W. Doucette            

        James W. Doucette

        Senior Vice President and Treasurer

Regions Bank, as Trustee

By:  /s/ Wallace Duke                        

    Wallace Duke

    Vice President

3

EX-4.2

Exhibit 4.2

ELEVENTH SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of March 31, 2016, among CHS/COMMUNITY HEALTH SYSTEMS, INC., a Delaware corporation (the “Issuer”), the party identified as a New Subsidiary Guarantor on the signature pages hereto (the “New Subsidiary Guarantor”) and REGIONS BANK, as Trustee under the Indenture (the “Trustee”).

W I T N E S S E T H:

WHEREAS, each of the Issuer, the Guarantors and the Trustee have heretofore executed and delivered an Indenture as amended, supplemented, waived or otherwise modified (the “Indenture”), dated as of July 18, 2012, providing for the issuance of the 7.125% Senior Notes due 2020 (the “Securities”);

WHEREAS, the undersigned New Subsidiary Guarantor has deemed it advisable and in its best interest to execute and deliver this Supplemental Indenture, and to become a New Subsidiary Guarantor under the Indenture; and

WHEREAS, pursuant to Section 9.01(4) of the Indenture, the Trustee, the Issuer and the New Subsidiary Guarantor are authorized to execute and deliver this Supplemental Indenture.

NOW THEREFORE, in consideration of the foregoing and for good and valuable consideration, the receipt of which is hereby acknowledged, the Issuer, the New Subsidiary Guarantor and the Trustee mutually covenant and agree for the equal and ratable benefit of the Holders of the Securities as follows:

SECTION 1. Capitalized Terms. Capitalized terms used herein but not defined shall have the meanings assigned to them in the Indenture.

SECTION 2. Guaranties. The New Subsidiary Guarantor hereby agrees to guarantee the Issuer’s obligations under the Securities on the terms and subject to the conditions set forth in Article 10 of the Indenture and to be bound by all other applicable provisions of the Indenture as a Subsidiary Guarantor.

SECTION 3. Ratification of Indenture; Supplemental Indentures Part of Indenture. Except as expressly amended hereby, the Indenture is in all respects ratified and confirmed and all the terms, conditions and provisions thereof shall remain in full force and effect. This Supplemental Indenture shall form a part of the Indenture for all purposes, shall inure to the benefit of the Trustee and every Holder of Securities heretofore or hereafter authenticated and the Issuer, the Trustee and every Holder of Securities heretofore or hereafter authenticated and delivered shall be bound hereby.

SECTION 4. Governing Law. THIS SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.

SECTION 5. Trustee Makes No Representation. The Trustee makes no representation as to the validity or sufficiency of this Supplemental Indenture.

SECTION 6. Counterparts. The parties may sign any number of copies of this Supplemental Indenture. Each signed copy shall be an original, but all of them together represent the same agreement. The exchange of copies of this Supplemental Indenture and of signature pages by facsimile or other electronic transmission shall constitute effective execution and delivery of this Supplemental Indenture as to the parties hereto and may be used in lieu of the original Supplemental Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or other electronic transmission shall be deemed to be their original signatures for all purposes.

SECTION 7. Effect of Headings. The Section headings herein are for convenience only and shall not effect the construction of this Supplemental Indenture.

1

IN WITNESS WHEREOF, the parties have caused this Supplemental Indenture to be duly executed as of this 31^st day of March, 2016.

CHS/Community Health Systems, Inc.,

a Delaware corporation

By: /s/ James W. Doucette                

     James W. Doucette

     Senior Vice President and Treasurer

Laredo Texas Hospital Company, L.P.,

a Texas limited partnership

By: Webb Hospital Corporation, its general partner

    By: /s/ James W. Doucette            

        James W. Doucette

        Senior Vice President and Treasurer

Regions Bank, as Trustee

By: /s/ Wallace Duke                        

    Wallace Duke

    Vice President

2

EX-4.3

Exhibit 4.3

ELEVENTH SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of March 31, 2016, among CHS/COMMUNITY HEALTH SYSTEMS, INC., a Delaware corporation (the “Issuer”), the party identified as a New Subsidiary Guarantor on the signature pages hereto (the “New Subsidiary Guarantor”), REGIONS BANK, as Trustee under the Indenture (the “Trustee”) and Credit Suisse AG (the “Collateral Agent”).

W I T N E S S E T H:

WHEREAS, each of the Issuer, the Guarantors and the Trustee have heretofore executed and delivered an Indenture as amended, supplemented, waived or otherwise modified (the “Indenture”), dated as of August 17, 2012, providing for the issuance of the 5.125% Senior Secured Notes due 2018 (the “Securities”);

WHEREAS, the undersigned New Subsidiary Guarantor has deemed it advisable and in its best interest to execute and deliver this Supplemental Indenture, and to become a New Subsidiary Guarantor under the Indenture; and

WHEREAS, pursuant to Section 9.01(4) of the Indenture, the Trustee, the Collateral Agent, the Issuer and the New Subsidiary Guarantor are authorized to execute and deliver this Supplemental Indenture.

NOW THEREFORE, in consideration of the foregoing and for good and valuable consideration, the receipt of which is hereby acknowledged, the Issuer, the New Subsidiary Guarantor and the Trustee mutually covenant and agree for the equal and ratable benefit of the Holders of the Securities as follows:

SECTION 1. Capitalized Terms. Capitalized terms used herein but not defined shall have the meanings assigned to them in the Indenture.

SECTION 2. Guaranties. The New Subsidiary Guarantor hereby agrees to guarantee the Issuer’s obligations under the Securities on the terms and subject to the conditions set forth in Article 10 of the Indenture and to be bound by all other applicable provisions of the Indenture as a Subsidiary Guarantor.

SECTION 3. Ratification of Indenture; Supplemental Indentures Part of Indenture. Except as expressly amended hereby, the Indenture is in all respects ratified and confirmed and all the terms, conditions and provisions thereof shall remain in full force and effect. This Supplemental Indenture shall form a part of the Indenture for all purposes, shall inure to the benefit of the Trustee and every Holder of Securities heretofore or hereafter authenticated and the Issuer, the Trustee and every Holder of Securities heretofore or hereafter authenticated and delivered shall be bound hereby.

SECTION 4. Governing Law. THIS SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.

SECTION 5. Trustee Makes No Representation. The Trustee makes no representation as to the validity or sufficiency of this Supplemental Indenture.

SECTION 6. Counterparts. The parties may sign any number of copies of this Supplemental Indenture. Each signed copy shall be an original, but all of them together represent the same agreement. The exchange of copies of this Supplemental Indenture and of signature pages by facsimile or other electronic transmission shall constitute effective execution and delivery of this Supplemental Indenture as to the parties hereto and may be used in lieu of the original Supplemental Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or other electronic transmission shall be deemed to be their original signatures for all purposes.

1

SECTION 7. Benefits Acknowledged. The New Subsidiary Guarantor’s Note Guarantee is subject to the terms and conditions set forth in the Indenture. The New Subsidiary Guarantor acknowledges that it will receive direct and indirect benefits from the financing arrangements contemplated by the Indenture and this Supplemental Indenture and that the guarantee and waivers made by it pursuant to its Note Guarantee are knowingly made in contemplation of such benefits.

SECTION 8. Effect of Headings. The Section headings herein are for convenience only and shall not effect the construction of this Supplemental Indenture.

[Signature page follows]

2

IN WITNESS WHEREOF, the parties have caused this Supplemental Indenture to be duly executed as of this 31^st day of March, 2016.

CHS/Community Health Systems, Inc.,

a Delaware corporation

By: /s/ James W. Doucette                

     James W. Doucette

     Senior Vice President and Treasurer

Laredo Texas Hospital Company, L.P.,

a Texas limited partnership

By: Webb Hospital Corporation, its general partner

    By: /s/ James W. Doucette            

        James W. Doucette

        Senior Vice President and Treasurer

Regions Bank, as Trustee

By: /s/ Wallace Duke                        

    Wallace Duke

    Vice President

3

Credit Suisse AG, Cayman Islands Branch, as Collateral Agent

By: /s/ Robert Hetu                          

    Name: Robert Hetu

    Title: Authorized Signatory

By: /s/ Warren Van Heyst                

    Name: Warren Van Heyst

    Title: Authorized Signatory

4

EX-4.4

Exhibit 4.4

EIGHTH SUPPLEMENTAL INDENTURE, (this “Supplemental Indenture”) dated as of March 31, 2016, by and among CHS/Community Health Systems, Inc., a Delaware corporation (“Issuer”), the party that is a signatory hereto as a Guarantor (the “Guaranteeing Subsidiary”), Credit Suisse AG, as Collateral Agent, and Regions Bank, as Trustee under the Indenture referred to below.

W I T N E S S E T H:

WHEREAS, each of the Issuer, the Guarantors and the Trustee have heretofore executed and delivered an indenture dated as of January 27, 2014 (as amended, supplemented, waived or otherwise modified, the “Indenture”), providing for the issuance on such date of an aggregate principal amount of $1,000,000,000 of 5.125% Senior Secured Notes due 2021 (the “Notes”) of the Issuer;

WHEREAS, the Indenture provides that the Guaranteeing Subsidiary shall execute and deliver to the Trustee and the Collateral Agent a supplemental indenture pursuant to which the Guaranteeing Subsidiary shall unconditionally guarantee all of the Issuer’s Obligations under the Notes and the Indenture on the terms and conditions set forth herein and under the Indenture (the “Note Guarantee”), each on the terms and conditions set forth herein; and

WHEREAS, pursuant to Section 9.1 of the Indenture, the Issuer, any Guarantor and the Trustee are authorized to execute and deliver this Supplemental Indenture to amend or supplement the Indenture, without the consent of any Holder;

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the Issuer, the Guaranteeing Subsidiary and the Trustee mutually covenant and agree for the benefit of the Trustee, the Collateral Agent and the Holders of the Notes as follows:

ARTICLE I

DEFINITIONS

SECTION 1.1. Defined Terms. As used in this Supplemental Indenture, terms defined in the Indenture or in the preamble or recitals hereto are used herein as therein defined. The words “herein,” “hereof” and “hereby” and other words of similar import used in this Supplemental Indenture refer to this Supplemental Indenture as a whole and not to any particular section hereof.

ARTICLE II

AGREEMENT TO BE BOUND; GUARANTEE

SECTION 2.1. Agreement to be Bound. The Guaranteeing Subsidiary hereby becomes a party to the Indenture as a “Guarantor” and as such will have all of the rights and be subject to all of the obligations and agreements of a “Guarantor” under the Indenture.

SECTION 2.2. Guarantee. The Guaranteeing Subsidiary agrees, on a joint and several basis with all the existing Guarantors, to fully, unconditionally and irrevocably Guarantee to each Holder of the Notes, the Trustee and the Collateral Agent the Guaranteed Obligations pursuant to Article X of the Indenture as and to the extent provided for therein.

1

ARTICLE III

MISCELLANEOUS

SECTION 3.1. Notices. All notices and other communications to the Guarantors shall be given as provided in the Indenture.

SECTION 3.2. Merger and Consolidation. The Guaranteeing Subsidiary shall not sell or otherwise dispose of all or substantially all of its assets to, or consolidate with or merge with or into, another Person (other than the Issuer or any Restricted Subsidiary that is a Guarantor or becomes a Guarantor concurrently with the transaction) except in accordance with Section 4.1(e) of the Indenture.

SECTION 3.3. Release of Guarantee. The Note Guarantees hereunder may be released in accordance with Section 10.2 of the Indenture.

SECTION 3.4. Parties. Nothing expressed or mentioned herein is intended or shall be construed to give any Person, firm or corporation, other than the Holders and the Trustee, any legal or equitable right, remedy or claim under or in respect of this Supplemental Indenture or the Indenture or any provision herein or therein contained

SECTION 3.5. Governing Law. This Supplemental Indenture shall be governed by, and construed in accordance with, the laws of the State of New York.

SECTION 3.6. Severability. In case any provision in this Supplemental Indenture shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and such provision shall be ineffective only to the extent of such invalidity, illegality or unenforceability.

SECTION 3.7. Benefits Acknowledged. The Guaranteeing Subsidiary’s Note Guarantee is subject to the terms and conditions set forth in the Indenture. The Guaranteeing Subsidiary acknowledges that it will receive direct and indirect benefits from the financing arrangements contemplated by the Indenture and this Supplemental Indenture and that the guarantee and waivers made by it pursuant to its Note Guarantee are knowingly made in contemplation of such benefits.

SECTION 3.8. Ratification of Indenture; Supplemental Indentures Part of Indenture. Except as expressly amended hereby, the Indenture is in all respects ratified and confirmed and all the terms, conditions and provisions thereof shall remain in full force and effect. This Supplemental Indenture shall form a part of the Indenture for all purposes, and every Holder of Notes heretofore or hereafter authenticated and delivered shall be bound hereby.

SECTION 3.9. The Trustee and the Collateral Agent. Neither the Trustee nor the Collateral Agent make any representation or warranty as to the validity or sufficiency of this Supplemental Indenture or with respect to the recitals contained herein, all of which recitals are made solely by the other parties hereto.

SECTION 3.10. Counterparts. The parties hereto may sign any number of copies of this Supplemental Indenture. Each signed copy shall be an original, but all of them together represent the same agreement. The exchange of copies of this Supplemental Indenture and of signature pages by facsimile or other electronic transmission shall constitute effective execution and delivery of this Supplemental Indenture as to the parties hereto and may be used in lieu of the original Supplemental Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or other electronic transmission shall be deemed to be their original signatures for all purposes.

2

SECTION 3.11. Execution and Delivery. The Guaranteeing Subsidiary agrees that its Note Guarantee shall remain in full force and effect notwithstanding any absence on each Note of a notation of any such Note Guarantee.

SECTION 3.12. Headings. The headings of the Articles and the Sections in this Supplemental Indenture are for convenience of reference only and shall not be deemed to alter or affect the meaning or interpretation of any provisions hereof.

[Signature page follows]

3

IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed as of the date first above written.

Laredo Texas Hospital Company, L.P.,
a Texas limited partnership
By: Webb Hospital Corporation, its general partner
By:	/s/ James W. Doucette
	James W. Doucette
	Senior Vice President and Treasurer

4

Acknowledged by:
CHS/Community Health Systems, Inc.
By:	/s/ James W. Doucette
	James W. Doucette
	Senior Vice President and Treasurer

5

Regions Bank,
as Trustee
By:	/s/ Wallace Duke
	Wallace Duke
	Vice President

6

Credit Suisse AG, Cayman Islands Branch,
as Collateral Agent
By:	/s/ Robert Hetu
	Name: Robert Hetu
	Title: Authorized Signatory
By:	/s/ Warren Van Heyst
	Name: Warren Van Heyst
	Title: Authorized Signatory

7

EX-4.5

Exhibit 4.5

EIGHTH SUPPLEMENTAL INDENTURE, (this “Supplemental Indenture”) dated as of March 31, 2016, by and among CHS/Community Health Systems, Inc., a Delaware corporation (“Issuer”), the party that is a signatory hereto as a Guarantor (the “Guaranteeing Subsidiary”) and Regions Bank, as Trustee under the Indenture referred to below.

W I T N E S S E T H:

WHEREAS, each of the Issuer, the Guarantors and the Trustee have heretofore executed and delivered an indenture dated as of January 27, 2014 (as amended, supplemented, waived or otherwise modified, the “Indenture”), providing for the issuance on such date of an aggregate principal amount of $3,000,000,000 of 6.875% Senior Notes due 2022 (the “Notes”) of the Issuer;

WHEREAS, the Indenture provides that the Guaranteeing Subsidiary shall execute and deliver to the Trustee a supplemental indenture pursuant to which the Guaranteeing Subsidiary shall unconditionally guarantee all of the Issuer’s Obligations under the Notes and the Indenture on the terms and conditions set forth herein and under the Indenture (the “Note Guarantee”), each on the terms and conditions set forth herein; and

WHEREAS, pursuant to Section 9.1 of the Indenture, the Issuer, any Guarantor and the Trustee are authorized to execute and deliver this Supplemental Indenture to amend or supplement the Indenture, without the consent of any Holder;

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the Issuer, the Guaranteeing Subsidiary and the Trustee mutually covenant and agree for the benefit of the Trustee and the Holders of the Notes as follows:

ARTICLE I

DEFINITIONS

SECTION 1.1. Defined Terms. As used in this Supplemental Indenture, terms defined in the Indenture or in the preamble or recitals hereto are used herein as therein defined. The words “herein,” “hereof” and “hereby” and other words of similar import used in this Supplemental Indenture refer to this Supplemental Indenture as a whole and not to any particular section hereof.

ARTICLE II

AGREEMENT TO BE BOUND; GUARANTEE

SECTION 2.1. Agreement to be Bound. The Guaranteeing Subsidiary hereby becomes a party to the Indenture as a “Guarantor” and as such will have all of the rights and be subject to all of the obligations and agreements of a “Guarantor” under the Indenture.

SECTION 2.2. Guarantee. The Guaranteeing Subsidiaries agrees, on a joint and several basis with all the existing Guarantors, to fully, unconditionally and irrevocably Guarantee to each Holder of the Notes and the Trustee the Guaranteed Obligations pursuant to Article X of the Indenture as and to the extent provided for therein.

1

ARTICLE III

MISCELLANEOUS

SECTION 3.1. Notices. All notices and other communications to the Guarantors shall be given as provided in the Indenture.

SECTION 3.2. Merger and Consolidation. The Guaranteeing Subsidiary shall not sell or otherwise dispose of all or substantially all of its assets to, or consolidate with or merge with or into, another Person (other than the Issuer or any Restricted Subsidiary that is a Guarantor or becomes a Guarantor concurrently with the transaction) except in accordance with Section 4.1(e) of the Indenture.

SECTION 3.3. Release of Guarantee. The Note Guarantees hereunder may be released in accordance with Section 10.2 of the Indenture.

SECTION 3.4. Parties. Nothing expressed or mentioned herein is intended or shall be construed to give any Person, firm or corporation, other than the Holders and the Trustee, any legal or equitable right, remedy or claim under or in respect of this Supplemental Indenture or the Indenture or any provision herein or therein contained

SECTION 3.5. Governing Law. This Supplemental Indenture shall be governed by, and construed in accordance with, the laws of the State of New York.

SECTION 3.6. Severability. In case any provision in this Supplemental Indenture shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and such provision shall be ineffective only to the extent of such invalidity, illegality or unenforceability.

SECTION 3.7. Benefits Acknowledged. The Guaranteeing Subsidiary’s Note Guarantee is subject to the terms and conditions set forth in the Indenture. The Guaranteeing Subsidiary acknowledges that it will receive direct and indirect benefits from the financing arrangements contemplated by the Indenture and this Supplemental Indenture and that the guarantee and waivers made by it pursuant to its Note Guarantee are knowingly made in contemplation of such benefits.

SECTION 3.8. Ratification of Indenture; Supplemental Indentures Part of Indenture. Except as expressly amended hereby, the Indenture is in all respects ratified and confirmed and all the terms, conditions and provisions thereof shall remain in full force and effect. This Supplemental Indenture shall form a part of the Indenture for all purposes, and every Holder of Notes heretofore or hereafter authenticated and delivered shall be bound hereby.

SECTION 3.9. The Trustee. The Trustee makes no representation or warranty as to the validity or sufficiency of this Supplemental Indenture or with respect to the recitals contained herein, all of which recitals are made solely by the other parties hereto.

SECTION 3.10. Counterparts. The parties hereto may sign any number of copies of this Supplemental Indenture. Each signed copy shall be an original, but all of them together represent the same agreement. The exchange of copies of this Supplemental Indenture and of signature pages by facsimile or other electronic transmission shall constitute effective execution and delivery of this Supplemental Indenture as to the parties hereto and may be used in lieu of the original Supplemental Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or other electronic transmission shall be deemed to be their original signatures for all purposes.

2

SECTION 3.11. Execution and Delivery. The Guaranteeing Subsidiary agrees that its Note Guarantee shall remain in full force and effect notwithstanding any absence on each Note of a notation of any such Note Guarantee.

SECTION 3.12. Headings. The headings of the Articles and the Sections in this Supplemental Indenture are for convenience of reference only and shall not be deemed to alter or affect the meaning or interpretation of any provisions hereof.

[Signature page follows]

3

IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed as of the date first above written.

Laredo Texas Hospital Company, L.P.,
a Texas limited partnership
By:	Webb Hospital Corporation, its general partner
	By: /s/ James W. Doucette
	James W. Doucette
	Senior Vice President and Treasurer

4

Acknowledged by:
CHS/Community Health Systems, Inc.
By:	/s/ James W. Doucette
	James W. Doucette
	Senior Vice President and Treasurer

5

Regions Bank,
as Trustee
By:	/s/ Wallace Duke
	Wallace Duke
	Vice President

6

EX-10.1

Exhibit 10.1

PERFORMANCE BASED RESTRICTED STOCK AWARD AGREEMENT

(Most Highly Compensated Executive Officers)

Community Health Systems, Inc.

2009 Stock Option and Award Plan

THIS AGREEMENT between you and Community Health Systems, Inc., a Delaware corporation (the “Company”) governs an Award of the Company’s Restricted Stock in the amount and on the date specified in your Award notification (the “Date of Grant”).

WHEREAS, the Company has adopted the Community Health Systems, Inc. 2009 Stock Option and Award Plan (the “Plan”) in order to provide additional incentive to certain employees and directors of the Company and its Subsidiaries;

WHEREAS, the Compensation Committee of the Company’s Board of Directors (the “Committee”) has determined to grant to you this Award of Restricted Stock as provided herein to encourage your efforts toward the continuing success of the Company;

WHEREAS, the Committee has determined to condition the Award on the attainment of certain performance-based criteria to better align your economic interests with those of the other stockholders of the Company and to ensure that the compensation attributable to this Award constitutes “qualified performance-based compensation” pursuant to Code §162(m) and the regulations promulgated thereunder; and

WHEREAS, the Committee has established the Performance Objectives (as defined in Section 3.1 below) (a) utilizing objectively determinable criteria, (b) on a date which is prior to the ninetieth (90^th) day of the Company’s fiscal year, and (c) at a time when the attainment of the Performance Objectives is substantially uncertain.

NOW, THEREFORE, the parties hereto agree as follows:

1. Grant of Restricted Stock.

1.1         The Company hereby grants to you this Award of Shares of Performance Based Restricted Stock in the number set out in an electronic notification by the Company’s stock option plan administrator, as may be appointed from time to time (the “Plan Administrator”). The Shares of Performance Based Restricted Stock granted pursuant to this Award shall be issued in the form of a book entry of Shares in your name as soon as reasonably practicable after the Date of Grant and shall be subject to your (or your estate’s, if applicable) acknowledgement and acceptance of this Agreement by electronic means to the Plan Administrator as provided in Section 9 hereof, or as you have been otherwise instructed.

1.2         This Agreement shall be construed in accordance and consistent with, and subject to, the provisions of the Plan (the provisions of which are hereby incorporated by reference) and, except as otherwise expressly set forth herein, the capitalized terms used in this Agreement shall have the same definitions as set forth in the Plan.

2. Restrictions on Transfer.

The Shares of Performance Based Restricted Stock issued under this Agreement may not be sold, transferred or otherwise disposed of and may not be pledged or otherwise hypothecated until all restrictions on such Performance Based Restricted Stock shall have lapsed in the manner provided in Section 3, 4 or 5 hereof.

1

3. Performance Objectives; Lapse of Restrictions.

3.1         The Award is subject to the Company attaining at least one of the following “Performance Objectives” (herein so called): (i) the Company’s “Adjusted EBITDA for the fiscal year” in which granted, as reported by the Company in its earnings release for such fiscal year, shall be not less than the amount which is ninety percent (90%) of the low end of the range of projected “Adjusted EBITDA for the fiscal year” in which granted as stated in the Company’s Current Report on Form 8-K filed with the SEC for the current fiscal year; and/or (ii) the Company’s “net operating revenues for the fiscal year” in which granted, as reported by the Company in its earnings release for such fiscal year, shall be not less than the amount which is ninety percent (90%) of the low end of the range of projected “net operating revenues for the fiscal year” in which granted as stated in the Company’s Current Report on Form 8-K filed with the SEC for the current fiscal year. The Performance Objectives shall be adjusted upward or downward in the event the Company enters into one or more material acquisition or divestiture transactions and as a result thereof or in connection therewith files one or more Current Reports on Form 8-K issuing revised guidance to investors projecting a higher or lower “Adjusted EBITDA for the fiscal year” in which granted and/or a higher or lower “net operating revenues for the fiscal year” in which granted (but only to the extent such change in guidance is attributable to the material acquisition and/or divestiture transactions). The adjusted Performance Objectives shall be ninety percent (90%) of the low end of the range of the revised projected “Adjusted EBITDA for the fiscal year” in which granted and/or ninety percent (90%) of the low end of the range of the revised projected “net operating revenues for the fiscal year” in which granted. For purposes of this Agreement, “material acquisition” or “material divestiture” transaction shall mean any single transaction or series of related transactions in which the consideration exceeds fifteen percent (15%) of the Company’s assets on a consolidated basis and shall also specifically include the contemplated transaction in which the Company distributes the stock of Quorum Health Corporation to its stockholders, if such distribution occurs.

3.2         Except as provided in Sections 4, 5 and 6 hereof, if neither of the Performance Objectives is attained, the Award shall lapse in its entirety.

3.3         Except as provided in Sections 4, 5 and 6 hereof, if at least one of the Performance Objectives is attained, one-third (1/3) of the number of Shares of Performance Based Restricted Stock issued hereunder (rounded to the nearest whole Share, if necessary) shall vest, and the restrictions with respect to such Performance Based Restricted Stock shall lapse, on each of the first three (3) anniversaries of the Date of Grant.

4. Effect of Certain Terminations of Employment.

If your employment terminates as a result of your death or Disability, in each case if such termination occurs on or after the Date of Grant, all Shares of Performance Based Restricted Stock which have not become vested in accordance with Section 3 or 5 hereof shall vest, and the restrictions thereon shall lapse as of the date of such termination. If your employment is terminated by your employer for any reason other than for Cause, then your Award shall continue until such time as it is determined that at least one of the Performance Objectives set forth in Section 3.1 above has been attained, and if attained, then the restrictions as to the entire Award shall lapse on the first anniversary of the Date of Grant (or if the termination occurs after at least one of the Performance Objectives has been attained, the restrictions as to the entire Award shall immediately lapse upon such termination). If, however, neither of the Performance Objectives is attained, the Award shall lapse in its entirety.

2

5. Effect of Change in Control.

In the event of a Change in Control of the Company at any time on or after the Date of Grant, the terms of the Plan shall control the vesting of any Shares of Performance Based Restricted Stock which have not become vested in accordance with Section 3 or 4 hereof.

6. Forfeiture of Performance Based Restricted Stock.

Upon the termination of your employment by you, the Company or its Subsidiaries for any reason other than those set forth in Section 4 hereof prior to such vesting, in addition to the circumstance described in Section 9(a) hereof, any and all Shares of Performance Based Restricted Stock which have not become vested in accordance with Section 3, 4 or 5 hereof shall be forfeited and shall revert to the Company.

7. Delivery of Restricted Stock.

7.1 Except as otherwise provided in Section 7.2 hereof, evidence of the book entry of Shares or, if requested by you prior to such lapse of restrictions, a stock certificate with respect to the Shares of Performance Based Restricted Stock for which the restrictions have lapsed pursuant to Section 3, 4 or 5 hereof, shall be delivered to you as soon as practicable following the date on which the restrictions on such Shares of Performance Based Restricted Stock have lapsed, free of all restrictions hereunder.

7.2 Evidence of the book entry of Shares with respect to Shares of Performance Based Restricted Stock in respect of which the restrictions have lapsed upon your death pursuant to Section 4 hereof or, if requested by the executors or administrators of your estate upon such lapse of restrictions, a stock certificate with respect to such Shares of Performance Based Restricted Stock, shall be delivered to the executors or administrators of your estate as soon as practicable following the Company’s receipt of notification of your death, free of all restrictions hereunder. In the event of your death, all references herein to “you” shall also include your executors, administrators, heirs or assigns.

8. Dividends and Voting Rights.

Subject to Section 9(a) hereof, upon issuance of the Shares of Performance Based Restricted Stock, you shall have all of the rights of a stockholder with respect to such Shares, including the right to vote the Shares and to receive all dividends or other distributions paid or made with respect thereto; provided, however, that dividends or distributions declared or paid on the Performance Based Restricted Stock by the Company shall be deferred and reinvested in Shares of Performance Based Restricted Stock based on the Fair Market Value of a Share of the Company’s common stock on the date such dividend or distribution is paid or made (provided that no fractional Shares will be issued), and the additional Shares of Performance Based Restricted Stock thus acquired shall be subject to the same restrictions on transfer and forfeiture and the same vesting schedule as the Performance Based Restricted Stock in respect of which such dividends or distributions were made.

9. Acknowledgement and Acceptance of Award Agreement.

(a)         The Shares of Performance Based Restricted Stock granted to you pursuant to this Award shall be subject to your acknowledgement and acceptance of the Award and the terms of this Agreement to the Company or its Plan Administrator (including by electronic means, if so provided) no later than the earlier of (i) 180 days from the Date of Grant and (ii) the date that is immediately prior to the date that the Performance Based Restricted Stock vests pursuant to Section 4 or 5 hereof (the “Return Date”); provided that if you die before your Return Date, this requirement shall be deemed to

3

be satisfied if the executor or administrator of your estate acknowledges and accepts this Agreement through the Company or its Plan Administrator no later than ninety (90) days following your death (the “Executor Return Date”). If this Agreement is not so acknowledged and accepted on or prior to your Return Date or the Executor Return Date, as applicable, the Award of Shares of Performance Based Restricted Stock evidenced by this Agreement shall be forfeited, and neither you nor your heirs, executors, administrators or successors shall have any rights with respect thereto.

(b)         If this Agreement is so acknowledged and accepted on or prior to your Return Date or the Executor Return Date, as applicable, all dividends and other distributions paid or made with respect to the Shares of Performance Based Restricted Stock granted hereunder prior to your Return Date or the Executor Return Date shall be treated in the manner provided in Section 8 hereof.

10. No Right to Continued Employment.

Nothing in this Agreement or the Plan shall interfere with or limit in any way the right of the Company or its Subsidiaries to terminate your employment, nor confer upon you any right to continuing employment by the Company or any of its Subsidiaries or continuing service as a Board member.

11. Withholding of Taxes.

Prior to the delivery to you of a stock certificate or evidence of the book entry of Shares with respect to the Shares of Performance Based Restricted Stock in respect of which all restrictions have lapsed, you shall pay to the Company or the Company’s Plan Administrator, the federal, state and local income taxes and other amounts as may be required by law to be withheld by the Company (the “Withholding Taxes”) with respect to such Performance Based Restricted Stock. By acknowledging and accepting this Agreement in the manner provided in Section 9 hereof, you shall be deemed to elect to have the Company or the Plan Administrator withhold a portion of such Performance Based Restricted Stock having an aggregate Fair Market Value equal to the Withholding Taxes in satisfaction thereof, such election to continue in effect until you notify the Company or its Plan Administrator before such delivery that you shall satisfy such obligation in cash, in which event the Company or the Plan Administrator shall not withhold a portion of such Performance Based Restricted Stock as otherwise provided in this Section 11.

12. Acknowledgement that You Are Bound by the Plan.

By acknowledging and accepting this Award and the terms of this Agreement you hereby confirm the availability and your review of a copy of the Plan and the Prospectus, and other documents provided to you in connection with this Award by the Company or its Plan Administrator, and you agree to be bound by all the terms and provisions thereof.

13. Modification of Agreement.

This Agreement may be modified, amended, supplemented or terminated, and any terms or conditions may be waived, but only by a written instrument executed by both parties hereto; provided that the Company may modify, amend, supplement or terminate this Agreement in a writing signed by the Company without any further action by you if such modification, amendment, supplement or termination does not adversely affect your rights hereunder.

4

14. Severability.

Should any provision of this Agreement be held by a court of competent jurisdiction to be unenforceable or invalid for any reason, the remaining provisions of this Agreement shall not be affected by such holding and shall continue in full force in accordance with their terms.

15. Governing Law.

The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of Delaware without giving effect to the conflicts of laws principles thereof.

16. Successors in Interest.

This Agreement shall inure to the benefit of and be binding upon any successor to the Company. This Agreement shall inure to the benefit of your legal representatives. All obligations imposed upon the Company and all rights granted to you under this Agreement shall be binding upon the Company’s successors and upon your heirs, executors, administrators and successors.

17. Resolution of Disputes.

Any dispute or disagreement which may arise under, or as a result of, or in any way relate to, the interpretation, construction or application of this Agreement shall first be referred to the Chief Executive Officer for informal resolution, and if necessary, referred to the Committee for its determination. Any determination made hereunder shall be final, binding and conclusive on you, your heirs, executors, administrators and successors, and the Company and its Subsidiaries for all purposes.

18. Entire Agreement.

This Agreement and the terms and conditions of the Plan constitute the entire understanding between you and the Company and its Subsidiaries, and supersede all other agreements, whether written or oral, with respect to the Award.

19. Headings.

The headings of this Agreement are inserted for convenience only and do not constitute a part of this Agreement.

20. Notice.

All notifications and other communications hereunder shall be in writing and, unless otherwise provided herein, shall be deemed to have been given when received by the party to whom such notice is to be given at its address set forth below, or such other address for the party as shall be specified by notice given pursuant hereto:

(a)     If to the Company, by regular mail to:

Community Health Systems, Inc.

4000 Meridian Boulevard

Franklin, TN 37067

Attention: General Counsel

(b)     If to you or your legal representative, to such person at the address as reflected in the records of the Company.

5

21. Consent to Jurisdiction.

Each party hereby irrevocably and unconditionally consents to submit to the exclusive jurisdiction of the courts of the State of Tennessee and of the United States of America, in each case located in the County of Williamson, for any actions, suits or proceedings arising out of or relating to this Agreement, the Award or the Plan and the transactions contemplated hereby and thereby (“Litigation”) (and agrees not to commence any Litigation except in any such court), and further agrees that service of process, summons, notice or document by U.S. certified mail to such party’s respective address set forth in Section 20 hereof shall be effective service of process for any Litigation brought against such party in any such court. Each party hereby irrevocably and unconditionally waives any objection to the laying of venue of any litigation in the courts of the State of Tennessee or of the United States of America, in each case located in the County of Williamson, and hereby further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any Litigation brought in any such court has been brought in an inconvenient forum.

22.       Deemed Execution. On the date of your electronic acceptance of the terms of the Award and this Agreement, this Agreement shall be deemed to have been executed and delivered by you and the Company.

COMMUNITY HEALTH SYSTEMS, INC.

6

EX-12

Exhibit 12

STATEMENT RE: COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES

(DOLLARS IN MILLIONS)

	Three Months Ended
	March 31, 2016
Earnings
Income from continuing operations before provision for income taxes	$	63
Income from equity investees		(20)
Distributed income from equity investees		2
Interest and amortization of deferred finance costs		251
Amortization of capitalized interest		5
Implicit rental interest expense		30
Total Earnings	$	331
Fixed Charges
Interest and amortization of deferred finance costs	$	251
Capitalized interest		1
Implicit rental interest expense		30
Total Fixed Charges	$	282
Ratio of Earnings to Fixed Charges		1.17	x

EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, Wayne T. Smith, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Community Health Systems, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal controls over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/  Wayne T. Smith

Wayne T. Smith

Chairman of the Board

and Chief Executive Officer

Date: May 3, 2016

EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, W. Larry Cash, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Community Health Systems, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal controls over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/  W. Larry Cash

W. Larry Cash

President of Financial Services,

Chief Financial Officer and Director

Date: May 3, 2016

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT

TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Community Health Systems, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Wayne T. Smith, Chairman of the Board and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/  Wayne T. Smith

Wayne T. Smith

Chairman of the Board and

Chief Executive Officer

May 3, 2016

EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT

TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Community Health Systems, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, W. Larry Cash, President of Financial Services and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/  W. Larry Cash

W. Larry Cash

President of Financial Services, Chief Financial

Officer and Director

May 3, 2016

XML

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2016	Apr. 28, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	COMMUNITY HEALTH SYSTEMS INC
Entity Central Index Key	0001108109
Document Type	10-Q
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31
Trading Symbol	CYH
Amendment Flag	false
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		113,754,186

XML

Condensed Consolidated Statements of Income - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Condensed Consolidated Statements of Income [Abstract]
Operating revenues (net of contractual allowances and discounts)	$ 5,754	$ 5,646
Provision for bad debts	755	735
Net operating revenues	4,999	4,911
Operating costs and expenses:
Salaries and benefits	2,317	2,257
Supplies	799	762
Other operating expenses	1,173	1,099
Government settlement and related costs		8
Electronic health records incentive reimbursement	(18)	(26)
Rent	119	116
Depreciation and amortization	298	296
Impairment of long-lived assets	17
Total operating costs and expenses	4,705	4,512
Income from operations	294	399
Interest expense, net	251	241
Loss from early extinguishment of debt		8
Equity in earnings of unconsolidated affiliates	(20)	(18)
Income from continuing operations before income taxes	63	168
Provision for income taxes	26	56
Income from continuing operations	37	112
Discontinued operations, net of taxes:
Loss from operations of entities sold or held for sale		(11)
Impairment of hospitals sold or held for sale	(1)	(1)
Loss on sale, net		(1)
Loss from discontinued operations, net of taxes	(1)	(13)
Net income	36	99
Less: Net income attributable to noncontrolling interests	25	20
Net income attributable to Community Health Systems, Inc. stockholders	$ 11	$ 79
Basic earnings (loss) per share attributable to Community Health Systems, Inc. common stockholders:
Continuing operations	$ 0.11	$ 0.80
Discontinued operations	(0.01)	(0.11)
Net income	0.10	0.69
Diluted earnings (loss) per share attributable to Community Health Systems, Inc. common stockholders:
Continuing operations	0.11	0.79
Discontinued operations	(0.01)	(0.11)
Net income	$ 0.10	$ 0.68
Weighted-average number of shares outstanding:
Basic	110,247,867	114,419,590
Diluted	110,309,372	115,057,668

XML

Condensed Consolidated Statements of Comprehensive (Loss) Income - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Condensed Consolidated Statements of Comprehensive (Loss) Income [Abstract]
Net income	$ 36	$ 99
Other comprehensive (loss) income, net of income taxes:
Net change in fair value of interest rate swaps, net of tax	(19)	(9)
Net change in fair value of available-for-sale securities, net of tax	2	1
Amortization and recognition of unrecognized pension cost components, net of tax	1	1
Other comprehensive loss	(16)	(7)
Comprehensive income	20	92
Less: Comprehensive income attributable to noncontrolling interests	25	20
Comprehensive (loss) income attributable to Community Health Systems, Inc. stockholders	$ (5)	$ 72

XML

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 181	$ 184
Patient accounts receivable, net of allowance for doubtful accounts of $4,051 and $4,110 at March 31, 2016 and December 31, 2015, respectively	3,723	3,611
Supplies	587	580
Prepaid income taxes	2	27
Prepaid expenses and taxes	218	197
Other current assets (including assets of hospitals held for sale of $5 and $17 at March 31, 2016 and December 31, 2015, respectively)	545	567
Total current assets	5,256	5,166
Property and equipment	15,084	14,906
Less accumulated depreciation and amortization	(4,980)	(4,794)
Property and equipment, net	10,104	10,112
Goodwill	9,022	8,965
Other assets, net (including assets of hospitals held for sale of $25 and $41 at March 31, 2016 and December 31, 2015, respectively)	2,342	2,352
Total assets	26,724	26,595
Current liabilities:
Current maturities of long-term debt	249	229
Accounts payable	1,179	1,258
Accrued interest	158	227
Accrued liabilities (including liabilities of hospitals held for sale of $2 and $6 at March 31, 2016 and December 31, 2015, respectively)	1,468	1,358
Total current liabilities	3,054	3,072
Long-term debt	16,665	16,556
Deferred income taxes	599	593
Other long-term liabilities	1,723	1,698
Total liabilities	22,041	21,919
Redeemable noncontrolling interests in equity of consolidated subsidiaries	$ 565	$ 571
Community Health Systems, Inc. stockholders' equity:
Preferred stock, $.01 par value per share, 100,000,000 shares authorized; none issued
Common stock, $.01 par value per share, 300,000,000 shares authorized; 114,731,736 shares issued and 113,756,187 shares outstanding at March 31, 2016, and 113,732,933 shares issued and 112,757,384 shares outstanding at December 31, 2015	$ 1	$ 1
Additional paid-in capital	1,952	1,963
Treasury stock, at cost, 975,549 shares at March 31, 2016 and December 31, 2015	(7)	(7)
Accumulated other comprehensive loss	(89)	(73)
Retained earnings	2,146	2,135
Total Community Health Systems, Inc. stockholders' equity	4,003	4,019
Noncontrolling interests in equity of consolidated subsidiaries	115	86
Total equity	4,118	4,105
Total liabilities and equity	$ 26,724	$ 26,595

XML

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
Condensed Consolidated Balance Sheets [Abstract]
Allowance for doubtful patient accounts	$ 4,051	$ 4,110
Other current assets of hospitals held for sale	5	17
Noncurrent assets of hospitals held for sale	25	41
Current liabilities of hospitals held for sale	$ 2	$ 6
Preferred stock, par value per share	$ 0.01	$ 0.01
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Common stock, par value per share	$ 0.01	$ 0.01
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	114,731,736	113,732,933
Common stock, shares outstanding	113,756,187	112,757,384
Treasury stock, shares	975,549	975,549

XML

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities:
Net income	$ 36	$ 99
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization	298	296
Government settlement and related costs		8
Stock-based compensation expense	14	14
Loss on sale, net		1
Impairment of hospitals sold or held for sale	1	2
Impairment of long-lived assets	17
Loss from early extinguishment of debt		8
Other non-cash expenses, net	14	(7)
Changes in operating assets and liabilities, net of effects of acquisitions and divestitures:
Patient accounts receivable	(109)	(202)
Supplies, prepaid expenses and other current assets	(14)	14
Accounts payable, accrued liabilities and income taxes	64	(284)
Other	(27)	(10)
Net cash provided by (used in) operating activities	294	(61)
Cash flows from investing activities:
Acquisitions of facilities and other related equipment	(99)	(13)
Purchases of property and equipment	(224)	(241)
Proceeds from disposition of hospitals and other ancillary operations	12	62
Proceeds from sale of property and equipment	4	3
Purchases of available-for-sale securities	(37)	(59)
Proceeds from sales of available-for-sale securities	40	56
Increase in other investments	(67)	(39)
Net cash used in investing activities	(371)	(231)
Cash flows from financing activities:
Proceeds from exercise of stock options		17
Repurchase of restricted stock shares for payroll tax withholding requirements	(7)	(20)
Deferred financing costs and other debt-related costs		(20)
Redemption of noncontrolling investments in joint ventures	(16)	(7)
Distributions to noncontrolling investors in joint ventures	(18)	(23)
Borrowings under credit agreements	1,564	1,251
Proceeds from receivables facility	31	75
Repayments of long-term indebtedness	(1,480)	(1,268)
Net cash provided by financing activities	74	5
Net change in cash and cash equivalents	(3)	(287)
Cash and cash equivalents at beginning of period	184	509
Cash and cash equivalents at end of period	181	222
Supplemental disclosure of cash flow information:
Interest payments	(307)	(300)
Income tax (payments) refunds, net	$ 0	$ (1)

XML

Basis of Presentation and Significant Accounting Policies

3 Months Ended

Mar. 31, 2016

Basis of Presentation and Significant Accounting Policies [Abstract]

Basis of Presentation and Significant Accounting Policies Disclosure

1.  BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

The unaudited condensed consolidated financial statements of Community Health Systems, Inc. (the “Parent” or “Parent Company”) and its subsidiaries (the “Company”) as of March 31, 2016 and December 31, 2015 and for the three-month ended March 31, 2016 and 2015, have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). In the opinion of management, such information contains all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for such periods. All intercompany transactions and balances have been eliminated. The results of operations for the three months ended March 31, 2016, are not necessarily indicative of the results to be expected for the full fiscal year ending December 31, 2016. Certain information and disclosures normally included in the notes to condensed consolidated financial statements have been condensed or omitted as permitted by the rules and regulations of the Securities and Exchange Commission (the “SEC”). The Company believes the disclosures are adequate to make the information presented not misleading. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2015, contained in the Company’s Annual Report on Form 10-K filed with the SEC on February 17, 2016 (“2015 Form 10-K”).

Noncontrolling interests in less-than-wholly-owned consolidated subsidiaries of the Parent are presented as a component of total equity on the condensed consolidated balance sheets to distinguish between the interests of the Parent Company and the interests of the noncontrolling owners. Noncontrolling interests that are redeemable or may become redeemable at a fixed or determinable price at the option of the holder or upon the occurrence of an event outside of the control of the Company are presented in mezzanine equity on the condensed consolidated balance sheets.

Throughout these notes to the condensed consolidated financial statements, Community Health Systems, Inc., and its consolidated subsidiaries are referred to on a collective basis as the “Company.” This drafting style is not meant to indicate that the publicly traded Parent or any particular subsidiary of the Parent owns or operates any asset, business, or property. The hospitals, operations and businesses described in this filing are owned and operated, and management services provided, by distinct and indirect subsidiaries of Community Health Systems, Inc.

Allowance for Doubtful Accounts. Accounts receivable are reduced by an allowance for amounts that could become uncollectible in the future. Substantially all of the Company’s receivables are related to providing healthcare services to patients at its hospitals and affiliated businesses.

The Company estimates the allowance for doubtful accounts by reserving a percentage of all self-pay accounts receivable without regard to aging category, based on collection history, adjusted for expected recoveries and any anticipated changes in trends. The Company’s ability to estimate the allowance for doubtful accounts is not impacted by not utilizing an aging of net accounts receivable as the Company believes that substantially all of the risk exists at the point in time such accounts are identified as self-pay. For all other non-self-pay payor categories, the Company reserves an estimated amount on historical collection rates for the uncontractualized portion of all accounts aging over 365 days from the date of discharge. These amounts represent an immaterial percentage of the outstanding accounts receivable. The percentage used to reserve for all self-pay accounts is based on the Company’s collection history. The Company collects substantially all of its third-party insured receivables, which include receivables from governmental agencies.

Collections are impacted by the economic ability of patients to pay and the effectiveness of the Company’s collection efforts. Significant changes in payor mix, business office operations, economic conditions or trends in federal and state governmental healthcare coverage could affect the Company’s collection of accounts receivable and the estimates of the collectability of future accounts receivable and are considered in the Company’s estimates of accounts receivable collectability. The Company also continually reviews its overall reserve adequacy by monitoring historical cash collections as a percentage of trailing net revenue less provision for bad debts, as well as by analyzing current period net revenue and admissions by payor classification, aged accounts receivable by payor, days revenue outstanding, the composition of self-pay receivables between pure self-pay patients and the patient responsibility portion of third-party insured receivables and the impact of recent acquisitions and dispositions.

Operating revenues, net of contractual allowances and discounts (but before the provision for bad debts), recognized during the three months ended March 31, 2016 and 2015, were as follows (in millions):

	Three Months Ended
	March 31,
	2016		2015
Medicare	$	1,431	$	1,398
Medicaid		593		586
Managed Care and other third-party payors		3,022		2,946
Self-pay		708		716
Total	$	5,754	$	5,646

Electronic Health Records Incentive Reimbursement. The federal government has implemented a number of regulations and programs designed to promote the use of electronic health records (“EHR”) technology and, pursuant to the Health Information Technology for Economic and Clinical Health Act (“HITECH”), established requirements for a Medicare and Medicaid incentive payments program for eligible hospitals and professionals that adopt and meaningfully use certified EHR technology.  The Company utilizes a gain contingency model to recognize EHR incentive payments. Recognition occurs when the eligible hospitals adopt or demonstrate meaningful use of certified EHR technology for the applicable payment period and have available the Medicare cost report information for the relevant full cost report year used to determine the final incentive payment.

Medicaid EHR incentive payments are calculated based on prior period Medicare cost report information available at the time when eligible hospitals adopt, implement, upgrade or demonstrate meaningful use of certified EHR technology. Since the information for the relevant full Medicare cost report year is available at the time of attestation, the incentive income from resolving the gain contingency is recognized when eligible hospitals adopt, implement, upgrade or demonstrate meaningful use of certified EHR technology.

Medicare EHR incentive payments are calculated based on the Medicare cost report information for the full cost report year that began during the federal fiscal year in which meaningful use is demonstrated. Since the necessary information is only available at the end of the relevant full Medicare cost report year and after the cost report is settled, the incentive income from resolving the gain contingency is recognized when eligible hospitals demonstrate meaningful use of certified EHR technology and the information for the applicable full Medicare cost report year to determine the final incentive payment is available.

In some instances, the Company may receive estimated Medicare EHR incentive payments prior to when the Medicare cost report information used to determine the final incentive payment is available. In these instances, recognition of the gain for EHR incentive payments is deferred until all recognition criteria described above are met.

Eligibility for annual Medicare incentive payments is dependent on providers successfully attesting to the meaningful use of EHR technology. Medicaid incentive payments are available to providers in the first payment year that they adopt, implement or upgrade certified EHR technology; however, providers must demonstrate meaningful use of such technology in any subsequent payment years to qualify for additional incentive payments. Medicaid EHR incentive payments are fully funded by the federal government and administered by the states; however, the states are not required to offer EHR incentive payments to providers.

The Company recognized approximately $18 million and $26 million for the three months ended March 31, 2016 and 2015, respectively, of incentive reimbursement for HITECH incentives from Medicare and Medicaid related to certain of the Company’s hospitals and for certain of the Company’s employed physicians that have demonstrated meaningful use of certified EHR technology or have completed attestations to their adoption or implementation of certified EHR technology.  These incentive reimbursements are presented as a reduction of operating costs and expenses on the condensed consolidated statements of income.  The Company received cash related to the incentive reimbursement for HITECH incentives of approximately $85 million and $54 million for the three months ended March 31, 2016 and 2015, respectively. The Company recorded $34 million and $75 million as deferred revenue in connection with the receipt of these payments at March 31, 2016 and 2015, respectively, as all criteria for gain recognition had not been met.

New Accounting Pronouncements. In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. This ASU provides companies the option of applying a full or modified retrospective approach upon adoption. This ASU is effective for fiscal years beginning after December 15, 2016. However, the FASB recently issued a final ASU that defers the effective date by one year, with early adoption permitted for annual periods beginning after December 15, 2016. The Company expects to adopt this ASU on January 1, 2018 and is currently evaluating its plan for adoption and the impact on its revenue recognition policies, procedures and control framework and the resulting impact on its consolidated financial position, results of operations and cash flows.

In April 2015, the FASB issued ASU 2015-03, which requires debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct reduction from the carrying amount of that debt liability, consistent with the accounting for debt discounts. The ASU did not change the measurement or recognition guidance for debt issuance costs. This ASU is effective for fiscal years beginning after December 31, 2015. The Company adopted this ASU on January 1, 2016, which resulted in the reclassification of approximately $266 million of debt issuance costs from other long-term assets to a reduction of the related long-term debt. The adoption of this ASU was applied retroactively to all periods presented, and had no impact on the Company’s results of operations or cash flows.

In November 2015, the FASB issued ASU 2015-17, which amended the balance sheet classification requirements for deferred income taxes to simplify their presentation in the statement of financial position. The ASU requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. This ASU is effective for fiscal years beginning after December 31, 2016, with early adoption permitted. The Company early adopted the provisions of this ASU for the presentation and classification of its deferred tax assets at December 31, 2015. The effect of this change primarily resulted in the current portion of deferred income taxes at December 31, 2015 being included in the noncurrent deferred income tax liability.

In January 2016, the FASB issued ASU 2016-01, which amends the measurement, presentation and disclosure requirements for equity investments, other than those accounted for under the equity method or that require consolidation of the investee. The ASU eliminates the classification of equity investments as available-for-sale with any changes in fair value of such investments recognized in other comprehensive income, and requires entities to measure equity investments at fair value, with any changes in fair value recognized in net income. This ASU is effective for fiscal years beginning after December 15, 2017, with early adoption permitted. The Company expects to adopt this ASU on January 1, 2018, and is currently evaluating the impact that adoption of this ASU will have on its consolidated financial position and results of operations.

In February 2016, the FASB issued ASU 2016-02, which amends the accounting for leases, requiring lessees to recognize most leases on their balance sheet with a right-of-use asset and a lease liability. Leases will be classified as either finance or operating leases, which will impact the expense recognition of such leases over the lease term. The ASU also modifies the lease classification criteria for lessors and eliminates some of the real estate leasing guidance previously applied for certain leasing transactions. This ASU is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company expects to adopt this ASU on January 1, 2019. Because of the number of leases the Company utilizes to support its operations, the adoption of this ASU is expected to have a significant impact on the Company’s consolidated financial position and results of operations. Management is currently evaluating the extent of this anticipated impact on the Company’s consolidated financial position and results of operations, and the quantitative and qualitative factors that will impact the Company as part of the adoption of this ASU, as well as any changes to its leasing strategy that may occur because of the changes to the accounting and recognition of leases.

In March 2016, the FASB issued ASU 2016-09, which was issued to simplify some of the accounting guidance for share-based compensation. Among the areas impacted by the amendments in this ASU is the accounting for income taxes related to share-based payments, accounting for forfeitures, classification of awards as equity or liabilities, and classification on the statement of cash flows. This ASU is effective for fiscal years beginning after December 15, 2016, with early adoption permitted. The Company expects to adopt this ASU on January 1, 2017. Management is evaluating the impact that the adoption of this ASU will have on its consolidated financial position, results of operations and cash flows.

XML

Accounting for Stock-Based Compensation

3 Months Ended

Mar. 31, 2016

Accounting for Stock-Based Compensation [Abstract]

Accounting for Stock-Based Compensation Disclosure

*

2.  ACCOUNTING FOR STOCK-BASED COMPENSATION

Stock-based compensation awards have been granted under the Community Health Systems, Inc. Amended and Restated 2000 Stock Option and Award Plan, amended and restated as of March 20, 2013 (the “2000 Plan”), and the Community Health Systems, Inc. 2009 Stock Option and Award Plan, amended and restated as of March 19, 2014 (the “2009 Plan”). In addition, at the annual meeting of stockholders to be held on May 17, 2016 (the “2016 Annual Meeting”), the Company’s stockholders will be voting on whether or not to approve the amendment and restatement of the 2009 Plan (the “Amended 2009 Plan”) which was approved by the Board on March 16, 2016, subject to stockholder approval at the 2016 Annual Meeting. 

The 2000 Plan allowed for the grant of incentive stock options intended to qualify under Section 422 of the Internal Revenue Code (the “IRC”), as well as stock options which do not so qualify, stock appreciation rights, restricted stock, restricted stock units, performance-based shares or units and other share awards. Prior to being amended in 2009, the 2000 Plan also allowed for the grant of phantom stock.  Persons eligible to receive grants under the 2000 Plan include the Company’s directors, officers, employees and consultants. All options granted under the 2000 Plan have been “nonqualified” stock options for tax purposes. Generally, vesting of these granted options occurs in one-third increments on each of the first three anniversaries of the award date. Options granted prior to 2005 have a 10-year contractual term, options granted in 2005 through 2007 have an eight-year contractual term and options granted in 2008 through 2011 have a 10-year contractual term.  The Company has not granted stock option awards under the 2000 Plan since 2011.  Pursuant to the amendment and restatement of the 2000 Plan dated March 20, 2013, no further grants will be awarded under the 2000 Plan. 

The 2009 Plan provides (and, if approved by the Company’s stockholders at the 2016 Annual Meeting, the Amended 2009 Plan will provide) for the grant of incentive stock options intended to qualify under Section 422 of the IRC and for the grant of stock options which do not so qualify, stock appreciation rights, restricted stock, restricted stock units, performance-based shares or units and other share awards. Persons eligible to receive grants under the 2009 Plan include (and, if approved by the Company’s stockholders at the 2016 Annual Meeting, the Amended 2009 Plan will include) the Company’s directors, officers, employees and consultants. To date, all options granted under the 2009 Plan have been “nonqualified” stock options for tax purposes. Generally, vesting of these granted options occurs in one-third increments on each of the first three anniversaries of the award date. Options granted in 2011 or later have a 10-year contractual term.  As of March 31, 2016, 1,122,376 shares of unissued common stock were reserved for future grants under the 2009 Plan. In addition, if the Amended 2009 Plan is approved by the Company’s stockholders at the 2016 Annual Meeting, then 5,000,000 additional shares of unissued common stock would be reserved for future grants under the Amended 2009 Plan.

The exercise price of all options granted under the 2000 Plan and the 2009 Plan has been equal to the fair value of the Company’s common stock on the option grant date. 

The following table reflects the impact of total compensation expense related to stock-based equity plans on the reported operating results for the respective periods (in millions): 

	Three Months Ended
	March 31,
	2016		2015
Effect on income from continuing operations before income taxes	$	(14)	$	(14)
Effect on net income	$	(8)	$	(8)

At March 31, 2016, $66 million of unrecognized stock-based compensation expense related to outstanding unvested restricted stock and restricted stock units (the terms of which are summarized below) was expected to be recognized over a weighted-average period of 24 months. There is no expense to be recognized related to stock options. There were no modifications to awards during the three months ended March 31, 2016 and 2015.

Options outstanding and exercisable under the 2000 Plan and the 2009 Plan as of March 31, 2016, and changes during the three-month period following December 31, 2015, were as follows (in millions, except share and per share data): 

				Weighted-	Aggregate
				Average	Intrinsic
		Weighted-		Remaining	Value as of
		Average		Contractual	March 31,
	Shares	Exercise Price		Term	2016
Outstanding at December 31, 2015	1,232,158	$	31.65
Granted	-		-
Exercised	-		-
Forfeited and cancelled	(9,334)		29.85
Outstanding at March 31, 2016	1,222,824	$	31.66	3.8 years	$	-
Exercisable at March 31, 2016	1,222,824	$	31.66	3.8 years	$	-

No stock options were granted during the three months ended March 31, 2016 and 2015.  The aggregate intrinsic value (the number of in-the-money stock options multiplied by the difference between the Company’s closing stock price on the last trading day of the reporting period ($18.51) and the exercise price of the respective stock options) in the table above represents the amount that would have been received by the option holders had all option holders exercised their options on March 31, 2016. This amount changes based on the market value of the Company’s common stock. The aggregate intrinsic value of options exercised during the three months ended March 31, 2015 was $5 million. There were no options exercised during the three months ended March 31, 2016. The aggregate intrinsic value of options vested and expected to vest approximates that of the outstanding options. 

The Company has also awarded restricted stock under the 2000 Plan and the 2009 Plan to its directors and employees of certain subsidiaries. The restrictions on these shares generally lapse in one-third increments on each of the first three anniversaries of the award date. Certain of the restricted stock awards granted to the Company’s senior executives contain a performance objective that must be met in addition to any time-based vesting requirements. If the performance objective is not attained, the awards will be forfeited in their entirety.  Once the performance objective has been attained, restrictions will lapse in one-third increments on each of the first three anniversaries of the award date.  In addition, 835,000 restricted stock awards granted March 1, 2014 had a performance objective that was measured based on the realization of synergies related to the acquisition of Health Management Associates, Inc. (“HMA”) over a two-year period that began on February 1, 2014.  The performance objective could be met in part in the first year or in whole or in part over such two-year period.  Depending on the degree of attainment of the performance objective, restrictions would lapse on a portion of the award grant over the first three anniversaries of the award date at a level dependent upon the amount of synergies realized. If the synergies related to the HMA merger had not reached a certain level, then the awards would have been forfeited in their entirety.  Based on the synergy levels attained in the first annual measurement period ended on January 31, 2015, the performance objective for the first measurement period was met, and one-third of the awards vested on March 1, 2015. Based on the synergy levels attained in the second annual measurement period ended on January 31, 2016, the performance objective for the second measurement period was also met, so the full amount of each award has been earned and one-third of the awards vested on March 1, 2016. The remaining one-third of each award will vest on March 1, 2017. Notwithstanding the above-mentioned performance objectives and vesting requirements, the restrictions with respect to restricted stock granted under the 2000 Plan and the 2009 Plan will lapse earlier in the event of death, disability or termination of employment by the Company for any reason other than for cause of the holder of the restricted stock, or change in control of the Company. Restricted stock awards subject to performance standards that have not yet been satisfied are not considered outstanding for purposes of determining earnings per share until the performance objectives have been satisfied. 

Restricted stock outstanding under the 2000 Plan and the 2009 Plan as of March 31, 2016, and changes during the three-month period following December 31, 2015, were as follows (in millions, except share and per share data): 

		Weighted-
		Average Grant
	Shares	Date Fair Value
Unvested at December 31, 2015	2,845,579	$	44.18
Granted	1,340,000		15.48
Vested	(1,301,337)		43.36
Forfeited	(4,667)		43.05
Unvested at March 31, 2016	2,879,575		31.20

Restricted stock units (“RSUs”) have been granted to the Company’s outside directors under the 2000 Plan and the 2009 Plan. On March 1, 2015, each of the Company’s outside directors received a grant under the 2009 Plan of 3,504 RSUs. On March 1, 2016, each of the Company’s outside directors received a grant under the 2009 Plan of 11,017 RSUs. Both the 2015 and 2016 grants had a grant date fair value of approximately $170,000. Vesting of these RSUs occurs in one-third increments on each of the first three anniversaries of the award date. 

RSUs outstanding under the 2000 Plan and the 2009 Plan as of March 31, 2016, and changes during the three-month period following December 31, 2015, were as follows (in millions, except share and per share data): 

		Weighted-
		Average Grant
	Shares	Date Fair Value
Unvested at December 31, 2015	42,678	$	44.59
Granted	77,119		15.43
Vested	(21,432)		43.60
Forfeited	-		-
Unvested at March 31, 2016	98,365		21.95

XML

Cost of Revenue

3 Months Ended

Mar. 31, 2016

Cost of Revenue [Abstract]

Cost of Revenue Disclosure

3. COST OF REVENUE

Substantially all of the Company’s operating costs and expenses are “cost of revenue” items. Operating costs that could be classified as general and administrative by the Company would include the Company’s corporate office costs at its Franklin, Tennessee office, which were $60 million and $77 million for the three months ended March 31, 2016 and 2015, respectively. Included in these corporate office costs is stock-based compensation of $14 million for both the three months ended March 31, 2016 and 2015.

XML

Use of Estimates

3 Months Ended

Mar. 31, 2016

Use of Estimates [Abstract]

Use of Estimates Disclosure

4. USE OF ESTIMATES

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements. Actual results could differ from these estimates under different assumptions or conditions.

XML

Acquisitions and Divestitures

3 Months Ended

Mar. 31, 2016

Acquisitions And Divestitures [Abstract]

Acquisitions and Divestitures Disclosure

5.  ACQUISITIONS AND DIVESTITURES

Acquisitions

The Company accounts for all transactions that represent business combinations using the acquisition method of accounting, where the identifiable assets acquired, the liabilities assumed and any noncontrolling interest in the acquired entity are recognized and measured at their fair values on the date the Company obtains control in the acquiree.  Such fair values that are not finalized for reporting periods following the acquisition date are estimated and recorded as provisional amounts.  Adjustments to these provisional amounts during the measurement period (defined as the date through which all information required to identify and measure the consideration transferred, the assets acquired, the liabilities assumed and any noncontrolling interests has been obtained, limited to one year from the acquisition date) are recorded as of the date of acquisition.  Any material impact to comparative information for periods after acquisition, but before the period in which adjustments are identified, is reflected in those prior periods as if the adjustments were considered as of the acquisition date. Goodwill is determined as the excess of the fair value of the consideration conveyed in the acquisition over the fair value of the net assets acquired.

Excluding acquisition and integration expenses related to the acquisition of HMA, approximately $2 million of acquisition costs related to prospective and closed acquisitions were expensed during both the three months ended March 31, 2016 and March 31, 2015 and are included in other operating expenses on the condensed consolidated statements of income. Approximately $1 million of acquisition and related integration expense related to the HMA acquisition were recognized during the three months ended March 31, 2015.

On March 1, 2016, one or more subsidiaries of the Company completed the acquisition of an 80% ownership interest in a joint venture entity with Indiana University Health that includes substantially all of the assets of IU Health La Porte Hospital in La Porte, Indiana (227 licensed beds) and IU Health Starke Hospital in Knox, Indiana (50 licensed beds), and affiliated outpatient centers and physician practices. The total cash consideration paid for long-lived assets and working capital in this joint venture was approximately $69 million and $10 million, respectively, with additional consideration of $32 million assumed in liabilities, for a total consideration of $96 million. Based upon the Company’s preliminary purchase price allocation relating to this acquisition as of March 31, 2016, approximately $49 million of goodwill has been recorded. The preliminary allocation of the purchase price has been determined by the Company based on available information and is subject to settling amounts related to purchased working capital and final appraisals of tangible and intangible assets. Adjustments to the purchase price allocation are not expected to be material.

Other Acquisitions

During the three months ended March 31, 2016, one or more subsidiaries of the Company paid approximately $4 million to acquire the operating assets and related businesses of certain physician practices, clinics and other ancillary businesses that operate within the communities served by the Company’s affiliated hospitals. In connection with these acquisitions, during the three months ended March 31, 2016, the Company allocated approximately $2 million of the consideration paid to property and equipment and net working capital and the remainder, approximately $7 million consisting of intangible assets that do not qualify for separate recognition, to goodwill. The value of the noncontrolling interest recorded in these acquisitions was $5million.

Divestitures

In April 2014, FASB issued ASU 2014-08, which changes the requirements for reporting discontinued operations. A discontinued operation continues to include a component of an entity or a group of components of an entity, or a business activity. However, in a shift reflecting stakeholder concerns that too many disposals of small groups of assets that were recurring in nature qualified for reporting as discontinued operations, a disposal of a component of an entity or a group of components of an entity will be required to be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results. A business or nonprofit activity that, on acquisition, meets the criteria to be classified as held for sale will still be a discontinued operation. Additional disclosures will be required for significant components of the entity that are disposed of or are held for sale but do not qualify as discontinued operations. This ASU is effective for fiscal years beginning after December 15, 2014 and is to be applied on a prospective basis for disposals or components initially classified as held for sale after that date. The Company adopted this ASU on January 1, 2015 and the adoption resulted in the following divestitures occurring subsequent to the date of adoption being included in continuing operations for the three months ended March 31, 2016 and 2015 (the impact of the adoption of ASU 2014-08 in relation to the hospitals and other assets spun off to Quorum Health Corporation (“QHC”) are discussed in footnote 6 below).

Effective February 1, 2016, one or more subsidiaries of the Company sold Lehigh Regional Medical Center (88 licensed beds) in Lehigh Acres, Florida, (“Lehigh”) and related outpatient services to Prime Healthcare Services, Inc. (“Prime”) for approximately $11 million in cash. In connection with the divestiture of Lehigh, the Company recorded an impairment charge of approximately $4 million related to the allocated goodwill during the three months ended March 31, 2016.

Effective January 1, 2016, one or more subsidiaries of the Company sold Bartow Regional Medical Center (72 licensed beds) in Bartow, Florida, (“Bartow”) and related outpatient services to BayCare Health Systems, Inc. for approximately $60 million in cash, which was received at a preliminary closing on December 31, 2015. In connection with the divestiture of Bartow, the Company recorded an impairment charge of approximately $5 million related to the allocated goodwill during the three months ended March 31, 2016.

Effective July 31, 2015, one or more subsidiaries of the Company sold certain assets used in the operation of Payson Regional Medical Center (44 licensed beds) in Payson, Arizona (“Payson”) to Banner Health for approximately $20 million in cash. The Company previously operated Payson under the terms of an operating lease with Mogollon Health Alliance, Inc., an Arizona nonprofit corporation, that expired on July 31, 2015. The lease termination and sale closed effective July 31, 2015.

Pursuant to the Company’s adoption of ASU 2014-08, the divestiture of Lehigh, Bartow and Payson do not meet the requirement for presentation in discontinued operations. The financial results included in discontinued operations for divestitures or hospitals held for sale at December 31, 2014, prior to the Company’s adoption of ASU 2014-08, are summarized below.

During the three months ended June 30, 2015, one or more subsidiaries of the Company finalized an agreement to terminate the lease and cease operations of Fallbrook Hospital (47 licensed beds) in Fallbrook, California. In agreeing to terminate the lease, the Company received approximately $3 million in cash from the Fallbrook Healthcare District, as the landlord, as consideration for certain operating assets of the hospital.

Effective April 1, 2015, one or more subsidiaries of the Company sold Chesterfield General Hospital (59 licensed beds) in Cheraw, South Carolina and Marlboro Park Hospital (102 licensed beds) in Bennettsville, South Carolina and related outpatient services to M/C Healthcare, LLC for approximately $4 million in cash.

Effective March 1, 2015 one or more subsidiaries of the Company sold Dallas Regional Medical Center (202 licensed beds) in Mesquite, Texas to Prime for approximately $25 million in cash.

Effective March 1, 2015 one or more subsidiaries of the Company sold Riverview Regional Medical Center (281 licensed beds) in Gadsden, Alabama to Prime for approximately $25 million in cash. This hospital was required to be divested by the Federal Trade Commission as a condition of its approval of the HMA merger.

Effective February 1, 2015, one or more subsidiaries of the Company sold Harris Hospital (133 licensed beds) in Newport, Arkansas and related healthcare services to White County Medical Center in Searcy, Arkansas for approximately $5 million in cash.

Effective January 1, 2015, one or more subsidiaries of the Company sold Carolina Pines Regional Medical Center (116 licensed beds) in Hartsville, South Carolina and related outpatient services to Capella Healthcare for approximately $74 million in cash, which was received at the closing on December 31, 2014. This hospital was required to be divested by the Federal Trade Commission as a condition of its approval of the HMA merger.

During the year ended December 31, 2014, the Company made the decision to sell and began actively marketing several smaller hospitals, which are classified as held for sale at March 31, 2016. In addition, HMA entered into a definitive agreement to sell Williamson Memorial Hospital (76 licensed beds) located in Williamson, West Virginia prior to the HMA merger, and the Company has continued the effort to divest this facility. In connection with management’s decision to sell these facilities and the sale of the seven hospitals (excluding Payson) noted above during 2015, the Company has classified the results of operations of the above mentioned hospitals as discontinued operations in the accompanying condensed consolidated statements of income, and classified these hospitals as held for sale in the accompanying condensed consolidated balance sheet.

Net operating revenues and loss from discontinued operations for the respective periods are as follows (in millions):

	Three Months Ended
	March 31,
	2016		2015
Net operating revenues	$	27	$	56
Loss from operations of entities sold or held for sale
before income taxes		-		(17)
Impairment of hospitals sold or held for sale		(2)		(1)
Loss on sale, net		-		(1)
Loss from discontinued operations, before taxes		(2)		(19)
Income tax benefit		(1)		(6)
Loss from discontinued operations, net of taxes	$	(1)	$	(13)

Interest expense was allocated to discontinued operations based on sale proceeds available for debt repayment.

Other Hospital Closures

During the three months ended March 31, 2016, the Company announced the planned closure of McNairy Regional Hospital in Selmer, Tennessee, scheduled for the second quarter of 2016. The Company recorded an impairment charge of approximately $7 million during the three months ended March 31, 2016, to adjust the value of the supplies inventory and long-lived assets of this hospital, including property and equipment and capitalized software costs, based on their estimated fair value and future utilization.

XML

Spin-Off of Quorum Health Corporation

3 Months Ended

Mar. 31, 2016

Spin-Off of Quorum Health Corporation [Abstract]

Spin-Off of Quorum Health Corporation Disclosure

6.  SPIN-OFF OF QUORUM HEALTH CORPORATION

On August 3, 2015, the Company announced a plan to spin off 38 hospitals and Quorum Health Resources, LLC into Quorum Health Corporation, an independent, publicly traded corporation. The transaction was structured to be generally tax free to the Company and its stockholders.

On April 29, 2016, the Company completed the spin-off of QHC and distributed, on a pro rata basis, all of the shares of QHC common stock to the Company’s stockholders of record as of April 22, 2016. These stockholders of record as of April 22, 2016 received a distribution of one share of QHC common stock for every four shares of Company common stock held as of the record date plus cash in lieu of any fractional shares. Immediately following the completion of the spin-off, the Company’s stockholders owned 100% of the outstanding shares of QHC common stock. Following the spin-off, QHC became an independent public company with its common stock listed for trading under the symbol “QHC” on the New York Stock Exchange.

In connection with the spin-off, the Company and QHC entered into a separation and distribution agreement as well as certain ancillary agreements on April 29, 2016. These agreements allocate between the Company and QHC the various assets, employees, liabilities and obligations (including investments, property and employee benefits and tax-related assets and liabilities) that comprise the separate companies and govern certain relationships between, and activities of, the Company and QHC for a period of time after the spin-off.

The results of operations for QHC have continued to be presented in continuing operations in the condensed consolidated statement of income as the Company has determined that the spin-off of QHC does not meet the criteria as discontinued operations under ASU 2014-08.

XML

Income Taxes

3 Months Ended

Mar. 31, 2016

Income Taxes [Abstract]

Income Taxes Disclosure

7.  INCOME TAXES

The total amount of unrecognized benefit that would affect the effective tax rate, if recognized, was approximately $5 million as of March 31, 2016. A total of approximately $3 million of interest and penalties is included in the amount of the liability for uncertain tax positions at March 31, 2016. It is the Company’s policy to recognize interest and penalties related to unrecognized benefits in its condensed consolidated statements of income as income tax expense.

It is possible the amount of unrecognized tax benefit could change in the next 12 months as a result of a lapse of the statute of limitations and settlements with taxing authorities; however, the Company does not anticipate the change will have a material impact on the Company’s condensed consolidated results of operations or condensed consolidated financial position.

The Company, or one of its subsidiaries, files income tax returns in the United States federal jurisdiction and various state jurisdictions. The Company has extended the federal statute of limitations through March 31, 2017 for Triad Hospitals, Inc. for the tax periods ended December 31, 1999, December 31, 2000, April 30, 2001, June 30, 2001, December 31, 2001, December 31, 2002, December 31, 2003, December 31, 2004, December 31, 2005, December 31, 2006 and July 25, 2007. With few exceptions, the Company is no longer subject to state income tax examinations for years prior to 2011. The Company’s federal income tax returns for the 2009 and 2010 tax years are currently under examination by the Internal Revenue Service. The Company believes the results of these examinations will not be material to its consolidated results of operations or consolidated financial position. The Company has extended the federal statute of limitations through December 31, 2016 for Community Health Systems, Inc. for the tax periods ended December 31, 2007, 2008, 2009 and 2010, and through March 31, 2017 for the tax periods ended December 31, 2011 and 2012.

The Company’s effective tax rates were 41.3% and 33.2% for the three months ended March 31, 2016 and 2015, respectively. The increase in the Company’s effective tax rate for the three months ended March 31, 2016, when compared to the three months ended March 31, 2015, was primarily related to a disproportionate substantial decrease in income from continuing operations before income taxes, when compared to an increase in net income attributable to noncontrolling interests for those same periods, which is not tax affected in the condensed consolidated statement of income. Including the expense related to income attributable to noncontrolling interests, the effective tax rate for the three months ended March 31, 2016 and 2015 would have been 68.4% and 37.8%, respectively. The increase in the Company’s effective tax rate for the three months ended March 31, 2016 is primarily due to the impact of permanent tax differences recognized as part of the hospitals divested by the Company during this three-month period.

Cash paid for income taxes, net of refunds received, resulted in net cash paid of less than $1 million and $1 million during the three months ended March 31, 2016 and 2015, respectively.

XML

Goodwill and Other Intangible Assets

3 Months Ended

Mar. 31, 2016

Goodwill and Other Intangible Assets [Abstract]

Goodwill and Other Intangible Assets Disclosure

8.  GOODWILL AND OTHER INTANGIBLE ASSETS  

Goodwill

The changes in the carrying amount of goodwill for the three months ended March 31, 2016 are as follows (in millions):

Balance as of December 31, 2015	$	8,965
Goodwill acquired as part of acquisitions during current year		57
Balance as of March 31, 2016	$	9,022

Goodwill is allocated to each identified reporting unit, which is defined as an operating segment or one level below the operating segment (referred to as a component of the entity). Management has determined that the Company’s operating segments and hospital management services operations meet the criteria to be classified as reporting units. At March 31, 2016, the hospital operations reporting unit, the home care agency operations reporting unit and the hospital management services reporting unit had approximately $8.9 billion, $47 million and $33 million, respectively, of goodwill. 

Goodwill is evaluated for impairment at the same time every year and when an event occurs or circumstances change that, more likely than not, reduce the fair value of the reporting unit below its carrying value. There is a two-step method for determining goodwill impairment. Step one is to compare the fair value of the reporting unit with the unit’s carrying amount, including goodwill. If this test indicates the fair value is less than the carrying value, then step two is required to compare the implied fair value of the reporting unit’s goodwill with the carrying value of the reporting unit’s goodwill. The Company performed its last annual goodwill evaluation during the fourth quarter of 2015. No impairment was indicated by this evaluation.  The next annual goodwill evaluation will be performed during the fourth quarter of 2016. 

The Company estimates the fair value of the related reporting units using both a discounted cash flow model as well as an EBITDA multiple model. The cash flow forecasts are adjusted by an appropriate discount rate based on the Company’s estimate of a market participant’s weighted-average cost of capital. These models are both based on the Company’s best estimate of future revenues and operating costs and are reconciled to the Company’s consolidated market capitalization, with consideration of the amount a potential acquirer would be required to pay, in the form of a control premium, in order to gain sufficient ownership to set policies, direct operations and control management decisions.  

Intangible Assets

No intangible assets other than goodwill were acquired during the three months ended March 31, 2016.  The gross carrying amount of the Company’s other intangible assets subject to amortization was $79 million at March 31, 2016 and $82 million at December 31, 2015 and the net carrying amount was $27 million at March 31, 2016 and $31 million at December 31, 2015. The carrying amount of the Company’s other intangible assets not subject to amortization was $120 million March 31, 2016 and $121 million at December 31, 2015, respectively. Other intangible assets are included in other assets, net on the Company’s condensed consolidated balance sheets. Substantially all of the Company’s intangible assets are contract-based intangible assets related to operating licenses, management contracts, or non-compete agreements entered into in connection with prior acquisitions. 

The weighted-average remaining amortization period for the intangible assets subject to amortization is approximately four years. There are noexpected residual values related to these intangible assets. Amortization expense on these intangible assets was $4 million and $3 million  during the three months ended March 31, 2016 and 2015, respectively.  Amortization expense on intangible assets is estimated to be $11 million for the remainder of 2016, $5 million in 2017, $4 million in 2018, $2 million in 2019, $2 million in 2020, $2 million in 2021 and $1 million thereafter.   

The gross carrying amount of capitalized software for internal use was approximately  $1.5 billion at both March 31, 2016 and December 31, 2015, and the net carrying amount considering accumulated amortization was approximately $737 million at March 31, 2016 and $771 million at December 31, 2015. The estimated amortization period for capitalized internal-use software is generally three years, except for capitalized costs related to significant system conversions, which is generally eight to ten years.  There is no expected residual value for capitalized internal-use software. At March 31, 2016, there was approximately $56 million of capitalized costs for internal-use software that is currently in the development stage and will begin amortization once the software project is complete and ready for its intended use. Amortization expense on capitalized internal-use software was $55 million and $53 million during the three months ended March 31, 2016 and 2015, respectively. Amortization expense on capitalized internal-use software is estimated to be $165 million for the remainder of 2016, $185 million in 2017, $102 million in 2018, $74 million in 2019, $65 million in 2020, $60 million in 2021 and $86 million thereafter.

XML

Earnings Per Share

3 Months Ended

Mar. 31, 2016

Earnings Per Share [Abstract]

Earnings Per Share Disclosure

9.  EARNINGS PER SHARE

The following table sets forth the components of the numerator and denominator for the computation of basic and diluted earnings per share for income from continuing operations, discontinued operations and net income attributable to Community Health Systems, Inc. common stockholders (in millions, except share data):  

	Three Months Ended
	March 31,
	2016		2015
Numerator:
Income from continuing operations, net of taxes	$	37	$	112
Less: Income from continuing operations attributable
to noncontrolling interests, net of taxes		25		20
Income from continuing operations attributable to
Community Health Systems, Inc. common
stockholders — basic and diluted	$	12	$	92
Loss from discontinued operations, net of taxes	$	(1)	$	(13)
Less: Loss from discontinued operations attributable
to noncontrolling interests, net of taxes		-		-
Loss from discontinued operations attributable to
Community Health Systems, Inc. common
stockholders — basic and diluted	$	(1)	$	(13)
Denominator:
Weighted-average number of shares outstanding — basic		110,247,867		114,419,590
Effect of dilutive securities:
Restricted stock awards		45,257		181,120
Employee stock options		13,038		452,659
Other equity-based awards		3,210		4,299
Weighted-average number of shares outstanding — diluted		110,309,372		115,057,668

	Three Months Ended
	March 31,
	2016		2015
Dilutive securities outstanding not included in
the computation of earnings per
share because their effect is antidilutive:
Employee stock options and restricted stock awards		2,672,726		-

XML

Stockholders' Equity

3 Months Ended

Mar. 31, 2016

Stockholders' Equity [Abstract]

Stockholders' Equity Disclosure

10.  STOCKHOLDERS’ EQUITY   

Authorized capital shares of the Company include 400,000,000 shares of capital stock consisting of 300,000,000 shares of common stock and 100,000,000 shares of preferred stock. Each of the aforementioned classes of capital stock has a par value of $0.01 per share. Shares of preferred stock, none of which were outstanding as of March 31, 2016, may be issued in one or more series having such rights, preferences and other provisions as determined by the Board of Directors without approval by the holders of common stock.

On November 6, 2015, the Company adopted a new open market repurchase program for up to 10,000,000 shares of the Company’s common stock, not to exceed $300 million in repurchases. The repurchase program will expire on the earlier of November 5, 2018, when the maximum number of shares has been repurchased, or when the maximum dollar amount has been expended. During the year ended December 31, 2015, the Company repurchased and retired 532,188 shares at a weighted-average price of $27.31 per share, which is the cumulative number of shares repurchased and retired under this program. No shares were repurchased under this program during the three months ended March 31, 2016.

On December 10, 2014, the Company adopted an open market repurchase program for up to 5,000,000 shares of the Company’s common stock, not to exceed $150 million in repurchases. This repurchase program expired on December 1, 2015. No shares were repurchased under this program during the three months ended March 31, 2015.

The Company is a holding company which operates through its subsidiaries.  The Company’s Credit Facility and the indentures governing the senior and senior secured notes contain various covenants under which the assets of the subsidiaries of the Company are subject to certain restrictions relating to, among other matters, dividends and distributions, as referenced in the paragraph below.  

With the exception of a special cash dividend of $0.25 per share paid by the Company in December 2012, historically, the Company has not paid any cash dividends. Subject to certain exceptions, the Company’s Credit Facility limits the ability of the Company’s subsidiaries to pay dividends and make distributions to the Company, and limits the Company’s ability to pay dividends and/or repurchase stock, to an amount not to exceed $200 million in the aggregate plus an additional $25 million in any particular year plus the aggregate amount of proceeds from the exercise of stock options. The indentures governing the senior and senior secured notes also restrict the Company’s subsidiaries from, among other matters, paying dividends and making distributions to the Company, which thereby limits the Company’s ability to pay dividends and/or repurchase stock. As of March 31, 2016, under the most restrictive test under these agreements (and subject to certain exceptions), the Company has approximately $318 million remaining available with which to pay permitted dividends and/or repurchase shares of stock or its senior and senior secured notes.

The following schedule presents the reconciliation of the carrying amount of total equity, equity attributable to the Company, and equity attributable to the noncontrolling interests for the three-month period ended March 31, 2016 (in millions):

			Community Health Systems, Inc. Stockholders
	Redeemable Noncontrolling Interest		Common Stock		Additional Paid-In Capital		Treasury Stock		Accumulated Other Comprehensive Income (Loss)		Retained Earnings		Noncontrolling Interest		Total Stockholders’ Equity
Balance, December 31, 2015	$	571	$	1	$	1,963	$	(7)	$	(73)	$	2,135	$	86	$	4,105
Comprehensive income		19		-		-		-		(16)		11		6		1
Distributions to noncontrolling
interests, net of contributions		(14)		-		-		-		-		-		(4)		(4)
Purchase of subsidiary shares
from noncontrolling interests		(10)		-		(3)		-		-		-		(3)		(6)
Other reclassifications of
noncontrolling interests		(1)		-		-		-		-		-		1		1
Noncontrolling interests in
acquired entity		-		-		-		-		-		-		29		29
Income tax payable increase
from vesting of restricted shares		-		-		(15)		-		-		-		-		(15)
Cancellation of restricted
stock for tax withholdings
on vested shares		-		-		(7)		-		-		-		-		(7)
Share-based compensation		-		-		14		-		-		-		-		14
Balance, March 31, 2016	$	565	$	1	$	1,952	$	(7)	$	(89)	$	2,146	$	115	$	4,118

The following schedule discloses the effects of changes in the Company’s ownership interest in its less-than-wholly-owned subsidiaries on Community Health Systems, Inc. stockholders’ equity (in millions):

	Three Months Ended
	March 31, 2016
Net income attributable to Community Health Systems,
Inc. stockholders	$	11
Transfers to the noncontrolling interests:
Net decrease in Community Health Systems, Inc. paid-in
capital for  purchase of subsidiary partnership interests		(3)
Net transfers to the noncontrolling interests		(3)
Change to Community Health Systems, Inc. stockholders’ equity
from net income attributable to Community Health Systems,
Inc. stockholders and transfers to noncontrolling interests	$	8

XML

Equity Investments

3 Months Ended

Mar. 31, 2016

Equity Investments [Abstract]

Equity Investments Disclosure

11.  EQUITY INVESTMENTS

As of March 31, 2016, the Company owned equity interests of 27.5% in four hospitals in Las Vegas, Nevada, and 26.1% in one hospital in Las Vegas, Nevada, in which Universal Health Services, Inc. (“UHS”) owns the majority interest, and an equity interest of 38.0% in three hospitals in Macon, Georgia, in which HCA Holdings, Inc. (“HCA”) owns the majority interest.  

Summarized combined financial information for these unconsolidated entities in which the Company owns an equity interest is as follows (in millions):

	Three Months Ended
	March 31,
	2016		2015
Revenues	$	415	$	375
Operating costs and expenses		324		315
Income from continuing operations before taxes		91		60

The summarized financial information was derived from the financial information provided to the Company by those unconsolidated entities. 

In March 2005, the Company began purchasing items, primarily medical supplies, medical equipment and pharmaceuticals, under an agreement with HealthTrust Purchasing Group, L.P. (“HealthTrust”), a group purchasing organization in which the Company is a noncontrolling partner. As part of the HMA merger, the Company acquired HMA’s ownership in HealthTrust. As of March 31, 2016, the Company had a 24.7% ownership interest in HealthTrust.

The Company’s investment in all of its unconsolidated affiliates was $504 million at March 31, 2016 and $479 million December 31, 2015, and is included in other assets, net in the accompanying condensed consolidated balance sheets. Included in the Company’s results of operations is the Company’s equity in pre-tax earnings from all of its investments in unconsolidated affiliates, which was $20 million and $18 million for the three months ended March 31, 2016 and 2015, respectively.

XML

Long-Term Debt

3 Months Ended

Mar. 31, 2016

Long-term Debt [Abstract]

Long-Term Debt Disclosure

12.  LONG-TERM DEBT

Long-term debt consists of the following (in millions): 

	March 31,		December 31,
	2016		2015
Credit Facility:
Term A Loan	$	820	$	844
Term F Loan		1,668		1,671
Term G Loan		1,565		1,568
Term H Loan		2,879		2,884
Revolving credit loans		323		147
8% Senior Notes due 2019		1,993		1,992
7⅛% Senior Notes due 2020		1,187		1,186
5⅛% Senior Secured Notes due 2018		1,588		1,587
5⅛% Senior Secured Notes due 2021		968		967
6⅞% Senior Notes due 2022		2,924		2,921
Receivables Facility		699		699
Capital lease obligations		219		227
Other		81		92
Total debt		16,914		16,785
Less current maturities		(249)		(229)
Total long-term debt	$	16,665	$	16,556

Credit Facility

The Company’s wholly-owned subsidiary, CHS, has senior secured financing under a credit facility with a syndicate of financial institutions led by Credit Suisse, as administrative agent and collateral agent. In connection with the HMA merger, the Company and CHS entered into a third amendment and restatement of its credit facility (the “Credit Facility”), providing for additional financing and recapitalization of certain of the Company’s term loans, including (i) the replacement of the revolving credit facility with a new $1.0 billion revolving facility maturing in 2019 (the “Revolving Facility”), (ii) the addition of a new $1.0 billion Term A facility due 2019 (the “Term A Facility”), (iii) a Term D facility in an aggregate principal amount equal to approximately $4.6 billion due 2021 (which included certain term C loans that were converted into such Term D facility (collectively, the “Term D Facility”)), (iv) the conversion of certain term C loans into Term E Loans and the borrowing of new Term E Loans in an aggregate principal amount of approximately $1.7 billion due 2017 and (v) the addition of flexibility commensurate with the Company’s post-acquisition structure. In addition to funding a portion of the consideration in connection with the HMA merger, some of the proceeds of the Term A Facility and Term D Facility were used to refinance the outstanding $637 million existing term A facility due 2016 and the $60 million of term B loans due 2014, respectively. The Revolving Facility includes a subfacility for letters of credit. On March 9, 2015, CHS entered into Amendment No. 1 and Incremental Term Loan Assumption Agreement to refinance the existing Term E Loans due 2017 into Term F Loans due 2018, in an original aggregated principal amount of $1.7 billion. On May 18, 2015, CHS entered into an Incremental Term Loan Assumption Agreement to provide for a new $1.6 billion incremental Term G facility and a new approximately $2.9 billion incremental Term H facility. The proceeds of the Term G facility and Term H facility were used to repay the Company’s existing Term D facility in full.

The loans under the Credit Facility bear interest on the outstanding unpaid principal amount at a rate equal to an applicable percentage plus, at CHS’ option, either (a) an Alternate Base Rate (as defined) determined by reference to the greater of (1) the Prime Rate (as defined) announced by Credit Suisse or (2) the Federal Funds Effective Rate (as defined) plus 0.50% or (3) the adjusted London Interbank Offered Rate (“LIBOR”) on such day for a three-month interest period commencing on the second business day after such day plus 1% or (b) LIBOR.  Loans in respect of the Revolving Facility and the Term A Facility will accrue interest at a rate per annum initially equal to LIBOR plus 2.75%, in the case of LIBOR borrowings, and Alternate Base Rate plus 1.75%, in the case of Alternate Base Rate borrowings. In addition, the margin in respect of the Revolving Facility and the Term A Facility will be subject to adjustment determined by reference to a leverage-based pricing grid. Loans in respect of the Term F Facility will accrue interest at a rate per annum equal to LIBOR plus 3.25%, in the case of LIBOR borrowings, and Alternate Base Rate plus 2.25%, in the case of Alternate Base Rate Borrowings. The Term G Loan and Term H Loan will accrue interest at a rate per annum equal to LIBOR plus 2.75% and 3.00%, respectively, in the case of LIBOR borrowings, and Alternate Base Rate plus 1.75% and 2.00%, respectively, in the case of Alternate Base Rate Borrowings. The Term G Loan and the Term H Loan are subject to a 1.00% LIBOR floor and a 2.00%Alternate Base Rate floor.

The term loan facility must be prepaid in an amount equal to (1) 100% of the net cash proceeds of certain asset sales and dispositions by the Company and its subsidiaries, subject to certain exceptions and reinvestment rights, (2) 100% of the net cash proceeds of issuances of certain debt obligations or receivables-based financing by the Company and its subsidiaries, subject to certain exceptions, and (3) 50%, subject to reduction to a lower percentage based on the Company’s leverage ratio (as defined in the Credit Facility generally as the ratio of total debt on the date of determination to the Company’s EBITDA, as defined, for the four quarters most recently ended prior to such date), of excess cash flow (as defined) for any year, subject to certain exceptions. Voluntary prepayments and commitment reductions are permitted in whole or in part, without any premium or penalty, subject to minimum prepayment or reduction requirements. 

The borrower under the Credit Facility is CHS. All of the obligations under the Credit Facility are unconditionally guaranteed by the Company and certain of its existing and subsequently acquired or organized domestic subsidiaries. All obligations under the Credit Facility and the related guarantees are secured by a perfected first priority lien or security interest in substantially all of the assets of the Company, CHS and each subsidiary guarantor, including equity interests held by the Company, CHS or any subsidiary guarantor, but excluding, among others, the equity interests of non-significant subsidiaries, syndication subsidiaries, securitization subsidiaries and joint venture subsidiaries. 

CHS has agreed to pay letter of credit fees equal to the applicable percentage then in effect with respect to Eurodollar rate loans under the Revolving Facility times the maximum aggregate amount available to be drawn under all letters of credit outstanding under the subfacility for letters of credit. The issuer of any letter of credit issued under the subfacility for letters of credit will also receive a customary fronting fee and other customary processing charges. CHS is obligated to pay commitment fees of 0.50% per annum (subject to adjustment based upon the Company’s leverage ratio) on the unused portion of the Revolving Facility.

The Credit Facility contains customary representations and warranties, subject to limitations and exceptions, and customary covenants restricting the Company’s and its subsidiaries’ ability, subject to certain exceptions, to, among other things (1) declare dividends, make distributions or redeem or repurchase capital stock, (2) prepay, redeem or repurchase other debt, (3) incur liens or grant negative pledges, (4) make loans and investments and enter into acquisitions and joint ventures, (5) incur additional indebtedness or provide certain guarantees, (6) make capital expenditures, (7) engage in mergers, acquisitions and asset sales, (8) conduct transactions with affiliates, (9) alter the nature of the Company’s businesses, (10) grant certain guarantees with respect to physician practices, (11) engage in sale and leaseback transactions or (12) change the Company’s fiscal year. The Company is also required to comply with specified financial covenants (consisting of a maximum secured net leverage ratio and an interest coverage ratio) and various affirmative covenants. The Company was in compliance with all such covenants at March 31, 2016.

Events of default under the Credit Facility include, but are not limited to, (1) CHS’ failure to pay principal, interest, fees or other amounts under the credit agreement when due (taking into account any applicable grace period), (2) any representation or warranty proving to have been materially incorrect when made, (3) covenant defaults subject, with respect to certain covenants, to a grace period, (4) bankruptcy events, (5) a cross default to certain other debt, (6) certain undischarged judgments (not paid within an applicable grace period), (7) a change of control, (8) certain ERISA-related defaults and (9) the invalidity or impairment of specified security interests, guarantees or subordination provisions in favor of the administrative agent or lenders under the Credit Facility. 

As of March 31, 2016, the availability for additional borrowings under the Credit Facility, after taking into account the $334 million outstanding at that date, was approximately $666 million pursuant to the Revolving Facility, of which $68 million was set aside for outstanding letters of credit. CHS has the ability to amend the Credit Facility to provide for one or more tranches of term loans or increases in the Revolving Facility in an aggregate principal amount of $1.5 billion, which CHS has not yet accessed. As of March 31, 2016, the weighted-average interest rate under the Credit Facility, excluding swaps, was 4.3%. 

8% Senior Notes due 2019 

On November 22, 2011, CHS completed its offering of $1.0 billion aggregate principal amount of 8% Senior Notes due 2019 (the “8% Senior Notes”), which were issued in a private placement.  The net proceeds from this issuance, together with available cash on hand, were used to finance the purchase of up to $1.0 billion aggregate principal amount of CHS’ then outstanding 8⅞% Senior Notes and related fees and expenses.  On March 21, 2012, CHS completed the secondary offering of an additional $1.0 billion aggregate principal amount of 8% Senior Notes, which were issued in a private placement (at a premium of 102.5%).  The net proceeds from this issuance were used to finance the purchase of approximately $850 million aggregate principal amount of CHS’ then outstanding 8⅞% Senior Notes, to pay related fees and expenses and for general corporate purposes.  The 8% Senior Notes bear interest at 8% per annum, payable semiannually in arrears on May 15 and November 15, commencing May 15, 2012. Interest on the 8% Senior Notes accrues from the date of original issuance. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months. 

On and after November 15, 2015, CHS is entitled, at its option, to redeem all or a portion of the 8% Senior Notes upon not less than 30 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below: 

Period	Redemption Price
November 15, 2015 to November 14, 2016	104.000	%
November 15, 2016 to November 14, 2017	102.000	%
November 15, 2017 to November 15, 2019	100.000	%

Pursuant to a registration rights agreement entered into at the time of the issuance of the 8% Senior Notes, as a result of an exchange offer made by CHS, substantially all of the 8% Senior Notes issued in November 2011 and March 2012 were exchanged in May 2012 for new notes (the “8% Exchange Notes”) having terms substantially identical in all material respects to the 8% Senior Notes (except that the 8% Exchange Notes were issued under a registration statement pursuant to the Securities Act of 1933, as amended (the “1933 Act”)). References to the 8% Senior Notes shall also be deemed to include the 8% Exchange Notes unless the context provides otherwise. 

7⅛% Senior Notes due 2020 

On July 18, 2012, CHS completed an underwritten public offering under its automatic shelf registration filed with the SEC of $1.2 billion aggregate principal amount of 7⅛% Senior Notes due 2020 (the “7⅛% Senior Notes”).  The net proceeds from this issuance were used to finance the purchase or redemption of $934 million aggregate principal amount plus accrued interest of CHS’ outstanding 8⅞% Senior Notes, to pay for consents delivered in connection therewith, to pay related fees and expenses, and for general corporate purposes. The 7⅛% Senior Notes bear interest at 7.125% per annum, payable semiannually in arrears on July 15 and January 15, commencing January 15, 2013. Interest on the 7⅛% Senior Notes accrues from the date of original issuance. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months. 

Except as set forth below, CHS is not entitled to redeem the 7⅛% Senior Notes prior to July 15, 2016. 

Prior to July 15, 2016, CHS may redeem some or all of the 7⅛% Senior Notes at a redemption price equal to 100% of the principal amount of the notes redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the 7⅛% Senior Notes indenture. On and after July 15, 2016, CHS is entitled, at its option, to redeem all or a portion of the 7⅛% Senior Notes upon not less than 30 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below: 

Period	Redemption Price
July 15, 2016 to July 14, 2017	103.563	%
July 15, 2017 to July 14, 2018	101.781	%
July 15, 2018 to July 15, 2020	100.000	%

5⅛% Senior Secured Notes due 2018 

On August 17, 2012, CHS completed an underwritten public offering under its automatic shelf registration filed with the SEC of $1.6 billion aggregate principal amount of 5⅛% Senior Secured Notes due 2018 (the “2018 Senior Secured Notes”).  The net proceeds from this issuance, together with available cash on hand, were used to finance the prepayment of $1.6 billion of the outstanding term loans due 2014 under the Credit Facility and related fees and expenses.  The 2018 Senior Secured Notes bear interest at 5.125% per annum, payable semiannually in arrears on August 15 and February 15, commencing February 15, 2013. Interest on the 2018 Senior Secured Notes accrues from the date of original issuance. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months. The 2018 Senior Secured Notes are secured by a first-priority lien subject to a shared lien of equal priority with certain other obligations, including obligations under the Credit Facility, and subject to prior ranking liens permitted by the indenture governing the 2018 Senior Secured Notes on substantially the same assets, subject to certain exceptions, that secure CHS’ obligations under the Credit Facility. 

On and after August 15, 2015, CHS is entitled, at its option, to redeem all or a portion of the 2018 Senior Secured Notes upon not less than 30 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below: 

Period	Redemption Price
August 15, 2015 to August 14, 2016	102.563	%
August 15, 2016 to August 14, 2017	101.281	%
August 15, 2017 to August 15, 2018	100.000	%

5⅛% Senior Secured Notes due 2021 

On January 27, 2014, CHS issued $1.0 billion aggregate principal amount of 5⅛% Senior Secured Notes due 2021 (the “2021 Senior Secured Notes”) in connection with the HMA merger, which were issued in a private placement.  The net proceeds from this issuance were used to finance the HMA merger.  The 2021 Senior Secured Notes bear interest at 5.125% per annum, payable semiannually in arrears on February 1 and August 1, commencing August 1, 2014. Interest on the 2021 Senior Secured Notes accrues from the date of original issuance. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months. The 2021 Senior Secured Notes are secured by a first-priority lien, subject to a shared lien of equal priority with certain other obligations, including obligations under the Credit Facility, and subject to prior ranking liens permitted by the indenture governing the 2021 Senior Secured Notes, on substantially the same assets, subject to certain exceptions, that secure CHS’ obligations under the Credit Facility. 

Except as set forth below, CHS is not entitled to redeem the 2021 Senior Secured Notes prior to February 1, 2017. 

Prior to February 1, 2017, CHS is entitled, at its option, to redeem a portion of the 2021 Senior Secured Notes (not to exceed 40% of the outstanding principal amount) at a redemption price equal to 105.125% of the principal amount of the notes redeemed plus accrued and unpaid interest, with the proceeds from certain equity offerings.  Prior to February 1, 2017, CHS may redeem some or all of the 2021 Senior Secured Notes at a redemption price equal to 100% of the principal amount of the notes redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the 2021 Senior Secured Notes indenture. On and after February 1, 2017, CHS is entitled, at its option, to redeem all or a portion of the 2021 Senior Secured Notes upon not less than 30 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below: 

Period	Redemption Price
February 1, 2017 to January 31, 2018	103.844	%
February 1, 2018 to January 31, 2019	102.563	%
February 1, 2019 to January 31, 2020	101.281	%
February 1, 2020 to January 31, 2021	100.000	%

Pursuant to a registration rights agreement entered into at the time of the issuance of the 2021 Senior Secured Notes, as a result of an exchange offer made by CHS, all of the 2021 Senior Secured Notes issued in January 2014 were exchanged in October 2014 for new notes (the “2021 Exchange Notes”) having terms substantially identical in all material respects to the 2021 Senior Secured Notes (except that the exchange notes were issued under a registration statement pursuant to the 1933 Act).  References to the 2021 Senior Secured Notes shall be deemed to be the 2021 Exchange Notes unless the context provides otherwise.

6⅞% Senior Notes due 2022 

On January 27, 2014, CHS issued $3.0 billion aggregate principal amount of 6⅞% Senior Notes due 2022 (the “6⅞% Senior Notes”) in connection with the HMA merger, which were issued in a private placement.  The net proceeds from this issuance were used to finance the HMA merger.  The 6⅞% Senior Notes bear interest at 6.875% per annum, payable semiannually in arrears on February 1 and August 1, commencing August 1, 2014. Interest on the 6⅞% Senior Notes accrues from the date of original issuance. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months. 

Except as set forth below, CHS is not entitled to redeem the 6⅞% Senior Notes prior to February 1, 2018. 

Prior to February 1, 2017, CHS is entitled, at its option, to redeem a portion of the 6⅞% Senior Notes (not to exceed 40% of the outstanding principal amount) at a redemption price equal to 106.875% of the principal amount of the notes redeemed plus accrued and unpaid interest, with the proceeds from certain public equity offerings.  Prior to February 1, 2018, CHS may redeem some or all of the 6⅞% Senior Notes at a redemption price equal to 100% of the principal amount of the notes redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the 6⅞% Senior Notes indenture. On and after February 1, 2018, CHS is entitled, at its option, to redeem all or a portion of the 6⅞% Senior Notes upon not less than 30 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below: 

Period	Redemption Price
February 1, 2018 to January 31, 2019	103.438	%
February 1, 2019 to January 31, 2020	101.719	%
February 1, 2020 to January 31, 2022	100.000	%

Pursuant to a registration rights agreement entered into at the time of the issuance of the 6⅞% Senior Notes, as a result of an exchange offer made by CHS, all of the 6⅞% Senior Notes issued in January 2014 were exchanged in October 2014 for new notes (the “6⅞% Exchange Notes”) having terms substantially identical in all material respects to the 6⅞% Senior Notes (except that the exchange notes were issued under a registration statement pursuant to the 1933 Act).  References to the 6⅞% Senior Notes shall be deemed to be the 6⅞% Exchange Notes unless the context provides otherwise.

Receivables Facility 

On March 21, 2012, through certain of its subsidiaries, CHS entered into an accounts receivable loan agreement (the “Receivables Facility”) with a group of lenders and banks, Credit Agricolé Corporate and Investment Bank, as a managing agent and as the administrative agent, and The Bank of Nova Scotia, as a managing agent.  On March 7, 2013, CHS and certain of its subsidiaries amended the Receivables Facility to add an additional managing agent, The Bank of Tokyo-Mitsubishi UFJ, Ltd., to increase the size of the facility from $300 million to $500 million and to extend the scheduled termination date. Additional subsidiaries also agreed to participate in the Receivables Facility as of that date. On March 31, 2014, CHS and certain of its subsidiaries amended the Receivables Facility to increase the size of the facility from $500 million to $700 million and to extend the scheduled termination date. Additional subsidiaries also agreed to participate in the Receivables Facility as of that date. On November 13, 2015, CHS and certain of its subsidiaries amended the Receivables Facility to extend the scheduled termination date and amend certain other provisions thereof. The existing and future non-self pay patient-related accounts receivable (the “Receivables”) for certain affiliated hospitals serve as collateral for the outstanding borrowings under the Receivables Facility. The interest rate on the borrowings is based on the commercial paper rate plus an applicable interest rate spread.  Unless earlier terminated or subsequently extended pursuant to its terms, the Receivables Facility will expire on November 13, 2017,  subject to customary termination events that could cause an early termination date. CHS maintains effective control over the Receivables because, pursuant to the terms of the Receivables Facility, the Receivables are sold from certain of CHS’ subsidiaries to CHS, and CHS then sells or contributes the Receivables to a special-purpose entity that is wholly-owned by CHS.  The wholly-owned special-purpose entity in turn grants security interests in the Receivables in exchange for borrowings obtained from the group of third-party lenders and banks of up to $700 million outstanding from time to time based on the availability of eligible Receivables and other customary factors. The group of third-party lenders and banks do not have recourse to CHS or its subsidiaries beyond the assets of the wholly-owned special-purpose entity that collateralizes the loan.  The Receivables and other assets of the wholly-owned special-purpose entity will be available first and foremost to satisfy the claims of the creditors of such entity. The outstanding borrowings pursuant to the Receivables Facility at March 31, 2016 totaled $699 million and are classified as long-term debt on the condensed consolidated balance sheet. At March 31, 2016, the carrying amount of Receivables included in the Receivables Facility totaled approximately $1.7 billion and is included in patient accounts receivable on the condensed consolidated balance sheet. 

The Company has transitioned all of its hospitals to the ICD-10 coding system, which was required of all healthcare providers covered by the Health Insurance Portability and Accountability Act (“HIPAA”). This transition involved a significant capital investment in technology and coding of the Company’s information systems, as well as significant costs related to training of staff involved with coding and billing. As noted in the Company’s 2015 Annual Report on Form 10-K, the potential for delay in billing and collection on patient receivables resulting from these changes or from new payment systems and processes implemented by third-party payors could have an adverse effect on the quality of receivables that serve as collateral under the Receivables Facility, resulting in a potential default or repayment of outstanding borrowings. Should such a repayment of borrowings under the Receivables Facility be required, the Company has availability, and expects that it will continue to have availability, under its Revolving Facility to provide sufficient financial resources and liquidity to fund the repayment.

Loss from Early Extinguishment of Debt 

The financing transactions discussed above resulted in a loss from the early extinguishment of debt of $8 million for the three months ended March 31, 2015, and an after-tax loss of $5 million for the three months ended March 31, 2015. 

Other Debt

As of March 31, 2016, other debt consisted primarily of the mortgage obligation on the Company’s corporate headquarters and other obligations maturing in various installments through 2020.

To limit the effect of changes in interest rates on a portion of the Company’s long-term borrowings, the Company is a party to 15 separate interest swap agreements in effect at March 31, 2016, with an aggregate notional amount for currently effective swaps of $3.5 billion. On each of these swaps, the Company receives a variable rate of interest based on the three-month LIBOR in exchange for the payment of a fixed rate of interest. The Company currently pays, on a quarterly basis, interest on the Revolving Facility and the Term A Facility at a rate per annum equal to LIBOR plus 2.75%. Loans in respect of the Term F Facility accrue interest at a rate per annum equal to LIBOR plus 3.25%.  The Term G Loan and Term H Loan accrue interest at a rate per annum equal to LIBOR plus 2.75% and 3.00%, in the case of LIBOR borrowings, respectively, and Alternate Base Rate plus 1.75% and 2.00%, respectively, in the case of Alternate Base Rate Borrowings. The Term G Loan and the Term H Loan are subject to a 1.00% LIBOR floor and a 2.00%Alternate Base Rate floor. See Note 13 for additional information regarding these swaps.

The Company paid interest of $307 million and $300 million on borrowings during the three months ended March 31, 2016 and 2015, respectively. 

XML

Fair Value of Financial Instruments

3 Months Ended

Mar. 31, 2016

Fair Value of Financial Instruments [Abstract]

Fair Value of Financial Instruments Disclosure

13.  FAIR VALUE OF FINANCIAL INSTRUMENTS

The fair value of financial instruments has been estimated by the Company using available market information as of March 31, 2016 and December 31, 2015, and valuation methodologies considered appropriate. The estimates presented in the table below are not necessarily indicative of amounts the Company could realize in a current market exchange (in millions): 

	March 31, 2016				December 31, 2015
	Carrying		Estimated Fair		Carrying		Estimated Fair
	Amount		Value		Amount		Value
Assets:
Cash and cash equivalents	$	181	$	181	$	184	$	184
Available-for-sale securities		268		268		271		271
Trading securities		63		63		61		61
Liabilities:
Contingent Value Right		2		2		2		2
Credit Facility		7,255		7,255		7,114		7,115
8% Senior Notes		1,993		1,954		1,992		2,018
7⅛% Senior Notes		1,187		1,141		1,186		1,193
2018 Senior Secured Notes		1,588		1,615		1,587		1,610
2021 Senior Secured Notes		968		1,010		967		997
6⅞% Senior Notes		2,924		2,715		2,921		2,858
Receivables Facility and other debt		780		780		791		791

The estimated fair value is determined using the methodologies discussed below in accordance with accounting standards related to the determination of fair value based on the U.S. GAAP fair value hierarchy as discussed in Note 14.  The estimated fair value for financial instruments with a fair value that does not equal its carrying value is considered a Level 1 valuation.  The Company utilizes the market approach and obtains indicative pricing from the administrative agent to the Credit Facility to determine fair values or through publicly available subscription services such as Bloomberg where relevant. 

Cash and cash equivalents.  The carrying amount approximates fair value due to the short-term maturity of these instruments (less than three months). 

Available-for-sale securities.  Estimated fair value is based on closing price as quoted in public markets or other various valuation techniques. 

Trading securities.  Estimated fair value is based on closing price as quoted in public markets. 

Contingent Value Right. Estimated fair value is based on the closing price as quoted on the public market where the CVR is traded.

Credit Facility.  Estimated fair value is based on publicly available trading activity and supported with information from the Company’s bankers regarding relevant pricing for trading activity among the Company’s lending institutions. 

8% Senior Notes.  Estimated fair value is based on the closing market price for these notes. 

7⅛% Senior Notes.  Estimated fair value is based on the closing market price for these notes. 

2018 Senior Secured Notes.  Estimated fair value is based on the closing market price for these notes. 

2021 Senior Secured Notes.  Estimated fair value is based on the closing market price for these notes.

6⅞% Senior Notes.  Estimated fair value is based on the closing market price for these notes. 

Receivables Facility and other debt.  The carrying amount of the Receivables Facility and all other debt approximates fair value due to the nature of these obligations. 

Interest rate swaps.  The fair value of interest rate swap agreements is the amount at which they could be settled, based on estimates calculated by the Company using a discounted cash flow analysis based on observable market inputs and validated by comparison to estimates obtained from the counterparty. The Company incorporates credit valuation adjustments (“CVAs”) to appropriately reflect both its own nonperformance or credit risk and the respective counterparty’s nonperformance or credit risk in the fair value measurements. In adjusting the fair value of its interest rate swap agreements for the effect of nonperformance or credit risk, the Company has considered the impact of any netting features included in the agreements. 

The Company assesses the effectiveness of its hedge instruments on a quarterly basis. For the three months ended March 31, 2016 and 2015, the Company completed an assessment of the cash flow hedge instruments and determined the hedges to be highly effective. The Company has also determined that the ineffective portion of the hedges do not have a material effect on the Company’s consolidated financial position, operations or cash flows. The counterparties to the interest rate swap agreements expose the Company to credit risk in the event of nonperformance. However, at March 31, 2016, all of the swap agreements entered into by the Company were in a net liability position such that the Company would be required to make the net settlement payments to the counterparties; the Company does not anticipate nonperformance by those counterparties. The Company does not hold or issue derivative financial instruments for trading purposes. 

Interest rate swaps consisted of the following at March 31, 2016:  

Swap #	Notional Amount (in millions)		Fixed Interest Rate		Termination Date	Fair Value (in millions)
1	$	300	3.447	%	August 6, 2016	$	3
2		100	3.401	%	August 19, 2016		1
3		200	3.429	%	August 19, 2016		2
4		200	3.500	%	August 30, 2016		2
5		100	3.005	%	November 30, 2016		2
6		200	2.055	%	July 25, 2019		7
7		200	2.059	%	July 25, 2019		7
8		400	1.882	%	August 30, 2019		7
9		200	2.515	%	August 30, 2019		8
10		200	2.613	%	August 30, 2019		8
11		300	2.041	%	August 30, 2020		7
12		300	2.738	%	August 30, 2020		16
13		300	2.892	%	August 30, 2020		17
14		300	2.363	%	January 27, 2021		11
15		200	2.368	%	January 27, 2021		7

The Company is exposed to certain risks relating to its ongoing business operations. The risk managed by using derivative instruments is interest rate risk. Interest rate swaps are entered into to manage interest rate fluctuation risk associated with the term loans in the Credit Facility. Companies are required to recognize all derivative instruments as either assets or liabilities at fair value in the condensed consolidated statement of financial position. The Company designates its interest rate swaps as cash flow hedges. For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of the gain or loss on the derivative is reported as a component of other comprehensive income (“OCI”) and reclassified into earnings in the same period or periods during which the hedged transactions affect earnings. Gains and losses on the derivative representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current earnings. 

Assuming no change in March 31, 2016 interest rates, approximately $46 million of interest expense resulting from the spread between the fixed and floating rates defined in each interest rate swap agreement will be recognized during the next 12 months. If interest rate swaps do not remain highly effective as a cash flow hedge, the derivatives’ gains or losses resulting from the change in fair value reported through OCI will be reclassified into earnings. 

The following tabular disclosure provides the amount of pre-tax loss recognized as a component of OCI during the three months ended March 31, 2016 and 2015 (in millions): 

	Amount of Pre-Tax Loss Recognized in
	OCI (Effective Portion)
Derivatives in Cash Flow Hedging Relationships	Three Months Ended March 31,
	2016		2015
Interest rate swaps	$	(43)	$	(22)

The following tabular disclosure provides the location of the effective portion of the pre-tax loss reclassified from accumulated other comprehensive loss (“AOCL”) into interest expense on the condensed consolidated statements of income during the three months ended March 31, 2016 and 2015 (in millions):

	Amount of Pre-Tax Loss Reclassified from
Location of Loss Reclassified from	AOCL into Income (Effective Portion)
AOCL into Income (Effective Portion)	Three Months Ended March 31,
	2016		2015
Interest expense, net	$	14	$	9

The fair values of derivative instruments in the condensed consolidated balance sheets as of March 31, 2016 and December 31, 2015 were as follows (in millions):

Asset Derivatives

Liability Derivatives

March 31, 2016

December 31, 2015

March 31, 2016

December 31, 2015

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Derivatives      designated as hedging instruments

Other assets, net

$

-

Other assets, net

$

-

Other long-term liabilities

$

105

Other long-term liabilities

$

76

XML

Fair Value

3 Months Ended

Mar. 31, 2016

Fair Value [Abstract]

Fair Value Disclosure

14.  FAIR VALUE

Fair Value Hierarchy

Fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, the Company utilizes the U.S. GAAP fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumption about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy). 

The inputs used to measure fair value are classified into the following fair value hierarchy: 

Level 1:  Quoted market prices in active markets for identical assets or liabilities. 

Level 2:  Observable market-based inputs or unobservable inputs that are corroborated by market data. 

Level 3: Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 includes values determined using pricing models, discounted cash flow methodologies, or similar techniques reflecting the Company’s own assumptions. 

In instances where the determination of the fair value hierarchy measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment of factors specific to the asset or liability. Transfers between levels within the fair value hierarchy are recognized by the Company on the date of the change in circumstances that requires such transfer. There were notransfers between levels during the three month periods ending March 31, 2016 or March 31, 2015. 

The following table sets forth, by level within the fair value hierarchy, the financial assets and liabilities recorded at fair value on a recurring basis as of March 31, 2016 and December 31, 2015 (in millions): 

	March 31, 2016		Level 1		Level 2		Level 3
Available-for-sale securities	$	268	$	154	$	114	$	-
Trading securities		63		63		-		-
Total assets	$	331	$	217	$	114	$	-
Contingent Value Right (CVR)	$	2	$	2	$	-	$	-
CVR-related liability		261		-		-		261
Fair value of interest rate swap agreements		105		-		105		-
Total liabilities	$	368	$	2	$	105	$	261
	December 31, 2015		Level 1		Level 2		Level 3
Available-for-sale securities	$	271	$	155	$	116	$	-
Trading securities		61		61		-		-
Total assets	$	332	$	216	$	116	$	-
Contingent Value Right (CVR)	$	2	$	2	$	-	$	-
CVR-related liability		261		-		-		261
Fair value of interest rate swap agreements		76		-		76		-
Total liabilities	$	339	$	2	$	76	$	261

Available-for-sale Securities

Available-for-sale securities and trading securities classified as Level 1 are measured using quoted market prices. Level 2 available-for-sale securities primarily consisted of: (i) bonds and notes issued by the United States government and its agencies, domestic and foreign corporations and foreign governments; and (ii) preferred securities issued by domestic and foreign corporations. The estimated fair values of these securities are determined using various valuation techniques, including a multi-dimensional relational model that incorporates standard observable inputs and assumptions such as benchmark yields, reported trades, broker/dealer quotes, issuer spreads, benchmark securities, bids/offers and other pertinent reference data.

Contingent Value Right (CVR)

The CVR represents the estimate of the fair value for the contingent consideration paid to HMA shareholders as part of the HMA merger. The CVR is listed on the NASDAQ and the valuation at March 31, 2016 is based on the quoted trading price for the CVR on the last day of the period. Changes in the estimated fair value of the CVR are recorded through the condensed consolidated statement of income.

CVR-related Liability

The CVR-related legal liability represents the Company’s estimate of fair value at March 31, 2016 of the liability associated with the legal matters assumed in the HMA merger, which are included in accrued liabilities in the accompanying condensed consolidated balance sheet.  This liability did not include those matters previously accrued by HMA as a probable contingency, which were settled and paid during the year ended December 31, 2015. To develop the estimate of fair value, the Company engaged an independent third-party valuation firm to measure the liability.  The valuation was made utilizing the Company’s estimates of future outcomes for each legal case and simulating future outcomes based on the timing, probability and distribution of several scenarios using a Monte Carlo simulation model. Other inputs were then utilized for discounting the liability to the measurement date. The HMA legal matters underlying this fair value estimate were evaluated by management to determine the likelihood and impact of each of the potential outcomes. Using that information, as well as the potential correlation and variability associated with each case, a fair value was determined for the estimated future cash outflows to conclude or settle the HMA legal matters included in the analysis, excluding legal fees (which are expensed as incurred). Because of the unobservable nature of the majority of the inputs used to value the liability, the Company has classified the fair value measurement as a Level 3 measurement in the fair value hierarchy.

The fair value of the CVR-related legal liability will be measured each reporting period using similar measurement techniques, updated for the assumptions and facts existing at that date for each of the underlying legal matters. Changes in the fair value of the CVR related legal liability are recorded in future periods through the condensed consolidated statement of income.

Fair Value of Interest Rate Swap Agreements

The valuation of the Company’s interest rate swap agreements is determined using market valuation techniques, including discounted cash flow analysis on the expected cash flows of each agreement. This analysis reflects the contractual terms of the agreement, including the period to maturity, and uses observable market-based inputs, including forward interest rate curves. The fair value of interest rate swap agreements are determined by netting the discounted future fixed cash payments and the discounted expected variable cash receipts. The variable cash receipts are based on the expectation of future interest rates based on observable market forward interest rate curves and the notional amount being hedged. 

The Company incorporates CVAs to appropriately reflect both its own nonperformance or credit risk and the respective counterparty’s nonperformance or credit risk in the fair value measurements. In adjusting the fair value of its interest rate swap agreements for the effect of nonperformance or credit risk, the Company has considered the impact of any netting features included in the agreements. The CVA on the Company’s interest rate swap agreements resulted in a decrease in the fair value of the related liability of $6 million and an after-tax adjustment of $4 million to OCI at March 31, 2016. The CVA on the Company’s interest rate swap agreements resulted in a decrease in the fair value of the related liability of $4 million and an after-tax adjustment of $2 million to OCI at December 31, 2015.

The majority of the inputs used to value the Company’s interest rate swap agreements, including the forward interest rate curves and market perceptions of the Company’s credit risk used in the CVAs, are observable inputs available to a market participant. As a result, the Company has determined that the interest rate swap valuations are classified in Level 2 of the fair value hierarchy.

XML

Segment Information

3 Months Ended

Mar. 31, 2016

Segment Information [Abstract]

Segment Information Disclosure

15.  SEGMENT INFORMATION

The Company operates in two distinct operating segments, represented by hospital operations (which includes its general acute care hospitals and related healthcare entities that provide inpatient and outpatient healthcare services) and home care agency operations (which provide in-home outpatient care). 

Only the hospital operations segment meets the criteria as a separate reportable segment. The financial information for the home care agency segment does not meet the quantitative thresholds for a separate identifiable reportable segment and is combined into the corporate and all other reportable segment.

The distribution between reportable segments of the Company’s net operating revenues and income from continuing operations before income taxes is summarized in the following tables (in millions):

	Three Months Ended March 31,
	2016		2015
Net operating revenues:
Hospital operations	$	4,944	$	4,857
Corporate and all other		55		54
Total	$	4,999	$	4,911
Income from continuing operations before
income taxes:
Hospital operations	$	143	$	273
Corporate and all other		(80)		(105)
Total	$	63	$	168

XML

Other Comprehensive Income

3 Months Ended

Mar. 31, 2016

Stockholders' Equity [Abstract]

Other Comprehensive Income Disclosure

16. OTHER COMPREHENSIVE INCOME

The following tables present information about items reclassified out of accumulated other comprehensive income (loss) by component for the three months ended March 31, 2016 and 2015 (in millions, net of tax):

					Change in
	Change in Fair		Change in Fair		Unrecognized		Accumulated Other
	Value of Interest		Value of Available		Pension Cost		Comprehensive
	Rate Swaps		for Sale Securities		Components		Income (Loss)
Balance as of December 31, 2015	$	(48)	$	1	$	(26)	$	(73)
Other comprehensive (loss)
income before reclassifications		(28)		2		-		(26)
Amounts reclassified from
accumulated other
comprehensive income		9		-		1		10
Net current-period other
comprehensive (loss) income		(19)		2		1		(16)
Balance as of March 31, 2016	$	(67)	$	3	$	(25)	$	(89)

					Change in
	Change in Fair		Change in Fair		Unrecognized		Accumulated Other
	Value of Interest		Value of Available		Pension Cost		Comprehensive
	Rate Swaps		for Sale Securities		Components		Income (Loss)
Balance as of December 31, 2014	$	(43)	$	7	$	(27)	$	(63)
Other comprehensive (loss)
income before reclassifications		(15)		1		-		(14)
Amounts reclassified from
accumulated other
comprehensive income		6		-		1		7
Net current-period other
comprehensive (loss) income		(9)		1		1		(7)
Balance as of March 31, 2015	$	(52)	$	8	$	(26)	$	(70)

The following tables present a subtotal for each significant reclassification to net income out of AOCL and the line item affected in the accompanying condensed consolidated statement of income for the three months ended March 31, 2016 and 2015 (in millions):

	Amount reclassified
		from AOCL	Affected line item in the
Details about accumulated other	Three Months Ended		statement where net
comprehensive income (loss) components	March 31, 2016		income is presented
Gains and losses on cash flow hedges
Interest rate swaps	$	(14)	Interest expense, net
		5	Tax benefit
	$	(9)	Net of tax
Amortization of defined benefit pension items
Prior service costs	$	(1)	Salaries and benefits
Actuarial losses		-	Salaries and benefits
		(1)	Total before tax
		-	Tax benefit
	$	(1)	Net of tax

	Amount reclassified
		from AOCL	Affected line item in the
Details about accumulated other	Three Months Ended		statement where net
comprehensive income (loss) components	March 31, 2015		income is presented
Gains and losses on cash flow hedges
Interest rate swaps	$	(9)	Interest expense, net
		3	Tax benefit
	$	(6)	Net of tax
Amortization of defined benefit pension items
Prior service costs	$	-	Salaries and benefits
Actuarial losses		(1)	Salaries and benefits
		(1)	Total before tax
		-	Tax benefit
	$	(1)	Net of tax

XML

Contingencies

3 Months Ended

Mar. 31, 2016

Contingencies [Abstract]

Contingencies Disclosure

17.   CONTINGENCIES

The Company is a party to various legal, regulatory and governmental proceedings incidental to its business. Based on current knowledge, management does not believe that loss contingencies arising from pending legal, regulatory and governmental matters, including the matters described herein, will have a material adverse effect on the consolidated financial position or liquidity of the Company. However, in light of the inherent uncertainties involved in pending legal, regulatory and governmental matters, some of which are beyond the Company’s control, and the very large or indeterminate damages sought in some of these matters, an adverse outcome in one or more of these matters could be material to the Company’s results of operations or cash flows for any particular reporting period.

With respect to all legal, regulatory and governmental proceedings, the Company considers the likelihood of a negative outcome. If the Company determines the likelihood of a negative outcome with respect to any such matter is probable and the amount of the loss can be reasonably estimated, the Company records an accrual for the estimated loss for the expected outcome of the matter. If the likelihood of a negative outcome with respect to material matters is reasonably possible and the Company is able to determine an estimate of the possible loss or a range of loss, whether in excess of a related accrued liability or where there is no accrued liability, the Company discloses the estimate of the possible loss or range of loss. However, the Company is unable to estimate a possible loss or range of loss in some instances based on the significant uncertainties involved in, and/or the preliminary nature of, certain legal, regulatory and governmental matters.

In connection with the spin-off, the Company agreed to indemnify QHC for certain liabilities relating to outcomes or events occurring prior to the closing of the spin-off, including (i) certain claims and proceedings that were known to be outstanding at or prior to the consummation of the spin-off and involved multiple facilities and (ii) certain claims, proceedings and investigations by governmental authorities or private plaintiffs related to activities occurring at or related to QHC’s healthcare facilities prior to the closing date of the spin-off, but only to the extent, in the case of clause (ii), that such claims are covered by insurance policies maintained by the Company, including professional liability and employer practices. In this regard, the Company will continue to be responsible for HMA Legal Matters (as defined below) covered by the CVR agreement that relate to QHC’s business following the consummation of the spin-off, and any amounts payable by the Company in connection therewith will continue to reduce the amount payable by the Company in respect of the CVRs.  Notwithstanding the foregoing, the Company will not indemnify QHC in respect of any claims or proceedings arising out of or related to the business operations of Quorum Health Resources, LLC at any time or QHC’s compliance with its corporate integrity agreement.

HMA Legal Matters and Related CVR

The CVR agreement entitles the holder to receive a one-time cash payment of up to $1.00 per CVR, subject to downward adjustment based on the final resolution of certain litigation, investigations (whether formal or informal, including subpoenas), or other actions or proceedings related to HMA or its affiliates existing on or prior to July 29, 2013 (the date of the Company’s merger agreement with HMA) as more specifically provided in the CVR agreement (all such matters are referred to as the “HMA Legal Matters”), which include, but are not limited to, investigation and litigation matters as previously disclosed by HMA in public filings with the SEC and/or as described in more detail below. The adjustment reducing the ultimate amount paid to holders of the CVR is determined based on the amount of losses incurred by the Company in connection with the HMA Legal Matters as more specifically provided in the CVR agreement, which generally includes the amount paid for damages, costs, fees and expenses (including, without limitation, attorneys’ fees and expenses), and all fines, penalties, settlement amounts, indemnification obligations and other liabilities (all such losses are referred to as “HMA Losses”). If the aggregate amount of HMA Losses exceeds a deductible of $18 million, then the amount payable in respect of each CVR shall be reduced (but not below zero) by an amount equal to the quotient obtained by dividing: (a) the product of (i) all losses in excess of the deductible and (ii) 90%; by (b) the number of CVRs outstanding on the date on which final resolution of the existing litigation occurs. There are 264,544,053 CVRs outstanding as of the date hereof. If total HMA Losses (including HMA Losses that have occurred to date as noted in the table below) exceed approximately $312 million, then the holders of the CVRs will not be entitled to any payment in respect of the CVRs.

The CVRs do not have a finite payment date.  Any payments the Company makes under the CVR agreement will be payable within 60 days after the final resolution of the HMA Legal Matters. The CVRs are unsecured obligations of CHS and all payments under the CVRs will be subordinated in right of payment to the prior payment in full of all of the Company’s senior obligations (as defined in the CVR agreement), which include outstanding indebtedness of the Company (subject to certain exceptions set forth in the CVR agreement) and the HMA Losses. The CVR agreement permits the Company to acquire all or some of the CVRs, whether in open market transactions, private transactions or otherwise. As of March 31, 2016, the Company had acquired no CVRs.

The following table represents the impact of legal expenses paid or incurred to date and settlements paid or deemed final as of March 31, 2016 on the amounts owed to CVR holders (in millions):

			Allocation of Expenses and Settlements Paid
							Reduction to
	Total Expenses				CHS		Amount Owed
	and Settlement				Responsibility		to CVR Holders
	Cost		Deductible		at 10%		at 90%
As of December 31, 2015	$	58	$	18	$	4	$	36
Settlements paid		-		-		-		-
Legal expenses incurred
and/or paid during
the three months ended
March 31, 2016		1		-		-		1
As of March 31, 2016	$	59	$	18	$	4	$	37

Amounts owed to CVR holders are dependent on the ultimate resolution of the HMA Legal Matters and determination of HMA Losses incurred. The settlement of any or all of the claims and expenses incurred on behalf of the Company in defending itself will (subject to the deductible) reduce the amounts owed to the CVR holders.

Underlying the CVR agreement are a number of claims included in the HMA Legal Matters asserted against HMA.  The Company has recorded a liability in connection with those claims as part of the acquired assets and liabilities at the date of acquisition pursuant to the provisions of Financial Accounting Standards Board Accounting Standards Codification Topic 805 “Business Combinations.”  For the estimate of the Company’s liabilities associated with the HMA Legal Matters that will be covered by the CVR and were not previously accrued by HMA, the Company recorded a liability of $284 million as part of the acquisition accounting for the HMA merger based on the Company’s estimate of fair value of such liabilities as of the date of acquisition. There was no change in the liability during the three months ended March 31, 2016 and the fair value of such liabilities of $261 million as of March 31, 2016 is recorded in other long-term liabilities on the accompanying condensed consolidated balance sheet. As of March 31, 2016, there is currently no accrual recorded for the probable contingency claims underlying the CVR agreement. The estimated liability for probable contingency claims underlying the CVR agreement that was previously recorded by HMA, and reflected in the purchase accounting for HMA as an acquired liability has been settled and was paid during the year ended December 31, 2015. In addition, although legal fees are not included in the amounts currently accrued, such legal fees are taken into account in determining HMA Losses under the CVR agreement. Certain significant HMA Legal Matters underlying these liabilities are discussed in greater detail below.

HMA Matters Recorded at Fair Value

Medicare/Medicaid Billing Lawsuits

Beginning during the week of December 16, 2013, eleven qui tam lawsuits filed by private individuals against HMA were unsealed in various United States district courts. The United States has elected to intervene in all or part of eight of these matters; namely U.S. ex rel. Craig Brummer v. Health Management Associates, Inc. et al. (Middle District Georgia) (“Brummer”); U.S. ex rel. Ralph D. Williams v. Health Management Associates, Inc. et al. (Middle District Georgia) (“Williams”); U.S. ex rel. Scott H. Plantz, M.D. et al. v. Health Management Associates, Inc., et al. (Northern District Illinois) (“Plantz”); U.S. ex rel. Thomas L. Mason, M.D. et al. v. Health Management Associates, Inc. et al. (Western District North Carolina) (“Mason”); U.S. ex rel. Jacqueline Meyer, et al. v. Health Management Associates, Inc., Gary Newsome et al. (“Jacqueline Meyer”) (District of South Carolina); U.S. ex rel. George Miller, et al. v. Health Management Associates, Inc. (Eastern District of Pennsylvania) (“Miller”); U.S. ex rel. Bradley Nurkin v. Health Management Associates, Inc. et al. (Middle District of Florida) (“Nurkin”); and U.S. ex rel. Paul Meyer v. Health Management Associates, Inc. et al. (Southern District Florida) (“Paul Meyer”). The United States has elected to intervene with respect to allegations in these cases that certain HMA hospitals inappropriately admitted patients and then submitted reimbursement claims for treating those individuals to federal healthcare programs in violation of the False Claims Act or that certain HMA hospitals had inappropriate financial relationships with physicians which violated the Stark law, the Anti-Kickback Statute, and the False Claims Act.  Certain of these complaints also allege the same actions violated various state laws which prohibit false claims. The United States has declined to intervene in three of the eleven matters, namely U.S. ex rel. Anita France, et al. v. Health Management Associates, Inc. (Middle District Florida) (“France”) which involved allegations of wrongful billing and was settled; U.S. ex rel. Sandra Simmons v. Health Management Associates, Inc. et al. (Eastern District Oklahoma) (“Simmons”) which alleges unnecessary surgery by an employed physician and which was settled as to all allegations except alleged wrongful termination; and U.S. ex rel. David Napoliello, M.D. v. Health Management Associates, Inc. (Middle District Florida) (“Napoliello”) which alleges inappropriate admissions.  On April 3, 2014, the Multi District Litigation Panel ordered the transfer and consolidation for pretrial proceedings of the eight intervened cases, plus the Napoliello matter, to the District of the District of Columbia under the name In Re: Health Management Associates, Inc. Qui Tam Litigation.  On June 2, 2014, the court entered a stay of this matter until October 6, 2014, which was subsequently extended until February 27, 2015, May 27, 2015, September 25, 2015, January 25, 2016, and now until May 25, 2016. The Company intends to defend against the allegations in these matters, but also continues to cooperate with the government in the ongoing investigation of these allegations. The Company has been in discussions with the Civil Division of the United States Department of Justice (“DOJ”)regarding the resolutions of these matters. During the first quarter of 2015, the Company was informed that the Criminal Division continues to investigate former executive-level employees of HMA, and continues to consider whether any HMA entities should be held criminally liable for the acts of the former HMA employees. The Company is voluntarily cooperating with these inquiries and has not been served with any subpoenas or other legal process.

Summary of Recorded Amounts

The table below presents a reconciliation of the beginning and ending liability balances (in millions) during the three months ended March 31, 2016with respect to the Company’s fair value determination in connection with HMA Legal Matters that were not previously accrued by HMA, the estimated liability in connection with HMA Legal Matters that were previously recorded by HMA as a probable contingency, and the remaining contingencies of the Company in respect of which an accrual has been recorded. In addition, future legal fees (which are expensed as incurred) and costs related to possible indemnification and criminal investigation matters associated with the HMA Legal Matters have not been accrued or included in the table below. Furthermore, although not accrued, such costs, if incurred, will be taken into account in determining the total amount of reductions applied to the amounts owed to CVR holders.

	CVR Related		CVR Related Liability		Other
	Liability		for Probable		Probable
	at Fair Value		Contingencies		Contingencies
Balance as of December 31, 2015	$	261	$	-	$	10
Expense (income)		-		-		-
Cash payments		-		-		(3)
Balance as of March 31, 2016	$	261	$	-	$	7

With respect to the “Other Probable Contingencies” referenced in the chart above, in accordance with applicable accounting guidance, the Company establishes a liability for litigation, regulatory and governmental matters for which, based on information currently available, the Company believes that a negative outcome is known or is probable and the amount of the loss is reasonably estimable. For all such matters (whether or not discussed in this contingencies footnote), such amounts have been recorded in other accrued liabilities on the condensed consolidated balance sheet and are included in the table above in the “Other Probable Contingencies” column. Due to the uncertainties and difficulty in predicting the ultimate resolution of these contingencies, the actual amount could differ from the estimated amount reflected as a liability on the condensed consolidated balance sheet.

In the aggregate, attorneys’ fees and other costs incurred but not included in the table above related to probable contingencies, and CVR-related contingencies accounted for at fair value, totaled $1 million and $4 million for the three months ended March 31, 2016 and 2015, respectively, and are included in other operating expenses in the accompanying condensed consolidated statements of income.

Matters for which an Outcome Cannot be Assessed

For all of the legal matters below, the Company cannot at this time assess what the outcome may be and is further unable to determine any estimate of loss or range of loss.  Because the matters below are at a preliminary stage and other factors, there are not sufficient facts available to make these assessments. 

Class Action Shareholder Federal Securities Cases.  Three purported class action cases have been filed in the United States District Court for the Middle District of Tennessee; namely, Norfolk County Retirement System v. Community Health Systems, Inc., et al., filed May 9, 2011; De Zheng v. Community Health Systems, Inc., et al., filed May 12, 2011; and Minneapolis Firefighters Relief Association v. Community Health Systems, Inc., et al., filed June 21, 2011. All three seek class certification on behalf of purchasers of the Company’s common stock between July 27, 2006 and April 11, 2011 and allege that misleading statements resulted in artificially inflated prices for the Company’s common stock. In December 2011, the cases were consolidated for pretrial purposes and NYC Funds and its counsel were selected as lead plaintiffs/lead plaintiffs’ counsel. In lieu of ruling on the Company’s motion to dismiss, the court permitted the plaintiffs to file a first amended consolidated class action complaint, which was filed on October 5, 2015. The Company’s motion to dismiss was filed on November 4, 2015 and oral argument was held on April 11, 2016. Discovery is also continuing. The Company believes this consolidated matter is without merit and will vigorously defend this case.

Shareholder Derivative Actions.  Three purported shareholder derivative actions have also been filed in the United States District Court for the Middle District of Tennessee; Plumbers and Pipefitters Local Union No. 630 Pension Annuity Trust Fund v. Wayne T. Smith, et al., filed May 24, 2011; Roofers Local No. 149 Pension Fund v. Wayne T. Smith, et al., filed June 21, 2011; and Lambert Sweat v. Wayne T. Smith, et al., filed October 5, 2011. These three cases allege breach of fiduciary duty arising out of allegedly improper inpatient admission practices, mismanagement, waste and unjust enrichment. These cases have been consolidated into a single, consolidated action. The plaintiffs filed an operative amended derivative complaint in these three consolidated actions on March 15, 2012. The Company’s motion to dismiss was argued on June 13, 2013. On September 27, 2013, the court issued an order granting in part and denying in part the Company’s motion to dismiss. An initial case management order was entered on November 11, 2014, but no trial date has been set. Discovery is continuing. The Company believes all of the plaintiffs’ claims are without merit and will vigorously defend them.

XML

Subsequent Events

3 Months Ended

Mar. 31, 2016

Subsequent Events [Abstract]

Subsequent Events Disclosure

18.  SUBSEQUENT EVENTS 

The Company evaluated all material events occurring subsequent to the balance sheet date for events requiring disclosure or recognition in the condensed consolidated financial statements.

On April 29, 2016, the Company completed the spin-off of QHC and distributed, on a pro rata basis, all of the shares of QHC common stock to the Company’s stockholders of record as of April 22, 2016. These stockholders of record as of April 22, 2016 received a distribution of one share of QHC common stock for every four shares of Company common stock held as of the record date plus cash in lieu of any fractional shares. Immediately following the completion of the spin-off, the Company’s stockholders owned 100% of the outstanding shares of QHC common stock. Following the spin-off, QHC became an independent public company with its common stock listed for trading under the symbol “QHC” on the New York Stock Exchange.

In connection with the spin-off, the Company and QHC entered into a separation and distribution agreement as well as certain ancillary agreements on April 29, 2016. These agreements allocate between the Company and QHC the various assets, employees, liabilities and obligations (including investments, property and employee benefits and tax-related assets and liabilities) that comprise the separate companies and govern certain relationships between, and activities of, the Company and QHC for a period of time after the spin-off.

Pursuant to a special distribution paid by QHC to the Company as part of the series of transactions engaged in to complete the spin-off, the Company received approximately $1.2 billion in cash generated from the net proceeds of certain financing arrangements entered into by QHC as part of the separation. The Company has used approximately $194 million of such proceeds to repay a portion of its Term F Loans due 2018. In addition, on May 2, 2016, the Company commenced a cash tender offer for up to $900 million of its approximately $1.6 billion aggregate principal amount outstanding of 5⅛% Senior Secured Notes due 2018 as noted in a press release issued by the Company on such date. The Company intends to use remaining proceeds from such special distribution to repay other outstanding debt and to pay certain expenses incurred in connection with the spin-off and such debt repayment transactions.

As part of the separation and distribution of QHC to the Company’s stockholders, the Company will record the distribution of the assets and liabilities of the QHC entities from its consolidated balance sheet on a historical cost basis as a dividend from stockholders’ equity, and no gain or loss will be recorded.

On April 1, 2016, one or more subsidiaries of the Company completed the acquisition of an 80% interest in Physicians’ Specialty Hospital (20 licensed beds), a Medicare-certified specialty surgical hospital in Fayetteville, Arkansas. The total cash consideration paid at closing was approximately $13 million.

On April 29, 2016, the Company entered into a definitive agreement with UHS to sell its unconsolidated minority equity interests in Valley Health System LLC, a joint venture with UHS representing four hospitals in Las Vegas, Nevada, in which the Company owns a 27.5% interest, and in Summerlin Hospital Medical Center LLC, a joint venture with UHS representing one hospital in Las Vegas, Nevada, in which the Company owns a 26.1% interest. The Company will receive $445 million in cash from UHS in return for the sale of its equity interests in the second quarter of 2016.

XML

Supplemental Condensed Consolidating Financial Information

3 Months Ended

Mar. 31, 2016

Supplemental Condensed Consolidating Financial Information [Abstract]

Supplemental Condensed Consolidating Financial Information Disclosure

19.  SUPPLEMENTAL CONDENSED CONSOLIDATING FINANCIAL INFORMATION

The Senior Notes due 2019, 2020 and 2022, which are senior unsecured obligations of CHS, and the 5⅛% Senior Secured Notes due 2018 and 2021 (collectively, “the Notes”) are guaranteed on a senior basis by the Company and by certain of its existing and subsequently acquired or organized 100% owned domestic subsidiaries.  The Notes are fully and unconditionally guaranteed on a joint and several basis, with exceptions considered customary for such guarantees, limited to the release of the guarantee when a subsidiary guarantor’s capital stock is sold, or a sale of all of the subsidiary guarantor’s assets used in operations. The following condensed consolidating financial statements present Community Health Systems, Inc. (as parent guarantor), CHS (as the issuer), the subsidiary guarantors, the subsidiary non-guarantors and eliminations. These condensed consolidating financial statements have been prepared and presented in accordance with SEC Regulation S-X Rule 3-10 “Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered.” 

The accounting policies used in the preparation of this financial information are consistent with those elsewhere in the condensed consolidated financial statements of the Company, except as noted below: 

•Intercompany receivables and payables are presented gross in the supplemental condensed consolidating balance sheets. 

•Cash flows from intercompany transactions are presented in cash flows from financing activities, as changes in intercompany balances with affiliates, net. 

•Income tax expense is allocated from the parent guarantor to the income producing operations (other guarantors and non-guarantors) and the issuer through stockholders’ equity. As this approach represents an allocation, the income tax expense allocation is considered non-cash for statement of cash flow purposes. 

•Interest expense, net has been presented to reflect net interest expense and interest income from outstanding long-term debt and intercompany balances. 

The Company’s intercompany activity consists primarily of daily cash transfers for purposes of cash management, the allocation of certain expenses and expenditures paid for by the Parent on behalf of its subsidiaries, and the push down of investment in its subsidiaries. This activity also includes the intercompany transactions between consolidated entities as part of the Receivables Facility that is further discussed in Note 12. The Company’s subsidiaries generally do not purchase services from one another; thus, the intercompany transactions do not represent revenue generating transactions. All intercompany transactions eliminate in consolidation. 

From time to time, subsidiaries of the Company sell and/or repurchase noncontrolling interests in consolidated subsidiaries, which may change subsidiaries between guarantors and non-guarantors.

Condensed Consolidating Statement of Income
Three Months Ended March 31, 2016
	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
	(In millions)
Operating revenues (net of contractual
allowances and discounts)	$	-	$	(6)	$	3,766	$	1,994	$	-	$	5,754
Provision for bad debts		-		-		532		223		-		755
Net operating revenues		-		(6)		3,234		1,771		-		4,999
Operating costs and expenses:
Salaries and benefits		-		-		1,282		1,035		-		2,317
Supplies		-		-		543		256		-		799
Other operating expenses		-		-		817		356		-		1,173
Electronic health records incentive reimbursement		-		-		(11)		(7)		-		(18)
Rent		-		-		65		54		-		119
Depreciation and amortization		-		-		211		87		-		298
Impairment of long-lived assets		-		-		12		5		-		17
Total operating costs and expenses		-		-		2,919		1,786		-		4,705
Income from operations		-		(6)		315		(15)		-		294
Interest expense, net		-		35		200		16		-		251
Equity in earnings of unconsolidated affiliates		(11)		(62)		17		-		36		(20)
Income from continuing operations before income taxes		11		21		98		(31)		(36)		63
Provision for (benefit from) income taxes		-		10		37		(21)		-		26
Income from continuing operations		11		11		61		(10)		(36)		37
Discontinued operations, net of taxes:
Loss from operations of entities sold or held for sale		-		-		(1)		1		-		-
Impairment of hospitals sold or held for sale		-		-		-		(1)		-		(1)
Loss from discontinued operations, net of taxes		-		-		(1)		-		-		(1)
Net income		11		11		60		(10)		(36)		36
Less: Net income attributable to noncontrolling interests		-		-		-		25		-		25
Net income attributable to Community Health Systems,
Inc. stockholders	$	11	$	11	$	60	$	(35)	$	(36)	$	11

Condensed Consolidating Statement of Income
Three Months Ended March 31, 2015
	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
	(In millions)
Operating revenues (net of contractual
allowances and discounts)	$	-	$	(5)	$	3,488	$	2,163	$	-	$	5,646
Provision for bad debts		-		-		447		288		-		735
Net operating revenues		-		(5)		3,041		1,875		-		4,911
Operating costs and expenses:
Salaries and benefits		-		-		1,222		1,035		-		2,257
Supplies		-		-		492		270		-		762
Other operating expenses		-		-		708		391		-		1,099
Government settlement and related costs		-		-		8		-		-		8
Electronic health records incentive reimbursement		-		-		(17)		(9)		-		(26)
Rent		-		-		61		55		-		116
Depreciation and amortization		-		-		200		96		-		296
Total operating costs and expenses		-		-		2,674		1,838		-		4,512
Income from operations		-		(5)		367		37		-		399
Interest expense, net		-		21		211		9		-		241
Loss from early extinguishment of debt		-		8		-		-		-		8
Equity in earnings of unconsolidated affiliates		(79)		(104)		(5)		-		170		(18)
Income from continuing operations before income taxes		79		70		161		28		(170)		168
Provision for (benefit from) income taxes		-		(9)		61		4		-		56
Income from continuing operations		79		79		100		24		(170)		112
Discontinued operations, net of taxes:
Loss from operations of entities sold or held for sale		-		-		-		(11)		-		(11)
Impairment of hospitals sold or held for sale		-		-		(1)		-		-		(1)
Loss on sale, net		-		-		2		(3)		-		(1)
Loss from discontinued operations, net of taxes		-		-		1		(14)		-		(13)
Net income		79		79		101		10		(170)		99
Less: Net income attributable to noncontrolling interests		-		-		-		20		-		20
Net income attributable to Community Health
Systems, Inc. stockholders	$	79	$	79	$	101	$	(10)	$	(170)	$	79

Condensed Consolidating Statement of Comprehensive Income (Loss)
Three Months Ended March 31, 2016
	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
		(In millions)
Net income	$	11	$	11	$	60	$	(10)	$	(36)	$	36
Other comprehensive income (loss), net of income taxes:
Net change in fair value of interest rate swaps, net of tax		(19)		(19)		-		-		19		(19)
Net change in fair value of available-for-sale securities,
net of tax		2		2		2		-		(4)		2
Amortization and recognition of unrecognized pension
cost components, net of tax		1		1		1		-		(2)		1
Other comprehensive income (loss)		(16)		(16)		3		-		13		(16)
Comprehensive income		(5)		(5)		63		(10)		(23)		20
Less: Comprehensive income attributable to
noncontrolling interests		-		-		-		25		-		25
Comprehensive (loss) income attributable to
Community Health Systems, Inc. stockholders	$	(5)	$	(5)	$	63	$	(35)	$	(23)	$	(5)

Condensed Consolidating Statement of Comprehensive Income (Loss)
Three Months Ended March 31, 2015
	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
		(In millions)
Net income	$	79	$	79	$	101	$	10	$	(170)	$	99
Other comprehensive income (loss), net of income taxes:
Net change in fair value of interest rate swaps, net of tax		(9)		(9)		-		-		9		(9)
Net change in fair value of available-for-sale securities,
net of tax		1		1		1		-		(2)		1
Amortization and recognition of unrecognized pension
cost components, net of tax		1		1		1		-		(2)		1
Other comprehensive income (loss)		(7)		(7)		2		-		5		(7)
Comprehensive income		72		72		103		10		(165)		92
Less: Comprehensive income attributable to
noncontrolling interests		-		-		-		20		-		20
Comprehensive income (loss) attributable to
Community Health Systems, Inc. stockholders	$	72	$	72	$	103	$	(10)	$	(165)	$	72

Condensed Consolidating Balance Sheet
March 31, 2016
	Parent				Other		Non -
	Guarantor		Issuer		Guarantors		Guarantors		Eliminations		Consolidated
	(In millions)
ASSETS
Current assets:
Cash and cash equivalents	$	-	$	-	$	12	$	169	$	-	$	181
Patient accounts receivable, net of allowance
for doubtful accounts		-		-		1,232		2,491		-		3,723
Supplies		-		-		408		179		-		587
Prepaid income taxes		2		-		-		-		-		2
Prepaid expenses and taxes		-		-		146		72		-		218
Other current assets		-		-		347		198		-		545
Total current assets		2		-		2,145		3,109		-		5,256
Intercompany receivable		1,178		16,776		1,638		6,299		(25,891)		-
Property and equipment, net		-		-		6,924		3,180		-		10,104
Goodwill		-		-		5,462		3,560		-		9,022
Other assets, net		-		-		2,349		1,258		(1,265)		2,342
Net investment in subsidiaries		3,433		21,416		7,859		-		(32,708)		-
Total assets	$	4,613	$	38,192	$	26,377	$	17,406	$	(59,864)	$	26,724
LIABILITIES AND EQUITY
Current liabilities:
Current maturities of long-term debt	$	-	$	175	$	65	$	9	$	-	$	249
Accounts payable		-		-		874		305		-		1,179
Accrued interest		-		156		1		1		-		158
Accrued liabilities		4		-		956		508		-		1,468
Total current liabilities		4		331		1,896		823		-		3,054
Long-term debt		-		15,739		128		798		-		16,665
Intercompany payable		-		17,347		18,975		13,775		(50,097)		-
Deferred income taxes		599		-		-		-		-		599
Other long-term liabilities		8		1,342		1,343		295		(1,265)		1,723
Total liabilities		611		34,759		22,342		15,691		(51,362)		22,041
Redeemable noncontrolling interests in
equity of consolidated subsidiaries		-		-		-		565		-		565
Equity:
Community Health Systems, Inc. stockholders’
equity:
Preferred stock		-		-		-		-		-		-
Common stock		1		-		-		-		-		1
Additional paid-in capital		1,951		1,328		1,530		1,042		(3,899)		1,952
Treasury stock, at cost		(7)		-		-		-		-		(7)
Accumulated other comprehensive loss		(89)		(89)		(21)		(1)		111		(89)
Retained earnings		2,146		2,194		2,526		(6)		(4,714)		2,146
Total Community Health Systems, Inc.
stockholders’ equity		4,002		3,433		4,035		1,035		(8,502)		4,003
Noncontrolling interests in equity of
consolidated subsidiaries		-		-		-		115		-		115
Total equity		4,002		3,433		4,035		1,150		(8,502)		4,118
Total liabilities and equity	$	4,613	$	38,192	$	26,377	$	17,406	$	(59,864)	$	26,724

Condensed Consolidating Balance Sheet
December 31, 2015
	Parent				Other		Non -
	Guarantor		Issuer		Guarantors		Guarantors		Eliminations		Consolidated
	(In millions)
ASSETS
Current assets:
Cash and cash equivalents	$	-	$	-	$	25	$	159	$	-	$	184
Patient accounts receivable, net of allowance
for doubtful accounts		-		-		1,197		2,414		-		3,611
Supplies		-		-		400		180		-		580
Prepaid income taxes		27		-		-		-		-		27
Prepaid expenses and taxes		-		-		138		59		-		197
Other current assets		-		-		356		211		-		567
Total current assets		27		-		2,116		3,023		-		5,166
Intercompany receivable		1,159		16,544		1,491		6,404		(25,598)		-
Property and equipment, net		-		-		6,863		3,249		-		10,112
Goodwill		-		-		5,460		3,505		-		8,965
Other assets, net		-		-		2,153		1,245		(1,046)		2,352
Net investment in subsidiaries		3,438		20,964		8,035		-		(32,437)		-
Total assets	$	4,624	$	37,508	$	26,118	$	17,426	$	(59,081)	$	26,595
LIABILITIES AND EQUITY
Current liabilities:
Current maturities of long-term debt	$	-	$	162	$	57	$	10	$	-	$	229
Accounts payable		-		-		866		392		-		1,258
Accrued interest		-		226		-		1		-		227
Accrued liabilities		4		-		901		453		-		1,358
Total current liabilities		4		388		1,824		856		-		3,072
Long-term debt		-		15,604		151		801		-		16,556
Intercompany payable		-		16,861		19,021		13,764		(49,646)		-
Deferred income taxes		593		-		-		-		-		593
Other long-term liabilities		8		1,217		1,149		370		(1,046)		1,698
Total liabilities		605		34,070		22,145		15,791		(50,692)		21,919
Redeemable noncontrolling interests in
equity of consolidated subsidiaries		-		-		-		571		-		571
Equity:
Community Health Systems, Inc. stockholders’
equity:
Preferred stock		-		-		-		-		-		-
Common stock		1		-		-		-		-		1
Additional paid-in capital		1,963		1,324		1,506		967		(3,797)		1,963
Treasury stock, at cost		(7)		-		-		-		-		(7)
Accumulated other comprehensive loss		(73)		(73)		(22)		(3)		98		(73)
Retained earnings		2,135		2,187		2,489		14		(4,690)		2,135
Total Community Health Systems, Inc.
stockholders’ equity		4,019		3,438		3,973		978		(8,389)		4,019
Noncontrolling interests in equity of
consolidated subsidiaries		-		-		-		86		-		86
Total equity		4,019		3,438		3,973		1,064		(8,389)		4,105
Total liabilities and equity	$	4,624	$	37,508	$	26,118	$	17,426	$	(59,081)	$	26,595

Condensed Consolidating Statement of Cash Flows
Three Months Ended March 31, 2016
	Parent				Other		Non -
	Guarantor		Issuer		Guarantors		Guarantors		Eliminations		Consolidated
	(In millions)
Net cash (used in) provided by operating
activities	$	-	$	(223)	$	420	$	97	$	-	$	294
Cash flows from investing activities:
Acquisitions of facilities and other related
equipment		-		-		(2)		(97)		-		(99)
Purchases of property and equipment		-		-		(159)		(65)		-		(224)
Proceeds from disposition of hospitals
and other ancillary operations		-		-		12		-		-		12
Proceeds from sale of property and equipment		-		-		3		1		-		4
Purchases of available-for-sale securities		-		-		(12)		(25)		-		(37)
Proceeds from sales of available-for-sale securities		-		-		10		30		-		40
Increase in other investments		-		-		(53)		(14)		-		(67)
Net cash used in investing activities		-		-		(201)		(170)		-		(371)
Cash flows from financing activities:
Repurchase of restricted stock shares for payroll
tax withholding requirements		(7)		-		-		-		-		(7)
Redemption of noncontrolling investments in joint
ventures		-		-		-		(16)		-		(16)
Distributions to noncontrolling investors in joint
ventures		-		-		-		(18)		-		(18)
Changes in intercompany balances with
affiliates, net		7		89		(215)		119		-		-
Borrowings under credit agreements		-		1,563		1		-		-		1,564
Proceeds from receivables facility		-		-		-		31		-		31
Repayments of long-term indebtedness		-		(1,429)		(18)		(33)		-		(1,480)
Net cash provided by (used in) financing
activities		-		223		(232)		83		-		74
Net change in cash and cash equivalents		-		-		(13)		10		-		(3)
Cash and cash equivalents at beginning of period		-		-		25		159		-		184
Cash and cash equivalents at end of period	$	-	$	-	$	12	$	169	$	-	$	181

Condensed Consolidating Statement of Cash Flows
Three Months Ended March 31, 2015
	Parent				Other		Non -
	Guarantor		Issuer		Guarantors		Guarantors		Eliminations		Consolidated
	(In millions)
Net cash (used in) provided by operating
activities	$	(10)	$	(123)	$	23	$	49	$	-	$	(61)
Cash flows from investing activities:
Acquisitions of facilities and other related
equipment		-		-		(11)		(2)		-		(13)
Purchases of property and equipment		-		-		(199)		(42)		-		(241)
Proceeds from disposition of hospitals
and other ancillary operations		-		-		4		58		-		62
Proceeds from sale of property and equipment		-		-		-		3		-		3
Purchases of available-for-sale securities		-		-		(22)		(37)		-		(59)
Proceeds from sales of available-for-sale securities		-		-		19		37		-		56
Increase in other investments		-		-		(30)		(9)		-		(39)
Net cash used in investing activities		-		-		(239)		8		-		(231)
Cash flows from financing activities:
Proceeds from exercise of stock options		17		-		-		-		-		17
Repurchase of restricted stock shares for payroll
tax withholding requirements		(20)		-		-		-		-		(20)
Deferred financing costs and other
debt-related costs		-		(20)		-		-		-		(20)
Redemption of noncontrolling investments in joint
ventures		-		-		-		(7)		-		(7)
Distributions to noncontrolling investors in joint
ventures		-		-		-		(23)		-		(23)
Changes in intercompany balances with
affiliates, net		13		77		(101)		11		-		-
Borrowings under credit agreements		-		1,250		1		-		-		1,251
Proceeds from receivables facility		-		-		-		75		-		75
Repayments of long-term indebtedness		-		(1,184)		(15)		(69)		-		(1,268)
Net cash provided by (used in) financing
activities		10		123		(115)		(13)		-		5
Net change in cash and cash equivalents		-		-		(331)		44		-		(287)
Cash and cash equivalents at beginning of period		-		-		368		141		-		509
Cash and cash equivalents at end of period	$	-	$	-	$	37	$	185	$	-	$	222

XML

Basis of Presentation and Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2016

Basis of Presentation and Significant Accounting Policies [Abstract]

Basis of Accounting, Policy

The unaudited condensed consolidated financial statements of Community Health Systems, Inc. (the “Parent” or “Parent Company”) and its subsidiaries (the “Company”) as of March 31, 2016 and December 31, 2015 and for the three-month ended March 31, 2016 and 2015, have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). In the opinion of management, such information contains all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for such periods. All intercompany transactions and balances have been eliminated. The results of operations for the three months ended March 31, 2016, are not necessarily indicative of the results to be expected for the full fiscal year ending December 31, 2016. Certain information and disclosures normally included in the notes to condensed consolidated financial statements have been condensed or omitted as permitted by the rules and regulations of the Securities and Exchange Commission (the “SEC”). The Company believes the disclosures are adequate to make the information presented not misleading. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2015, contained in the Company’s Annual Report on Form 10-K filed with the SEC on February 17, 2016 (“2015 Form 10-K”).

Consolidation, Policy

Noncontrolling interests in less-than-wholly-owned consolidated subsidiaries of the Parent are presented as a component of total equity on the condensed consolidated balance sheets to distinguish between the interests of the Parent Company and the interests of the noncontrolling owners. Noncontrolling interests that are redeemable or may become redeemable at a fixed or determinable price at the option of the holder or upon the occurrence of an event outside of the control of the Company are presented in mezzanine equity on the condensed consolidated balance sheets.

Throughout these notes to the condensed consolidated financial statements, Community Health Systems, Inc., and its consolidated subsidiaries are referred to on a collective basis as the “Company.” This drafting style is not meant to indicate that the publicly traded Parent or any particular subsidiary of the Parent owns or operates any asset, business, or property. The hospitals, operations and businesses described in this filing are owned and operated, and management services provided, by distinct and indirect subsidiaries of Community Health Systems, Inc.

Allowance for Doubtful Accounts, Policy

Allowance for Doubtful Accounts. Accounts receivable are reduced by an allowance for amounts that could become uncollectible in the future. Substantially all of the Company’s receivables are related to providing healthcare services to patients at its hospitals and affiliated businesses.

The Company estimates the allowance for doubtful accounts by reserving a percentage of all self-pay accounts receivable without regard to aging category, based on collection history, adjusted for expected recoveries and any anticipated changes in trends. The Company’s ability to estimate the allowance for doubtful accounts is not impacted by not utilizing an aging of net accounts receivable as the Company believes that substantially all of the risk exists at the point in time such accounts are identified as self-pay. For all other non-self-pay payor categories, the Company reserves an estimated amount on historical collection rates for the uncontractualized portion of all accounts aging over 365 days from the date of discharge. These amounts represent an immaterial percentage of the outstanding accounts receivable. The percentage used to reserve for all self-pay accounts is based on the Company’s collection history. The Company collects substantially all of its third-party insured receivables, which include receivables from governmental agencies.

Collections are impacted by the economic ability of patients to pay and the effectiveness of the Company’s collection efforts. Significant changes in payor mix, business office operations, economic conditions or trends in federal and state governmental healthcare coverage could affect the Company’s collection of accounts receivable and the estimates of the collectability of future accounts receivable and are considered in the Company’s estimates of accounts receivable collectability. The Company also continually reviews its overall reserve adequacy by monitoring historical cash collections as a percentage of trailing net revenue less provision for bad debts, as well as by analyzing current period net revenue and admissions by payor classification, aged accounts receivable by payor, days revenue outstanding, the composition of self-pay receivables between pure self-pay patients and the patient responsibility portion of third-party insured receivables and the impact of recent acquisitions and dispositions.

Electronic Health Records Incentive Reimbursement Policy

Electronic Health Records Incentive Reimbursement. The federal government has implemented a number of regulations and programs designed to promote the use of electronic health records (“EHR”) technology and, pursuant to the Health Information Technology for Economic and Clinical Health Act (“HITECH”), established requirements for a Medicare and Medicaid incentive payments program for eligible hospitals and professionals that adopt and meaningfully use certified EHR technology.  The Company utilizes a gain contingency model to recognize EHR incentive payments. Recognition occurs when the eligible hospitals adopt or demonstrate meaningful use of certified EHR technology for the applicable payment period and have available the Medicare cost report information for the relevant full cost report year used to determine the final incentive payment.

Medicaid EHR incentive payments are calculated based on prior period Medicare cost report information available at the time when eligible hospitals adopt, implement, upgrade or demonstrate meaningful use of certified EHR technology. Since the information for the relevant full Medicare cost report year is available at the time of attestation, the incentive income from resolving the gain contingency is recognized when eligible hospitals adopt, implement, upgrade or demonstrate meaningful use of certified EHR technology.

Medicare EHR incentive payments are calculated based on the Medicare cost report information for the full cost report year that began during the federal fiscal year in which meaningful use is demonstrated. Since the necessary information is only available at the end of the relevant full Medicare cost report year and after the cost report is settled, the incentive income from resolving the gain contingency is recognized when eligible hospitals demonstrate meaningful use of certified EHR technology and the information for the applicable full Medicare cost report year to determine the final incentive payment is available.

In some instances, the Company may receive estimated Medicare EHR incentive payments prior to when the Medicare cost report information used to determine the final incentive payment is available. In these instances, recognition of the gain for EHR incentive payments is deferred until all recognition criteria described above are met.

Eligibility for annual Medicare incentive payments is dependent on providers successfully attesting to the meaningful use of EHR technology. Medicaid incentive payments are available to providers in the first payment year that they adopt, implement or upgrade certified EHR technology; however, providers must demonstrate meaningful use of such technology in any subsequent payment years to qualify for additional incentive payments. Medicaid EHR incentive payments are fully funded by the federal government and administered by the states; however, the states are not required to offer EHR incentive payments to providers.  

The Company recognized approximately $18 million and $26 million for the three months ended March 31, 2016 and 2015, respectively, of incentive reimbursement for HITECH incentives from Medicare and Medicaid related to certain of the Company’s hospitals and for certain of the Company’s employed physicians that have demonstrated meaningful use of certified EHR technology or have completed attestations to their adoption or implementation of certified EHR technology.  These incentive reimbursements are presented as a reduction of operating costs and expenses on the condensed consolidated statements of income.  The Company received cash related to the incentive reimbursement for HITECH incentives of approximately $85 million and $54 million for the three months ended March 31, 2016 and 2015, respectively. The Company recorded $34 million and $75 million as deferred revenue in connection with the receipt of these payments at March 31, 2016 and 2015, respectively, as all criteria for gain recognition had not been met.

New Accounting Pronouncements, Policy

New Accounting Pronouncements. In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. This ASU provides companies the option of applying a full or modified retrospective approach upon adoption. This ASU is effective for fiscal years beginning after December 15, 2016. However, the FASB recently issued a final ASU that defers the effective date by one year, with early adoption permitted for annual periods beginning after December 15, 2016. The Company expects to adopt this ASU on January 1, 2018 and is currently evaluating its plan for adoption and the impact on its revenue recognition policies, procedures and control framework and the resulting impact on its consolidated financial position, results of operations and cash flows.

In April 2015, the FASB issued ASU 2015-03, which requires debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct reduction from the carrying amount of that debt liability, consistent with the accounting for debt discounts. The ASU did not change the measurement or recognition guidance for debt issuance costs. This ASU is effective for fiscal years beginning after December 31, 2015. The Company adopted this ASU on January 1, 2016, which resulted in the reclassification of approximately $266 million of debt issuance costs from other long-term assets to a reduction of the related long-term debt. The adoption of this ASU was applied retroactively to all periods presented, and had no impact on the Company’s results of operations or cash flows.

In November 2015, the FASB issued ASU 2015-17, which amended the balance sheet classification requirements for deferred income taxes to simplify their presentation in the statement of financial position. The ASU requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. This ASU is effective for fiscal years beginning after December 31, 2016, with early adoption permitted. The Company early adopted the provisions of this ASU for the presentation and classification of its deferred tax assets at December 31, 2015. The effect of this change primarily resulted in the current portion of deferred income taxes at December 31, 2015 being included in the noncurrent deferred income tax liability.

In January 2016, the FASB issued ASU 2016-01, which amends the measurement, presentation and disclosure requirements for equity investments, other than those accounted for under the equity method or that require consolidation of the investee. The ASU eliminates the classification of equity investments as available-for-sale with any changes in fair value of such investments recognized in other comprehensive income, and requires entities to measure equity investments at fair value, with any changes in fair value recognized in net income. This ASU is effective for fiscal years beginning after December 15, 2017, with early adoption permitted. The Company expects to adopt this ASU on January 1, 2018, and is currently evaluating the impact that adoption of this ASU will have on its consolidated financial position and results of operations.

In February 2016, the FASB issued ASU 2016-02, which amends the accounting for leases, requiring lessees to recognize most leases on their balance sheet with a right-of-use asset and a lease liability. Leases will be classified as either finance or operating leases, which will impact the expense recognition of such leases over the lease term. The ASU also modifies the lease classification criteria for lessors and eliminates some of the real estate leasing guidance previously applied for certain leasing transactions. This ASU is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company expects to adopt this ASU on January 1, 2019. Because of the number of leases the Company utilizes to support its operations, the adoption of this ASU is expected to have a significant impact on the Company’s consolidated financial position and results of operations. Management is currently evaluating the extent of this anticipated impact on the Company’s consolidated financial position and results of operations, and the quantitative and qualitative factors that will impact the Company as part of the adoption of this ASU, as well as any changes to its leasing strategy that may occur because of the changes to the accounting and recognition of leases.

In March 2016, the FASB issued ASU 2016-09, which was issued to simplify some of the accounting guidance for share-based compensation. Among the areas impacted by the amendments in this ASU is the accounting for income taxes related to share-based payments, accounting for forfeitures, classification of awards as equity or liabilities, and classification on the statement of cash flows. This ASU is effective for fiscal years beginning after December 15, 2016, with early adoption permitted. The Company expects to adopt this ASU on January 1, 2017. Management is evaluating the impact that the adoption of this ASU will have on its consolidated financial position, results of operations and cash flows.

XML

Acquisitions and Divestitures (Policies)

3 Months Ended

Mar. 31, 2016

Acquisitions And Divestitures [Abstract]

Business Combinations Policy

Acquisitions

The Company accounts for all transactions that represent business combinations using the acquisition method of accounting, where the identifiable assets acquired, the liabilities assumed and any noncontrolling interest in the acquired entity are recognized and measured at their fair values on the date the Company obtains control in the acquiree.  Such fair values that are not finalized for reporting periods following the acquisition date are estimated and recorded as provisional amounts.  Adjustments to these provisional amounts during the measurement period (defined as the date through which all information required to identify and measure the consideration transferred, the assets acquired, the liabilities assumed and any noncontrolling interests has been obtained, limited to one year from the acquisition date) are recorded as of the date of acquisition.  Any material impact to comparative information for periods after acquisition, but before the period in which adjustments are identified, is reflected in those prior periods as if the adjustments were considered as of the acquisition date. Goodwill is determined as the excess of the fair value of the consideration conveyed in the acquisition over the fair value of the net assets acquired.

XML

Goodwill and Other Intangible Assets (Policies)

3 Months Ended

Mar. 31, 2016

Goodwill and Intangible Asset Impairment [Abstract]

Goodwill, Policy

Goodwill is allocated to each identified reporting unit, which is defined as an operating segment or one level below the operating segment (referred to as a component of the entity). Management has determined that the Company’s operating segments and hospital management services operations meet the criteria to be classified as reporting units. At March 31, 2016, the hospital operations reporting unit, the home care agency operations reporting unit and the hospital management services reporting unit had approximately $8.9 billion, $47 million and $33 million, respectively, of goodwill. 

Goodwill is evaluated for impairment at the same time every year and when an event occurs or circumstances change that, more likely than not, reduce the fair value of the reporting unit below its carrying value. There is a two-step method for determining goodwill impairment. Step one is to compare the fair value of the reporting unit with the unit’s carrying amount, including goodwill. If this test indicates the fair value is less than the carrying value, then step two is required to compare the implied fair value of the reporting unit’s goodwill with the carrying value of the reporting unit’s goodwill. The Company performed its last annual goodwill evaluation during the fourth quarter of 2015. No impairment was indicated by this evaluation.  The next annual goodwill evaluation will be performed during the fourth quarter of 2016. 

The Company estimates the fair value of the related reporting units using both a discounted cash flow model as well as an EBITDA multiple model. The cash flow forecasts are adjusted by an appropriate discount rate based on the Company’s estimate of a market participant’s weighted-average cost of capital. These models are both based on the Company’s best estimate of future revenues and operating costs and are reconciled to the Company’s consolidated market capitalization, with consideration of the amount a potential acquirer would be required to pay, in the form of a control premium, in order to gain sufficient ownership to set policies, direct operations and control management decisions.  

XML

Fair Value of Financial Instruments (Policies)

3 Months Ended

Mar. 31, 2016

Fair Value of Financial Instruments [Abstract]

Fair Value of Financial Instruments, Policy

The estimated fair value is determined using the methodologies discussed below in accordance with accounting standards related to the determination of fair value based on the U.S. GAAP fair value hierarchy as discussed in Note 14.  The estimated fair value for financial instruments with a fair value that does not equal its carrying value is considered a Level 1 valuation.  The Company utilizes the market approach and obtains indicative pricing from the administrative agent to the Credit Facility to determine fair values or through publicly available subscription services such as Bloomberg where relevant. 

Cash and cash equivalents.  The carrying amount approximates fair value due to the short-term maturity of these instruments (less than three months). 

Available-for-sale securities.  Estimated fair value is based on closing price as quoted in public markets or other various valuation techniques. 

Trading securities.  Estimated fair value is based on closing price as quoted in public markets. 

Contingent Value Right. Estimated fair value is based on the closing price as quoted on the public market where the CVR is traded.

Credit Facility.  Estimated fair value is based on publicly available trading activity and supported with information from the Company’s bankers regarding relevant pricing for trading activity among the Company’s lending institutions. 

8% Senior Notes.  Estimated fair value is based on the closing market price for these notes. 

7⅛% Senior Notes.  Estimated fair value is based on the closing market price for these notes. 

2018 Senior Secured Notes.  Estimated fair value is based on the closing market price for these notes. 

2021 Senior Secured Notes.  Estimated fair value is based on the closing market price for these notes.

6⅞% Senior Notes.  Estimated fair value is based on the closing market price for these notes. 

Receivables Facility and other debt.  The carrying amount of the Receivables Facility and all other debt approximates fair value due to the nature of these obligations. 

Interest rate swaps.  The fair value of interest rate swap agreements is the amount at which they could be settled, based on estimates calculated by the Company using a discounted cash flow analysis based on observable market inputs and validated by comparison to estimates obtained from the counterparty. The Company incorporates credit valuation adjustments (“CVAs”) to appropriately reflect both its own nonperformance or credit risk and the respective counterparty’s nonperformance or credit risk in the fair value measurements. In adjusting the fair value of its interest rate swap agreements for the effect of nonperformance or credit risk, the Company has considered the impact of any netting features included in the agreements. 

XML

Fair Value (Policies)

3 Months Ended

Mar. 31, 2016

Fair Value [Abstract]

Fair Value Measurement, Policy

Fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, the Company utilizes the U.S. GAAP fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumption about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy). 

The inputs used to measure fair value are classified into the following fair value hierarchy: 

Level 1:  Quoted market prices in active markets for identical assets or liabilities. 

Level 2:  Observable market-based inputs or unobservable inputs that are corroborated by market data. 

Level 3: Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 includes values determined using pricing models, discounted cash flow methodologies, or similar techniques reflecting the Company’s own assumptions. 

In instances where the determination of the fair value hierarchy measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment of factors specific to the asset or liability. Transfers between levels within the fair value hierarchy are recognized by the Company on the date of the change in circumstances that requires such transfer. There were notransfers between levels during the three month periods ending March 31, 2016 or March 31, 2015. 

XML

Commitments and Contingencies (Policies)

3 Months Ended

Mar. 31, 2016

Contingencies [Abstract]

Legal Costs, Policy

The Company is a party to various legal, regulatory and governmental proceedings incidental to its business. Based on current knowledge, management does not believe that loss contingencies arising from pending legal, regulatory and governmental matters, including the matters described herein, will have a material adverse effect on the consolidated financial position or liquidity of the Company. However, in light of the inherent uncertainties involved in pending legal, regulatory and governmental matters, some of which are beyond the Company’s control, and the very large or indeterminate damages sought in some of these matters, an adverse outcome in one or more of these matters could be material to the Company’s results of operations or cash flows for any particular reporting period.

With respect to all legal, regulatory and governmental proceedings, the Company considers the likelihood of a negative outcome. If the Company determines the likelihood of a negative outcome with respect to any such matter is probable and the amount of the loss can be reasonably estimated, the Company records an accrual for the estimated loss for the expected outcome of the matter. If the likelihood of a negative outcome with respect to material matters is reasonably possible and the Company is able to determine an estimate of the possible loss or a range of loss, whether in excess of a related accrued liability or where there is no accrued liability, the Company discloses the estimate of the possible loss or range of loss. However, the Company is unable to estimate a possible loss or range of loss in some instances based on the significant uncertainties involved in, and/or the preliminary nature of, certain legal, regulatory and governmental matters.

XML

Supplemental Condensed Consolidating Financial Information (Policies)

3 Months Ended

Mar. 31, 2016

Supplemental Condensed Consolidating Financial Information [Abstract]

Guarantor Financial Information Policy

These condensed consolidating financial statements have been prepared and presented in accordance with SEC Regulation S-X Rule 3-10 “Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered.” 

The accounting policies used in the preparation of this financial information are consistent with those elsewhere in the condensed consolidated financial statements of the Company, except as noted below: 

•Intercompany receivables and payables are presented gross in the supplemental condensed consolidating balance sheets. 

•Cash flows from intercompany transactions are presented in cash flows from financing activities, as changes in intercompany balances with affiliates, net. 

•Income tax expense is allocated from the parent guarantor to the income producing operations (other guarantors and non-guarantors) and the issuer through stockholders’ equity. As this approach represents an allocation, the income tax expense allocation is considered non-cash for statement of cash flow purposes. 

•Interest expense, net has been presented to reflect net interest expense and interest income from outstanding long-term debt and intercompany balances. 

The Company’s intercompany activity consists primarily of daily cash transfers for purposes of cash management, the allocation of certain expenses and expenditures paid for by the Parent on behalf of its subsidiaries, and the push down of investment in its subsidiaries. This activity also includes the intercompany transactions between consolidated entities as part of the Receivables Facility that is further discussed in Note 12. The Company’s subsidiaries generally do not purchase services from one another; thus, the intercompany transactions do not represent revenue generating transactions. All intercompany transactions eliminate in consolidation. 

From time to time, subsidiaries of the Company sell and/or repurchase noncontrolling interests in consolidated subsidiaries, which may change subsidiaries between guarantors and non-guarantors.

XML

Basis of Presentation and Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2016

Basis of Presentation and Significant Accounting Policies [Abstract]

Schedule of Operating Revenues, Net of Contractual Allowances and Discounts (But Before the Provision for Bad Debts)

	Three Months Ended
	March 31,
	2016		2015
Medicare	$	1,431	$	1,398
Medicaid		593		586
Managed Care and other third-party payors		3,022		2,946
Self-pay		708		716
Total	$	5,754	$	5,646

XML

Accounting for Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2016

Accounting for Stock-Based Compensation [Abstract]

Schedule of Share-based Compensation Expense

	Three Months Ended
	March 31,
	2016		2015
Effect on income from continuing operations before income taxes	$	(14)	$	(14)
Effect on net income	$	(8)	$	(8)

Schedule of Share-based Compensation, Stock Options, Activity

				Weighted-	Aggregate
				Average	Intrinsic
		Weighted-		Remaining	Value as of
		Average		Contractual	March 31,
	Shares	Exercise Price		Term	2016
Outstanding at December 31, 2015	1,232,158	$	31.65
Granted	-		-
Exercised	-		-
Forfeited and cancelled	(9,334)		29.85
Outstanding at March 31, 2016	1,222,824	$	31.66	3.8 years	$	-
Exercisable at March 31, 2016	1,222,824	$	31.66	3.8 years	$	-

Schedule of Share-based Compensation, Restricted Stock, Activity

		Weighted-
		Average Grant
	Shares	Date Fair Value
Unvested at December 31, 2015	2,845,579	$	44.18
Granted	1,340,000		15.48
Vested	(1,301,337)		43.36
Forfeited	(4,667)		43.05
Unvested at March 31, 2016	2,879,575		31.20

Schedule of Share-based Compensation, Restricted Stock Units Award, Activity

		Weighted-
		Average Grant
	Shares	Date Fair Value
Unvested at December 31, 2015	42,678	$	44.59
Granted	77,119		15.43
Vested	(21,432)		43.60
Forfeited	-		-
Unvested at March 31, 2016	98,365		21.95

XML

Acquisitions and Divestitures (Tables)

3 Months Ended

Mar. 31, 2016

Acquisitions And Divestitures [Abstract]

Schedule of Net Operating Revenues and Income (Loss) and Assets and Liabilities Classified as Discontinued Operations

	Three Months Ended
	March 31,
	2016		2015
Net operating revenues	$	27	$	56
Loss from operations of entities sold or held for sale
before income taxes		-		(17)
Impairment of hospitals sold or held for sale		(2)		(1)
Loss on sale, net		-		(1)
Loss from discontinued operations, before taxes		(2)		(19)
Income tax benefit		(1)		(6)
Loss from discontinued operations, net of taxes	$	(1)	$	(13)

XML

Goodwill and Other Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2016

Goodwill and Other Intangible Assets [Abstract]

Schedule of Goodwill

Balance as of December 31, 2015	$	8,965
Goodwill acquired as part of acquisitions during current year		57
Balance as of March 31, 2016	$	9,022

XML

Earnings Per Share (Tables)

3 Months Ended

Mar. 31, 2016

Earnings Per Share [Abstract]

Schedule of Calculation of Numerator and Denominator in Earnings Per Share

	Three Months Ended
	March 31,
	2016		2015
Numerator:
Income from continuing operations, net of taxes	$	37	$	112
Less: Income from continuing operations attributable
to noncontrolling interests, net of taxes		25		20
Income from continuing operations attributable to
Community Health Systems, Inc. common
stockholders — basic and diluted	$	12	$	92
Loss from discontinued operations, net of taxes	$	(1)	$	(13)
Less: Loss from discontinued operations attributable
to noncontrolling interests, net of taxes		-		-
Loss from discontinued operations attributable to
Community Health Systems, Inc. common
stockholders — basic and diluted	$	(1)	$	(13)
Denominator:
Weighted-average number of shares outstanding — basic		110,247,867		114,419,590
Effect of dilutive securities:
Restricted stock awards		45,257		181,120
Employee stock options		13,038		452,659
Other equity-based awards		3,210		4,299
Weighted-average number of shares outstanding — diluted		110,309,372		115,057,668

Schedule of Antidilutive Securities

	Three Months Ended
	March 31,
	2016		2015
Dilutive securities outstanding not included in
the computation of earnings per
share because their effect is antidilutive:
Employee stock options and restricted stock awards		2,672,726		-

XML

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2016

Stockholders' Equity [Abstract]

Schedule of Stockholders' Equity

			Community Health Systems, Inc. Stockholders
	Redeemable Noncontrolling Interest		Common Stock		Additional Paid-In Capital		Treasury Stock		Accumulated Other Comprehensive Income (Loss)		Retained Earnings		Noncontrolling Interest		Total Stockholders’ Equity
Balance, December 31, 2015	$	571	$	1	$	1,963	$	(7)	$	(73)	$	2,135	$	86	$	4,105
Comprehensive income		19		-		-		-		(16)		11		6		1
Distributions to noncontrolling
interests, net of contributions		(14)		-		-		-		-		-		(4)		(4)
Purchase of subsidiary shares
from noncontrolling interests		(10)		-		(3)		-		-		-		(3)		(6)
Other reclassifications of
noncontrolling interests		(1)		-		-		-		-		-		1		1
Noncontrolling interests in
acquired entity		-		-		-		-		-		-		29		29
Income tax payable increase
from vesting of restricted shares		-		-		(15)		-		-		-		-		(15)
Cancellation of restricted
stock for tax withholdings
on vested shares		-		-		(7)		-		-		-		-		(7)
Share-based compensation		-		-		14		-		-		-		-		14
Balance, March 31, 2016	$	565	$	1	$	1,952	$	(7)	$	(89)	$	2,146	$	115	$	4,118

Schedule of Impact of Noncontrolling Interest to Stockholders' Equity

	Three Months Ended
	March 31, 2016
Net income attributable to Community Health Systems,
Inc. stockholders	$	11
Transfers to the noncontrolling interests:
Net decrease in Community Health Systems, Inc. paid-in
capital for  purchase of subsidiary partnership interests		(3)
Net transfers to the noncontrolling interests		(3)
Change to Community Health Systems, Inc. stockholders’ equity
from net income attributable to Community Health Systems,
Inc. stockholders and transfers to noncontrolling interests	$	8

XML

Equity Investments (Tables)

3 Months Ended

Mar. 31, 2016

Equity Investments [Abstract]

Schedule of Financial Information Related to Unconsolidated Entities Included in Consolidated Statement of Income

	Three Months Ended
	March 31,
	2016		2015
Revenues	$	415	$	375
Operating costs and expenses		324		315
Income from continuing operations before taxes		91		60

XML

Long-Term Debt (Tables)

3 Months Ended

Mar. 31, 2016

Debt Instrument [Line Items]

Schedule of Debt

	March 31,		December 31,
	2016		2015
Credit Facility:
Term A Loan	$	820	$	844
Term F Loan		1,668		1,671
Term G Loan		1,565		1,568
Term H Loan		2,879		2,884
Revolving credit loans		323		147
8% Senior Notes due 2019		1,993		1,992
7⅛% Senior Notes due 2020		1,187		1,186
5⅛% Senior Secured Notes due 2018		1,588		1,587
5⅛% Senior Secured Notes due 2021		968		967
6⅞% Senior Notes due 2022		2,924		2,921
Receivables Facility		699		699
Capital lease obligations		219		227
Other		81		92
Total debt		16,914		16,785
Less current maturities		(249)		(229)
Total long-term debt	$	16,665	$	16,556

Senior Notes at 8.0, Due 2019 [Member] | Senior Notes [Member]

Debt Instrument [Line Items]

Schedule of Early Redemption Prices on Notes

Period	Redemption Price
November 15, 2015 to November 14, 2016	104.000	%
November 15, 2016 to November 14, 2017	102.000	%
November 15, 2017 to November 15, 2019	100.000	%

Senior Notes at 7.125, Due 2020 [Member] | Senior Notes [Member]

Debt Instrument [Line Items]

Schedule of Early Redemption Prices on Notes

Period	Redemption Price
July 15, 2016 to July 14, 2017	103.563	%
July 15, 2017 to July 14, 2018	101.781	%
July 15, 2018 to July 15, 2020	100.000	%

Senior Secured Notes At 5.125 Due 2018 [Member] | Senior Secured Notes [Member]

Debt Instrument [Line Items]

Schedule of Early Redemption Prices on Notes

Period	Redemption Price
August 15, 2015 to August 14, 2016	102.563	%
August 15, 2016 to August 14, 2017	101.281	%
August 15, 2017 to August 15, 2018	100.000	%

Senior Secured Notes at 5.125, Due 2021 [Member] | Senior Secured Notes [Member]

Debt Instrument [Line Items]

Schedule of Early Redemption Prices on Notes

Period	Redemption Price
February 1, 2017 to January 31, 2018	103.844	%
February 1, 2018 to January 31, 2019	102.563	%
February 1, 2019 to January 31, 2020	101.281	%
February 1, 2020 to January 31, 2021	100.000	%

Senior Notes at 6.875, Due 2022 [Member] | Senior Notes [Member]

Debt Instrument [Line Items]

Schedule of Early Redemption Prices on Notes

Period	Redemption Price
February 1, 2018 to January 31, 2019	103.438	%
February 1, 2019 to January 31, 2020	101.719	%
February 1, 2020 to January 31, 2022	100.000	%

XML

Fair Value of Financial Instruments (Tables)

3 Months Ended

Mar. 31, 2016

Fair Value of Financial Instruments [Abstract]

Schedule of Estimated Fair Value of Financial Instruments, by Balance Sheet Grouping

	March 31, 2016				December 31, 2015
	Carrying		Estimated Fair		Carrying		Estimated Fair
	Amount		Value		Amount		Value
Assets:
Cash and cash equivalents	$	181	$	181	$	184	$	184
Available-for-sale securities		268		268		271		271
Trading securities		63		63		61		61
Liabilities:
Contingent Value Right		2		2		2		2
Credit Facility		7,255		7,255		7,114		7,115
8% Senior Notes		1,993		1,954		1,992		2,018
7⅛% Senior Notes		1,187		1,141		1,186		1,193
2018 Senior Secured Notes		1,588		1,615		1,587		1,610
2021 Senior Secured Notes		968		1,010		967		997
6⅞% Senior Notes		2,924		2,715		2,921		2,858
Receivables Facility and other debt		780		780		791		791

Schedule of Interest Rate Swaps

Swap #	Notional Amount (in millions)		Fixed Interest Rate		Termination Date	Fair Value (in millions)
1	$	300	3.447	%	August 6, 2016	$	3
2		100	3.401	%	August 19, 2016		1
3		200	3.429	%	August 19, 2016		2
4		200	3.500	%	August 30, 2016		2
5		100	3.005	%	November 30, 2016		2
6		200	2.055	%	July 25, 2019		7
7		200	2.059	%	July 25, 2019		7
8		400	1.882	%	August 30, 2019		7
9		200	2.515	%	August 30, 2019		8
10		200	2.613	%	August 30, 2019		8
11		300	2.041	%	August 30, 2020		7
12		300	2.738	%	August 30, 2020		16
13		300	2.892	%	August 30, 2020		17
14		300	2.363	%	January 27, 2021		11
15		200	2.368	%	January 27, 2021		7

Schedule of Pre-tax (Loss) Gain Recognized as a Component of Other Comprehensive Income

	Amount of Pre-Tax Loss Recognized in
	OCI (Effective Portion)
Derivatives in Cash Flow Hedging Relationships	Three Months Ended March 31,
	2016		2015
Interest rate swaps	$	(43)	$	(22)

Schedule of Effective Portion of the Pre-tax Loss Reclassified from AOCL into Interest Expense on the Consolidated Statements of Income

	Amount of Pre-Tax Loss Reclassified from
Location of Loss Reclassified from	AOCL into Income (Effective Portion)
AOCL into Income (Effective Portion)	Three Months Ended March 31,
	2016		2015
Interest expense, net	$	14	$	9

Schedule of the Fair Value of Derivative Instruments in the Consolidated Balance Sheet

Asset Derivatives

Liability Derivatives

March 31, 2016

December 31, 2015

March 31, 2016

December 31, 2015

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Derivatives      designated as hedging instruments

Other assets, net

$

-

Other assets, net

$

-

Other long-term liabilities

$

105

Other long-term liabilities

$

76

XML

Fair Value (Tables)

3 Months Ended

Mar. 31, 2016

Fair Value [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

	March 31, 2016		Level 1		Level 2		Level 3
Available-for-sale securities	$	268	$	154	$	114	$	-
Trading securities		63		63		-		-
Total assets	$	331	$	217	$	114	$	-
Contingent Value Right (CVR)	$	2	$	2	$	-	$	-
CVR-related liability		261		-		-		261
Fair value of interest rate swap agreements		105		-		105		-
Total liabilities	$	368	$	2	$	105	$	261
	December 31, 2015		Level 1		Level 2		Level 3
Available-for-sale securities	$	271	$	155	$	116	$	-
Trading securities		61		61		-		-
Total assets	$	332	$	216	$	116	$	-
Contingent Value Right (CVR)	$	2	$	2	$	-	$	-
CVR-related liability		261		-		-		261
Fair value of interest rate swap agreements		76		-		76		-
Total liabilities	$	339	$	2	$	76	$	261

XML

Segment Information (Tables)

3 Months Ended

Mar. 31, 2016

Segment Information [Abstract]

Schedule of Segment Reporting Information by Segment

	Three Months Ended March 31,
	2016		2015
Net operating revenues:
Hospital operations	$	4,944	$	4,857
Corporate and all other		55		54
Total	$	4,999	$	4,911
Income from continuing operations before
income taxes:
Hospital operations	$	143	$	273
Corporate and all other		(80)		(105)
Total	$	63	$	168

XML

Other Comprehensive Income (Tables)

3 Months Ended

Mar. 31, 2016

Stockholders' Equity [Abstract]

Schedule of Changes in Accumulated Other Comprehensive Income by Component

					Change in
	Change in Fair		Change in Fair		Unrecognized		Accumulated Other
	Value of Interest		Value of Available		Pension Cost		Comprehensive
	Rate Swaps		for Sale Securities		Components		Income (Loss)
Balance as of December 31, 2015	$	(48)	$	1	$	(26)	$	(73)
Other comprehensive (loss)
income before reclassifications		(28)		2		-		(26)
Amounts reclassified from
accumulated other
comprehensive income		9		-		1		10
Net current-period other
comprehensive (loss) income		(19)		2		1		(16)
Balance as of March 31, 2016	$	(67)	$	3	$	(25)	$	(89)

					Change in
	Change in Fair		Change in Fair		Unrecognized		Accumulated Other
	Value of Interest		Value of Available		Pension Cost		Comprehensive
	Rate Swaps		for Sale Securities		Components		Income (Loss)
Balance as of December 31, 2014	$	(43)	$	7	$	(27)	$	(63)
Other comprehensive (loss)
income before reclassifications		(15)		1		-		(14)
Amounts reclassified from
accumulated other
comprehensive income		6		-		1		7
Net current-period other
comprehensive (loss) income		(9)		1		1		(7)
Balance as of March 31, 2015	$	(52)	$	8	$	(26)	$	(70)

Schedule of Amounts Reclassified Out of Accumulated Other Comprehensive Income

	Amount reclassified
		from AOCL	Affected line item in the
Details about accumulated other	Three Months Ended		statement where net
comprehensive income (loss) components	March 31, 2016		income is presented
Gains and losses on cash flow hedges
Interest rate swaps	$	(14)	Interest expense, net
		5	Tax benefit
	$	(9)	Net of tax
Amortization of defined benefit pension items
Prior service costs	$	(1)	Salaries and benefits
Actuarial losses		-	Salaries and benefits
		(1)	Total before tax
		-	Tax benefit
	$	(1)	Net of tax

	Amount reclassified
		from AOCL	Affected line item in the
Details about accumulated other	Three Months Ended		statement where net
comprehensive income (loss) components	March 31, 2015		income is presented
Gains and losses on cash flow hedges
Interest rate swaps	$	(9)	Interest expense, net
		3	Tax benefit
	$	(6)	Net of tax
Amortization of defined benefit pension items
Prior service costs	$	-	Salaries and benefits
Actuarial losses		(1)	Salaries and benefits
		(1)	Total before tax
		-	Tax benefit
	$	(1)	Net of tax

XML

Contingencies (Tables)

3 Months Ended

Mar. 31, 2016

Contingencies [Abstract]

Impact of Legal Expenses Paid or Incurred to Date and Settlements Paid or Deemed Final

			Allocation of Expenses and Settlements Paid
							Reduction to
	Total Expenses				CHS		Amount Owed
	and Settlement				Responsibility		to CVR Holders
	Cost		Deductible		at 10%		at 90%
As of December 31, 2015	$	58	$	18	$	4	$	36
Settlements paid		-		-		-		-
Legal expenses incurred
and/or paid during
the three months ended
March 31, 2016		1		-		-		1
As of March 31, 2016	$	59	$	18	$	4	$	37

Schedule Reconciliation of the Beginning and Ending Liability Balances in Connection with Probable Contingencies

	CVR Related		CVR Related Liability		Other
	Liability		for Probable		Probable
	at Fair Value		Contingencies		Contingencies
Balance as of December 31, 2015	$	261	$	-	$	10
Expense (income)		-		-		-
Cash payments		-		-		(3)
Balance as of March 31, 2016	$	261	$	-	$	7

XML

Supplemental Condensed Consolidating Financial Information (Tables)

3 Months Ended

Mar. 31, 2016

Supplemental Condensed Consolidating Financial Information [Abstract]

Schedule of Condensed Consolidating Statement of Income

Condensed Consolidating Statement of Income
Three Months Ended March 31, 2016
	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
	(In millions)
Operating revenues (net of contractual
allowances and discounts)	$	-	$	(6)	$	3,766	$	1,994	$	-	$	5,754
Provision for bad debts		-		-		532		223		-		755
Net operating revenues		-		(6)		3,234		1,771		-		4,999
Operating costs and expenses:
Salaries and benefits		-		-		1,282		1,035		-		2,317
Supplies		-		-		543		256		-		799
Other operating expenses		-		-		817		356		-		1,173
Electronic health records incentive reimbursement		-		-		(11)		(7)		-		(18)
Rent		-		-		65		54		-		119
Depreciation and amortization		-		-		211		87		-		298
Impairment of long-lived assets		-		-		12		5		-		17
Total operating costs and expenses		-		-		2,919		1,786		-		4,705
Income from operations		-		(6)		315		(15)		-		294
Interest expense, net		-		35		200		16		-		251
Equity in earnings of unconsolidated affiliates		(11)		(62)		17		-		36		(20)
Income from continuing operations before income taxes		11		21		98		(31)		(36)		63
Provision for (benefit from) income taxes		-		10		37		(21)		-		26
Income from continuing operations		11		11		61		(10)		(36)		37
Discontinued operations, net of taxes:
Loss from operations of entities sold or held for sale		-		-		(1)		1		-		-
Impairment of hospitals sold or held for sale		-		-		-		(1)		-		(1)
Loss from discontinued operations, net of taxes		-		-		(1)		-		-		(1)
Net income		11		11		60		(10)		(36)		36
Less: Net income attributable to noncontrolling interests		-		-		-		25		-		25
Net income attributable to Community Health Systems,
Inc. stockholders	$	11	$	11	$	60	$	(35)	$	(36)	$	11

Condensed Consolidating Statement of Income
Three Months Ended March 31, 2015
	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
	(In millions)
Operating revenues (net of contractual
allowances and discounts)	$	-	$	(5)	$	3,488	$	2,163	$	-	$	5,646
Provision for bad debts		-		-		447		288		-		735
Net operating revenues		-		(5)		3,041		1,875		-		4,911
Operating costs and expenses:
Salaries and benefits		-		-		1,222		1,035		-		2,257
Supplies		-		-		492		270		-		762
Other operating expenses		-		-		708		391		-		1,099
Government settlement and related costs		-		-		8		-		-		8
Electronic health records incentive reimbursement		-		-		(17)		(9)		-		(26)
Rent		-		-		61		55		-		116
Depreciation and amortization		-		-		200		96		-		296
Total operating costs and expenses		-		-		2,674		1,838		-		4,512
Income from operations		-		(5)		367		37		-		399
Interest expense, net		-		21		211		9		-		241
Loss from early extinguishment of debt		-		8		-		-		-		8
Equity in earnings of unconsolidated affiliates		(79)		(104)		(5)		-		170		(18)
Income from continuing operations before income taxes		79		70		161		28		(170)		168
Provision for (benefit from) income taxes		-		(9)		61		4		-		56
Income from continuing operations		79		79		100		24		(170)		112
Discontinued operations, net of taxes:
Loss from operations of entities sold or held for sale		-		-		-		(11)		-		(11)
Impairment of hospitals sold or held for sale		-		-		(1)		-		-		(1)
Loss on sale, net		-		-		2		(3)		-		(1)
Loss from discontinued operations, net of taxes		-		-		1		(14)		-		(13)
Net income		79		79		101		10		(170)		99
Less: Net income attributable to noncontrolling interests		-		-		-		20		-		20
Net income attributable to Community Health
Systems, Inc. stockholders	$	79	$	79	$	101	$	(10)	$	(170)	$	79

Schedule of Condensed Consolidating Statement of Comprehensive Income

Condensed Consolidating Statement of Comprehensive Income (Loss)
Three Months Ended March 31, 2016
	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
		(In millions)
Net income	$	11	$	11	$	60	$	(10)	$	(36)	$	36
Other comprehensive income (loss), net of income taxes:
Net change in fair value of interest rate swaps, net of tax		(19)		(19)		-		-		19		(19)
Net change in fair value of available-for-sale securities,
net of tax		2		2		2		-		(4)		2
Amortization and recognition of unrecognized pension
cost components, net of tax		1		1		1		-		(2)		1
Other comprehensive income (loss)		(16)		(16)		3		-		13		(16)
Comprehensive income		(5)		(5)		63		(10)		(23)		20
Less: Comprehensive income attributable to
noncontrolling interests		-		-		-		25		-		25
Comprehensive (loss) income attributable to
Community Health Systems, Inc. stockholders	$	(5)	$	(5)	$	63	$	(35)	$	(23)	$	(5)

Condensed Consolidating Statement of Comprehensive Income (Loss)
Three Months Ended March 31, 2015
	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
		(In millions)
Net income	$	79	$	79	$	101	$	10	$	(170)	$	99
Other comprehensive income (loss), net of income taxes:
Net change in fair value of interest rate swaps, net of tax		(9)		(9)		-		-		9		(9)
Net change in fair value of available-for-sale securities,
net of tax		1		1		1		-		(2)		1
Amortization and recognition of unrecognized pension
cost components, net of tax		1		1		1		-		(2)		1
Other comprehensive income (loss)		(7)		(7)		2		-		5		(7)
Comprehensive income		72		72		103		10		(165)		92
Less: Comprehensive income attributable to
noncontrolling interests		-		-		-		20		-		20
Comprehensive income (loss) attributable to
Community Health Systems, Inc. stockholders	$	72	$	72	$	103	$	(10)	$	(165)	$	72

Schedule of Condensed Consolidating Balance Sheet

Condensed Consolidating Balance Sheet
March 31, 2016
	Parent				Other		Non -
	Guarantor		Issuer		Guarantors		Guarantors		Eliminations		Consolidated
	(In millions)
ASSETS
Current assets:
Cash and cash equivalents	$	-	$	-	$	12	$	169	$	-	$	181
Patient accounts receivable, net of allowance
for doubtful accounts		-		-		1,232		2,491		-		3,723
Supplies		-		-		408		179		-		587
Prepaid income taxes		2		-		-		-		-		2
Prepaid expenses and taxes		-		-		146		72		-		218
Other current assets		-		-		347		198		-		545
Total current assets		2		-		2,145		3,109		-		5,256
Intercompany receivable		1,178		16,776		1,638		6,299		(25,891)		-
Property and equipment, net		-		-		6,924		3,180		-		10,104
Goodwill		-		-		5,462		3,560		-		9,022
Other assets, net		-		-		2,349		1,258		(1,265)		2,342
Net investment in subsidiaries		3,433		21,416		7,859		-		(32,708)		-
Total assets	$	4,613	$	38,192	$	26,377	$	17,406	$	(59,864)	$	26,724
LIABILITIES AND EQUITY
Current liabilities:
Current maturities of long-term debt	$	-	$	175	$	65	$	9	$	-	$	249
Accounts payable		-		-		874		305		-		1,179
Accrued interest		-		156		1		1		-		158
Accrued liabilities		4		-		956		508		-		1,468
Total current liabilities		4		331		1,896		823		-		3,054
Long-term debt		-		15,739		128		798		-		16,665
Intercompany payable		-		17,347		18,975		13,775		(50,097)		-
Deferred income taxes		599		-		-		-		-		599
Other long-term liabilities		8		1,342		1,343		295		(1,265)		1,723
Total liabilities		611		34,759		22,342		15,691		(51,362)		22,041
Redeemable noncontrolling interests in
equity of consolidated subsidiaries		-		-		-		565		-		565
Equity:
Community Health Systems, Inc. stockholders’
equity:
Preferred stock		-		-		-		-		-		-
Common stock		1		-		-		-		-		1
Additional paid-in capital		1,951		1,328		1,530		1,042		(3,899)		1,952
Treasury stock, at cost		(7)		-		-		-		-		(7)
Accumulated other comprehensive loss		(89)		(89)		(21)		(1)		111		(89)
Retained earnings		2,146		2,194		2,526		(6)		(4,714)		2,146
Total Community Health Systems, Inc.
stockholders’ equity		4,002		3,433		4,035		1,035		(8,502)		4,003
Noncontrolling interests in equity of
consolidated subsidiaries		-		-		-		115		-		115
Total equity		4,002		3,433		4,035		1,150		(8,502)		4,118
Total liabilities and equity	$	4,613	$	38,192	$	26,377	$	17,406	$	(59,864)	$	26,724

Condensed Consolidating Balance Sheet
December 31, 2015
	Parent				Other		Non -
	Guarantor		Issuer		Guarantors		Guarantors		Eliminations		Consolidated
	(In millions)
ASSETS
Current assets:
Cash and cash equivalents	$	-	$	-	$	25	$	159	$	-	$	184
Patient accounts receivable, net of allowance
for doubtful accounts		-		-		1,197		2,414		-		3,611
Supplies		-		-		400		180		-		580
Prepaid income taxes		27		-		-		-		-		27
Prepaid expenses and taxes		-		-		138		59		-		197
Other current assets		-		-		356		211		-		567
Total current assets		27		-		2,116		3,023		-		5,166
Intercompany receivable		1,159		16,544		1,491		6,404		(25,598)		-
Property and equipment, net		-		-		6,863		3,249		-		10,112
Goodwill		-		-		5,460		3,505		-		8,965
Other assets, net		-		-		2,153		1,245		(1,046)		2,352
Net investment in subsidiaries		3,438		20,964		8,035		-		(32,437)		-
Total assets	$	4,624	$	37,508	$	26,118	$	17,426	$	(59,081)	$	26,595
LIABILITIES AND EQUITY
Current liabilities:
Current maturities of long-term debt	$	-	$	162	$	57	$	10	$	-	$	229
Accounts payable		-		-		866		392		-		1,258
Accrued interest		-		226		-		1		-		227
Accrued liabilities		4		-		901		453		-		1,358
Total current liabilities		4		388		1,824		856		-		3,072
Long-term debt		-		15,604		151		801		-		16,556
Intercompany payable		-		16,861		19,021		13,764		(49,646)		-
Deferred income taxes		593		-		-		-		-		593
Other long-term liabilities		8		1,217		1,149		370		(1,046)		1,698
Total liabilities		605		34,070		22,145		15,791		(50,692)		21,919
Redeemable noncontrolling interests in
equity of consolidated subsidiaries		-		-		-		571		-		571
Equity:
Community Health Systems, Inc. stockholders’
equity:
Preferred stock		-		-		-		-		-		-
Common stock		1		-		-		-		-		1
Additional paid-in capital		1,963		1,324		1,506		967		(3,797)		1,963
Treasury stock, at cost		(7)		-		-		-		-		(7)
Accumulated other comprehensive loss		(73)		(73)		(22)		(3)		98		(73)
Retained earnings		2,135		2,187		2,489		14		(4,690)		2,135
Total Community Health Systems, Inc.
stockholders’ equity		4,019		3,438		3,973		978		(8,389)		4,019
Noncontrolling interests in equity of
consolidated subsidiaries		-		-		-		86		-		86
Total equity		4,019		3,438		3,973		1,064		(8,389)		4,105
Total liabilities and equity	$	4,624	$	37,508	$	26,118	$	17,426	$	(59,081)	$	26,595

Schedule of Condensed Consolidating Statement of Cash Flows

Condensed Consolidating Statement of Cash Flows
Three Months Ended March 31, 2016
	Parent				Other		Non -
	Guarantor		Issuer		Guarantors		Guarantors		Eliminations		Consolidated
	(In millions)
Net cash (used in) provided by operating
activities	$	-	$	(223)	$	420	$	97	$	-	$	294
Cash flows from investing activities:
Acquisitions of facilities and other related
equipment		-		-		(2)		(97)		-		(99)
Purchases of property and equipment		-		-		(159)		(65)		-		(224)
Proceeds from disposition of hospitals
and other ancillary operations		-		-		12		-		-		12
Proceeds from sale of property and equipment		-		-		3		1		-		4
Purchases of available-for-sale securities		-		-		(12)		(25)		-		(37)
Proceeds from sales of available-for-sale securities		-		-		10		30		-		40
Increase in other investments		-		-		(53)		(14)		-		(67)
Net cash used in investing activities		-		-		(201)		(170)		-		(371)
Cash flows from financing activities:
Repurchase of restricted stock shares for payroll
tax withholding requirements		(7)		-		-		-		-		(7)
Redemption of noncontrolling investments in joint
ventures		-		-		-		(16)		-		(16)
Distributions to noncontrolling investors in joint
ventures		-		-		-		(18)		-		(18)
Changes in intercompany balances with
affiliates, net		7		89		(215)		119		-		-
Borrowings under credit agreements		-		1,563		1		-		-		1,564
Proceeds from receivables facility		-		-		-		31		-		31
Repayments of long-term indebtedness		-		(1,429)		(18)		(33)		-		(1,480)
Net cash provided by (used in) financing
activities		-		223		(232)		83		-		74
Net change in cash and cash equivalents		-		-		(13)		10		-		(3)
Cash and cash equivalents at beginning of period		-		-		25		159		-		184
Cash and cash equivalents at end of period	$	-	$	-	$	12	$	169	$	-	$	181

Condensed Consolidating Statement of Cash Flows
Three Months Ended March 31, 2015
	Parent				Other		Non -
	Guarantor		Issuer		Guarantors		Guarantors		Eliminations		Consolidated
	(In millions)
Net cash (used in) provided by operating
activities	$	(10)	$	(123)	$	23	$	49	$	-	$	(61)
Cash flows from investing activities:
Acquisitions of facilities and other related
equipment		-		-		(11)		(2)		-		(13)
Purchases of property and equipment		-		-		(199)		(42)		-		(241)
Proceeds from disposition of hospitals
and other ancillary operations		-		-		4		58		-		62
Proceeds from sale of property and equipment		-		-		-		3		-		3
Purchases of available-for-sale securities		-		-		(22)		(37)		-		(59)
Proceeds from sales of available-for-sale securities		-		-		19		37		-		56
Increase in other investments		-		-		(30)		(9)		-		(39)
Net cash used in investing activities		-		-		(239)		8		-		(231)
Cash flows from financing activities:
Proceeds from exercise of stock options		17		-		-		-		-		17
Repurchase of restricted stock shares for payroll
tax withholding requirements		(20)		-		-		-		-		(20)
Deferred financing costs and other
debt-related costs		-		(20)		-		-		-		(20)
Redemption of noncontrolling investments in joint
ventures		-		-		-		(7)		-		(7)
Distributions to noncontrolling investors in joint
ventures		-		-		-		(23)		-		(23)
Changes in intercompany balances with
affiliates, net		13		77		(101)		11		-		-
Borrowings under credit agreements		-		1,250		1		-		-		1,251
Proceeds from receivables facility		-		-		-		75		-		75
Repayments of long-term indebtedness		-		(1,184)		(15)		(69)		-		(1,268)
Net cash provided by (used in) financing
activities		10		123		(115)		(13)		-		5
Net change in cash and cash equivalents		-		-		(331)		44		-		(287)
Cash and cash equivalents at beginning of period		-		-		368		141		-		509
Cash and cash equivalents at end of period	$	-	$	-	$	37	$	185	$	-	$	222

XML

Basis of Presentation and Significant Accounting Policies (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Jan. 01, 2016
Allowance for Doubtful Accounts, Policy [Abstract]
Number of days from the date of discharge over which all accounts are reserved 100%	365 days
Electronic Health Records Reimbursement, Policy [Abstract]
Electronic health records incentive reimbursement under HITECH	$ 18	$ 26
Electronic Health Records Incentive Reimbursement, Cash Received	85	54
Reclassification of debt issuance costs			$ 266
Electronic Health Records Incentive Reimbursements [Member]
Electronic Health Records Reimbursement, Policy [Abstract]
Deferred Revenue	$ 34	$ 75

XML

Basis of Presentation and Significant Accounting Policies (Schedule of Operating Revenue, Net of Contractual Allowances and Discounts (But Before the Provision for Bad Debts)) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Operating revenues (net of contractual allowances and discounts)	$ 5,754	$ 5,646
Medicare [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Operating revenues (net of contractual allowances and discounts)	1,431	1,398
Medicaid [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Operating revenues (net of contractual allowances and discounts)	593	586
Managed Care And Other Third Party Payors [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Operating revenues (net of contractual allowances and discounts)	3,022	2,946
Self-Pay [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Operating revenues (net of contractual allowances and discounts)	$ 708	$ 716

XML

Accounting for Stock-Based Compensation (Narrative) (Details) - USD ($)				3 Months Ended
	Mar. 01, 2016	Mar. 01, 2015	Mar. 01, 2014	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Unrecognized Compensation Costs on Nonvested Awards				$ 66,000,000
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition				24 months
Aggregate intrinsic value of options exercised					$ 5,000,000
Common Class A [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Price				$ 18.51
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights				one-third increments on each of the first three anniversaries of the award date
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			835,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period				2 years
Restricted Stock, Performance-Based Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights				one-third increments on each of the first three anniversaries of the award date
Plan 2000 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights				one-third increments on each of the first three anniversaries of the award date
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant				0
Plan 2009 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights				one-third increments on each of the first three anniversaries of the award date
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant				1,122,376
Plan 2009 [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights				one-third increments on each of the first three anniversaries of the award date
Fair value of units granted	$ 170,000	$ 170,000
Share-based Compensation, Number of Shares Received by Each Director	11,017	3,504
Plan 2009 Amended and Restated [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized				5,000,000
Contractual Term of Option Granted Prior to 2005 [Member] | Plan 2000 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation Contractual Term of Option Granted				10 years
Contractual Term of Option Granted From 2005 Through 2007 [Member] | Plan 2000 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation Contractual Term of Option Granted				8 years
Contractual Term Of Option Granted From 2008 Through 2011 [Member] | Plan 2000 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation Contractual Term of Option Granted				10 years
Contractual Term of Option Granted in 2011 or Later [Member] | Plan 2009 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation Contractual Term of Option Granted				10 years

XML

Accounting for Stock-Based Compensation (Schedule of Share-based Compensation Expense) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Accounting for Stock-Based Compensation [Abstract]
Effect on income from continuing operations before income taxes	$ (14)	$ (14)
Effect on net income	$ (8)	$ (8)

XML

Accounting for Stock-Based Compensation (Schedule of Share-based Compensation, Stock Options, Activity) (Details) - Employee Stock Option [Member]	3 Months Ended
	Mar. 31, 2016 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance, shares | shares	1,232,158
Forfeited and Cancelled, Shares | shares	(9,334)
Ending Balance, shares | shares	1,222,824
Beginning of Period, Weighted Average Exercise Price | $ / shares	$ 31.65
Forfeited and Cancelled, Weighted Average Exercise Price | $ / shares	29.85
End of Period, Weighted Average Exercise Price | $ / shares	$ 31.66
Weighted Average Remaining Contractual Term	3 years 9 months 18 days
Exercisable, Shares | shares	1,222,824
Exercisable, Weighted Average Exercise Price | $ / shares	$ 31.66
Exercisable, Weighted Average Remaining Contractual Term	3 years 9 months 18 days

XML

Accounting for Stock-Based Compensation (Schedule of Share-based Compensation, Restricted Stock, Activity) (Details) - Restricted Stock [Member]	3 Months Ended
	Mar. 31, 2016 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance, Unvested Shares | shares	2,845,579
Granted, Shares | shares	1,340,000
Vested, Shares | shares	(1,301,337)
Forfeited, Shares | shares	(4,667)
Ending Balance, Unvested Shares | shares	2,879,575
Beginning of Period, Weighted Average Grant Date Fair Value | $ / shares	$ 44.18
Granted, Weighted Average Grant Date Fair Value | $ / shares	15.48
Vested, Weighted Average Grant Date Fair Value | $ / shares	43.36
Forfeited, Weighted Average Grant Date Fair Value | $ / shares	43.05
End of Period, Weighted Average Grant Date Fair Value | $ / shares	$ 31.20

XML

Accounting for Stock Based Compensation (Schedule of Share-based Compensation, Restricted Stock Units, Activity) (Details) - Restricted Stock Units (RSUs) [Member]	3 Months Ended
	Mar. 31, 2016 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance, Unvested Shares | shares	42,678
Granted, Shares | shares	77,119
Vested, Shares | shares	(21,432)
Ending Balance, Unvested Shares | shares	98,365
Beginning of Period, Weighted Average Grant Date Fair Value | $ / shares	$ 44.59
Granted, Weighted Average Grant Date Fair Value | $ / shares	15.43
Vested, Weighted Average Grant Date Fair Value | $ / shares	43.60
End of Period, Weighted Average Grant Date Fair Value | $ / shares	$ 21.95

XML

Cost of Revenue (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cost of Revenue [Abstract]
Corporate Office Costs	$ 60	$ 77
Share-based Compensation	$ 14	$ 14

XML

Acquisitions and Divestitures (Acquisitions Narrative) (Details) $ / shares in Units, $ in Millions		3 Months Ended
	Mar. 01, 2016 USD ($) item	Mar. 31, 2016 USD ($) $ / shares	Mar. 31, 2015 USD ($)	Dec. 31, 2015 USD ($)
Business Acquisition [Line Items]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Changes, Purchase of Interest by Parent		$ 3
Business Acquisition, Purchase Price Allocation, Goodwill		$ 9,022		$ 8,965
Business Combination Contingent Consideration Arrangements, Contingent Value Right, Amount Per Share | $ / shares		$ 1.00
Loss from early extinguishment of debt			$ (8)
Loss on Extinguishment of Debt, Net of Tax			(5)
Indiana University Health [Member]
Business Acquisition [Line Items]
Business Acquisition, Effective Date of Acquisition		Mar. 01, 2016
Business Acquisition, Cost of Acquired Entity, Cash Paid for Fixed Assets	$ 69
Business Acquisition, Cost of Acquired Entity, Cash Paid for Working Capital	10
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	32
Business Acquisition, Cost of Acquired Entity, Purchase Price	$ 96
Business Acquisition, Purchase Price Allocation, Goodwill		$ 49
Business Acquisition, Percentage of Voting Interests Acquired	80.00%
IU Health La Porte Hospital [Member]
Business Acquisition [Line Items]
Business Acquisition, Number of Licensed Hospital or Facility Beds | item	227
IU Health Starke Hospital [Member]
Business Acquisition [Line Items]
Business Acquisition, Number of Licensed Hospital or Facility Beds | item	50
Health Management Associates, Inc. [Member]
Business Acquisition [Line Items]
Business Combination, Acquisition Related Costs			1
Excluding Health Management Associates Inc [Member]
Business Acquisition [Line Items]
Business Combination, Acquisition Related Costs		2	$ 2
Physician Practices Clinics and Other Ancillary Businesses [Member]
Business Acquisition [Line Items]
Business Combination, Assumed Noncontrolling Interest, Fair Value		5
Business Acquisition, Cost of Acquired Entity, Cash Paid		4
Business Acquisition, Purchase Price Allocation, Property, Plant and Equipment		2
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		$ 7

XML

Acquisitions and Divestitures (Divestitures Narrative) (Details) $ in Millions								3 Months Ended
	Feb. 01, 2016 USD ($) item	Jan. 01, 2016 USD ($) item	Jul. 31, 2015 USD ($) item	Apr. 01, 2015 USD ($) item	Mar. 01, 2015 USD ($) item	Feb. 01, 2015 USD ($) item	Dec. 31, 2014 USD ($)	Mar. 31, 2016 USD ($) item	Dec. 31, 2015 USD ($)	Jun. 30, 2015 USD ($) item	Mar. 31, 2015 USD ($)	Jan. 01, 2015 item
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of Hospitals Sold | item								7
Proceeds from Divestiture of Businesses, Net of Cash Divested								$ 12			$ 62
Impairment of goodwill									$ 0
Impairment of long-lived assets								$ 17
Riverview Regional Medical Center [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Date								Mar. 01, 2015
Number of licensed beds | item					281
Proceeds from Divestiture of Businesses, Net of Cash Divested					$ 25
Carolina Pines Regional Medical Center [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Date								Jan. 01, 2015
Number of licensed beds | item												116
Proceeds from Divestiture of Businesses, Net of Cash Divested							$ 74
Williamson Memorial Hospital [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds | item								76
Harris Hospital [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Date								Feb. 01, 2015
Number of licensed beds | item						133
Proceeds from Divestiture of Businesses, Net of Cash Divested						$ 5
Dallas Regional Medical Center [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Date								Mar. 01, 2015
Number of licensed beds | item					202
Proceeds from Divestiture of Businesses, Net of Cash Divested					$ 25
Chesterfield General Hospital [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds | item				59
Chesterfield General Hospital and Marlboro Park Hospital [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Date								Apr. 01, 2015
Proceeds from Divestiture of Businesses, Net of Cash Divested				$ 4
Marlboro Park Hospital [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds | item				102
Fallbrook Hospital [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds | item										47
Proceeds from Divestiture of Businesses, Net of Cash Divested										$ 3
Payson Regional Hospital [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Date								Jul. 31, 2015
Number of licensed beds | item			44
Proceeds from Divestiture of Businesses, Net of Cash Divested			$ 20
Lehigh Regional Medical Center [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Date								Feb. 01, 2016
Number of licensed beds | item	88
Proceeds from Divestiture of Businesses, Net of Cash Divested	$ 11
Impairment of long-lived assets								$ 4
Bartow Regional Medical Center [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Date								Jan. 01, 2016
Number of licensed beds | item		72
Proceeds from Divestiture of Businesses, Net of Cash Divested		$ 60
Impairment of long-lived assets								$ 5
McNairy Regional Hospital [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment of long-lived assets								$ 7

XML

Acquisitions and Divestitures (Schedule of Net Operating Revenues and Income (Loss) and Assets and Liabilities Classified as Discontinued Operations) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Acquisitions And Divestitures [Abstract]
Net operating revenues	$ 27	$ 56
Loss from operations of entities sold or held for sale before income taxes		(17)
Impairment of hospitals sold or held for sale	(2)	(1)
Loss on sale, net		(1)
Loss from discontinued operations, before taxes	(2)	(19)
Income tax benefit	(1)	(6)
Loss from discontinued operations, net of taxes	$ (1)	$ (13)

XML

Spin-Off of Quorum Health Corporation (Details)	Aug. 03, 2015 item
Quorum Health Corporation [Member] | Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations, Spinoff [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of hospitals owned and leased by the Company	38

XML

Income Taxes (Income Tax Contingency and Taxes Paid Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Tax Contingency [Abstract]
Unrecognized benefit that would affect the effective tax rate	$ 5
Amount of interest and penalties included in liabilities for uncertain tax positions	$ 3
Effective Income Tax Rate, Continuing Operations	41.30%	33.20%
Cash Paid for Income Taxes, Net of Refunds Received [Abstract]
Cash paid for income taxes (refunds received), net	$ 0	$ 1
Adjusted for the Expense Related to Income Attributable to Noncontrolling Interest [Member]
Income Tax Contingency [Abstract]
Effective Income Tax Rate, Continuing Operations	68.40%	37.80%

XML

Goodwill and Other Intangible Assets (Schedule of Goodwill) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Goodwill [Roll Forward]
Balance, beginning of year	$ 8,965
Goodwill acquired as part of acquisitions during current year	57
Impairment or allocation of goodwill to hospitals held for sale		$ 0
Balance, end of year	$ 9,022	$ 8,965

XML

Goodwill and Other Intangible Assets (Goodwill Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2015	Mar. 31, 2016
Goodwill [Line Items]
Goodwill	$ 8,965	$ 9,022
Goodwill, Impairment Loss	$ 0
Hospital Operations [Member]
Goodwill [Line Items]
Goodwill		8,900
Home Care Agency Operations Reporting Unit [Member]
Goodwill [Line Items]
Goodwill		47
Hospital Management Services Reporting Unit [Member]
Goodwill [Line Items]
Goodwill		$ 33

XML

Goodwill and Other Intangible Assets (Other Intangible Assets Narrative) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired during the year	$ 0
Finite-Lived Intangible Assets, Gross	79,000,000		$ 82,000,000
Finite-Lived Intangible Assets, Net	27,000,000		31,000,000
Indefinite-Lived Intangible Assets (Excluding Goodwill)	120,000,000		121,000,000
Capitalized Computer Software, Gross	1,500,000,000		1,500,000,000
Capitalized Computer Software, Net	737,000,000		$ 771,000,000
Capitalized Computer Software, Development Stage Costs	$ 56,000,000
Finite-Lived Intangible Assets, Except Capitalized Internal-Use Software [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Weighted-Average Useful Life	4 years
Acquired Finite-lived Intangible Asset, Residual Value	$ 0
Amortization expense	4,000,000	$ 3,000,000
Amortization expense for remainder 2016	11,000,000
Amortization expense for 2017	5,000,000
Amortization expense for 2018	4,000,000
Amortization expense for 2019	2,000,000
Amortization expense for 2020	2,000,000
Amortization expense for 2021	2,000,000
Amortization expense thereafter	1,000,000
Capitalized Internal Use Software [Member]
Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Asset, Residual Value	0
Amortization expense	55,000,000	$ 53,000,000
Amortization expense for remainder 2016	165,000,000
Amortization expense for 2017	185,000,000
Amortization expense for 2018	102,000,000
Amortization expense for 2019	74,000,000
Amortization expense for 2020	65,000,000
Amortization expense for 2021	60,000,000
Amortization expense thereafter	$ 86,000,000
Capitalized Internal Use Software, Except Significant System Conversions [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Weighted-Average Useful Life	3 years
Minimum [Member] | Capitalized Internal Use Software, Significant System Conversions [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Weighted-Average Useful Life	8 years
Maximum [Member] | Capitalized Internal Use Software, Significant System Conversions [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Weighted-Average Useful Life	10 years

XML

Earnings Per Share (Schedule of Calculation of Numerator and Denominator in Earnings Per Share) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Numerator:
Income from continuing operations, net of taxes	$ 37	$ 112
Less: Income from continuing operations attributable to noncontrolling interests, net of taxes	25	20
Income from continuing operations attributable to Community Health Systems, Inc. common stockholders - basic and diluted	12	92
Loss from discontinued operations, net of taxes	(1)	(13)
Loss from discontinued operations attributable to Community Health Systems, Inc. common stockholders - basic and diluted	$ (1)	$ (13)
Denominator:
Weighted-average number of shares outstanding - basic	110,247,867	114,419,590
Effect of dilutive securities:
Restricted stock awards	45,257	181,120
Employee stock options	13,038	452,659
Other equity-based awards	3,210	4,299
Weighted-average number of shares outstanding - diluted	110,309,372	115,057,668

XML

Earnings Per Share (Schedule of Antidilutive Securities (Details)	3 Months Ended
	Mar. 31, 2016 shares
Earnings Per Share [Abstract]
Employee stock options and restricted stock awards	2,672,726

XML

Stockholders' Equity (Narrative) (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2012
Class of Stock [Line Items]
Total capital stock, shares authorized	400,000,000		400,000,000
Common stock, shares authorized	300,000,000		300,000,000
Preferred stock, shares authorized	100,000,000		100,000,000
Common stock, par value per share	$ 0.01		$ 0.01
Preferred stock, par value per share	$ 0.01		$ 0.01
Preferred stock, shares outstanding	0
Common Stock, Dividends, Per Share, Cash Paid				$ 0.25
Maximum amount of dividends or stock repurchases permissible under the Credit Facility	$ 200,000,000
Annual amount of dividends or stock repurchases permissible under the Credit Facility	25,000,000
Amount available for dividend payments, stock repurchases or Senior Notes repurchases at period end	$ 318,000,000
Open Market Repurchase Program for Common Stock, Adopted November 6, 2015 [Member]
Class of Stock [Line Items]
Maximum number of shares authorized for repurchase	10,000,000
Maximum value of shares authorized under repurchase program	$ 300,000,000
Number of shares repurchased and retired	0		532,188
Weighted-average price of repurchased and retired shares, per share			$ 27.31
Open Market Repurchase Program for Common Stock, Adopted December 10, 2014 [Member]
Class of Stock [Line Items]
Maximum number of shares authorized for repurchase	5,000,000
Maximum value of shares authorized under repurchase program	$ 150,000,000
Number of shares repurchased and retired		0

XML

Stockholders' Equity (Schedule of Stockholders' Equity) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2016 USD ($)
Equity, beginning balance	$ 4,105
Redeemable Noncontrolling Interests, beginning balance	571
Comprehensive income including portion attributable to nonredeemable noncontrolling interests	1
Distributions to noncontrolling interests, net of contributions	(4)
Purchase of subsidiary shares from noncontrolling interests	(6)
Other reclassifications of noncontrolling interests	1
Noncontrolling interests in acquired entity	29
Income tax payable increase from vesting of restricted shares	(15)
Cancellation of restricted stock for tax withholdings on vested shares	(7)
Share-based compensation	14
Equity, ending balance	4,118
Redeemable Noncontrolling Interests, ending balance	565
Redeemable Noncontrolling Interests (Non- Equity) [Member]
Redeemable Noncontrolling Interests, beginning balance	571
Comprehensive income attributable to redeemable noncontrolling interest	19
Distributions to redeemable noncontrolling interests, net of contributions	(14)
Purchase of subsidiary shares from noncontrolling interests	(10)
Other reclassifications of redeemable noncontrolling interests	(1)
Redeemable Noncontrolling Interests, ending balance	565
Common Stock [Member]
Equity, beginning balance	1
Equity, ending balance	1
Additional Paid-in Capital [Member]
Equity, beginning balance	1,963
Purchase of subsidiary shares from noncontrolling interests	(3)
Income tax payable increase from vesting of restricted shares	(15)
Cancellation of restricted stock for tax withholdings on vested shares	(7)
Share-based compensation	14
Equity, ending balance	1,952
Treasury Stock [Member]
Equity, beginning balance	(7)
Equity, ending balance	(7)
Accumulated Other Comprehensive (Loss) Income [Member]
Equity, beginning balance	(73)
Comprehensive income including portion attributable to nonredeemable noncontrolling interests	(16)
Equity, ending balance	(89)
Retained Earnings [Member]
Equity, beginning balance	2,135
Comprehensive income including portion attributable to nonredeemable noncontrolling interests	11
Equity, ending balance	2,146
Noncontrolling Interests [Member]
Equity, beginning balance	86
Comprehensive income including portion attributable to nonredeemable noncontrolling interests	6
Distributions to noncontrolling interests, net of contributions	(4)
Purchase of subsidiary shares from noncontrolling interests	(3)
Other reclassifications of noncontrolling interests	1
Noncontrolling interests in acquired entity	29
Equity, ending balance	$ 115

XML

Stockholders' Equity (Schedule of Impact of Noncontrolling Interest to Stockholders' Equity) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Stockholders' Equity [Abstract]
Net income attributable to Community Health Systems, Inc. stockholders	$ 11	$ 79
Net decrease in Community Health Systems, Inc. paid-in capital for purchase of subsidiary partnership interests	(3)
Net transfers to the noncontrolling interests	(3)
Change to Community Health Systems, Inc. stockholders' equity from net income attributable to Community Health Systems, Inc. stockholders and transfers to noncontrolling interests	$ 8

XML

Equity Investments (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Schedule of Equity Method Investments [Line Items]
Equity Method Investments	$ 504		$ 479
Equity in earnings of unconsolidated affiliates	$ 20	$ 18
Four Hospitals in Las Vegas, Nevada [Member]
Schedule of Equity Method Investments [Line Items]
Equity Method Investment, Ownership Percentage	27.50%
One Hospital in Las Vegas, Nevada [Member]
Schedule of Equity Method Investments [Line Items]
Equity Method Investment, Ownership Percentage	26.10%
Three Hospitals in Macon Georgia, [Member]
Schedule of Equity Method Investments [Line Items]
Equity Method Investment, Ownership Percentage	38.00%
HealthTrust [Member]
Schedule of Equity Method Investments [Line Items]
Equity Method Investment, Ownership Percentage	24.70%

XML

Equity Investments (Schedule of Financial Information Related to Unconsolidated Entities Included in Consolidated Statement of Income) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Equity Investments [Abstract]
Revenues	$ 415	$ 375
Operating costs and expenses	324	315
Income from continuing operations before taxes	$ 91	$ 60

XML

Long-Term Debt (Schedule of Debt) (Details) - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Debt	$ 16,914	$ 16,785
Current maturities of long-term debt	(249)	(229)
Long-term debt	16,665	16,556
Secured Debt [Member] | Credit Facility, Term Loan A [Member]
Debt Instrument [Line Items]
Debt	820	844
Secured Debt [Member] | Credit Facility, Term Loan F [Member]
Debt Instrument [Line Items]
Debt	1,668	1,671
Secured Debt [Member] | Credit Facility, Term Loan G [Member]
Debt Instrument [Line Items]
Debt	1,565	1,568
Secured Debt [Member] | Credit Facility, Term Loan H [Member]
Debt Instrument [Line Items]
Debt	2,879	2,884
Line of Credit [Member] | Credit Facility, Revolving Credit Loans [Member]
Debt Instrument [Line Items]
Debt	323	147
Senior Notes [Member] | Senior Notes at 8.0, Due 2019 [Member]
Debt Instrument [Line Items]
Debt	1,993	1,992
Senior Notes [Member] | Senior Notes at 7.125, Due 2020 [Member]
Debt Instrument [Line Items]
Debt	1,187	1,186
Senior Notes [Member] | Senior Notes at 6.875, Due 2022 [Member]
Debt Instrument [Line Items]
Debt	2,924	2,921
Senior Secured Notes [Member] | Senior Secured Notes At 5.125 Due 2018 [Member]
Debt Instrument [Line Items]
Debt	1,588	1,587
Senior Secured Notes [Member] | Senior Secured Notes at 5.125, Due 2021 [Member]
Debt Instrument [Line Items]
Debt	968	967
Receivables Facility [Member] | Receivables Facility, Name [Member]
Debt Instrument [Line Items]
Debt	699	699
Capital Lease Obligations [Member]
Debt Instrument [Line Items]
Debt	219	227
Unsecured Debt [Member]
Debt Instrument [Line Items]
Debt	$ 81	$ 92

XML

Long-Term Debt (Credit Facility as Amended, Amendments and Modifications Narrative) (Details) - USD ($)	May. 18, 2015	Mar. 09, 2015	Jan. 27, 2014	Jan. 26, 2014
Credit Facility, Term Loan B, Initial Funding [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Balance of Remaining Non-extended Term Loans				$ 60,000,000
Credit Facility, Term Loan F [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount		$ 1,700,000,000
Credit Facility, Term Loan G [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 1,600,000,000
Credit Facility, Term Loan H [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 2,900,000,000
Credit Facility, Term Loan A, March 6, 2012 Amendment [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Balance of Remaining Non-extended Term Loans				$ 637,000,000
Credit Facility, Revolving Credit Loans, Third Amendment and Restatement [Member] | Line of Credit [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity			$ 1,000,000,000
Credit Facility, Term Loan A, Third Amendment and Restatement [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount			1,000,000,000
Credit Facility, Term Loan D, Third Amendment and Restatement [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount			4,600,000,000
Credit Facility, Term Loan E, Third Amendment and Restatement [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount			$ 1,700,000,000

XML

Long-Term Debt (Credit Facility Terms Narrative) (Details)	3 Months Ended
	Mar. 31, 2016
Credit Facility, Revolving Credit Loans [Member] | Line of Credit [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.50%
Credit Facility, Term Loans [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Equivalent Percentage of Term Loan Facility Related to Net Cash Proceeds of Certain Asset Sales and Dispositions by Company and Its Subsidiaries	100.00%
Equivalent Percentage of Term Loan Facility Related to Net Cash Proceeds of Issuance of Certain Debt Obligations or Receivables Based Financing by Company and Its Subsidiaries	100.00%
Equivalent Percentage of Term Loan Facility Subject to Reduction to Lower Percentage Based on Company Leverage Ratio	50.00%
Alternate Base Rate [Member] | Credit Facility, Term Loan A [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	1.75%
Alternate Base Rate [Member] | Credit Facility, Term Loan F [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	2.25%
Alternate Base Rate [Member] | Credit Facility, Term Loan G [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	1.75%
Alternate Base Rate [Member] | Credit Facility, Term Loan H [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	2.00%
Alternate Base Rate [Member] | Credit Facility, Term Loan G and Term Loan H [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Derivative, Floor Interest Rate	2.00%
Federal Funds Effective Rate [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	0.50%
LIBOR [Member] | Credit Facility, Revolving Credit Loans [Member] | Line of Credit [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	1.00%
LIBOR [Member] | Credit Facility, Term Loan A [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	2.75%
LIBOR [Member] | Credit Facility, Term Loan F [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	3.25%
LIBOR [Member] | Credit Facility, Term Loan G [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	2.75%
LIBOR [Member] | Credit Facility, Term Loan H [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	3.00%
LIBOR [Member] | Credit Facility, Term Loan G and Term Loan H [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Derivative, Floor Interest Rate	1.00%

XML

Long-Term Debt (Credit Facility End of Period Disclosures Narrative) (Details)	3 Months Ended
	Mar. 31, 2016 USD ($) item
Credit Facility, Name [Member] | Credit Facility, Type of Debt [Member]
Debt Instrument [Line Items]
Minimum Number of Additional Tranches Available in Future | item	1
Aggregate Principal Amount of Each Tranche Available in Future	$ 1,500,000,000
Debt, Weighted Average Interest Rate	4.30%
Credit Facility, Revolving Credit Loans [Member] | Line of Credit [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Outstanding Amount	$ 334,000,000
Line of Credit Facility, Remaining Borrowing Capacity	666,000,000
Letters of Credit Outstanding, Amount	$ 68,000,000

XML

Long-Term Debt (Schedule of Early Redemption Prices on 8.0% Senior Notes) (Details) - Senior Notes at 8.0, Due 2019 [Member] - Senior Notes [Member]	3 Months Ended
	Mar. 31, 2016
Debt Instrument, Redemption, Period Three [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	104.00%
Debt Instrument, Redemption Period, Start Date	Nov. 15, 2015
Debt Instrument, Redemption Period, End Date	Nov. 14, 2016
Debt Instrument, Redemption, Period Four [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	102.00%
Debt Instrument, Redemption Period, Start Date	Nov. 15, 2016
Debt Instrument, Redemption Period, End Date	Nov. 14, 2017
Debt Instrument, Redemption, Period Five [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date	Nov. 15, 2017
Debt Instrument, Redemption Period, End Date	Nov. 15, 2019

XML

Long-Term Debt (Schedule of Early Redemption Prices on 7.125% Senior Notes) (Details) - Senior Notes at 7.125, Due 2020 [Member] - Senior Notes [Member]	3 Months Ended
	Mar. 31, 2016
Debt Instrument, Redemption, Period Three [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	103.563%
Debt Instrument, Redemption Period, Start Date	Jul. 15, 2016
Debt Instrument, Redemption Period, End Date	Jul. 14, 2017
Debt Instrument, Redemption, Period Four [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	101.781%
Debt Instrument, Redemption Period, Start Date	Jul. 15, 2017
Debt Instrument, Redemption Period, End Date	Jul. 14, 2018
Debt Instrument, Redemption, Period Five [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date	Jul. 15, 2018
Debt Instrument, Redemption Period, End Date	Jul. 15, 2020

XML

Long-Term Debt (Schedule of Early Redemption Prices on 5.125% Senior Secured Notes due 2018) (Details) - Senior Secured Notes At 5.125 Due 2018 [Member] - Senior Secured Notes [Member]	3 Months Ended
	Mar. 31, 2016
Debt Instrument, Redemption, Period Three [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	102.563%
Debt Instrument, Redemption Period, Start Date	Aug. 15, 2015
Debt Instrument, Redemption Period, End Date	Aug. 14, 2016
Debt Instrument, Redemption, Period Four [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	101.281%
Debt Instrument, Redemption Period, Start Date	Aug. 15, 2016
Debt Instrument, Redemption Period, End Date	Aug. 14, 2017
Debt Instrument, Redemption, Period Five [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date	Aug. 15, 2017
Debt Instrument, Redemption Period, End Date	Aug. 15, 2018

XML

Long-Term Debt (Schedule of Early Redemption Prices on 5.125% Senior Secured Notes due 2021) (Details) - Senior Secured Notes at 5.125, Due 2021 [Member] - Senior Secured Notes [Member]	3 Months Ended
	Mar. 31, 2016
Debt Instrument, Redemption, Period Three [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	103.844%
Debt Instrument, Redemption Period, Start Date	Feb. 01, 2017
Debt Instrument, Redemption Period, End Date	Jan. 31, 2018
Debt Instrument, Redemption, Period Four [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	102.563%
Debt Instrument, Redemption Period, Start Date	Feb. 01, 2018
Debt Instrument, Redemption Period, End Date	Jan. 31, 2019
Debt Instrument, Redemption, Period Five [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	101.281%
Debt Instrument, Redemption Period, Start Date	Feb. 01, 2019
Debt Instrument, Redemption Period, End Date	Jan. 31, 2020
Debt Instrument, Redemption, Period Six [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date	Feb. 01, 2020
Debt Instrument, Redemption Period, End Date	Jan. 31, 2021

XML

Long-Term Debt (Schedule of Early Redemption Prices on 6.785% Senior Notes) (Details) - Senior Notes at 6.875, Due 2022 [Member] - Senior Notes [Member]	3 Months Ended
	Mar. 31, 2016
Debt Instrument, Redemption, Period Three [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	103.438%
Debt Instrument, Redemption Period, Start Date	Feb. 01, 2018
Debt Instrument, Redemption Period, End Date	Jan. 31, 2019
Debt Instrument, Redemption, Period Four [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	101.719%
Debt Instrument, Redemption Period, Start Date	Feb. 01, 2019
Debt Instrument, Redemption Period, End Date	Jan. 31, 2020
Debt Instrument, Redemption, Period Five [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date	Feb. 01, 2020
Debt Instrument, Redemption Period, End Date	Jan. 31, 2022

XML

Long-Term Debt (8.0% Senior Notes, Due 2019 Narrative) (Details) - USD ($)	1 Months Ended			3 Months Ended	12 Months Ended
	Jul. 18, 2012	Mar. 21, 2012	Nov. 22, 2011	Mar. 31, 2016	Dec. 31, 2011
Senior Notes at 8.875, Due 2015 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Extinguishment of Debt, Amount	$ 934,000,000	$ 850,000,000			$ 1,000,000,000
Senior Notes at 8.0, Due 2019 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Offering Date				Nov. 22, 2011
Debt Instrument, Maturity Date				Nov. 15, 2019
Debt Instrument, Face Amount			$ 1,000,000,000
Debt Instrument, Interest Rate, Stated Percentage		8.00%	8.00%
Debt Instrument, Earliest Redemption Date				Nov. 15, 2015
Senior Notes at 8.0, Due 2019, March 21, 2012 Secondary Offering [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		8.00%
Senior Notes at 8.0, Due 2019, March 21, 2012 Secondary Offering [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Offering Date				Mar. 21, 2012
Debt Instrument, Face Amount		$ 1,000,000,000
Debt Instrument, Premium Percentage		102.50%
Debt Instrument, Redemption, Period Two [Member] | Senior Notes at 8.0, Due 2019 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Minimum Period Notice for Redemption of Debt			30 days
Maximum Period Notice for Redemption of Debt			60 days

XML

Long-Term Debt (7.125% Senior Notes, Due 2020 Narrative) (Details) - Senior Notes [Member] - USD ($)	1 Months Ended		3 Months Ended	12 Months Ended
	Jul. 18, 2012	Mar. 21, 2012	Mar. 31, 2016	Dec. 31, 2011
Senior Notes at 8.875, Due 2015 [Member]
Debt Instrument [Line Items]
Extinguishment of Debt, Amount	$ 934,000,000	$ 850,000,000		$ 1,000,000,000
Senior Notes at 7.125, Due 2020 [Member]
Debt Instrument [Line Items]
Debt Instrument, Offering Date			Jul. 18, 2012
Debt Instrument, Face Amount	$ 1,200,000,000
Debt Instrument, Interest Rate, Stated Percentage	7.125%
Debt Instrument, Earliest Redemption Date			Jul. 15, 2016
Debt Instrument, Redemption, Period Two [Member] | Senior Notes at 7.125, Due 2020 [Member]
Debt Instrument [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date			Jul. 15, 2015
Debt Instrument, Redemption Period, End Date			Jul. 15, 2016
Debt Instrument, Redemption, Description			plus a "make-whole" premium, as described in the 7⅛% Senior Notes indenture
Minimum Period Notice for Redemption of Debt	30 days
Maximum Period Notice for Redemption of Debt	60 days

XML

Long-Term Debt (5.125% Senior Notes, Due 2018 Narrative) (Details) - USD ($)	1 Months Ended	3 Months Ended
	Aug. 17, 2012	Mar. 31, 2016
Senior Secured Notes [Member] | Senior Secured Notes At 5.125 Due 2018 [Member]
Debt Instrument [Line Items]
Debt Instrument, Offering Date		Aug. 17, 2012
Debt Instrument, Face Amount	$ 1,600,000,000	$ 1,600,000,000
Debt Instrument, Interest Rate, Stated Percentage	5.125%
Secured Debt [Member] | Credit Facility, Term Loan B, Initial Funding [Member]
Debt Instrument [Line Items]
Extinguishment of Debt, Amount	$ 1,600,000,000
Debt Instrument, Redemption, Period Two [Member] | Senior Secured Notes [Member] | Senior Secured Notes At 5.125 Due 2018 [Member]
Debt Instrument [Line Items]
Minimum Period Notice for Redemption of Debt	30 days
Maximum Period Notice for Redemption of Debt	60 days

XML

Long-Term Debt (5.125% Senior Notes, Due 2021 Narrative) (Details) - Senior Secured Notes [Member] - Senior Secured Notes at 5.125, Due 2021 [Member] - USD ($)	1 Months Ended	3 Months Ended
	Jan. 27, 2014	Mar. 31, 2016
Debt Instrument [Line Items]
Debt Instrument, Offering Date		Jan. 27, 2014
Debt Instrument, Face Amount	$ 1,000,000,000
Debt Instrument, Interest Rate, Stated Percentage	5.125%
Debt Instrument, Earliest Redemption Date		Feb. 01, 2017
Debt Instrument, Redemption, Period One [Member]
Debt Instrument [Line Items]
Debt Instrument Redemption Price Percentage	105.125%
Debt Instrument, Redemption Period, End Date		Feb. 01, 2017
Debt Instrument, Redemption, Description		proceeds from certain equity offerings
Debt Instrument, Redemption, Period Two [Member]
Debt Instrument [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date		Feb. 01, 2016
Debt Instrument, Redemption Period, End Date		Feb. 01, 2017
Debt Instrument, Redemption, Description		plus a "make-whole" premium, as described in the 2021 Senior Secured Notes indenture
Minimum Period Notice for Redemption of Debt	30 days
Maximum Period Notice for Redemption of Debt	60 days
Maximum [Member] | Debt Instrument, Redemption, Period One [Member]
Debt Instrument [Line Items]
Max Principal Redeemable Using Proceeds from a Public Equity Offering, as a Percentage of Principal Amount	40.00%

XML

Long-Term Debt (6.785% Senior Notes, Due 2022 Narrative) (Details) - Senior Notes [Member] - Senior Notes at 6.875, Due 2022 [Member] - USD ($)	1 Months Ended	3 Months Ended
	Jan. 27, 2014	Mar. 31, 2016
Debt Instrument [Line Items]
Debt Instrument, Offering Date		Jan. 27, 2014
Debt Instrument, Face Amount	$ 3,000,000,000
Debt Instrument, Interest Rate, Stated Percentage	6.875%
Debt Instrument, Earliest Redemption Date		Feb. 01, 2018
Debt Instrument, Redemption, Period One [Member]
Debt Instrument [Line Items]
Debt Instrument Redemption Price Percentage	106.875%
Debt Instrument, Redemption Period, End Date		Feb. 01, 2018
Debt Instrument, Redemption, Description		proceeds from certain public equity offerings
Debt Instrument, Redemption, Period Two [Member]
Debt Instrument [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date		Feb. 01, 2017
Debt Instrument, Redemption Period, End Date		Feb. 01, 2018
Debt Instrument, Redemption, Description		plus a "make-whole" premium, as described in the 6⅞% Senior Notes indenture
Minimum Period Notice for Redemption of Debt	30 days
Maximum Period Notice for Redemption of Debt	60 days
Maximum [Member] | Debt Instrument, Redemption, Period One [Member]
Debt Instrument [Line Items]
Max Principal Redeemable Using Proceeds from a Public Equity Offering, as a Percentage of Principal Amount	40.00%

XML

Long-Term Debt (Receivables Facility Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015	Mar. 07, 2013	Mar. 21, 2012
Debt Instrument [Line Items]
Debt	$ 16,914	$ 16,785
Receivables Facility, Name [Member] | Receivables Facility [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Mar. 21, 2012
Maximum Borrowing Capacity of Receivables Facility				$ 300
Debt	$ 699	$ 699
Receivables Facility, March 7, 2013 Amendment [Member] | Receivables Facility [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Mar. 07, 2013
Maximum Borrowing Capacity of Receivables Facility			$ 500
Receivables Facility, November 13, 2015 Amendment [Member] | Receivables Facility [Member]
Debt Instrument [Line Items]
Debt Instrument, Maturity Date	Nov. 13, 2017
Maximum Borrowing Capacity of Receivables Facility	$ 700
Debt	699
Receivables included in the Receivables Facility	$ 1,700

XML

Long-Term Debt (Loss from Early Extinguishment of Debt Narrative) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2015 USD ($)
Extinguishment of Debt Disclosures [Abstract]
Loss from early extinguishment of debt	$ 8
Loss on Extinguishment of Debt, Net of Tax	$ 5

XML

Long-Term Debt (Other Debt and Interest Payments Narrative) (Details)	3 Months Ended
	Mar. 31, 2016 USD ($) item	Mar. 31, 2015 USD ($)
Debt Instrument [Line Items]
Interest Paid on borrowing	$ 307,000,000	$ 300,000,000
Interest Rate Swap [Member]
Debt Instrument [Line Items]
Derivative Liability, Number of Instruments Held | item	15
Interest Rate Swap, Currently Effective [Member]
Debt Instrument [Line Items]
Notional Amount, Liability	$ 3,500,000,000
Credit Facility, Revolving Credit Loans [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Derivative, Basis Spread on Variable Rate	2.75%
Credit Facility, Term Loan A [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Derivative, Basis Spread on Variable Rate	2.75%
Credit Facility, Term Loan F [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Derivative, Basis Spread on Variable Rate	3.25%
Secured Debt [Member] | Credit Facility, Term Loan G [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Derivative, Basis Spread on Variable Rate	2.75%
Secured Debt [Member] | Credit Facility, Term Loan G [Member] | Alternate Base Rate [Member]
Debt Instrument [Line Items]
Derivative, Basis Spread on Variable Rate	1.75%
Secured Debt [Member] | Credit Facility, Term Loan H [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Derivative, Basis Spread on Variable Rate	3.00%
Secured Debt [Member] | Credit Facility, Term Loan H [Member] | Alternate Base Rate [Member]
Debt Instrument [Line Items]
Derivative, Basis Spread on Variable Rate	2.00%
Secured Debt [Member] | Credit Facility, Term Loan G and Term Loan H [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Derivative, Floor Interest Rate	1.00%
Secured Debt [Member] | Credit Facility, Term Loan G and Term Loan H [Member] | Alternate Base Rate [Member]
Debt Instrument [Line Items]
Derivative, Floor Interest Rate	2.00%

XML

Fair Value of Financial Instruments (Schedule of Estimated Fair Value of Financial Instruments, by Balance Sheet Grouping) (Details) - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
Assets:
Available-for-sale securities	$ 268	$ 271
Trading securities	63	61
Liabilities:
Contingent Value Right, Fair Value Disclosure	2	2
Carrying Amount Measurement [Member]
Assets:
Cash and cash equivalents	181	184
Available-for-sale securities	268	271
Trading securities	63	61
Liabilities:
Contingent Value Right, Fair Value Disclosure	2	2
Carrying Amount Measurement [Member] | Credit Facility, Type of Debt [Member] | Credit Facility, Name [Member]
Liabilities:
Credit Facility, Fair Value Disclosure	7,255	7,114
Carrying Amount Measurement [Member] | Senior Notes [Member] | Senior Notes at 8.0, Due 2019 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	1,993	1,992
Carrying Amount Measurement [Member] | Senior Notes [Member] | Senior Notes at 7.125, Due 2020 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	1,187	1,186
Carrying Amount Measurement [Member] | Senior Notes [Member] | Senior Notes at 6.875, Due 2022 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	2,924	2,921
Carrying Amount Measurement [Member] | Senior Secured Notes [Member] | Senior Secured Notes At 5.125 Due 2018 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	1,588	1,587
Carrying Amount Measurement [Member] | Senior Secured Notes [Member] | Senior Secured Notes at 5.125, Due 2021 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	968	967
Carrying Amount Measurement [Member] | Receivables Facility and Other Debt, Type [Member] | Receivables Facility and Unsecured Debt [Member]
Liabilities:
Other Liabilities, Fair Value Disclosure	780	791
Estimate of Fair Value Measurement [Member]
Assets:
Cash and cash equivalents	181	184
Available-for-sale securities	268	271
Trading securities	63	61
Liabilities:
Contingent Value Right, Fair Value Disclosure	2	2
Estimate of Fair Value Measurement [Member] | Credit Facility, Type of Debt [Member] | Credit Facility, Name [Member]
Liabilities:
Credit Facility, Fair Value Disclosure	7,255	7,115
Estimate of Fair Value Measurement [Member] | Senior Notes [Member] | Senior Notes at 8.0, Due 2019 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	1,954	2,018
Estimate of Fair Value Measurement [Member] | Senior Notes [Member] | Senior Notes at 7.125, Due 2020 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	1,141	1,193
Estimate of Fair Value Measurement [Member] | Senior Notes [Member] | Senior Notes at 6.875, Due 2022 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	2,715	2,858
Estimate of Fair Value Measurement [Member] | Senior Secured Notes [Member] | Senior Secured Notes At 5.125 Due 2018 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	1,615	1,610
Estimate of Fair Value Measurement [Member] | Senior Secured Notes [Member] | Senior Secured Notes at 5.125, Due 2021 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	1,010	997
Estimate of Fair Value Measurement [Member] | Receivables Facility and Other Debt, Type [Member] | Receivables Facility and Unsecured Debt [Member]
Liabilities:
Other Liabilities, Fair Value Disclosure	$ 780	$ 791

XML

Fair Value of Financial Instruments (Schedule of Interest Rate Swaps) (Details) - Interest Rate Swap [Member]	3 Months Ended
	Mar. 31, 2016 USD ($)
Interest Rate Swaps One [Member]
Derivative [Line Items]
Notional Amount, Liability	$ 300,000,000
Fixed Interest Rate	3.447%
Termination Date	Aug. 06, 2016
Fair Value of Liability	$ 3,000,000
Interest Rate Swaps Two [Member]
Derivative [Line Items]
Notional Amount, Liability	$ 100,000,000
Fixed Interest Rate	3.401%
Termination Date	Aug. 19, 2016
Fair Value of Liability	$ 1,000,000
Interest Rate Swaps Three [Member]
Derivative [Line Items]
Notional Amount, Liability	$ 200,000,000
Fixed Interest Rate	3.429%
Termination Date	Aug. 19, 2016
Fair Value of Liability	$ 2,000,000
Interest Rate Swaps Four [Member]
Derivative [Line Items]
Notional Amount, Liability	$ 200,000,000
Fixed Interest Rate	3.50%
Termination Date	Aug. 30, 2016
Fair Value of Liability	$ 2,000,000
Interest Rate Swaps Five [Member]
Derivative [Line Items]
Notional Amount, Liability	$ 100,000,000
Fixed Interest Rate	3.005%
Termination Date	Nov. 30, 2016
Fair Value of Liability	$ 2,000,000
Interest Rate Swaps Six [Member]
Derivative [Line Items]
Notional Amount, Liability	$ 200,000,000
Fixed Interest Rate	2.055%
Termination Date	Jul. 25, 2019
Fair Value of Liability	$ 7,000,000
Interest Rate Swaps Seven [Member]
Derivative [Line Items]
Notional Amount, Liability	$ 200,000,000
Fixed Interest Rate	2.059%
Termination Date	Jul. 25, 2019
Fair Value of Liability	$ 7,000,000
Interest Rate Swaps Eight [Member]
Derivative [Line Items]
Notional Amount, Liability	$ 400,000,000
Fixed Interest Rate	1.882%
Termination Date	Aug. 30, 2019
Fair Value of Liability	$ 7,000,000
Interest Rate Swaps Nine [Member]
Derivative [Line Items]
Notional Amount, Liability	$ 200,000,000
Fixed Interest Rate	2.515%
Termination Date	Aug. 30, 2019
Fair Value of Liability	$ 8,000,000
Interest Rate Swaps Ten [Member]
Derivative [Line Items]
Notional Amount, Liability	$ 200,000,000
Fixed Interest Rate	2.613%
Termination Date	Aug. 30, 2019
Fair Value of Liability	$ 8,000,000
Interest Rate Swaps Eleven [Member]
Derivative [Line Items]
Notional Amount, Liability	$ 300,000,000
Fixed Interest Rate	2.041%
Termination Date	Aug. 30, 2020
Fair Value of Liability	$ 7,000,000
Interest Rate Swaps Twelve [Member]
Derivative [Line Items]
Notional Amount, Liability	$ 300,000,000
Fixed Interest Rate	2.738%
Termination Date	Aug. 30, 2020
Fair Value of Liability	$ 16,000,000
Interest Rate Swaps Thirteen [Member]
Derivative [Line Items]
Notional Amount, Liability	$ 300,000,000
Fixed Interest Rate	2.892%
Termination Date	Aug. 30, 2020
Fair Value of Liability	$ 17,000,000
Interest Rate Swaps Fourteen [Member]
Derivative [Line Items]
Notional Amount, Liability	$ 300,000,000
Fixed Interest Rate	2.363%
Termination Date	Jan. 27, 2021
Fair Value of Liability	$ 11,000,000
Interest Rate Swaps Fifteen [Member]
Derivative [Line Items]
Notional Amount, Liability	$ 200,000,000
Fixed Interest Rate	2.368%
Termination Date	Jan. 27, 2021
Fair Value of Liability	$ 7,000,000

XML

Fair Value of Financial Instruments (Narrative) (Details) $ in Millions	Mar. 31, 2016 USD ($)
Fair Value of Financial Instruments [Abstract]
Interest expense arising from spread in fixed and floating rates of interest rate swap agreements that will be recognized in next 12 months	$ 46

XML

Fair Value of Financial Instruments (Schedule of Pre-tax (Loss) Gain Recognized as a Component of Other Comprehensive Income) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash Flow Hedging [Member] | Interest Rate Swap [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Pre-Tax Loss Recognized in OCI (Effective Portion)	$ (43)	$ (22)

XML

Fair Value of Financial Instruments (Schedule of Effective Portion of the Pre-tax Loss Reclassified from AOCL into Interest Expense on the Consolidated Statements of Income) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Interest Expense [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Pre-Tax Loss Reclassified from AOCL into Income (Effective Portion)	$ 14	$ 9

XML

Fair Value of Financial Instruments (Schedule of the Fair Value of Derivative Instruments in the Consolidated Balance Sheet) (Details) - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
Designated as Hedging Instrument [Member] | Other Long-term Liabilities [Member]
Derivatives, Fair Value [Line Items]
Liability derivatives designated as hedging instruments	$ 105	$ 76

XML

Fair Value (Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis) (Details) - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	$ 268	$ 271
Trading securities	63	61
Total assets	331	332
Contingent Value Right (CVR)	2	2
CVR-related legal liability	261	261
Fair value of interest rate swap agreements	105	76
Total liabilities	368	339
Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	154	155
Trading securities	63	61
Total assets	217	216
Contingent Value Right (CVR)	2	2
Total liabilities	2	2
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	114	116
Total assets	114	116
Fair value of interest rate swap agreements	105	76
Total liabilities	105	76
Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
CVR-related legal liability	261	261
Total liabilities	$ 261	$ 261

XML

Fair Value (Narrative) (Details) - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015
Fair Value Disclosures [Line Items]
Fair Value, Assets, Level 1 to Level 2 Transfers, Amount	$ 0		$ 0
Fair Value, Assets, Level 2 to Level 1 Transfers, Amount	0		0
Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount	0		0
Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount	0		$ 0
CVR-related legal liability	0
Interest Rate Swap [Member]
Fair Value Disclosures [Line Items]
Credit risk valuation adjustment, decrease in fair value of liability	6	$ 4
Credit risk valuation adjustment, decrease in fair value of liability, net of tax	$ 4	$ 2

XML

Segment Information (Narrative) (Details)	3 Months Ended
	Mar. 31, 2016 segment
Segment Information [Abstract]
Number of Operating Segments	2

XML

Segment Information (Schedule of Segment Reporting Information by Segment) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Segment Reporting Information [Line Items]
Net operating revenues	$ 4,999	$ 4,911
Income (loss) from continuing operations before income taxes	63	168
Hospital Operations [Member]
Segment Reporting Information [Line Items]
Net operating revenues	4,944	4,857
Income (loss) from continuing operations before income taxes	143	273
Corporate and All Other Reporting Units [Member]
Segment Reporting Information [Line Items]
Net operating revenues	55	54
Income (loss) from continuing operations before income taxes	$ (80)	$ (105)

XML

Other Comprehensive Income (Schedule of Changes in Accumulated Other Comprehensive Income by Component) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Beginning Balance	$ (73)	$ (63)
Other comprehensive (loss) income before reclassifications	(26)	(14)
Amounts reclassified from accumulated other comprehensive income (loss)	10	7
Other comprehensive loss	(16)	(7)
Accumulated Other Comprehensive Income (Loss), Ending Balance	(89)	(70)
Change in Fair Value of Interest Rate Swaps [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Beginning Balance	(48)	(43)
Other comprehensive (loss) income before reclassifications	(28)	(15)
Amounts reclassified from accumulated other comprehensive income (loss)	9	6
Other comprehensive loss	(19)	(9)
Accumulated Other Comprehensive Income (Loss), Ending Balance	(67)	(52)
Change in Fair Value of Available for Sale Securities [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Beginning Balance	1	7
Other comprehensive (loss) income before reclassifications	2	$ 1
Amounts reclassified from accumulated other comprehensive income (loss)
Other comprehensive loss	2	$ 1
Accumulated Other Comprehensive Income (Loss), Ending Balance	3	8
Change in Unrecognized Pension Cost Components [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Beginning Balance	(26)	(27)
Amounts reclassified from accumulated other comprehensive income (loss)	1	1
Other comprehensive loss	1	1
Accumulated Other Comprehensive Income (Loss), Ending Balance	$ (25)	$ (26)

XML

Other Comprehensive Income (Schedule of Amounts Reclassified Out of Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Interest expense, net	$ 251	$ 241
Income from continuing operations before income taxes	63	168
Tax benefit	(26)	(56)
Net income attributable to Community Health Systems, Inc. stockholders	11	79
Change in Fair Value of Interest Rate Swaps [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Interest expense, net	(14)	(9)
Tax benefit	5	3
Net income attributable to Community Health Systems, Inc. stockholders	(9)	(6)
Change in Unrecognized Pension Cost Components [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Amortization of defined benefit pension items - Actuarial losses		(1)
Change in Unrecognized Pension Cost Components [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Amortization of defined benefit pension items - Prior service costs	(1)
Income from continuing operations before income taxes	(1)	(1)
Net income attributable to Community Health Systems, Inc. stockholders	$ (1)	$ (1)

XML

Contingencies (Contingencies Narrative) (Details) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2016 USD ($) item $ / shares	Mar. 31, 2015 USD ($)	Jan. 27, 2014 USD ($)
Loss Contingencies [Line Items]
Business Combination Contingent Consideration Arrangements, Contingent Value Right, Amount Per Share | $ / shares	$ 1.00
Deductible related to litigation and contingent value right	$ 18
Contingent value right, percentage multiplier	90.00%
Number of contingent value rights outstanding | item	264,544,053
Amount which CVR holders are no longer entitled to payment	$ 312
Contingent value right, period payable after final resolution	60 days
Business Combination, Contingent Consideration, Liability, Noncurrent	$ 261		$ 284
Business Combination, Contingent Consideration, Liability, Current	0
Pending Litigation [Member] | Legal Matters Where Negative Outcome is Known or Probable [Member]
Loss Contingencies [Line Items]
Legal Fees	$ 1	$ 4
Class Action Shareholder Federal Securities Cases [Member] | Pending Litigation [Member] | Litigation Matters For Which An Outcome Cannot Be Assessed [Member]
Loss Contingencies [Line Items]
Number of legal cases filed | item	3
Shareholder Derivative Actions [Member] | Pending Litigation [Member] | Litigation Matters For Which An Outcome Cannot Be Assessed [Member]
Loss Contingencies [Line Items]
Number of legal cases filed | item	3

XML

Contingencies (Impact of Legal Expenses Paid or Incurred to Date and Settlements Paid or Deemed Final) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2016 USD ($)
Loss Contingencies [Line Items]
As of December 31, 2015	$ 58
Legal expenses incurred and/or paid during the three months ended March 31, 2016	1
As of March 31, 2016	59
Deductible [Member]
Loss Contingencies [Line Items]
As of December 31, 2015	18
As of March 31, 2016	18
CHS Responsibility at 10% [Member]
Loss Contingencies [Line Items]
As of December 31, 2015	4
As of March 31, 2016	4
Reduction to Amount Owed to CVR Holders at 90% [Member]
Loss Contingencies [Line Items]
As of December 31, 2015	36
Legal expenses incurred and/or paid during the three months ended March 31, 2016	1
As of March 31, 2016	$ 37

XML

Contingencies (Schedule Reconciliation of the Beginning and Ending Liability Balances in Connection with Probable Contingencies) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Loss Contingency Accrual [Roll Forward]
Expense (income)		$ 8
Pending Litigation [Member] | CVR Related Liability at Fair Value [Member]
Loss Contingency Accrual [Roll Forward]
Beginning Balance	$ 261
Ending Balance	261
Pending Litigation [Member] | Other Probable Contingencies [Member]
Loss Contingency Accrual [Roll Forward]
Beginning Balance	10
Cash payments	(3)
Ending Balance	$ 7

XML

Subsequent Events (Narrative) (Details)			3 Months Ended
	Apr. 29, 2016 USD ($)	Apr. 01, 2016 USD ($) item	Mar. 31, 2016 USD ($)	Mar. 31, 2015 USD ($)	May. 02, 2016 USD ($)	Mar. 09, 2015 USD ($)	Aug. 17, 2012 USD ($)
Subsequent Event [Line Items]
Payments made for term loan under Credit Facility			$ 1,480,000,000	$ 1,268,000,000
Universal Health Services, Inc. [Member]
Subsequent Event [Line Items]
Disposal Date			Apr. 29, 2016
Physicians' Specialty Hospital [Member]
Subsequent Event [Line Items]
Business Acquisition, Date of Acquisition Agreement			Apr. 01, 2016
Subsequent Event [Member] | Quorum Health Corporation [Member]
Subsequent Event [Line Items]
Cash generated from spinoff	$ 1,200,000,000
Subsequent Event [Member] | Universal Health Services, Inc. [Member]
Subsequent Event [Line Items]
Proceeds from sale of equity method investments	445,000,000
Subsequent Event [Member] | Physicians' Specialty Hospital [Member]
Subsequent Event [Line Items]
Number of licensed beds | item		20
Business Acquisition, Cost of Acquired Entity, Purchase Price		$ 13,000,000
Business Acquisition, Percentage of Voting Interests Acquired		80.00%
Secured Debt [Member] | Credit Facility, Term Loan F [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount						$ 1,700,000,000
Secured Debt [Member] | Credit Facility, Term Loan F [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Payments made for term loan under Credit Facility	$ 194,000,000
Senior Secured Notes [Member] | Senior Secured Notes At 5.125 Due 2018 [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount			$ 1,600,000,000				$ 1,600,000,000
Senior Secured Notes [Member] | Senior Secured Notes At 5.125 Due 2018 [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Cash tender offer					$ 900,000,000
Four Hospitals in Las Vegas, Nevada [Member]
Subsequent Event [Line Items]
Company owned equity interests			27.50%
Four Hospitals in Las Vegas, Nevada [Member] | Subsequent Event [Member] | Universal Health Services, Inc. [Member]
Subsequent Event [Line Items]
Company owned equity interests	27.50%
One Hospital in Las Vegas, Nevada [Member]
Subsequent Event [Line Items]
Company owned equity interests			26.10%
One Hospital in Las Vegas, Nevada [Member] | Subsequent Event [Member] | Universal Health Services, Inc. [Member]
Subsequent Event [Line Items]
Company owned equity interests	26.10%

XML

Supplemental Condensed Consolidating Financial Information (Narrative) (Details)	3 Months Ended
	Mar. 31, 2016
Supplemental Condensed Consolidating Financial Information [Abstract]
Percentage of owned domestic subsidiaries which guaranteed senior notes	100.00%

XML

Supplemental Condensed Consolidating Financial Information (Schedule of Condensed Consolidating Statement of Income) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Condensed Consolidating Statements of Income (Unaudited)
Operating revenues (net of contractual allowances and discounts)	$ 5,754	$ 5,646
Provision for bad debts	755	735
Net operating revenues	4,999	4,911
Operating costs and expenses:
Salaries and benefits	2,317	2,257
Supplies	799	762
Other operating expenses	1,173	1,099
Government settlement and related costs		8
Electronic health records incentive reimbursement	(18)	(26)
Rent	119	116
Depreciation and amortization	298	296
Impairment of long-lived assets	17
Total operating costs and expenses	4,705	4,512
Income from operations	294	399
Interest expense, net	251	241
Loss from early extinguishment of debt		8
Equity in earnings of unconsolidated affiliates	(20)	(18)
Income from continuing operations before income taxes	63	168
Provision for (benefit from) income taxes	26	56
Income from continuing operations	37	112
Discontinued operations, net of taxes:
Loss from operations of entities sold or held for sale		(11)
Impairment of hospitals sold or held for sale	(1)	(1)
Loss on sale, net		(1)
Loss from discontinued operations, net of taxes	(1)	(13)
Net income	36	99
Less: Net income attributable to noncontrolling interests	25	20
Net income attributable to Community Health Systems, Inc. stockholders	11	79
Parent Company [Member]
Operating costs and expenses:
Equity in earnings of unconsolidated affiliates	(11)	(79)
Income from continuing operations before income taxes	11	79
Income from continuing operations	11	79
Discontinued operations, net of taxes:
Net income	11	79
Net income attributable to Community Health Systems, Inc. stockholders	11	79
Issuer [Member]
Condensed Consolidating Statements of Income (Unaudited)
Operating revenues (net of contractual allowances and discounts)	(6)	(5)
Net operating revenues	(6)	(5)
Operating costs and expenses:
Income from operations	(6)	(5)
Interest expense, net	35	21
Loss from early extinguishment of debt		8
Equity in earnings of unconsolidated affiliates	(62)	(104)
Income from continuing operations before income taxes	21	70
Provision for (benefit from) income taxes	10	(9)
Income from continuing operations	11	79
Discontinued operations, net of taxes:
Net income	11	79
Net income attributable to Community Health Systems, Inc. stockholders	11	79
Other Guarantor [Member]
Condensed Consolidating Statements of Income (Unaudited)
Operating revenues (net of contractual allowances and discounts)	3,766	3,488
Provision for bad debts	532	447
Net operating revenues	3,234	3,041
Operating costs and expenses:
Salaries and benefits	1,282	1,222
Supplies	543	492
Other operating expenses	817	708
Government settlement and related costs		8
Electronic health records incentive reimbursement	(11)	(17)
Rent	65	61
Depreciation and amortization	211	200
Impairment of long-lived assets	12
Total operating costs and expenses	2,919	2,674
Income from operations	315	367
Interest expense, net	200	211
Equity in earnings of unconsolidated affiliates	17	(5)
Income from continuing operations before income taxes	98	161
Provision for (benefit from) income taxes	37	61
Income from continuing operations	61	100
Discontinued operations, net of taxes:
Loss from operations of entities sold or held for sale	(1)
Impairment of hospitals sold or held for sale		(1)
Loss on sale, net		2
Loss from discontinued operations, net of taxes	(1)	1
Net income	60	101
Net income attributable to Community Health Systems, Inc. stockholders	60	101
Non-Guarantor Subsidiaries [Member]
Condensed Consolidating Statements of Income (Unaudited)
Operating revenues (net of contractual allowances and discounts)	1,994	2,163
Provision for bad debts	223	288
Net operating revenues	1,771	1,875
Operating costs and expenses:
Salaries and benefits	1,035	1,035
Supplies	256	270
Other operating expenses	356	391
Electronic health records incentive reimbursement	(7)	(9)
Rent	54	55
Depreciation and amortization	87	96
Impairment of long-lived assets	5
Total operating costs and expenses	1,786	1,838
Income from operations	(15)	37
Interest expense, net	16	9
Income from continuing operations before income taxes	(31)	28
Provision for (benefit from) income taxes	(21)	4
Income from continuing operations	(10)	24
Discontinued operations, net of taxes:
Loss from operations of entities sold or held for sale	1	(11)
Impairment of hospitals sold or held for sale	(1)
Loss on sale, net		(3)
Loss from discontinued operations, net of taxes		(14)
Net income	(10)	10
Less: Net income attributable to noncontrolling interests	25	20
Net income attributable to Community Health Systems, Inc. stockholders	(35)	(10)
Consolidation, Eliminations [Member]
Operating costs and expenses:
Equity in earnings of unconsolidated affiliates	36	170
Income from continuing operations before income taxes	(36)	(170)
Income from continuing operations	(36)	(170)
Discontinued operations, net of taxes:
Net income	(36)	(170)
Net income attributable to Community Health Systems, Inc. stockholders	$ (36)	$ (170)

XML

Supplemental Condensed Consolidating Financial Information (Schedule of Condensed Consolidating Statement of Comprehensive Income) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Condensed Consolidating Statement of Comprehensive Income (Unaudited)
Net income	$ 36	$ 99
Other comprehensive (loss) income, net of income taxes:
Net change in fair value of interest rate swaps, net of tax	(19)	(9)
Net change in fair value of available-for-sale securities, net of tax	2	1
Amortization and recognition of unrecognized pension cost components, net of tax	1	1
Other comprehensive loss	(16)	(7)
Comprehensive income	20	92
Less: Comprehensive income attributable to noncontrolling interests	25	20
Comprehensive (loss) income attributable to Community Health Systems, Inc. stockholders	(5)	72
Parent Company [Member]
Condensed Consolidating Statement of Comprehensive Income (Unaudited)
Net income	11	79
Other comprehensive (loss) income, net of income taxes:
Net change in fair value of interest rate swaps, net of tax	(19)	(9)
Net change in fair value of available-for-sale securities, net of tax	2	1
Amortization and recognition of unrecognized pension cost components, net of tax	1	1
Other comprehensive loss	(16)	(7)
Comprehensive income	(5)	72
Comprehensive (loss) income attributable to Community Health Systems, Inc. stockholders	(5)	72
Issuer [Member]
Condensed Consolidating Statement of Comprehensive Income (Unaudited)
Net income	11	79
Other comprehensive (loss) income, net of income taxes:
Net change in fair value of interest rate swaps, net of tax	(19)	(9)
Net change in fair value of available-for-sale securities, net of tax	2	1
Amortization and recognition of unrecognized pension cost components, net of tax	1	1
Other comprehensive loss	(16)	(7)
Comprehensive income	(5)	72
Comprehensive (loss) income attributable to Community Health Systems, Inc. stockholders	(5)	72
Other Guarantor [Member]
Condensed Consolidating Statement of Comprehensive Income (Unaudited)
Net income	60	101
Other comprehensive (loss) income, net of income taxes:
Net change in fair value of available-for-sale securities, net of tax	2	1
Amortization and recognition of unrecognized pension cost components, net of tax	1	1
Other comprehensive loss	3	2
Comprehensive income	63	103
Comprehensive (loss) income attributable to Community Health Systems, Inc. stockholders	63	103
Non-Guarantor Subsidiaries [Member]
Condensed Consolidating Statement of Comprehensive Income (Unaudited)
Net income	(10)	10
Other comprehensive (loss) income, net of income taxes:
Comprehensive income	(10)	10
Less: Comprehensive income attributable to noncontrolling interests	25	20
Comprehensive (loss) income attributable to Community Health Systems, Inc. stockholders	(35)	(10)
Consolidation, Eliminations [Member]
Condensed Consolidating Statement of Comprehensive Income (Unaudited)
Net income	(36)	(170)
Other comprehensive (loss) income, net of income taxes:
Net change in fair value of interest rate swaps, net of tax	19	9
Net change in fair value of available-for-sale securities, net of tax	(4)	(2)
Amortization and recognition of unrecognized pension cost components, net of tax	(2)	(2)
Other comprehensive loss	13	5
Comprehensive income	(23)	(165)
Comprehensive (loss) income attributable to Community Health Systems, Inc. stockholders	$ (23)	$ (165)

XML

Supplemental Condensed Consolidating Financial Information (Schedule of Condensed Consolidating Balance Sheet) (Details) - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 181	$ 184	$ 222	$ 509
Patient accounts receivable, net of allowance for doubtful accounts	3,723	3,611
Supplies	587	580
Prepaid income taxes	2	27
Prepaid expenses and taxes	218	197
Other current assets	545	567
Total current assets	5,256	5,166
Property and equipment, net	10,104	10,112
Goodwill	9,022	8,965
Other assets, net	2,342	2,352
Total assets	26,724	26,595
Current liabilities:
Current maturities of long-term debt	249	229
Accounts payable	1,179	1,258
Accrued interest	158	227
Accrued liabilities	1,468	1,358
Total current liabilities	3,054	3,072
Long-term debt	16,665	16,556
Deferred income taxes	599	593
Other long-term liabilities	1,723	1,698
Total liabilities	22,041	21,919
Redeemable noncontrolling interests in equity of consolidated subsidiaries	$ 565	$ 571
Community Health Systems, Inc. stockholders' equity:
Preferred stock
Common stock	$ 1	$ 1
Additional paid-in capital	1,952	1,963
Treasury stock, at cost	(7)	(7)
Accumulated other comprehensive loss	(89)	(73)	(70)	(63)
Retained earnings	2,146	2,135
Total Community Health Systems, Inc. stockholders' equity	4,003	4,019
Noncontrolling interests in equity of consolidated subsidiaries	115	86
Total equity	4,118	4,105
Total liabilities and equity	26,724	26,595
Parent Company [Member]
Current assets:
Prepaid income taxes	2	27
Total current assets	2	27
Intercompany receivable	1,178	1,159
Net investment in subsidiaries	3,433	3,438
Total assets	4,613	4,624
Current liabilities:
Accrued liabilities	4	4
Total current liabilities	4	4
Deferred income taxes	599	593
Other long-term liabilities	8	8
Total liabilities	611	605
Community Health Systems, Inc. stockholders' equity:
Common stock	1	1
Additional paid-in capital	1,951	1,963
Treasury stock, at cost	(7)	(7)
Accumulated other comprehensive loss	(89)	(73)
Retained earnings	2,146	2,135
Total Community Health Systems, Inc. stockholders' equity	4,002	4,019
Total equity	4,002	4,019
Total liabilities and equity	4,613	4,624
Issuer [Member]
Current assets:
Intercompany receivable	16,776	16,544
Net investment in subsidiaries	21,416	20,964
Total assets	38,192	37,508
Current liabilities:
Current maturities of long-term debt	175	162
Accrued interest	156	226
Total current liabilities	331	388
Long-term debt	15,739	15,604
Intercompany payable	17,347	16,861
Other long-term liabilities	1,342	1,217
Total liabilities	34,759	34,070
Community Health Systems, Inc. stockholders' equity:
Additional paid-in capital	1,328	1,324
Accumulated other comprehensive loss	(89)	(73)
Retained earnings	2,194	2,187
Total Community Health Systems, Inc. stockholders' equity	3,433	3,438
Total equity	3,433	3,438
Total liabilities and equity	38,192	37,508
Other Guarantor [Member]
Current assets:
Cash and cash equivalents	12	25	37	368
Patient accounts receivable, net of allowance for doubtful accounts	1,232	1,197
Supplies	408	400
Prepaid expenses and taxes	146	138
Other current assets	347	356
Total current assets	2,145	2,116
Intercompany receivable	1,638	1,491
Property and equipment, net	6,924	6,863
Goodwill	5,462	5,460
Other assets, net	2,349	2,153
Net investment in subsidiaries	7,859	8,035
Total assets	26,377	26,118
Current liabilities:
Current maturities of long-term debt	65	57
Accounts payable	874	866
Accrued interest	1
Accrued liabilities	956	901
Total current liabilities	1,896	1,824
Long-term debt	128	151
Intercompany payable	18,975	19,021
Other long-term liabilities	1,343	1,149
Total liabilities	22,342	22,145
Community Health Systems, Inc. stockholders' equity:
Additional paid-in capital	1,530	1,506
Accumulated other comprehensive loss	(21)	(22)
Retained earnings	2,526	2,489
Total Community Health Systems, Inc. stockholders' equity	4,035	3,973
Total equity	4,035	3,973
Total liabilities and equity	26,377	26,118
Non-Guarantor Subsidiaries [Member]
Current assets:
Cash and cash equivalents	169	159	$ 185	$ 141
Patient accounts receivable, net of allowance for doubtful accounts	2,491	2,414
Supplies	179	180
Prepaid expenses and taxes	72	59
Other current assets	198	211
Total current assets	3,109	3,023
Intercompany receivable	6,299	6,404
Property and equipment, net	3,180	3,249
Goodwill	3,560	3,505
Other assets, net	1,258	1,245
Total assets	17,406	17,426
Current liabilities:
Current maturities of long-term debt	9	10
Accounts payable	305	392
Accrued interest	1	1
Accrued liabilities	508	453
Total current liabilities	823	856
Long-term debt	798	801
Intercompany payable	13,775	13,764
Other long-term liabilities	295	370
Total liabilities	15,691	15,791
Redeemable noncontrolling interests in equity of consolidated subsidiaries	565	571
Community Health Systems, Inc. stockholders' equity:
Additional paid-in capital	1,042	967
Accumulated other comprehensive loss	(1)	(3)
Retained earnings	(6)	14
Total Community Health Systems, Inc. stockholders' equity	1,035	978
Noncontrolling interests in equity of consolidated subsidiaries	115	86
Total equity	1,150	1,064
Total liabilities and equity	17,406	17,426
Consolidation, Eliminations [Member]
Current assets:
Intercompany receivable	(25,891)	(25,598)
Other assets, net	(1,265)	(1,046)
Net investment in subsidiaries	(32,708)	(32,437)
Total assets	(59,864)	(59,081)
Current liabilities:
Intercompany payable	(50,097)	(49,646)
Other long-term liabilities	(1,265)	(1,046)
Total liabilities	(51,362)	(50,692)
Community Health Systems, Inc. stockholders' equity:
Additional paid-in capital	(3,899)	(3,797)
Accumulated other comprehensive loss	111	98
Retained earnings	(4,714)	(4,690)
Total Community Health Systems, Inc. stockholders' equity	(8,502)	(8,389)
Total equity	(8,502)	(8,389)
Total liabilities and equity	$ (59,864)	$ (59,081)

XML

Supplemental Condensed Consolidating Financial Information (Schedule of Condensed Consolidating Statement of Cash Flows) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities:
Net cash (used in) provided by operating activities	$ 294	$ (61)
Cash flows from investing activities:
Acquisitions of facilities and other related equipment	(99)	(13)
Purchases of property and equipment	(224)	(241)
Proceeds from disposition of hospitals and other ancillary operations	12	62
Proceeds from sale of property and equipment	4	3
Purchases of available-for-sale securities	(37)	(59)
Proceeds from sales of available-for-sale securities	40	56
Increase in other investments	(67)	(39)
Net cash used in investing activities	(371)	(231)
Cash flows from financing activities:
Proceeds from exercise of stock options		17
Repurchase of restricted stock shares for payroll tax withholding requirements	(7)	(20)
Deferred financing costs and other debt-related costs		(20)
Redemption of noncontrolling investments in joint ventures	(16)	(7)
Distributions to noncontrolling investors in joint ventures	(18)	(23)
Borrowings under credit agreements	1,564	1,251
Proceeds from receivables facility	31	75
Repayments of long-term indebtedness	(1,480)	(1,268)
Net cash provided by financing activities	74	5
Net change in cash and cash equivalents	(3)	(287)
Cash and cash equivalents at beginning of period	184	509
Cash and cash equivalents at end of period	181	222
Parent Company [Member]
Cash flows from operating activities:
Net cash (used in) provided by operating activities		(10)
Cash flows from financing activities:
Proceeds from exercise of stock options		17
Repurchase of restricted stock shares for payroll tax withholding requirements	(7)	(20)
Changes in intercompany balances with affiliates, net	7	13
Net cash provided by financing activities		10
Issuer [Member]
Cash flows from operating activities:
Net cash (used in) provided by operating activities	(223)	(123)
Cash flows from financing activities:
Deferred financing costs and other debt-related costs		(20)
Changes in intercompany balances with affiliates, net	89	77
Borrowings under credit agreements	1,563	1,250
Repayments of long-term indebtedness	(1,429)	(1,184)
Net cash provided by financing activities	223	123
Other Guarantor [Member]
Cash flows from operating activities:
Net cash (used in) provided by operating activities	420	23
Cash flows from investing activities:
Acquisitions of facilities and other related equipment	(2)	(11)
Purchases of property and equipment	(159)	(199)
Proceeds from disposition of hospitals and other ancillary operations	12	4
Proceeds from sale of property and equipment	3
Purchases of available-for-sale securities	(12)	(22)
Proceeds from sales of available-for-sale securities	10	19
Increase in other investments	(53)	(30)
Net cash used in investing activities	(201)	(239)
Cash flows from financing activities:
Changes in intercompany balances with affiliates, net	(215)	(101)
Borrowings under credit agreements	1	1
Repayments of long-term indebtedness	(18)	(15)
Net cash provided by financing activities	(232)	(115)
Net change in cash and cash equivalents	(13)	(331)
Cash and cash equivalents at beginning of period	25	368
Cash and cash equivalents at end of period	12	37
Non-Guarantor Subsidiaries [Member]
Cash flows from operating activities:
Net cash (used in) provided by operating activities	97	49
Cash flows from investing activities:
Acquisitions of facilities and other related equipment	(97)	(2)
Purchases of property and equipment	(65)	(42)
Proceeds from disposition of hospitals and other ancillary operations		58
Proceeds from sale of property and equipment	1	3
Purchases of available-for-sale securities	(25)	(37)
Proceeds from sales of available-for-sale securities	30	37
Increase in other investments	(14)	(9)
Net cash used in investing activities	(170)	8
Cash flows from financing activities:
Redemption of noncontrolling investments in joint ventures	(16)	(7)
Distributions to noncontrolling investors in joint ventures	(18)	(23)
Changes in intercompany balances with affiliates, net	119	11
Proceeds from receivables facility	31	75
Repayments of long-term indebtedness	(33)	(69)
Net cash provided by financing activities	83	(13)
Net change in cash and cash equivalents	10	44
Cash and cash equivalents at beginning of period	159	141
Cash and cash equivalents at end of period	$ 169	$ 185